Metabolic activation of drugs and other xenobiotics in hepatocellular carcinoma. by Lau, Grace S. N. & Chinese University of Hong Kong Graduate School. Division of Medical Sciences.
夏 
METABOLIC ACTIVATION OF DRUGS AND 
OTHER XENOBIOTICS M 
HEPATOCELLULAR CARCINOMA 
, � � . “ . 
I/-, i 
[:(‘ 1 3 SEP 1 
j 
Grace S.N. Lau 
SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 1 








 . V , 、 
TABLE OF CONTENTS 
List of Abbreviations i 
Abstract 1 
Chapter 1 General Introduction and Study Objectives 
1.1 Metabolic activation - role in drug toxicity and 
carcinogenesis 5 
1.2 Hepatocellular carcinoma 12 
1.2.1 Epidemiology 12 
1.2.2 Aetiological factors 17 
1.2.2.1 Hepatitis B virus infection 17 
1.2.2.2 Cirrhosis 24 
1.2.2.3 Aflatoxins 25 
1.2.2.4 Other factors 26 
1.2.2.5 Summary 29 
1.3 Study objectives 30 
Chapter 2 The Metabolism of Paracetamol in Healthy Subjects and in 
Patients with Liver Disease and Hepatocellular Carcinoma 
2.1 Introduction 34 
2.1.1. History of paracetamol 34 
2.1.2 Pharmacology of paracetamol 37 
2.1.3 Absorption, Distribution, Metabolism and Excretion . 38 
2.1.3.1 Absorption 38 
2.1.3.2 Distribution 41 
2.1.3.3 Metabolism 42 
! 
2.1.3.4 Excretion 57 
2.1.4 Toxicity and Overdosage 59 
2.2 Estimation of paracetamol and its metabolites in plasma and 
urine by high performance liquid chromatography 72 
2.2.1 Introduction 72 
2.2.2 Analytical method 76 
2.2.2.1 Materials 76 
2.2.2.2 Instrumentation 77 
2.2.2.3 Collection and storage of samples . . . . 79 
2.2.2.4 Chromatographic conditions 79 
2.2.3 Urine assay . • . 79 
2.2.3.1 Preparation of standards and test 
samples for urine assay 79 
2.2.3.2 Calculation of results for urine assay . . 80 
2.2.3.3 Results of urine assay 81 
2.2.3.4 Validation of urine assay 81 
2.2.4 Plasma assay ° 
2.2.4.1 Preparation of standards and test 
samples for plasma assay 83 
2.2.4.2 Calculation of results for plasma assay . 91 
2.2.4.3 Results of plasma assay 91 
2.2.4.4 Validation of plasma assay 93 99 2.2.5 Summary 
2.3 The pharmacokinetics of paracetamol in healthy subjects . . 103 
103 2.3.1 Introduction 103 2.3.2 Study protocol 103 2.3.3 Methods 
2.3.3.1 Subjects 103 
2.3.3.2 Drug administration and sampling . . . 104 
2.3.3.3 Drug analysis 108 
2.3.3.4 Calculations 108 
2.3.4 Pharmacokinetic analysis 109 113 2.3.5 Statistical analysis 114 2.3.6 Results 
2.3.6.1 Plasma Results 114 
2.3.6.2 Urine Results 118 
2.3.6.3 Pharmacokinetic Results 125 
2.3.6.4 Statistical Results 134 
2.3.7 Discussion � 
« 
2.4 The pharmacokinetics of paracetamol in healthy subjects, 
patients with liver disease and hepatocellular carcinoma . . . 155 
2.4.1 Introduction 155 
2.4.2 Study protocol 156 
2.4.3 Methods 156 
2.4.3.1 Subjects 156 
2.4.3.2 Drug administration and sampling . . . 157 
2.4.3.3 Drug analysis 160 
2.4.3.4 Calculations 160 
2.4.4 Pharmacokinetic analysis 161 
2.4.6 Results 162 
2.4.6.1 Plasma Results 162 
2.4.6.2 Urine Results 162 
2.4.6.3 Pharmacokinetic Results 179 
2.4.7 Discussion 194 
2.4.8 Summary 203 
Chapter 3 Metabolic Activation of Aflatoxin Bj in Healthy Subjects 
and in Patients with Liver Disease and Hepatocellular 
Carcinoma 
3.1 General introduction 206 
3.1.1 Chemical structures and properties 207 
3.1.2 Contamination of food by aflatoxins 209 
3.1.3 Metabolism of aflatoxins 210 
3.1.4 Human diseases possibly related to exposure to 
aflatoxins 226 
3.1.4.1 Acute aflatoxicosis 226 
3.1.4.2 Reye's syndrome 227 
3.1.4.3 Kwashiorkor 228 
3.1.4.4 Impaired immune function 229 
I 3.1.4.5 Hepatocellular carcinoma 230 
3.1.5 Biochemical and molecular epidemiology of 
aflatoxins ^^^ 
3.2 Development of an ELISA method to monitor AFBi exposure 
in human serum 237 
3.2.1 Introduction 237 
3.2.2 Preparation of all the components necessary for 
analysing AFBi-albumin adducts by ELISA 243 
3.2.2.1 Materials 243 
3.2.2.2 Preparation of rabbit AFB! antiserum . 244 
3.2.2.3 Preparation of the rat monoclonal 
antibody 244 
3.2.2.4 Concentration of cell culture supernatant 
by ammonium sulphate precipitation . 246 
3.2.2.5 Preparation of the BSA-AFBi 
conjugate 248 
3.2.2.6 Preparation of the immunoaffinity gel 250 
3.2.2.7 Preparation of the ELISA plates . . . . 251 
3.2.3 General procedures used in the analysis of A F B � 
albumin adducts 252 
3.2.3.1 Competitive ELISA binding assay . . . 253 
3.2.3.2 Sep-pak Ci8 cartridge 254 
3.2.3.3 Immunoaffinity column 255 
3.2.3.4 Evaporation process 255 
3.2.3.5 HPLC 256 
3.2.3.6 Radioactive counting 256 
3.2.3.7 Albumin isolation 257 
3.2.3.8 Digestion of albumin 257 
3.2.3.9 Animal procedures 258 
3.2.4 Validations 259 
3 2.4.1 Analysis of standard AFB! and AFBr 
lysine in ELISA 259 
3 2.4.2 Optimisation of antiserum dilution and 
concentration of coating antigen in 
ELISA 259 
3 2.4.3 Elution characteristics and capacity of 
the immunoaffinity column 261 
3.2.4.4 Comparison of immunoaffinity gels 
prepared with different affinity gels • . 261 
3.2.4.5 Immunoaffinity column experiment of 
AFBi-lysine 263 
3.2.4.6 HPLC Analysis of fractions from 
immunoaffinity column 263 
3.2.4.8 HPLC analysis of fractions from Sep-
Pak Ci8 cartridge 264 
3.2.4.9 Digestion of serum albumin by 
proteinase K 264 
3.2.4.10 Effect of ethanol in samples to be 
loaded onto Sep-Pak Qg cartridge . . . 265 
3.2.4.11 Effect of drying in a vacuum 
concentrator on recovery of 
radioactivity of ^H-AFBi 266 
3.2.4.12 Evaluation of the overall procedure for 
the analysis of serum albumin adducts 
of AFBi 267 
3.2.4.13 HPLC analysis of samples obtained 
after digestion and all clean-up 
procedures 268 
3.2.5 Results and discussion 268 
3.2.5.1 BSA-AFBi conjugate 268 
3.2.5.2 Treatment of experimental animals with 
3H_AFBI 270 
3.2.5.3 Optimisation of antiserum dilution and 
concentration of coating antigen in 
ELISA 272 
3 2.5.4 Analysis of standard AFBi and AFB!-
lysine in ELISA 275 
3.2.5.5 Sep-Pak Cig cartridge - elution 
characteristics and capacity 279 
3 2.5.6 E l u t i o n c h a r a c t e r i s t i c s of 
immunoaffinity columns 282 
3 2.5.7 Immunoaffinity column experiment of 
AFBi-lysine 290 
3 2.5.8 Digestion of serum albumin by 
proteinase K 295 
3.2.5.9 Effect of ethanol in samples to be 
applied onto Sep-Pak Qg cartridges . . 297 
3.2.5.10 Recovery of radioactivity after drying in 
a vacuum concentrator 300 
3.2.5.11 Recovery of the overall clean-up 
procedure for the analysis of serum 
albumin adducts of AFB! 300 
3.2.5.12 HPLC analysis of samples obtained 
after all clean-up procedures 305 
3.2.5.13 The use of rabbit anti-AFBj anti-serum 
and rat anti-AFBi monoclonal antibody 308 
3.2.6 Summary 309 
3.3 Monitoring of AFBi-albumin adducts in plasma of patients 
with liver disease and hepatocellular carcinoma 311 
3.3.1 Introduction 311 
3.3.2 Material and methods 314 
3.3.2.1 Subject 314 
3.3.2.2 Sample collections 315 
3.3.2.4 Assay for AFBi-albumin adducts . . . . 315 
3.3.2.5 Statistical analysis 318 
3.3.3 Results and discussion 318 
Chapter 4 Summary and Ideas for Further Studies 330 
Acknowledgements 333 
References : 335 
I Appendices 364 
I 
List of Abbreviations 
A A P 2-acetamidophenol 




AFBi-lysine Aflatoxin-lysine adduct 
AFBi-A^^-Gua 8,9-dihydro-8-(A^''-guanyl)~9-hydroxy AFBi 
AFBza 8,9-Dihydro-8-hydroxy aflatoxin B! 
A F M i Aflatoxin M j 
AFPi Aflatoinx Pj 
AFQi Aflatoxin Qi 
A N O V A Analysis of variance 
AUC Area under plasma concentration versus time curve 
BSA Bovine serum albumin 
BSA-AFBi Aflatoxin Bi-modified bovine serum albumin 
CI Plasma clearance 
Cmax Peak plasma concentrations 
CV Coefficient of variation 
DMSO Dimethyl sulphoxide 
ELISA Enzyme-linked immunosorbent assays 
F R M A N O V A Friedman repeated measures analysis of variance 
GSH Reduced glutathione 
GST Glutathione S-transferase 
H A T Hypoxanthine Aminopterin Thymidine 
HBcAg Hepatitis B virus core antigen 
^ ― — — — ^ 
Abbreviations ii 
HBsAg Hepatitis B virus surface antigen 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HGPRT Hypoxanthine guanine phosphoribosyl transferase 
HPLC High performance liquid chromatography 
lARC International Agency for Research on Cancer 
MRT Mean residence time 
NADPH Reduced nicotinamide adenine dinucleotide phosphate 
NAPQI N-acetyl-p-benzoquinoneimine 
PBS Phosphate buffered saline 
PBS-gelatin PBS with 0.25% gelatin 
PBS-Tween 20 PBS with 0.05% Tween 20 (Polyoxymethylenesorbitan 
monolaurate) 
ppb Parts per billion 
r Product moment correlation coefficient 
R Intraclass correlation coefficient of reliability 
RIA Radioimmunoassay 
RM ANOVA Repeated measures analysis of variance 
SD Standard deviation 
SNK Student-Newman-Keuls test 
t^^ Time to reach peak plasma concentration 
TMB 3，3�，5，5,-tetramethylbenzidine 
t 丨為 Half-life 
Vd Volume of distribution 
WHO World Health Organisation 
1 
Abstract 
The metabolic activation of many drugs and xenobiotics in vivo is effected through 
the large family of cytochrome P450s enzymes that catalyse a diverse spectrum of 
reactions including the metabolism of both endogenous and exogenous compounds. 
There is considerable evidence suggesting that changes in P450 activities can affect 
the in vivo toxicity of drugs in both animals and humans. Oxidative metabolism by 
cytochrome P450 enzymes has been implicated in the pathogenesis of cancer, 
through the formation of toxic intermediates and carcinogenic metabolites are formed 
from drugs and xenobiotics. A marked overall increase in the metabolic activation 
of the commonly used analgesic agent, paracetamol, was found in patients with 
hepatocellular carcinoma, as indicated by a much higher percentage recovery of the 
oxidative metabolites cysteine and mercapturate conjugates, compared to healthy 
controls and patients with chronic hepatitis B infection. It was thought that metabolic 
activation of some drugs and xenobiotics through the actions of specific cytochrome 
P450s may be enhanced in patients with hepatocellular carcinoma. 
The in vivo metabolic activation of two xenobiotics, namely paracetamol and 
aflatoxin B!，using different approaches, were studied in human subjects in this 
project. The first study involved a full pharmacokinetic study of paracetamol, whose 
hepatotoxicity is dependent on its in vivo metabolic activation. It was carried out in 
5 different groups of subjects: healthy subjects, patients with alcoholic liver disease, 
chronic hepatitis B infection, patients with impaired renal function and patients with 
hepatocellular carcinoma. 
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An HPLC method for the measurement of paracetamol and its metabolites in both 
plasma and urine was developed and validated. It involved minimum sample 
preparation and had excellent precision, accuracy and recovery. Pharmacokinetic 
modelling was carried with the aid of the SIPHAR pharmacokinetic programme 
(version 4.0) and parameters estimated for each subject include the area under the 
plasma concentration-time curve, clearance, elimination half-life, mean residence 
time and volume of distribution of paracetamol. In addition, urinary recovery data 
and metabolic clearances to each metabolite were also calculated. The aim of this 
part of this project was to elucidate the mechanisms of altered metabolism of 
paracetamol in patients with hepatocellular carcinoma. Following administration of 
a 20 mg kg-i body weight dose of paracetamol, the only statistically significant 
difference in the pharmacokinetics of paracetamol between subjects with 
hepatocellular carcinoma and subjects in other study groups was an enhanced 
oxidative metabolic pathway and thus increased metabolic clearance to the cysteine 
and mercapturate conjugates. The metabolic activation of paracetamol to the toxic 
intermediate, seemed to be genuinely enhanced among patients with hepatocellular 
carcinoma and a small proportion of patients with chronic liver diseases, and was not 
due to an impairment of other metabolic pathways. This enhanced metabolic 
activation by cytochrome P450s might also be involved in the formation of 
carcinogenic substances from other xenobiotics such as the mycotoxins aflatoxins 
with some implications in the pathogenesis of hepatocellular carcinoma. 
The other xenobiotic whose metabolic activation was studied in this project was the 
mycotoxin aflatoxin Bj (AFB,). There is considerable evidence indicating an 
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association between AFB! ingestion and liver cancer in humans but there is no 
published data on the possible human exposure and association with hepatocellular 
carcinoma in Hong Kong. In this study, an enzyme linked immunosorbent assay 
technique, using a rat monoclonal antibody raised against AFB!，was developed for 
monitoring the levels of the major AFBi-albumin adduct, AFBi-lysine, in human 
serum. The study procedure included a hydrolysis step of the serum albumin, clean 
up steps using Sep-Pak Qg cartridges and specific immunoaffinity columns. The 
method was validated using animals treated with ^H-AFBi. The overall recovery of 
the method was 23.3% and the absolute detection limit was about 2 pg AFBi per mg 
of albumin. This detection limit translates to a daily intake of approximately 2 ng 
AFBj and compares favourably with other published methods. 
Serum samples from 147 subjects were studied including patients with hepatocellular 
carcinoma, other liver diseases and individuals without evidence of any liver disease. 
As the formation of the albumin adduct must be preceded by the in vivo metabolic 
activation of AFBi to its reactive intermediate, the measurement of the albumin 
adduct also serves as an index of metabolic activation. Nevertheless, despite the very 
low detection limit offered by our assay, none of the serum samples studied showed 
a measurable level of the adduct. Previous validations on this assay indicate that it 
is unlikely that these results were false negatives. It is thus concluded that if AFB!-
albumin adducts existed in the serum of the study subjects at all, they were at 
extremely low levels, and the in vivo metabolic activation of AFB! is unlikely to play 
a major role in the aetiology of HCC in Hong Kong. 
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Chapter 1 
General Introduction and Study Objectives 
1 • 1 Metabolic activation - role in drug toxicity and carcinogenesis 
The biotransformation of relatively inert chemicals to highly reactive metabolites is 
commonly referred to as ‘metabolic activation', and is now recognised to be an 
initial event in several kinds of chemical-induced toxicities. One of the most well-
known and classic example is paracetamol toxicity. Therapeutic doses of the common 
and widely-prescribed antipyretic analgesic paracetamol, are very safe and virtually 
completely eliminated by hepatic metabolism and renal excretion within 24 hours. 
In normal healthy individuals, 5 - 10% of a therapeutic dose undergoes oxidative 
metabolism by cytochrome P450 dependent microsomal enzymes with the formation 
of a potentially hepatotoxic intermediate, probably N-acetyl-;?-benzoquinoneimine 
(Jollow, Mitchell, Potter, Davis, Gillette & Brodie，1973; Mitchell, Jollow, Potter, 
Davis, Gillette & Brodie, 1973a; Mitchell, Jollow, Potter, Gillette & Brodie, 1973b) 
(see Chapter 2 for details on the metabolism of paracetamol). This reactive 
intermediate is normally conjugated with hepatic reduced glutathione and excreted 
as inactive mercapturate and cysteine conjugates. In overdosage or when the hepatic 
glutathione store is depleted, the reactive intermediate can attack vital cell organelles 
and macromolecules, causing hepatic necrosis. Fig. 1.1 is a simplistic scheme for 
the role of metabolic activation in cellular toxicity. It is known that in some cases 
a single enzymatic reaction is involved in the metabolic activation of a chemical 
I 
while in others, several enzymatic and/or chemical reactions are involved in the 
generation of a chemically reactive metabolite. For example, there is evidence for 
the involvement of multiple forms of cytochrome P450 in the generation of the 
16 
Fig 1 .1 Ro le o f metabolic activation in cellular toxicity 
Drugs and Other Industrial 
and Environmental Chemicals 
Metabolic Activation 
\ f 
Chemically Reactive Metabolites 
Reactions with 
Cellular Macromolecules 
and/or Other Cell Constituents 
\ f 
Altered Cellular Biochemistry 
Cell Death Tumorigenesis 
Nelson, SD. Journal of Medicinal Chemistry 1982;25:753-65 , 
- ^ ^ ― — ^ ― . -
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reactive 8,9-epoxide from the hepatotoxic mycotoxin aflatoxin Bi (AFBi)(Forrester, 
Neal, Judah, Glancey & Wolf，1990). 
Apart from paracetamol, other examples of drugs that are metabolised to reactive 
products include the hydrazines (isoniazid, iproniazid, procarbazine and hydralazine), 
procainamide, the benzenoid aromatics (thalidomide, phenytoin), the nitroaromatics 
(nitrofurantoin, chloramphenicol and metronidazole) and a whole host of other 
commonly used drugs. A review on the metabolic activation of these agents has been 
provided by Nelson (Nelson, 1982). 
The metabolism of xenobiotics (foreign substances to the body including drugs and 
chemcials) in vivo has been classified broadly into two phases. Phase I reactions 
include oxidations, reductions and hydrolyses; whereas Phase II reactions are defined 
as conjugation reactions including glucuronidation, sulphation, acylation, methylation 
and conjugation with glutathione. Most drugs and other xenobiotics are metabolised 
into more polar compounds that can be rapidly removed from the body while others 
(pro-drugs) are transformed to therapeutically active metabolites. Since these are the 
same enzymes that catalyse the formation of reactive, toxic metabolites from some 
drugs，it seems clear that the structural features of drug molecules and their 
metabolites determine whether the metabolic reaction produces a detoxification 
product or a potentially toxic metabolite, and not differences in the nature of the 
catalytic reaction (Nelson, 1982). Two mechanisms are involved in the initiation of 
the chain of reactions that ultimately lead to toxicity: 
1. Covalent binding of reactive metabolite to tissue macro-molecules 
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2. Reactive metabolite-induced oxidative stress 
Covalent binding is considered an experimental parameter which serves as an index 
of metabolic activation or the formation of highly reactive metabolites which are 
often difficult to measure or even isolate. Very often radiolabelled drug is 
administered to animals or used as substrate in enzyme studies. The amount of 
radiolabel retained by various macromolecules including proteins and nucleic acids 
is then assayed after various steps of extraction. Another method is to subject these 
modified macromolecules to a digestion process and determine the structure of the 
ultimate adduct(s). This method poses many problems as it is difficult to ensure that 
some changes have not occurred during the digestion and workup process, therefore, 
it has not been possible to apply it widely to the study of a large number of drugs 
and chemicals. AFBi is one such toxic chemical whereby the chemical structure and 
properties of its major serum albumin and DNA adducts have been successfully 
elucidated (see Chapter 3 for detail review). 
Covalent binding studies have also been a useful tool during the investigation of the 
role of metabolic activation in the initation of the hepatic toxicity of paracetamol. 
Apart from demonstrating that a reactive intermediate was involved in the causation 
of hepatic toxicity, dose dependency of the toxicity of paracetamol was also shown. 
In general, the severity of drug/chemical toxicity involving metabolic activation as 
an intermediate step depends on: 
a. the proportion of the dose that is converted to reactive metabolite 
b. the proportion of reactive metabolite that becomes covalendy bound 
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c. the proportion of covalently bound metabolite that is attached to critical 
macromolecules and 
d. the proportion of (c) that cannot be replaced or repaired that leads to toxicity 
These factors can potentially be modified by endogenous or exogenous modalities 
and thus contribute to inter-individual variation in the susceptibility to the toxicity 
of various xenobiotics. These may include genetic predisposition, metabolising 
enzyme induction or inhibition by other environmental agents and the 
activity/capacity of other detoxification pathways. 
The other mechanism involved in the initiation of the chain of reactions that 
ultimately lead to toxicity is oxidative stress caused by the reactive metabolite. It 
requires redox cycling of a compound through radical intermediates that can reduce 
molecular oxygen to superoxide anion, then to hydrogen peroxide and hydroxyl 
radical, all of which are believed to be involved in the initiation of membrane lipid 
perioxidation, leading subsequently to cell death. Thus, deficiency of vitamin E, a 
known free radical scavanger, and selenium, required for the synthesis of most 
glutathione peroxidases (enzymes that destroy hydrogen perioxide), should enhance 
in vivo toxicity of drugs that appear to involve this mechanism. Examples of drugs 
causing toxicity by such mechanism include nitroaromatics and anthraquinone 
anticancer agents. 
The cytochrome P450 is a large family of enzymes that catalyse a diverse spectrum 
of reactions, including the metabolism of endogenous compounds such as cholesterol, 
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fatty acids and steroids and exogenous compounds such as drugs and environmental 
chemicals. Many different P450 isoenzymes have been purified from human liver 
and their corresponding cDNAs cloned and classified into families and subfamilies 
(Nebert, Nelson, Coon, Estabrook，Feyereisen, Fujii-Keriyama, Gonzalez, 
Guengerich, Gunsalus, Johnson, Loper, Sato, Waterman & Waxman，1991; 
Gonzalez, 1992). They are responsible for the metabolism of a wide range of 
endogenous and foreign compounds, and in man the transformation of many drugs 
and chemical carcinogens is mediated by the P450 system. Oxidative metabolism by 
cytochrome P450 has been implicated in the pathogenesis of cancer and is known to 
form carcinogen metabolites from xenobiotics such as polycyclic aromatic 
hydrocarbons e.g. benzo[a]pyrene and the mycotoxin AFBj (see Guengerich, 1988). 
Since the activation of potentially toxic substances and procarcinogens to their 
respective reactive forms is mediated by specific form(s) of the cytochrome P450 
enzymes, their relative expression will affect the amount generated or the rate of 
generation of the reactive intermediates. 
Considerable evidence suggests that changes in P450 composition can affect in vitro 
and in vivo metabolism of drugs in both animals and humans, but the evidence is less 
^ clear in the case of carcinogens. Supporting data have come from different lines of 
research. Animals with genetic predisposition for an altered cytochrome P450 
composition have enhanced tumour formation when challenged with some 
carcinogens. These tumours include lung tumour associated with 3-
methylcholanthrene, leukaemias (benzo[a]pyrene, 3-methylcholanthrene), brain 
tumour (3-methylcholanthrene) and lymphomas (dimethylbenz[a]anthracene) (Nebert, 
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Atlas, Guenthner & Kouri，1978; Levitt, Fysh，Jensen & Nebert，1979; Nebert, 
1981). Evidence for the association of cancer risk with P450 composition in humans 
is less well developed. A major line of investigation involved correlation of cancer 
risk with drug oxidation polymorphisms in humans. Idle et al. reported a possible 
relationship between the in vivo rate of debrisoquine 4-hydroxylation and the 
incidence of liver cancer in Nigerians, suggesting an aetiological role involving the 
metabolic activation of AFB! (Idle, Mahgoub，Sloan, Smith, Mbanefo & Bababunmi， 
1981), but the role of debrisoquine 4-hydroxylase in AFBj activation has not been 
established or supported. Extensive metabolisers of debrisoquine were also shown 
to have a significantly elevated risk of lung cancer (Idle, 1989). On the other hand, 
in a more recent study, increased risk of lung cancer was not seen in extensive 
metabolisers of debrisoquine, but paradoxically a significantly increased proportion 
of poor metabolisers was seen in leukaemia, bladder cancer and melanoma patients 
(Wolf, Smith, Gough, Moss, Vallis, Howard, Carey, Mills, McNee, Carmichael & 
Spurr, 1992). These associations suggest CYP2D6 (nomenclature according to 
Nebert (Nebert et al., 1 9 9 1))� t h e cytochrome P450 enzyme catalysing the 4-
hydroxylation of debrisoquine, is either directly involved in carcinogen detoxification 
and carcinogenesis or that the gene encoding this protein is in linkage with another 
cancer-causing gene. Recent studies revealed that the recovery of the oxidative 
metabolites of paracetamol in the 24 hour urine collection was much increased 
among patients with hepatocellular carcinoma, compared to healthy subjects and 
other patients with chronic liver diseases (Leung & Critchley，1991)，and among 
patients with bladder carcinoma (Dolara, Lodovici, Salvadori, Saltutti, Delle Rose, 
Selli & Kriebel, 1988). It was thought that an increased capability of forming the 
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reactive intermediate of paracetamol, through the catalytic actions of specific 
cytochrome P450s, might predispose an individual to these cancers. A major 
challenge still lies ahead in the research of P450 isoenzymes in order to understand 
their role in chemical carcinogenesis, and to determine the relative contribution of 
genetic and environmental factors in an individual's capacity to metabolize and 
activate carcinogens. Biochemical and immunological methods and molecular genetic 
approaches have been suggested to be the tools that can be employed today for 
pursuit in this area (Miles & Wolf，1991). 
1.2 Hepatocellular carcinoma 
1.2.1 Epidemiology 
Benign and malignant tumours may arise in the liver from the hepatocytes, bile duct 
epithelium or the supporting mesenchymal tissue. All are rare except hepatocellular 
carcinoma (HCC) (Christopherson & Mays, 1987). HCC occurs either as a single 
mass or as scattered nodules of tumours. Around 80% have pre-existing cirrhosis. 
The tumour tends to invade the portal and hepatic veins and spreads to the abdominal 
lymph-nodes and bones. Histologically, the tumour is typically composed of cells 
resembling hepatocytes. 
HCC is uncommon in the United States, United Kingdom and the countries of North 
Europe. But in other geographic areas, it ranks as one of the most common of all 
malignant neoplasms, at least in the male population. Areas of high incidence include 
Southeast Asia, the Western Pacific and Sub-Saharan Africa. Worldwide it has been 
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estimated that over 1,000,000 new cases occur each year (London, 1981). The 
estimates of the frequency of HCC and its epidemiology have probably been 
underestimated due to the difficulties in definitive diagnosis and correct classification 
of the cancer. 
There are striking geographic and racial variations in the occurrence of HCC and it 
is found most commonly in developing countries. The global picture is best defined 
by the grouping of countries or populations into: 
(1) very high rates ( > 20 per 100,000 males per year) 
(2) intermediate rates 
(3) low rates ( < 5 per 100,000 males per year) 
The occurence of HCC, according to different incidences, reported from different 
countries is list in Table 1.1. Another feature to illustrate this range of occurrence 
is that HCC is the most common cancer seen in Mozambique and Taiwan, the third 
most common in China and Hong Kong, but ranks only 22nd in the U.S.A. 
There is also considerable within-country variation, particularly in large countries 
such as China. Here the incidence is much higher in the northeast, east coastal area 
and southeast areas. 
Worldwide there are more males with HCC than females. Among Chinese and 
Africans, the ratio is about 4:1，but in Caucasians, there is only at most a twofold 
difference. Chinese immigrants in the U.S.A. retain this male excess risk. It is of 
patho-aetiological interest that immune response to infections by the hepatitis B virus 
14 
Table 1.1 Global distribution of hepatocellular carcinoma 
1. Very high rate (> 20/100,000 males pet y m ) 
S o u A � t Asia 
We$t m<i Southern Africa 
Chinese populatiom in Hong Kong 
i l i l i i l B ^ 
Singapore 
2. Intermediate rate (5-20/100,000 males per year) 
Japan 
Southern Europe 
Bulgaria, Poland, Yugoslavia, France, Hungary, 
Czechoslovakia, Belgium and Austria 
New Zealand Maoris Hawaiian s Chinese in the U.S. 









New Zealand non-Maori 
(Adapted from Linsell, 1987) 
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(HBV), as measured by the presence of antigens and antibodies does not demonstrate 
such a marked sex difference. Females generally remain carriers for a shorter period 
of time compared to males suggesting they deal more efficiently with the viral 
infection (Linsell, 1987). 
In all populations, the incidence increases with age. In countries of high incidence, 
there is a marked shift to the younger age groups. In Africa the average age is 
around 40 years of age and in Asia around 50 years of age. In Mozambique, the 
incidence in 25-34 year old males was 500 times the equivalent white population in 
the U.S.A. or the U.K.. However, in the 65-plus group, this excess decreased to 15 
times (Linsell, 1987). 
Hong Kong is also considered an endemic area for HCC where it is currently the 
2nd commonest cancer death in Hong Kong, after lung cancer. According to the 
1984 Cancer Registry published by the Hong Kong Government, there are more than 
1,000 new cases of HCC registered. The incidence rate was 28.6/100,000 for the 
male and 7.7/100,000 for the female (Medical and Health Department Hong Kong 
Government, 1984). A total of 1,000 cases were registered in the year with a male 
to female ratio of 4 to 1 and it accounted for 7.5% of all the cancer cases seen in 
Hong Kong. The incidence has nearly doubled in just over 20 years from 
16.9/100,000 per year for males in 1965 to 28.4/10,000 in 1987 (The Federation of 
Medical Societies, 1989) (see Table 1.2). 
Hong Kong lies in an endemic area of HCC along with the southeast coast of China, 
16 
Table 1.2 Incidence of hepatocellular carcinoma in Hong Kong 
> 1,000 new cases per year 
2nd commonest cancer death 
3SSS 9 
Median age 50 
Median survival 8 weeks 
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where the incidence is particularly high in the provinces Shanghai, Guangxi, Fujian, 
Jiangsu and Guangdong. In Hong Kong, the median age of presentation is around 50, 
a relatively young age compared to other cancers such as colon and lung cancers and 
the mortality rate tends to level out in the older age group. Most patients present late 
with hepatomegaly with an overall median survival of about 8 weeks if treatment 
cannot be instituted. If some treatment can be offered, including surgery and 
chemotherapy, the median survival can be prolonged to 18 weeks (Shiu, Dewar, 
Leung, Leung, Chan, Tao, Lui, Chan, Lau & Metreweli，1990). 
1.2.2 Aetiological factors 
Although the exact mechanisms of neoplastic transformation in HCC are still far 
from being fully understood, several factors have been strongly associated with the 
incidence of HCC and incriminated as aetiologic factors. These include: 
1. HBV infection 
2. Cirrhosis 
3. Aflatoxins 
4. Cigarette smoking 
5. Alcohol 
6. Non-A Non-B hepatitis infection 
1.2.2.1 Hepatitis B virus infection 
Much evidence has accumulated during the last two decades in support of a 
aetiological role of HBV in the development of HCC. The most important data came 
from epidemiology studies and research in the molecular biology area. 
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Epidemiology 
There is a geographic correlation between the incidence of HCC and the prevalence 
of chronic HBV infection. The global pattern of the carriage of HBsAg follows 
closely the division of HCC into high, intermediate and low areas (Linsell, 1987). 
There are estimated to be around 350 million chronic hepatitis B surface antigen 
carriers in the world. Correlation studies have demonstrated that there is a strong 
positive correlation between the incidence of HCC with the prevalence of the carrier 
state of the HBV surface antigen (HBsAg). Southeast Asia and sub-Saharan Africa 
which have very high HBsAg prevalence rates (over 10%), also have the highest 
incidence of HCC. On the other hand, the low incidence of HCC in Northern 
Europe, N. America and Australia correspond with a low HBsAg carrier rate in 
these areas (Lau & Lai，1990). This is depicted in Table 1.3. 
This close association between HCC and HBsAg carriers also applies to areas within 
a single country. In China, provinces south of the Yangtze river have a higher 
incidence of HBsAg carriage and HCC than those north of the river. However, this 
relationship is not consistently found in countries where HCC has a low overall 
incidence. In the U.S.A. and Australia, the HCC rates are higher than the overall 
HBsAg carrier rates. It was suggested that this may be related to high risk ethnic 
immigrants such as Chinese in the U.S.A. (Lau & Lai，1990). Greenland and Chile, 
on the other hand, have high HBsAg carrier rates but much lower than expected 
incidence of HCC. In the global sense, the incidence of HBV markers is consistently 
higher in HCC patients than in control populations from the same areas. This is also 
shown in a number of case control studies where the relative risks and attributable 
19 
Table 1.3 Death rates from hepatocellular carcinoma, and incidence of 
HBsAg in healthy carriers and in cases of HCC by 
countries/places 
Standardised 
death rate of 
Country/Place HCC per HBsAg carrier HBsAg in HCC 
100,000 in (%) (%) 
males 
Hong Kong ^ ^ 
Singapore (Chinese) 31.0 6.6 35.3 
Philippines - 15.5 70.0 
China 19.6 14.5 86.0 
Taiwan - 12.5 70.3 
Japan 12.5 2.6 40.3 
Thailand 4.1 9.8 71.4 
India 3.1 3.2 41.2 
S. Africa (Bantu) 19.2 9.0 61.6 
Uganda 6.5 6.5 55.2 
Senegal - 11.7 61.2 
Greece 16.8 4.7 63.1 
Italy 10.7 3.0 66.0 
Spain 10.4 0.3 35.0 
Britain 2.0 1.4 47.4 
Greenland 2.4* 10.0+ -
U.S.A. 1.4 0.3 17.0 
Australia 1.4 0.2 40.0 
* standardised death rate for primary liver cancers which include hepatocellular carcinomas, 
cholangiocarcinoma and hepatoblastomas 
+ between 10 - 20 years old 
{adapted from Lau and Lai, 1990) 
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risks were estimated to be much increased (Table 1.4). A large cohort study 
involving 22,707 subjects from Taiwan showed a relative risk of 217 for HBsAg 
carriers and a attributable risk of 93.9% (Beasley, Huang & Lin, 1981). The lack 
of association between HBV with other cancers and metastatic liver cancer suggests 
that this association is also specific. 
Molecular biology 
According to Zuckerman (Zuckerman, 1974), five criteria should be fulfilled for the 
establishment of the oncogenic role of a virus: 
(i) the infection must precede oncogenesis 
(ii) the tumour cells must contain antigens specific for the virus 
(iii) the tumour cells can produce the viral agent 
(iv) the virus can cause malignant transformation 
(V) active immunization against the virus will reduce the incidence of the tumour 
Evidence in support of these criteria has accumulated for the oncogenic role of HBV 
in the development of HCC from different aspects of research. The epidemiology 
data presented above indicated that in endemic areas, HBV infection preceded the 
development of HCC. 
In patients with HCC, HBsAg can commonly be demonstrated with histochemical 
stains or immunological techniques in the cytoplasm of non-malignant hepatocytes 
(Wu, 1978)，sometimes core antigen (HBcAg) is also identified in the nuclei (Nayak， 
Dhar，Sachdeva, Mittal, Seth, Sudarsanam, Reddy，Wagholikar & Reddy，1977). In 
a study done on 566 patients with liver disease from Hong Kong, HBsAg was 
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Table 1.4 Case-control studies on HBsAg and HCC 
No. of subjects HBsAg + (%) Relative Attributable 
Study population risk risk (%) 
HCC Controls HCC Controls 
Hong Kong 107 107 82.0 18.0 21.3 78.5 
China 50 50 86.0 22.0 17.0 77.9 
Philippines 104 84 70.0 18.0 10.8 63.9 
Greece 184 451 45.9 7.3 10.7 41.6 
Senegal 165 328 61.2 11.3 12.4 56.3 
S. Africa 289 213 61.6 11.3 12.6 56.7 
U.S.A. 86 161 17.9 0.0 17.0 -
(Adapted from Lau and Lai, 1990) 
Chapter 1 22 
identified in the liver in 50% of the patients with cirrhosis alone, 39% of HCC alone 
but 83% with HCC and cirrhosis (Gibson, Wu, Ho & Lauder, 1980). 
Hepatoma cell lines have been derived from HBV carriers with HCC. They are 
found to secrete HBsAg and were shown to have integrated HBV DNA (Ho, Wu & 
Mak, 1981). Integrated HBV DNA were also found in the liver of patients with 
chronic hepatitis and HCC. This was demonstrated in HCC patients from China, 
southern and west Africa, France, Greece and the U.S.A.. These data are consistent 
with the intepretation that integration of HBV DNA into the liver cell genome 
preceded the development of HCC (Linsell, 1987). HBV DNA was found in tumour 
tissue of HCC patients, even when they have no detectable HBV marker in their 
serum (Brechot, Degos, Lugassy, Thiers, Zafrani, Franco, Bismuth, Trepo, 
Benhamou & Wands, 1985). These further support other points in Zuckerman's 
criteria that the tumour cells can produce the viral agent and it can cause malignant 
transformation. A number of endemic countries, including Hong Kong and Taiwan, 
are carrying out vaccination programmes for high risk people and all newborn 
infants. These programmes will hopefully provide further support for the oncogenic 
role of HBV if the incidence of HCC turns out to be reduced by active 
immunization. 
Animal models 
The association of HBV with the development of HCC is also seen among other 
animal species. Hepatitis B-like viruses have been identified in animals, including 
Eastern woodchucks, ground squirrels and Pekin ducks. These viruses have the same 
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morphology and genomic organisation as human HBV but do not infect human. In 
the woodchuck, acute and chronic hepatitis as well as HCC have frequently been 
observed. In one study, woodchucks raised in the absence of external cocarcinogens 
were found to develop HCC as well (Popper, Roth, Purcell, Tennant & Gerin， 
1987). 
The following comment was issued by the World Health Organisation and illustrate 
the strong association of HBV with HCC: "All the published evidence is consistent 
with the interpretation that integration of HBV DNA into the genome of the 
hepatocyte precedes the development of hepatocellular carcinoma by months or 
years. Although these studies do not prove that HBV is oncogenic, the finding of 
HBV DNA in many patients with HCC and in all patients with HCC with markers of 
the virus is highly suggestive.“ 
Although the above points are highly supportive of the causal role of HBV in HCC, 
there are data from other studies indicating that other factors are involved: 
1. Some geographical areas with a high HBsAg positive rate do not have a 
correspondingly high HCC rate e.g. Greenland Eskimos (Melbye, Skinhoj, Nielsen, 
Vestergaard, Ebbesen, Hansen & Biggar, 1984). Furthermore, in Nigeria, the 
prevalence rates of HBV carriers are nearly identical in males and females, yet HCC 
occurs 5 times more frequently in the male than in the female, indicating some other 
factors are likely to be relevant in this population (Ayoola, 1984). 
2. A small proportion of HCC patients is negative for all HBV serologic markers 
and no HBV DNA integration can be demonstrated in the genome of their HCCs. 
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3. In Japan, the prevalence of HBsAg is declining but the frequency of HCC has 
tripled during the last 15 years. Non-A Non-B hepatitis virus has been suggested as 
a causative agent (Okuda, Isaburo, Hanai & Urano，1987). 
4. HCC in Africa presents at comparatively young age when compared to Asians. 
The role played by environmental factors e.g. other carcinogens in rural areas seems 
to be contributory. 
5. In the U.K., a prospective study of 613 HCC patients showed that cirrhosis, but 
not HBsAg positivity was the major risk factor (Zaman, Melia, Johnson, Portman, 
Johnson & Williams，1985). 
6. No oncogenes have yet been incriminated despite active research. 
1.2.2.2 Cirrhosis 
Cirrhosis is a common accompanying feature of HCC, occurring in 60 - 90% of 
HCC cases. It has been shown that different forms of cirrhosis carry varying risks 
in the development of HCC. In a prospective study of 613 HCC patients carried out 
in the U.K., cirrhosis was shown to be the major risk factor for the development of 
HCC and that HBsAg carriage was only important because it was a cause of 
cirrhosis. In this group, alcoholism was a more important cause of cirrhosis than 
HBV infection (Zaman et al., 1985). However, it was commented that since patients 
without previous symptomatic cirrhosis were not included in this study, the validity 
of the conclusions should be taken with reservation as it is well documented that the 
majority of HCC is associated with asymptomatic cirrhosis (Lau & Lai，1990). 
However, from two other studies, it was shown that the presence of cirrhosis 
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increased the relative risk of the development of HCC in HBsAg-positive patients 
(Gibson et al., 1980; Beasley et al” 1981). 
Several mechanisms have been suggested for the role played by cirrhosis in the 
development of HCC. It has been suggested that due to various aetiologies including 
viral infection and hepatocarcinogens, resistant hepatocytes undergo proliferation and 
regeneration accompanying the chronic necroinflammatory changes, leading to 
cirrhosis. These resistant hepatocytes become preneoplastic or neoplastic and undergo 
selective clonal cell expansion (Harris & Sun, 1984). This is supported by the 
finding in woodchucks that necroinflammation precedes the development of HCC 
(Popper et oL, 1987). An alternative mechanism is that the metabolic activation of 
hepatocarcinogens may be enhanced or their detoxification impaired in cirrhotic liver 
tissues, predisposing the individual to the carcinogenicity of these environmental 
agents (Lau & Lai，1990). 
1.2.2.3 Aflatoxins 
Many chemicals both naturally occurring and synthetic, have been shown to produce 
HCC in animal experiments but man is exposed to only a few of these potential 
carcinogens. Mycotoxins are produced by fungi on cereals and other foods which 
have been harvested and stored under hot and humid conditions. It is now clear that 
aflatoxins are the only members of this group for which there is sufficient evidence 
of hepatocarcinogenesis in man. Amongst the four major members of this group of 
mycotoxins, AFB, is the most toxic and carcinogenic. Its hepatotoxicity and 
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hepatocarcinogenicity are well documented in many animal models and in humans 
(see Section 3.1.4). Evidence of aflatoxin induced cancer risk in man has been issued 
by various institutions including the International Agency for Research on Cancer 
(lARC) and the World Health Organisation (WHO) (IARC, 1976; World Health 
Organization Task Group on Environmental Health Criteria for Mycotoxins, 1979; 
lARC, 1987). 
Correlation studies between the dietary intake of AFBi and the incidence of HCC 
have been done (Table 1.5). Although comparisons between these studies is not 
directly relevant as the methods employed for the analyses were different, these 
studies all showed a direct positive correlation between AFB! exposure and the 
incidence of HCC. Biochemical and molecular epidemiological data in support of 
AFBi as a human hepatocarcinogen have been obtained from a number of countries 
including The People's Republic of China, Swaiziland and Kenya (see Section 3.1.5 
for detail review). 
1.2.2.4 Other factors 
Some studies have shown increased incidence of HCC amongst smokers but no dose-
response relationship has yet been demonstrated (Garfinkel, 1980; Oshima, 
Tsukuma, Hiyama，Fujimoto, Yamano & Tanaka，1984). A report from Hong Kong 
indicated a relative risk of 3.3 of developing HCC among heavy smokers who are 
non-HBsAg carriers, compared to light and non-smokers (Lam, Yu, Leung & 
Henderson, 1982). This was taken to indicate that HBV infection and cigarette 
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Table 1.5 Epidemiological data supporting a dose-dependent 




Country Area intake Number of Incidence 
(ng kg] day-i)* cases (no./lO^ 
population per 
year)+ 
Kenya High altitude 3.5 4 1.23 
Thailand Songkhla 5.0 2 2.00 
Swaziland High veld 5.2 11 2.18 
Kenya Middle altitude 5.9 33 2.51 
Swaziland Mid veld 8.9 29 3.83 
Kenya Low altitude 10.0 49 4.01 
Swaziland Lebombo 15.4 4 4.27 
Thailand Ratburi 45.0 6 6.00 
Swaziland Low veld 43.1 42 9.18 
Mozambique Inhambane 222.1 101 16.1-25.4 
(Adapted from Peer and Linsell, 1977) 
Study period: 1 year in Tlmiland, 3 years in Mozambique and 4 years in Kenya and Swaziland 
* Estimated average daily intake expressed as ng of aflatoxin per kg of body weight 
+ Incidence expressed as number of new cases per 100,000 population per year 
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smoking were independent risk factor for HCC. However, other reports have showed 
no correlation between cigarette smoking and HCC incidence (Stemhagen, Slade, 
Altman & Bill, 1983; Austin, Delzell, Grufferman, Levine, Morrison, Stolley & 
Cole, 1986). 
Conflicting reports on the correlation between alcohol consumption and incidence of 
HCC are also found. There is no experimental evidence that alcohol is carcinogenic 
but some retrospective studies did show that a dose-dependent trend exists 
(Stemhagen et a!.., 1983; Austin et al., 1986). Nevertheless, the fact that only a 
proportion of alcoholics develop chronic liver disease and an even smaller proportion 
of them develop HCC seems to indicate that ethanol consumption alone is not a 
strong aetiologic factor in HCC. It is likely that alcohol is related to the development 
of HCC through hepatic cirrhosis and/or when there is coexisting chronic HBV 
infection (Lau & Lai，1990). 
In Japan, prevalence of HBsAg is declining but the frequency of HCC has tripled 
during the last 15 years. Non-A Non-B hepatitis virus has been suggested as a 
causative agent (Okuda et al, 1987). Infection by Non-A Non-B hepatitis virus 
typically occurs following blood transfusion. The time interval between the acute 
hepatitis to the development of HCC was found to be around 15 -18 years. About 
40% of the HCC cases in Japan had a history of past blood transfusion with an 
average time lapse of 20 years. 
It is now known that most of the post-transfusional Non-A Non-B hepatitis are 
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caused by Hepatitis C. The disease progresses to chronic hepatitis in up to 50% of 
patients acutely infected and 20% to cirrhosis. Advances in molecular biology have 
improved the accuracy of diagnosis and an assay for antibody to HCV has been 
developed (Choo, Kuo，Weiner, Overby, Bradley & Houghton, 1989). Its aetiologic 
role in HCC was discussed and reviewed recently (Tabor & Kobayashi，1992). 
/ 
1.2.2.5 Summary 
The mechanism of hepatocarcinogenesis is still far from clear but there are certain 
identifiable aetiologic factors associated with the development of HCC. These include 
infection by HBV, possible hepatocarcinogens with AFBj being most frequently 
implicated, liver cirrhosis, alcohol consumption and other hepatitis viruses. A multi-
factorial aetiology is favoured whereby synergism between such factors is important 
(Ayoola, 1984; Harris & Sun, 1984). Following insult to hepatocytes by viruses, 
alcohol and/or carcinogens, infected or injured cells will be eliminated rapidly. 
However, during transition to chronicity， resistant cells become 
preneoplastic/neoplastic with integrated HBV genetic material or mutated due to 
adduct formation with carcinogens e.g. AFB” leading to mutational hot spots 
(Bressac, Kew, Wands & Ozturk，1991; Harris, 1991; Hsu, Metcalf, Sun, Welsh, 
Wang & Harris, 1991). Cirrhosis often accompanies the proliferative stage of 
cellular repair and may cause more random viral integration and cellular gene 
expression (Lau & Lai, 1990). This may also predispose the hepatocytes to 
hepatocarcinogens due to altered metabolic activation of these agents or an 
impairment of their detoxification. 
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1.3 Study objectives 
The theme of this PhD thesis is on the metabolic activation of drugs and carcinogens 
in relation to toxicity and carcinogenesis. The interest in this area in The Department 
of Clinical Pharmacology stemmed from the findings of a previous study that showed 
a significantly increased percentage of oxidative metabolites of an oral 1.5 g dose of 
paracetamol in the 24 hour urine from patients with hepatocellular carcinoma (Leung 
& Critchley, 1991). The percentage recovery of these oxidative metabolites, the 
mercapturate and cysteine conjugates of paracetamol, is an index of the metabolic 
activation of paracetamol in vivo. A small proportion of patients with chronic 
hepatitis also had evidence of increased metabolic activation of paracetamol and this 
complemented earlier work which showed increased metabolic activation in some 
Caucasian chronic alcoholics (Critchley, Cregeen, Balali-Mood, Pentland & Prescott, 
1982). Although the most likely explanation for the increased fractional recovery of 
oxidative metabolites is increased activity of the cytochrome P450 enzymes, another 
possibility is impairment of the major pathways of metabolism i.e. glucuronide and 
sulphate conjugation. Reduced capacity for conjugation would slow up the 
elimination of paracetamol from the blood maintaining high concentrations for longer 
and promote paracetamol clearance through the cytochrome P450 pathway. However, 
if the latter explanation for increased oxidative metabolism was the case, then plasma 
paracetamol half lives would be correspondingly longer in patients with high urinary 
recoveries of oxidative metabolites. In our studies based solely on 24 hour urine 
collections, we could not calculate plasma paracetamol half lives directly to see 
whether they were significantly altered in the HCC patients, but they could be 
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estimated indirectly. For subjects with normal renal function, the renal excretion of 
unchanged paracetamol will be a direct function of the area under the plasma 
concentration-time curve (AUG) which in turn is a direct function of the plasma 
paracetamol half-life. There was no evidence of a significantly increased fractional 
urinary recovery of unchanged paracetamol in the HCC patients in our study with 
increased recoveries of the oxidative metabolites. Thus, the increased formation of 
oxidative metabolites does not appear to be due to impairment of the major 
conjugation pathways with an associated prolongation of plasma paracetamol half 
life. 
However, studies were clearly required involving measurement of plasma 
concentrations as well as urinary recoveries in order to confirm (or refute) the above 
assumptions. We would hope to show whether patients with evidence of increased 
metabolic activation have normal or prolonged plasma paracetamol half-lives and 
also confirm that there is a close relationship between plasma paracetamol half life, 
the AUG and the urinary recovery of unchanged paracetamol. One of the areas of 
interests we would like to address is thus the full pharmacokinetics of paracetamol 
in these patients with HCC and the differences, if any, from healthy subjects and 
patients with other liver diseases. The results from this pharmacokinetic study will 
help explain the mechanism of the increased metabolic activation of paracetamol in 
HCC patients and hopefully may shed light on the cause and significance of this 
finding. 
The aflatoxins, especially AFB,, have been implicated as human carcinogens which 
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play an aetiologic role in HCC. Although there is little information on the dietary 
exposure to AFBj in Hong Kong, our neighbouring provinces in China along the 
southeast coast, particularly Guangdong, Fujian, Jiangsu, Guangxi and Shanghai, 
have a high incidence of both HCC and dietary AFBi exposure. It is also of great 
interest that metabolic activation is a prerequisite for the toxicity and carcinogenicity 
of AFBi. Another objective of this project is to make an attempt to demonstrate any 
difference in the metabolic activation of AFBi by subjects with and without liver 
diseases, including chronic HBV infection, and patients with HCC. It may provide 
some clarification on the possible aetiologic role of AFBj in HCC in Hong Kong. 
Since there is no information available on the biochemical or molecular epidemiology 
of aflatoxins in Hong Kong, a study method that would provide information on both 
AFBi exposure and its in vivo metabolic activation was favoured. The other main 
task of this project was the development of a method to monitor AFBi-albumin 
adducts in human serum. If findings reveal modified metabolic activation of AFBj 
by patients with liver disease or HCC, it is hoped that further research can be 
pursued to elucidate any correlation with the increased metabolic activation of 
paracetamol in these same groups of patients. 
CUmjpMr 2 
The Metabolism of Paracetamol in Healthy 
Subjects and in Patients with Liver Disease and 
Hepatocellular Carcinoma 
Chapter 2 
The Metabolism of Paracetamol in Healthy Subjects and in 
Patients with Liver Disease and Hepatocellular Carcinoma 
2.1 Introduction 
2.1.1. History of paracetamol 
Derivatives of aniline were first used in the mid 19th century for their antipyretic 
effect. Acetanilide was produced from the acetylation of aniline and its introduction 
into medicine was the result of serendipity (Insel, 1992). It was believed that 
naphthalene, under investigation for the treatment of intestinal parasites, was 
substituted by mistake with acetanilide and its antipyretic properties revealed. Within 
a short time, acetanilide was introduced for clinical use as an antipyretic which 
stimulated interest in other aniline derivates and phenacetin was introduced the 
following year in 1887 (Spooner & Harvey, 1976). 
The use of paracetamol (N-acetyl-p-aminophenol) was first reported in 1893 by von 
Mehring (Spooner & Harvey, 1976) who concluded that because of its 
haemotological side effects of methaemoglobinaemia, it could not be recommended 
despite prompt antipyretic and analgesic actions. Thus acetanilide and phenacetin 
were the preparations predominantly used for the relief of fever well into the 20th 
century and by which time they were also being used for the relief of mild to 
moderate pain. 
« 
It was not until the late 1940, s when Brodie and his colleagues started to investigate 
the metabolism of acetanilide (Brodie & Axelrod，1948) and phenacetin (Brodie & 
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Axelrod, 1949) that the interest in paracetamol was revived. Their investigations 
showed that both acetanilide and phenacetin were metabolised into paracetamol and 
to which they owed their antipyretic and analgesic properties. The chemical 
structures of paracetamol and related compounds are shown in Fig. 2.1. It was found 
that the methaemoglobin forming side effects initially associated with paracetamol 
was due to contamination with p-phenetidine, another metabolite of phenacetin, and 
paracetamol was devoid of this side effect (Brodie & Axelrod, 1949). Thus, it was 
concluded that paracetamol was an effective analgesic and antipyretic agent which 
did not have the haematological side effects of acetanilide and phenacetin. 
Paracetamol was first introduced in Britain in 1956 as the branded product Panadol, 
each tablet containing 500 mg of paracetamol. It slowly gained acceptance and was 
first included in the British Pharmacopoeia in 1963. Ever since, the consumption of 
paracetamol has steadily risen annually, at the expense of the use of aspirin 
preparations. Phenacetin was condemned as the causative agent of analgesic 
nephropathy (Prescott, 1982) which combined with an apparent lack of therapeutic 
advantage over paracetamol led to its virtual commercial demise (Clissold, 1986). 
Branded combination products of paracetamol with codeine, dihydrocodeine, 
dextropropoxyphene and pentazocine were also introduced, as well as a large number 
of generic paracetamol preparations. The extent of the use of paracetamol and its 
world-wide acceptance reflects its safety and effectiveness in normal and proper 
therapeutic use. 
When used in the recommended therapeutic dosage, paracetamol is a safe and 
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Fig Chemical Structure of Paracetamol and Rela ted Compounds 
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effective analgesic for mild to moderate pain and also possesses an antipyretic action. 
It is well tolerated and produces few side effects (BNF, 1993). The most commonly 
reported adverse effect is hepatotoxicity which occurs following an acute overdosage. 
It damages the liver through the formation of a reactive intermediate. The 
mechanism by which paracetamol exerts its hepatotoxicity was elucidated by Mitchell 
and colleagues (Jollow, Mitchell, Potter, Davis, Gillette & Brodie，1973; Mitchell, 
Jollow, Potter, Davis, Gillette & Brodie, 1973a; Potter, Davis, Mitchell, Jollow, 
Gillette & Brodie, 1973). A small proportion of paracetamol is metabolised by the 
mixed function oxidases, cytochrome P450, to an electrophilic reactive intermediate. 
Normally this is inactivated by conjugation with reduced glutathione and further 
metabolised and excreted as the cysteine and mercapturate conjugates in the urine. 
When the store of glutathione is exhausted, such as following overdosage, this toxic 
reactive metabolite binds covalently to other nucleophiles such as vital cell elements 
resulting in liver necrosis. 
The elucidation of the metabolic pathways of paracetamol and its mechanism of 
hepatotoxicity allowed a rational approach to the treatment of paracetamol poisoning. 
Glutathione precursors and other sulphydryl compounds have been used with success 
in this respect (Prescott, 1983). 
2.1.2 Pharmacology of paracetamol 
Paracetamol has analgesic and antipyretic effects and an efficacy similar to aspirin. 
It is indicated for mild to moderate pain and is well tolerated in both adults and 
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children. However, it has weak anti-inflammatory effects which can only be 
demonstrated in animal models at doses considerably in excess of those required for 
analgesia (Insel, 1992). It has not been satisfactorily established why paracetamol is 
an effective analgesic but only a weak anti-inflammatory agent. The exact 
mechanisms of pain, fever and inflammation are not fully understood and the 
explanations for the actions of antipyretic analgesics are also incomplete. It has been 
suggested that both the release of CNS prostaglandins, involving central pain 
circuits, as well as sensitisation of peripheral pain receptors by locally released 
prostaglandins are involved in inflammatory hyperalgesia. There is some evidence 
suggesting that paracetamol has a weak inhibitory influence on peripheral 
prostaglandin biosynthesis but that it is a potent inhibitor of prostaglandin production 
within the central nervous system; therefore, it lacks substantial anti-inflammatory 
activity but the inhibition of CNS prostaglandins makes paracetamol an effective 
analgesic and antipyretic agent (Ferreira & Vane，1974; Flower, 1974). However, 
it is not known why central nervous system cyclo-oxygenase is more sensitive to 
paracetamol than peripheral cyclo-oxygenase. 
2.1.3 Absorption, Distribution, Metabolism and Excretion 
2.1.3.1 Absorption 
Paracetamol (molecular weight 151.2) is a moderately water and lipid soluble weak 
organic acid, with a pKa 9.5. It is largely un-ionised over the physiological range 
ofpH. It is invariably taken by mouth though rectal dosage forms are also available. 
After oral administration, paracetamol is absorbed rapidly and almost completely 
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(Rawlins, Henderson & Hijab，1977) from the upper gastro-intestinal tract by passive 
diffusion. It is only minimally absorbed from the stomach and the more rapid 
absorption from the small intestine is presumably due to the greater relative surface 
area. The rate of absorption largely depends on gastric emptying, which can be 
affected by the presence of food, posture, disease state and the effect of other drugs. 
Gastric emptying influences paracetamol absorption directly by controlling the rate 
at which the drug is delivered to the small intestine (Heading, Nimmo, Prescott & 
Tothill, 1973). The rate of absorption has been shown to be more rapid in fasting 
subjects but the concomitant administration of food produces little effect on the 
extent of absorption, as reflected by the comparable area under the plasma 
concentration versus time curve (AUG) (McGilveray & Mattok，1972). The effect 
on gastric emptying of food may also be attributed to dilution and possibly 
adsorption of drug onto food constituents (Prescott, 1974). Posture may inherently 
affect the gastric emptying rate. Paracetamol absorption seems to be slower during 
sleep (McGilveray & Mattok, 1972) and has been found to be delayed in subjects 
lying on the left side, due to slower gastric emptying in this position, compared to 
standing or lying on the right side (Nimmo, Heading, Tothill & Prescott, 1973; 
Renwick, Ahsan, Challenor, Daniels, Macklin, Waller & George，1992). Although 
Cmax values are lower, the total amounts absorbed do not differ. 
Pharmacological agents have also been demonstrated to affect the rate of paracetamol 
absorption. Agents which modify gastric emptying including propantheline, 
metoclopramide and opioids have been shown to have significant effects on its rate 
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of absorption (Nimmo et al., 1973; Nimmo, Heading, Wilson, Tothill & Prescott， 
1975). The effect of other disease states, including pyloric stenosis, achlorhydria, 
coeliac disease and thyroid dysfunction, on paracetamol absorption rate was reviewed 
by Forrest et al (Forrest, Clements & Prescott, 1982). Gastric emptying has not 
been shown to be significantly different between young and old volunteers and age 
did not seem to alter this rate-limiting step in paracetamol absorption (Gainsborough, 
Maskrey，Nelson, Keating, Sherwood, Jackson & Swift, 1993). 
In fasting healthy subjects, the absorption of paracetamol in solution is very rapid 
with peak plasma concentrations reached within 15-30 minutes (Prescott, 1980). 
Absorption from tablets is usually slower and the formulation may also influence the 
rate of absorption (Richter & Smith，1974; Ameer, Divoll, Abernethy, Greenblatt 
& Shargel，1983; Dougall, Cunningham & Nimmo, 1983). Inter-individual variation 
in paracetamol absorption, possibly governed by the rate of gastric emptying, can be 
a consideration (McGilveray & Mattok，1972; Prescott, 1974; Nash, Stein, Penno, 
Passananti & Vesell，1984). 
Following absorption, the systemic availability is incomplete, a variable proportion 
being lost through first-pass metabolism. It seems to be dose-dependent, decreasing 
from nearly 90% after a dose of 1-2 g，to 63% following 0.5 g (Rawlins et al” 
1977)，although Clements et al found that oral systemic availability was 80% and 
independent of dose (Clements, Critchley & Prescott, 1984). A gastric emptying 
study by Clements et al showed that mono-exponential emptying was often preceded 
by a short period during which a proportion of the dose passed rapidly through the 
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pylorus as a bolus or 'squirt' (Clements, Heading, Nimmo & Prescott，1978). A 
pharmacokinetic model was described which takes into account the influence of 
various rates and patterns of gastric emptying on paracetamol absorption. It describes 
the biphasic gastric emptying pattern most commonly seen in study subjects, in 
which a fraction of the total administered dose leaves the stomach rapidly within the 
first 10-15 minutes, followed by a monoexponential decrease of the remaining 
fraction. The commonly observed occurrence of two peaks early in the plasma 
concentration-time curve was said to be due to an interruption in gastric emptying. 
The first rapid decline in plasma concentration starts at the time when emptying from 
the stomach temporarily ceases. 
2.1.3.2 Distribution 
After absorption, paracetamol is rapidly and relatively uniformly distributed 
throughout most body tissues, achieving a tissue to plasma concentration ratio of 
near unity (Forrest et al., 1982; Clissold, 1986). In a group of healthy subject, the 
plasma concentration-time curves following intravenous administration are 
multiexponential and the initial short half-life (3-19 minutes) indicates a rapid 
distribution phase (Prescott, 1980). In the same group of subjects, paracetamol was 
administered orally and after the initial distribution phase, plasma concentrations 
declined in parallel with those after intravenous administration. The apparent volume 
of distribution increases from 0.5 1/kg bodyweight immediately after intravenous 
injection to about 0.9 1/kg after distribution is complete. Generally, this value is 
similar in healthy subjects, the elderly and various patient groups including patients 
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with epilepsy, Gilbert's syndrome and in anephric patients. 
There is no appreciable binding to erythrocytes in man or pigs over the range of 
plasma concentration of 50-300 jxg mH. Plasma protein binding only occurs at 
paracetamol concentrations greater than 60 /xg mH. At much higher concentrations, 
similar to those observed after toxic dose ingestion in man, the drug is bound 15 -
21% to plasma proteins. The glucuronide and sulphate conjugates of paracetamol do 
not bind to plasma proteins either (Gazzard, Ford-Hutchinson, Smith & Williams, 
1973; Lowenthal, 0ie, Van Stone, Briggs & Levy，1976; Morris & Levy，1984). 
2.1.3.3 Metabolism 
Paracetamol is extensively metabolised by the liver and only 2-5 % of a therapeutic 
dose is excreted as the unchanged drug in the urine. As has already been pointed 
out, this fraction is directly related to the plasma paracetamol AUC. Although 
metabolism in the gastrointestinal tract has also been observed in rats (Josting, 
Winne & Bock, 1976) and in man (Rogers, Back & Orme，1987a), this seems to be 
an insignificant site of metabolism as the percentage urinary recoveries of both 
paracetamol and its metabolites following oral and intravenous administration are 
similar (Clements et al., 1984). 
Although paracetamol is almost completely absorbed from the upper gastrointestinal 
tract, its bioavailability is only about 70-80% (Rawlins et al., 1977; Perucca & 
Richens, 1979; Clements et al, 1984)，being limited by first pass metabolism by the 
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liver. The bioavailability seems to be dose dependent, decreasing from about 89% 
after a 1 g dose to 63% after a 0.5 g dose (Rawlins et al, 1977)，but this was not 
confirmed by a more recent study (Clements et al., 1984). 
The major route of paracetamol metabolism is by conjugation at the hydroxyl group. 
After a therapeutic dose, the glucuronide and sulphate metabolites account for over 
80% of the metabolism. A minor fraction is converted by cytochrome P450-
dependent hepatic mixed function oxidases to a highly reactive alkylating metabolite, 
probably N-acetyl-p-benzoquinoneimine (NAPQI) (Miners & Kissinger, 1979; 
Dahlin, Miwa, Lu Sc Nelson，1984). This metabolite is usually rapidly inactivated 
by conjugation with reduced hepatic glutathione (GSH)�and is eventually eliminated 
as the cysteine and mercapturate metabolites in the urine. 
Unlike glucuronide conjugation, sulphate conjugation of paracetamol is dose 
dependent and becomes saturated within the therapeutic dose range. The limited 
capacity of this metabolic route is evident following both oral and intravenous 
administration (Levy & Yamada，1971; Clements et al” 1984). The decreased 
formation of the sulphate conjugate at higher doses of paracetamol is accompanied 
by a corresponding increase in the extent of glucuronide conjugation. In comparison 
the percentage recoveries of unchanged paracetamol, its cysteine and mercapturate 
conjugates are relatively constant within a subject, though there is large inter-subject 
variation. These metabolic pathways seem relatively unaffected by the dose 
administered and the route of administration when the dose is within the therapeutic 
range. 
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When the dose of paracetamol greatly exceeds the therapeutic range, the ability to 
inactivate the reactive metabolite by conjugation with GSH becomes limited. 
Normally, with therapeutic doses, the reactive metabolite is deactivated by 
conjugation with GSH (Jollow et al.’ 1973; Mitchell et al, 1973a; Mitchell, Jollow, 
Potter, Gillette & Brodie，1973b; Potter et al” 1973). The conjugate is then 
converted to the cysteine conjugate of paracetamol by loss of glutamyl and glycine 
moieties, catalysed by glutamyl transferase and dipeptidase respectively. The cysteine 
conjugate is then acetylated by N-acetyl transferase to form the mercapturate 
conjugate of paracetamol (Speirs, 1989). After overdosage, the hepatic GSH stores 
become depleted and the electrophilic reactive intermediate NAPQI, attacks other 
nucleophiles. The resulting hepatic necrosis is caused by the covalent binding of this 
reactive species to vital hepatic macromolecules. The major metabolic pathways of 
paracetamol are summarised in Fig. 2.2. 
Other minor metabolites including 3-hydroxy and 3-methoxyparacetamol (Andrews, 
Bond, Burnett, Saunders & Watson，1976) and 3-thiomethylparacetamol (Klutch, 
Levin, Chang, Vane & Conney, 1978) have also been detected in man after 
therapeutic doses. The 3-methoxyparacetamol metabolite was only found following 
overdosage (Knox & Jurand，1977; Knox & Jurand，1978). 
After a therapeutic dose of 20 mg/kg，the excretion of unchanged paracetamol and 
its metabolites is almost complete within 24 hours. The percentage recoveries of the 
various metabolites calculated as the percentage of the administered dose of the 
various metabolites were as follows: unchanged paracetamol 4%, glucuronide 55%, 
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sulphate 30%, cysteine and mercapturate, both 4% (Prescott, 1980). This excretion 
pattern is altered in overdose patients with only about 10-20% of the total ingested 
amount being excreted as the sulphate. There is a corresponding increase in the 
percentage recovery of glucuronide conjugate and unchanged drug in the urine which 
reflects the limited capacity of the sulphate conjugating metabolic pathway. As the 
amount of drug remaining in the body decreases, the fractional recovery of 
paracetamol sulphate progressively increases. 
The excretion patterns of the cysteine and mercapturate conjugates remained 
unchanged in a group of paracetamol overdose patients who did not develop liver 
damage, irrespective of the antidotal treatments given. These treatments were 
cysteamine, methionine, N-acetylcysteine and supportive care only. In another group 
of poisoned patients who developed severe liver damage, there was a significantly 
increased excretion of cysteine and mercapturate conjugates. The percentage 
recovery of these two metabolites was twice that from patients without liver damage. 
This reflects an increased proportion of the dose being converted to the toxic 
intermediate. At the peak of the excretion of these oxidative metabolites, which is 
usually about 30 hours after overdose, they account for up to 20-50% of the total 
amount of metabolites and unchanged paracetamol excreted (Prescott, 1980). 
The mean terminal elimination half-life of paracetamol has been reported to be 
within 1.5-2.5 hours after therapeutic doses given intravenously (Clements & 
Prescott, 1976; Rawlins et al., 1977; Perucca & Richens，1979; Prescott, 1980). 
Clements and Prescott commented that, depending on the method of weighting of 
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individual data points, there could be wide variations in the value obtained by non-
linear regression analysis (Clements & Prescott，1976). Beyond the absorption phase 
in oral administration, the plasma concentration of paracetamol decreases in parallel 
with that beyond the distribution phase after intravenous administration (Prescott, 
1980). Rawlins et al reported no difference in the plasma half-life after different 
oral doses nor between oral and intravenous dosing (Rawlins et al.，1977). The 
reported total body clearance values are about 5 ml kg i min'^ The physicochemical 
properties and pharmacokinetic parameters of paracetamol are shown in Appendix 
2.1. 
The determination of the pharmacokinetic properties of paracetamol using saliva 
samples has been evaluated by Lowenthal et al. and Maddem et al. (Lowenthal et 
al., 1976; Maddem, Miners, Collins & Jamieson，1985). It was shown that there is 
a linear correlation between paracetamol concentrations in saliva and plasma except 
for the first 1-3 hours when the concentrations in saliva are relatively higher due to 
retention of some of the orally ingested drug in the oral cavity. The use of salivary 
paracetamol levels has been widely applied in other pharmcokinetic studies 
(Mucklow, Fraser, Bulpitt, Kahn, Mould & Dollery，1980; Miners, Attwood & 
Birkett, 1983; Miners, Robson & Birkett 1986). 
The metabolism of paracetamol is age dependent. In neonates and young children, 
glucuronide conjugation is deficient. The ‘adult�pattern of metabolism of 
paracetamol was found to be present by 12 years of age, but in children up to the 
age of 9 years and newborn infants, paracetamol is eliminated principally as the 
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sulphate conjugate. The overall rates of elimination by neonates, children and adults 
are not different (Miller, Roberts & Fischer, 1976). In this study the dose of 
paracetamol was administered to the infant subjects directly via a nasogastric tube 
to ensure an accurate dose was given. In another study, infants received paracetamol 
via breast milk where the nursing mothers were given oral doses of paracetamol 
(Notarianni, Oldham & Bennett，1987). The dose of paracetamol received by 
individual infant was thus not known and the lag time between paracetamol 
administration to the mother and breast feeding also differed between individual 
infants. With various assumptions on the amount of milk ingested and the time of 
breast feeding after paracetamol administration to the mother, it was estimated that 
on average an infant received only 1.1% of the weigt-adjusted maternal single dose. 
Under such restricted circumstances and assumptions, it was found that the 
percentage recovery of the sulphate conjugate in the infant's urine was lower than 
in adult volunteers. There was also increased excretion of the parent drug but there 
was no significant increase in the excretion of the cysteine and mercapturate 
metabolites. The authors made the conclusion that there is a deficiency of sulphate 
conjugation in infants, and that either the formation of the reactive metabolite or its 
detoxication may be incompletely developed. The interpretation of this study is 
hampered by the lack of knowledge of the dose, which was very small, received by 
each infants and the stringent assumptions. 
The plasma paracetamol half-life has been noted to be prolonged in geriatric subjects 
when compared to young, healthy volunteers (Triggs, Nation, Long & Ashley，1975; 
Briant, Dorrington, Cleal & Williams，1976). Triggs et al reported no significant 
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difference in the plasma clearance or the apparent volume of distribution of 
paracetamol between geriatric and young subjects, whereas Briant et al. found the 
plasma clearance to be lower in geriatric subjects. In a more recent study where fit 
young subjects were compared with fit elderly subjects and frail elderly subjects, it 
was found that the elimination half-life was not significantly different between the 
fit young and fit elderly group but was prolonged in the frail elderly subjects 
(Wynne, Cope, Herd, Rawlins, James & Woodhouse，1990). Individual liver volume 
was estimated by ultrasound and paracetamol clearance expressed per unit volume 
of liver again showed no difference between the fit young and fit elderly subjects but 
that of frail elderly subjects was significantly reduced. This study indicates that age-
associated changes in paracetamol clearance are attributable to both changes in liver 
volume and in general health. The total paracetamol clearance per unit volume of 
liver was found to be similar in the fit young and elderly subjects but was 
significantly diminished in the frail elderly patients. Since the partial metabolic 
clearance to the glucuronide metabolite per unit volume of liver was significantly 
reduced, impairment of glucuronidation was suggested as another explanation of the 
diminished plasma clearance. An in vitro study using liver fractions from subjects 
of a wide age range (40 - 89) did not show a fall in glucuronidation and sulphation 
of paracetamol with increasing age and there was no significant correlation with age 
for the activity of these enzyme pathways (Herd, Wynne, Wright, James & 
Woodhouse, 1991). The authors concluded that age per se does not have a major 
effect on the activities of hepatic drug metabolising enzymes and that any age-related 
decrease in paracetamol clearance, observed in in vivo studies, is more likely to 
reflect reduced liver volume and liver blood flow. 
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Paracetamol clearance has been shown to be greater in males than females. In one 
investigation on 8 healthy males and 8 healthy females, paracetamol clearance was 
22% greater in males (Miners et al., 1983). In another study of 43 males and 71 
females, the clearance in the males was 14% greater (Mucklow et al.’ 1980). The 
elimination half-life was not found to be different between the sexes in either study. 
The difference was found to be entirely due to increased activity of the 
glucuronidation pathway in males. Sex differences in sulphation or oxidative 
metabolism have not been found (Miners et al., 1983). Pregnant women seem to 
have enhanced glucuronidation and oxidation activities (Miners et al., 1986). The 
apparent oral clearance was found to be 50% higher and the elimination half-life was 
28% lower in a group of pregnant women, compared to a group of non-pregnant 
women of similar age. The metabolic clearances of the glucuronide and oxidative 
metabolites were 75% and 88% higher respectively in the pregnant group. This may 
be related to the effect of hormonal control on glucuronidation as similar findings 
were also noted in females who were oral contraceptive steroid users (Mucklow et 
al., 1980; Miners et al., 1983). In these women, paracetamol clearance was 49% 
greater than the control females, with an increase of 78% and 36% in the metabolic 
clearances of the glucuronide and oxidative metabolites respectively. Although in 
both the pregnant women study and the oral contraceptive steroid users study, neither 
metabolic clearance of the sulphate metabolite nor unchanged paracetamol was 
different from the control females, there is evidence from a study by Critchley et al. 
that there is evidence of increased glucuronide conjugation at the expense of sulphate 
conjugation, possibly due to competition for sulphation in women taking oral 
contraceptives (Critchley, Nimmo, Woolhouse & Prescott，1983a). The authors from 
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the pregnant women study and the oral contraceptive steroid users study concluded 
that these two groups of females may be under increased risks of developing 
paracetamol-induced hepatotoxicity and the dosage requirements for effective 
analgesia may need to be re-evaluated, but whether these findings are of real clinical 
significance is questionable. At the same time, paracetamol was found to cause an 
increase in plasma concentrations of ethinyloestradiol, as a result of a reduction in 
the sulphation of the steroid (Rogers, Back, Stevenson, Grimmer & Orme，1987b). 
Women on oral contraceptive steroids who also regularly take paracetamol, as 
suggested by the authors, may have higher than required plasma concentrations of 
the steroid, but again, the clinical significance of this is not known. 
Since paracetamol is metabolised to a large extent by hepatic microsomal enzymes, 
drugs and other environmental factors, which alter the activity of these enzymes will 
affect paracetamol metabolism. Patients with enzyme induction due to treatment with 
anticonvulsants and rifampicin have lower plasma paracetamol concentrations, 
shorter paracetamol half-lives and higher plasma glucuronide concentrations 
compared to healthy controls (Prescott, Critchley, Balali-Mood & Pentland，1981). 
These changes are mirrored in the pattern of urinary metabolite excretion. There are 
correspondingly lower percentages of unchanged paracetamol and its sulphate 
conjugate and a higher percentage of the glucuronide conjugate in 24 hour urine 
collections, but there is no difference in the urinary excretion of the cysteine and 
mercapturate conjugates. Shorter half-life values have been found in patients on long 
term antiepileptic treatment (Perucca & Richens, 1979; Prescott et al., 1981; 
Miners, Attwood & Birkett，1984). In one study, subjects were pre-treated with 
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phenobarbitone for 5 days and a difference in the half-life value was not observed 
(Mitchell, Thorgeirsson, Potter, Jollow & Keiser，1974). As oxidative metabolism 
has not been shown to be enhanced in patients on antiepileptic treatment, they do not 
seem to be at higher risk of developing hepatotoxicity from therapeutic doses of 
paracetamol, though laboratory animals pre-treated with enzyme-inducing agents such 
as phenobarbitone, 3-methylcholanthrene and ethanol are more susceptible to 
paracetamol hepatotoxicity (Mitchell et aL, 1973a; Jollow, Thorgeirsson, Potter, 
Hashimoto & Mitchell，1974; Strubelt, Obermeier & Siegers，1978; Teschke, Stutz 
& Strohmeyer，1979). 
The activation of paracetamol by specific cytochrome P450 has not been studied until 
quite recently except that the oxidative metabolic pathway can be induced or 
suppressed by pre-treatment with certain drugs. Raucy et al. studied the metabolic 
activation of paracetamol to the reactive intermediate by human liver microsomes. 
It was found that oxidation by cytochrome P450 CYP2E1 accounts for 52% (range 
30-78%) of the metabolic activation of paracetamol and the other major cytochrome 
P450 enzymes that possesses extensive paracetamol-oxidising capacity is CYP1A2 
(Raucy, Lasker, Lieber & Black，1989). 
Pre-treatment with cimetidine, a liver enzyme inhibitor, does not affect the clearance 
or the individual metabolic pathways of paracetamol (Critchley, Dyson, Scott, Jarvie 
& Prescott，1983; Critchley, Scott, Jarvie, Dyson & Prescott，1983b; Miners et al., 
1984)，whereas sulphinpyrazone and propranolol pre-treatment increased and 
decreased paracetamol clearance, respectively (Miners etaJ., 1984; Baraka, Truman, 
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Ford & Roberts，1990). Cigarette smoking was found to increase paracetamol 
clearance in a group of London factory and office workers (Mucklow et al., 1980) 
but this was not confirmed by Miners et a l (Miners et al., 1984). Cigarette smoke 
contains polycyclic hydrocarbons which are powerful enzyme inducers and 
paracetamol clearance may be increased due to enhanced glucuronidation activity 
(Mucklow et al” 1980). 
The concomitant use of alcohol can affect the metabolism of paracetamol. In animal 
studies, chronic administration of ethanol has been shown to increase paracetamol 
hepatotoxicity due to enhanced microsomal production of the reactive metabolite, 
whereas acute administration seems to provide some protection against hepatic 
injury, resulting from its competition for mixed function oxidase (Sato, Matsuda & 
Lieber，1981; Maddrey, 1987). Acute administration of ethanol in human subjects 
also result in reduced urinary recovery of the oxidative metabolites following an oral 
dose of paracetamol (Critchley et al.’ 1983; Critchley et al., 1983b). There have 
been reports of severe liver damage in alcoholic patients who have taken paracetamol 
in therapeutic doses or doses which are not usually associated with severe 
hepatotoxicity (Goldfmger, Ahmed, Pitchumoni & Weseley，1978; Seeff, Cuccherini， 
Hyman, Zimmerman, Adler & Benjamin，1986; Floren, Thesleff & Nilsson，1987). 
The increased paracetamol hepatotoxicity in people with chronic ethanol consumption 
may result from both an induced cytochrome P450 mixed function oxidase system 
and as a depletion of the hepatic GSH store. The latter is also reflected by the 
common increase of serum gamma glutamyl transferase, an enzyme also responsible 
for the degradation of GSH, in the alcoholics (Lauterburg & Velez，1988). 
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Paracetamol metabolism is not altered in patients with chronic renal disease. The 
volume of distribution and elimination half-life values are not significantly different 
in these patients when compared to healthy volunteers. But the more polar 
metabolites, the glucuronide and the sulphate, accumulated in the plasma and the 
apparent volumes of distribution of these metabolites were lower. This also indicates 
that the kidneys do not contribute significantly to the metabolism of paracetamol 
(Lowenthal et aL, 1976; Prescott, Speirs, Critchley，Temple & Winney，1989; 
Martin, Temple, Winney & Prescott, 1991). 
In patients with chronic liver disease but normal plasma albumin concentrations and 
prothrombin time ratio, the plasma paracetamol half-life and clearance is similar to 
that seen in healthy subjects. But in those patients with cirrhosis who have low 
plasma albumin and an increased prothrombin time ratio, the elimination of 
paracetamol is grossly abnormal. The plasma half-life was found to be 4.25 士 1.15 
hours compared with 2.43 士 0.19 hours in the healthy controls (Forrest, 
Adriaenssens, Finlayson & Prescott，1979). A good correlation was demonstrated 
between the plasma half-life or clearance and the serum albumin concentration 
(Forrest, Finlayson, Adjepon-Yamoah & Prescott, 1977; Forrest et al., 1979; 
Forrest et al” 1982). The 24-hour urinary excretion of paracetamol and its 
glucuronide, sulphate, cysteine and mercapturate conjugates were not reported to be 
significantly different among healthy subjects, patients with mild liver disease and 
patients with severe liver disease (Forrest et aL, 1979). There seemed to be no 
evidence that patients with impaired liver function are at increased risk of 
hepatotoxicity when given a single therapeutic dose of paracetamol (Forrest et al” 
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1979). 
Patients with non-insulin dependent diabetes mellitus show no significant difference 
in paracetamol clearance, half-life or partial clearance to the glucuronide conjugate, 
when compared to healthy control subjects, though drug conjugation has been shown 
to be impaired in rats with experimentally induced diabetes (Kamali, Thomas & 
Femer, 1993). The partial clearance to the sulphate conjugate in diabetic patients is 
significantly reduced and the renal clearance is increased. The exact mechanism of 
these changes is uncertain. 
Shively et al. found a temporal variation in the terminal elimination half-life of 
paracetamol, it being significantly longer in normal volunteers when the dose was 
given at 6:00am rather than at 2:00pm (Shively & Vesell，1975). This was explained 
by a drop of 13% in the apparent volume of distribution value. This finding was not 
confirmed by a later study (Malan, Moncrieff & Bosch, 1985). 
Greater inter-individual variation in paracetamol metabolism has been observed 
compared to intra-individual variation (Caldwell, Davies & Smith，1980; Clements 
et al., 1984). The range of inter-individual variation in the urinary recovery of the 
glucuronide and sulphate conjugates is only 3-fold but that of the oxidative 
metabolites is 60-fold (Critchley, Nimmo, Gregson, Woolhouse & Prescott, 1986). 
The contribution to inter-individual variation by the cysteine and mercapturate 
pathway is thus much greater than that of glucuronide and sulphate conjugation. In 
a study of paracetamol metabolism in twins, intra-twin variations in the rate of 
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formation of the glucuronide and sulphate conjugates was found to be as large within 
monozygotic twins as within dizygotic twins. Also, the intra-twin correlation 
coefficients of these parameters in those living together were found to be almost 
twice those of twins living apart. These findings suggest that environmental factors 
are more predominant than genetic factors in the variations of paracetamol 
metabolism (Nash et al., 1984). 
Ethnic differences in the metabolism of paracetamol are well recognised. Mucklow 
et al. found that the plasma half-life was significantly longer and the plasma 
clearance was significantly slower in Asians working in London when compared with 
Caucasian subjects (Mucklow et al., 1980). In another study, the fractional recovery 
of the cysteine and mercapturate conjugates of paracetamol in the urine was 
significantly lower in Ghanaians and Kenyans compared to Caucasians from Scotland 
-5.2% and 4.4% compared to 9.3% (Critchley et al., 1986). This seems to indicate 
markedly reduced metabolic activation of paracetamol in Africans. Similarly, a lower 
fractional recovery of the oxidative metabolites has been found in Chinese and 
Indians living in Singapore (6% and 5.9% respectively) (Lee, Ti, Koh & Prescott， 
1992), but the value in Chinese was not confirmed in another study done in Australia 
(Osborne, Tonkin & Miners，1991). In this Australian study, the fractional recovery 
of the GSH derived conjugates in Chinese and Caucasian subjects was found to be 
9.2% and 10.0% respectively and they were not significantly different. These ethnic 
differences in paracetamol metabolism may be related to genetic or environmental 
factors, including differences in diet and protein intake (Nash et al., 1984; Critchley 
et a l . , 1986). 
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Increased oxidative metabolism of a therapeutic dose of paracetamol has been found 
in certain groups of cancer patients. Mercapturate conjugate excretion was higher in 
patients with bladder carcinoma compared to healthy volunteers and it was suggested 
that increased formation of reactive metabolites might predispose an individual to 
bladder cancer (Dolara, Lodovici, Salvador!，Saltutti, Delle Rose, Selli & Kriebel, 
1988). Similarly, Leung and Critchley found a higher proportion of oxidative 
metabolites in urine from patients with hepatocellular carcinoma. A few of their 
patients with chronic hepatitis B infection also excreted much higher than normal 
proportions of oxidative metabolites which again indicated increased microsomal 
cytochrome P450 activity (Leung & Critchley，1991). 
2.1.3.4 Excretion 
Both paracetamol and its metabolites are excreted rapidly in man. As paracetamol 
is a moderately lipid-soluble weak acid (pKa 9.5) and plasma protein binding is 
minimal in therapeutic concentrations (Gazzard et al., 1973; Lowenthal et al., 1976; 
Morris & Levy，1984)，it undergoes considerable glomerular filtration with 
subsequent passive tubular reabsorption. Its renal clearance is independent of urine 
pH, but there is a significant correlation with flow rate (Prescott & Wright, 1973; 
Miners, Osborne, Tonkin & Birkett，1992). In healthy subjects given a dose of 20 
mg/kg, the mean renal clearance of paracetamol was 13 ml/minute. The highly polar 
glucuronide and sulphate conjugates are both filtered at the glomerulus and actively 
secreted by the tubules. Their renal clearances are 130 ml/minute and 166 
ml/minute, respectively (Prescott, 1980). Accumulation of these metabolites occur 
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in chronic renal disease (Lowenthal et al” 1976; Prescott et al., 1989). 
Biliary excretion and enterohepatic circulation of paracetamol has been shown both 
in rats and in man (Siegers, Rozman & Klaassen，1983; Siegers, Loeser, Gieselmann 
& Oltmanns，1984). In rats, within 8 hours after an intravenous administration of 
100 mg/kg, 28.4% of the dose was excreted into bile (Siegers et al., 1983). In man, 
after an oral dose of Ig, the percentage was 2.6% (Siegers et al., 1984). The 
glucuronide, sulphate, cysteine, mercapturate metabolites of paracetamol, as well as 
the glutathione conjugate, were all found excreted in bile in the rat but the 
mercapturate and glutathione conjugates were not detected in bile in man. It was 
suggested that the glutathione conjugate is rapidly metabolised to the cysteine 
derivative before or during passage through the intestinal wall in the rat. The 
presence of high quantities of 7-glutamyl transpeptidase, the enzyme responsible for 
the degradation of reduced glutathione in human bile may be an explanation for its 
absence in human bile. However, these human subjects were patients with cholestasis 
and bile duct surgery and therefore might not have reflected the correct data in 
normal healthy subjects. In another study, bile was shown to be an important route 
of elimination for the cysteine conjugate in man and it accounts for 19.4% of the 
total excretion of the metabolite (Jayasinghe, Roberts & Read，1986). One interesting 
observation from these studies is that, in man, the ratio of the uriniary recoveries of 
the cysteine and mercapturate conjugates of paracetamol is almost always unity but 
the mercapturate conjugate has never been detected in human bile. A survey of 
existing literature did not reveal where the N-acetylation of paracetamol cysteine 
takes place. Since the plasma levels of the mercapturate conjugate seems to be 
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always lower than those of the cysteine conjugate following oral doses of 
paracetamol (see results, section 2.3.6.1), it may be speculated that at least some of 
the conversion of the cysteine conjugate to the mercapturate conjugate take place in 
the renal tubules prior to excretion . 
2.1.4 Toxicity and Overdosage 
Paracetamol is a drug with a long history, however, proper preclinical toxicity 
studies were not carried out before its marketing. It was not until it gained popularity 
that its hepatotoxicity with very high doses was recognised. Hepatic necrosis was 
first reported in cats and rats given large doses (Eder, 1964; Boyd & Bereczky， 
1966) and these reports were soon followed by those of severe and fatal liver damage 
in man following paracetamol overdosage (Davidson & Eastham，1966; Thomson & 
Prescott, 1966). 
The clinical symptoms of paracetamol overdosage can be divided into three stages. 
There are non-specific symptoms including nausea, vomiting and malaise within the 
first 24 hours. During the second stage, between 24-48 hours after the overdose, 
these symptoms usually become less severe. Right upper quadrant and abdominal 
pain may develop, together with hepatic tenderness and mild jaundice. Maximum 
derangement of liver function tests does not occur until at least the third day. Renal 
damage, though not as common, may also occur as indicated by decreased urine 
output and back pain during the first 48 hours. Recovery at this stage is usually rapid 
and complete. Phase 3 only occurs as a result of fulminant hepatic failure after 3 to 
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5 days. There are dramatic increases in the liver enzymes in plasma, aspartate and 
alanine aminotransferases (AST and ALT) to over 10,000 iu/L，reflecting the release 
of these enzymes from acutely damaged hepatocytes. Deepening jaundice, 
hypoglycaemia, coagulation defects and coma may occur in severely poisoned 
patients. I f death does not occur, normal liver function returns over a few weeks 
(Prescott, 1983; Prescott & Critchley，1983; Clissold, 1986). 
Other complications resulting from paracetamol poisoning include renal failure, 
pancreatitis, cardiotoxicity (Armour & Slater, 1993) and haematological 
abnormalities secondary to liver damage. Before specific antidotes were available, 
treatment was mainly supportive only. Severe liver damage following paracetamol 
overdose occurs in approximately 8% of patients and about 1% die from hepatic 
failure (Prescott, 1983). 
Since clinical symptoms and biochemical changes are not seen in patients with 
paracetamol poisoning until 2-3 days after ingestion, it is difficult to assess the 
severity of poisoning apart from predictions based on plasma paracetamol 
concentrations. Prolongation of paracetamol elimination half-life is normally seen 
following liver damage (Prescott, Wright, Roscoe & Brown，1971) but this cannot 
be used practically for assessment of possible liver damage at an early stage. In 
practical clinical settings, assessment of paracetamol overdose is determined by the 
plasma concentration, usually a single measurement, in relation to the time after 
ingestion. A ‘treatment line，is plotted by joining a 200 /ig/ml paracetamol plasma 
concentration at 4 hours after ingestion with 30 fig/ml at 15 hours on a 
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semilogarithmic graph of the paracetamol plasma concentrations against time after 
ingestion (Fig. 2.3). This is used to predict the possiblity of severe liver damage 
(Prescott et a l , 1971; James, Lesna, Roberts, Pulman, Douglas, Smith & Watson, 
1975; Prescott, 1983). Patients with plasma concentrations above the treatment line 
on this graph are likely to develop some degree of liver damage. Concentrations 
above the parallel line joining 300 jLtg/ml at 4 hours and 45 jLtg/ml at 15 hours 
indicate a 90% chance of developing severe liver damage. The assessment of plasma 
paracetamol concentrations before 4 hours following ingestion is unreliable as 
absorption from the gastrointestinal tract may not be complete. 
Other early markers of liver damage caused by paracetamol poisoning have been 
sought. Plasma glutathione S-transferase (GST) has been found to be raised ( > 100 
times normal values) early after paracetamol overdose as a result of cellular damage 
(Beckett, Chapman, Dyson & Hayes，1985). A change in the GST level can be seen 
4 hours after taking paracetamol in overdose and in patients who are successfully 
treated with the antidote N-acetylcysteine, peak GST levels are much lower than 
those found in patients with severe liver damage. Two distinct peaks in the plasma 
GST level are seen, the first one occurring around 12-40 hours after overdose and 
the other one around 40-50 hours, suggesting two distinct phases of hepatotoxicity. 
Prescott et a l also suggested the possibility of early liver damage i f the plasma half-
life of paracetamol is prolonged from the outset (Prescott et al., 1971). It has been 
postulated that the early release of GST may be due to mild diffuse hepatocelluar 
damage or that a certain population of the liver cells are more vulnerable (Beckett 
et a l . , 1985). 
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The mechanism of paracetamol hepatotoxicity was elucidated by Mitchell and 
colleagues at the National Institutes of Health, Bethesda, U.S.A.. A difference in the 
degree of severity of hepatic damage was found in laboratory animals including rats 
and mice pre-treated with agents which altered the rate of metabolism of 
paracetamol. Phenobarbitone, a liver enzyme inducing agent, enhanced the clearance 
of paracetamol but at the same time, also markedly potentiated the degree of hepatic 
necrosis. In contrast, piperonyl butoxide pre-treatment inhibited paracetamol 
metabolism and was able to confer protection against hepatic necrosis. It was 
concluded that a toxic metabolite rather than paracetamol itself was the cause of 
hepatocellular damage (Mitchell et a l , 1973a). Further studies using pH]-
paracetamol showed that large amounts of radiolabelled material were covalently 
bound to mouse liver protein in vivo when these animals were given an overdose. 
Both covalent binding and hepatic necrosis were shown to be dose dependent and the 
development of hepatic necrosis was always preceded by the occurrence of the peak 
level of radiolabel binding. The degree of binding in individual mice was also shown 
to be directly proportional to the severity of hepatic necrosis. These findings support 
the theory that paracetamol-induced hepatic necrosis is mediated through the covalent 
binding of a chemically reactive metabolite to vital hepatic macromolecules (Jollow 
et al, 1973). In vitro studies confirmed that a metabolite generated by cytochrome 
P450-dependent mixed function oxidase covalently binds to microsomal proteins. The 
extent of in vitro binding is affected by treatments that alter hepatic necrosis and in 
v/w binding. Pretreatment of animals with cobaltous chloride, an inhibitor of 
cytochrome P-450 synthesis, lowered the extent of covalent binding which showed 
that it did not occur directly but was dependent on the conversion of paracetamol to 
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an active metabolite formed in hepatic microsomes by a cytochrome-P450 mixed 
function oxidase (Potter et al” 1973). It was also postulated that the reactive 
intermediate was formed through N-hydroxylation, since this same reaction took 
place to a much greater extent, with another substance of a similar structure to 
paracetamol (2-acetylaminofluorene), in species susceptible to paracetamol-induced 
hepatic injury (Davis, Potter, Jollow & Mitchell, 1974). More recently, the binding 
of the reactive intermediate of paracetamol to hepatocyte intracellular structure was 
demonstrated by immunohistochemical detection in rats using rabbit antiserum 
specific against the paracetamol-protein adduct (Roberts, Bucci, Benson, Warbritton, 
McRae, Pumford & Hinson，1991). 
The role played by GSH in conferring protection against paracetamol induced hepatic 
necrosis was demonstrated by Mitchell et al.. Diethyl maleate, an agent that depletes 
hepatic GSH, was shown to potentiate hepatotoxicity when given to mice before 
paracetamol treatment, whereas treatment with cysteine, a GSH precursor, was able 
to protect the animals from hepatic injury secondary to hepatotoxic doses of 
paracetamol. The administration of paracetamol caused dose dependent depletion of 
hepatic GSH up to a maximum of about 75% depletion. Significant covalent binding 
of radio-labelled paracetamol to liver proteins was evident only when the dose of 
paracetamol caused a 70% or more depletion of hepatic GSH. Furthermore, 
pretreatments that alter hepatic GSH concentrations were shown to affect the extent 
of the covalent binding of the paracetamol metabolite to liver macromolecules. 
Diethyl maleate and cysteine increased and decreased the extent of binding to liver, 
respectively. No significant binding of paracetamol to skeletal or cardiac tissues was 
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observed (Mitchell et al.，1973b). Inter-species differences in the susceptibility to 
paracetamol hepatotoxicity correlated with the rate of paracetamol activation by 
hepatic microsomal enzymes to the potent reactive intermediate and also to the rate 
of hepatic GSH depletion (Davis et a l , 1974; Jollow et al” 1974; Potter, 
Thorgeirsson, Jollow & Michdl, 1974). These studies further support the theory that 
the reactive intermediate of paracetamol formed in vivo is preferentially detoxified 
by conjugation with GSH and that covalent binding to vital hepatic macromolecules 
only occurs when GSH availability is exceeded. The most susceptible animal, the 
hamster, produced the highest fraction of the mercapturate metabolite and the amount 
of this metabolite excreted in the urine was proportional to the dose administered 
until a hepatotoxic dose was reached. The fraction excreted as the mercapturate 
metabolite then decreased markedly, commensurated with the known depletion of 
hepatic GSH. 
The protective role of GSH against injury by the reactive intermediate of paracetamol 
has also been studied in man. The urinary recovery of the mercapturate metabolite, 
derived from the GSH-conjugated intermediate, is proportional to the dose of 
paracetamol given, ranging from 900-1800 mg. Thus the availability of GSH was not 
rate-limiting for conjugation after these doses (Mitchell et al., 1974). Extrapolating 
from animal studies that liver necrosis only occurs when more than 70% of hepatic 
GSH was depleted (Mitchell et al., 1973b; Potter et al., 1974)，it was estimated that 
a dose of over 15 g would be hepatotoxic in normal human subjects. This was found 
to agree with clinical observations. Pre-treatment with phenobarbitone, an enzyme-
inducing agents, was shown to increase the production of the mercapturate metabolite 
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in human subjects (Mitchell et a l , 1974). It was estimated that patients with induced 
drug-metabolising enzymes may be susceptible to as low as 10 grams of paracetamol. 
On the other hand, Prescott et al. did not find any difference in the production of the 
mercapturate conjugate after oral doses of paracetamol between healthy subjects and 
patients on long term antiepileptic drugs, including phenobarbitone and 
carbamazepine, and rifampicin, which are all known enzyme-inducing agents 
(Prescott et a l . , 1981). But the glucuronide conjugation was much enhanced in these 
epileptic patients and it was thought that the recovery of the mercapturate and 
cysteine conjugates have been reduced, as has the recovery of unchanged drug and 
the sulphate conjugate. The author concluded that some induction of the oxidative 
metabolism was likely but might not have been clinically significant. 
The highly reactive alkylating metabolite is most probably N-acetyl-p-
benzoquinoneimine (NAPQI) (Miners & Kissinger, 1979; Dahlin et al” 1984). The 
synthetic form of this reactive metabolite has been found to react, in vitro, with 
GSH, acetaminophen and reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) (Potter & Hinson，1986). NAPQI has been found to be severely cytotoxic, 
but not mutagenic, to Salmonella typhimurium and it has caused extensive DNA 
single-strand breaks in genotoxicity studies. This data seems to show that 
paracetamol can cause DNA interaction leading to damage at levels which are 
cytotoxic (Dybing, Holme, Gordon, Soderlund, Dahlin & Nelson, 1984). 
Accompanying depletion of hepatic GSH, high molecular weight protein aggregates 
were found when the liver homogenates and microsomes of rats given hepatotoxic 
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doses of paracetamol were separated by gel electrophoresis (Minamide, Hone & 
Awazu, 1992). This altered distribution pattern of proteins in the in vivo 
paracetamol-induced hepatotoxicity was the same as seen in in vitro lipid 
peroxidation in rat liver microsomes. Thus, lipid peroxidation was suggested as a 
contributing factor to paracetamol-induced hepatotoxicity. 
The elucidation of the underlying pathogenesis of the hepatic injury caused by 
paracetamol overdosage provided indications to its management. Since the hepatic 
GSH stores must be depleted before hepatic injury by the reactive intermediate can 
take place, it follows that i f the GSH store can be replenished in time, hepatic injury 
may be minimised. 
Parenterally administered GSH, a natural and non-toxic substance, was not able to 
produce a direct increase of intracellular levels of GSH in liver cells as it does not 
penetrate hepatocytes (Hahn, Wendel & Floh6，1978). However, Vina et al. did find 
an increase in hepatic GSH levels in mice treated with high doses of paracetamol 
after oral adminstration of GSH (Vina, Perez, Furukawa, Palacin & Vina, 1989). It 
was explained that oral GSH is converted to its constituent amino acids by intestinal 
enzymes and the increase in hepatic GSH requires active GSH synthesis in the liver 
from its constituents. It was found that the rate limiting factor of GSH synthesis is 
the availability of L-cysteine and so attempts to increase the hepatic levels of GSH 
have focused on the administration of sulphydryl compounds, including cysteamine, 
L-methionine, L-cysteine and N-acetylcysteine, which are all precusors of GSH. 
Another study on patients taking paracetamol daily in therapeutic doses showed that 
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paracetamol caused a significant decrease in the concentration of reduced glutathione 
in plasma. This loss was more conspicuous in patients who had shown signs of 
microsomal enzyme induction, probably due to enhanced metabolic activation. It was 
suggested that these findings reflect the hepatic intracellular glutathione status 
(Trenti, Bertolotti, Castellana, Ferrari, Pini & Stemieri, 1992). In this study, 
intravenous injection of GSH resulted in a considerable increase in free plasma GSH 
but was cleared from the circulation with a half-life of about 12 minutes, in 
agreement with results published by Lauterburg (Lauterburg & Velez，1988). It 
seemed that exogenous GSH could not raise the hepatic level directly but could only 
serve as a precursor in replenishing intracellular GSH stores. 
Of the possible precursors of glutathione that could be used in the treatment of acute 
paracetamol poisoning, cysteamine was the first sulphydryl compound used. 
Protection against paracetamol-induced hepatic injury was first shown in animal 
studies and later in man (Mitchell et al” 1974; Prescott, Newton, Swainson, Wright, 
Forrest & Matthew，1974; James et al•’ 1975; Prescott, Park & Proudfoot，1976). 
Although shown to be effective i f given within 10-12 hours of poisoning, cysteamine 
was never made available as a pharmaceutical preparation. Due to its unpleasant 
gastrointestinal and central nervous system side effects, safer and more convenient 
alternatives were looked for. 
I 
Methionine can only be given orally and it was used with some enthusiasm in the 
past (Crome, Vale, Volan, Widdop & Goulding，1976; Vale, Meredith & Goulding， 
1981). However, it appears to be less effective than intravenous cysteamine and N-
Chapter 2 69 
acetylcysteine, probably due to unreliable absorption, as nausea and vomiting are 
commonly associated with paracetamol overdosage. Methionine must also be given 
within 10-12 hours of paracetamol poisoning as late administration or delayed 
absorption may aggravate or precipitate hepatic encephalopathy (Canalese, Gimson, 
Davis & William, 1981). It has been suggested that addition of methionine to 
paracetamol tablets might protect against hepatotoxicity and nephrotoxicity and a 
formulation combining paracetamol and methionine is available in the U.K. 
(‘Pameton，）(Janes & Routledge, 1992). 
N-acetylcysteine has been used with much success in the treatment of paracetamol 
poisoning in man and is now considered to be a very effective antidote preventing 
liver damage, renal failure and death (Prescott, Ballantyne, Park, Adriaenssens & 
Proudfoot, 1977; Prescott, Illingworth, Critchley, Stewart, Adam & Proudfoot, 
1979; BNF, 1993). Although previous guidelines recommended that N-acetylcysteine 
be given within 10 hours of a paracetamol overdose where virtually complete 
protection can be achieved, more studies are now showing that some benefits are 
seen with late administration of the antidote, up to and beyond 24 hours after an 
overdose episode (Smilkstein, Knapp, Kulig & Rumack, 1988; Keays, Gove, Forbes, 
Alexander & Williams, 1989; Harrison, Keays, Bray, Alexander & Williams, 1990). 
The intravenous route is preferred to the oral route to avoid unreliable absorption, 
though the latter is more prevalent in the United States (Prescott, 1983; Janes & 
Routledge, 1992). It is usually administered as a total intravenous dose of 300 mg/kg 
over 20 hours (BNF, 1993). 
Chapter 2 70 
The protection offered by sulphydryl-containing compounds against paracetamol 
hepatotoxicity is presumed to be via the provision of GSH precusors but some direct 
combination with the reactive metabolite is possible. The exact mechanisms of 
protection are uncertain. They have all been found to reduce or prevent the covalent 
binding of the reactive intermediate of paracetamol, NAPQI, to vital cell structures. 
In addition, N-acetylcysteine stimulates the GSH conjugation of paracetamol in 
isolated rat hepatocytes and it is also capable of reacting with NAPQI itself (Huggett 
& Blair, 1983), whereas methionine does not react with NAPQI to any great extent. 
In overdose patients treated with N-acetylcysteine, the urinary excretion of the 
cysteine and mercapturate metabolites is increased (Prescott, 1980). 
Since some beneficial effects were seen even with late administration of N-
acetylcysteine when liver damage was evident, it was suggested that this antidote 
might have additional effects. Another postulated mechanism of paracetamol 
hepatotoxicity is that NAPQI oxidises thiol groups in key enzymes within the 
hepatocyte, in particular Ca^"^-translocases, leading to elevation of cytosolic calcium 
ions and eventual cell death. N-acetylcysteine may have an additional protective 
action through the reduction of these previously NAPQI-reduced thiol groups, 
permitting re-establishment of calcium homeostasis and thus preventing cell death 
(Janes & Routledge, 1992). 
I 
Further postulated mechanisms for the action of N-acetylcysteine in the protection 
against paracetamol hepatotoxicity were recently reviewed by Janes and Routledge 
(Janes & Routledge, 1992). These include the action of N-acetylcysteine as an 
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antioxidant to prevent inflammatory responses initiated by oxidative damage; 
preventing microvascular plugging which extend ischaemia around the zone of injury 
in the liver; and improving the microcirculation in hepatic failure by restoring 
normal vascular responsiveness to endothelial derived relaxant factor (EDRF). It was 
suggested that, whatever the mechanism, the increase in oxygen delivery to injured 
tissues may be important in any late response to N-acetylcysteine in paracetamol 
induced hepatotoxicity. 
I 
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2.2 Estimation of paracetamol and its metabolites in plasma and urine by 
high performance liquid chromatography 
2.2.1 Introduction 
Paracetamol is an over-the-counter-sales antipyretic analgesic. Despite being 
extremely safe when used in normal therapeutic doses, it can lead to hepatotoxicity 
and possibly fatal hepatic necrosis following acute overdosage. The antidote N-
acetylcysteine must be given early to prevent fulminant hepatic failure. Since the 
clinical symptoms of hepatic failure are not evident until 2-3 days after the ingestion 
of a paracetamol overdose, estimation of the plasma concentrations remains the only 
index of the likelihood of liver damage. A prediction nomogram was published by 
Prescott (Prescott et al.，1971; Prescott, 1983) (see also Fig. 2.3) and a plethora of 
assays have been developed for the estimation of paracetamol concentrations for the 
purpose of aiding in diagnosis and management of overdose patients. 
The methods available for the estimation of plasma paracetamol can be divided into 
4 main groups: 
(1) Colorimetry involving chemical derivatisation; 
(2) Measurement of the absorbance of the unmodified compound by UV 
spectrophotometry; 
(3) Chromatography including gas liquid chromatography and high performance 
liquid chromatography; 
(4) Immunoassays 
The earliest methods were based either on colorimetric techniques or the direct 
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measurement of the ultraviolet absorbance of unmodified paracetamol following 
extraction from plasma. Colorimetric techniques involve several chemical 
derivatisations including hydrolysis of paracetamol to p-aminophenol, reaction with 
dyes and nitration. Both colorimetry and spectrophotometry, although they can be 
carried out relatively rapidly and easily, suffered from the disadvantage of non-
specificity and interference from other compounds in the sample, in particular non-
steroidal anti-inflammatory drugs (Spooner, Reavey & Mcintosh, 1976). Acid 
hydrolysis converts not only unchanged paracetamol, but also its inactive metabolites 
to p-aminophenol, leading to falsely high results (Stewart & Watson, 1987). A 
positive error of 40-100% was noted, when this technique was compared with a high 
performance liquid chromatographic reference method which measured only 
unchanged paracetamol (Stewart, Adriaenssens, Jarvie & Prescott, 1979). Despite 
the drawbacks with acid hydrolysis, further 'improved' versions of the colorimetric 
method were published due to its relative simplicity and the rapidity of performance 
(Glynn & Kendal, 1975; Chambers & Jones, 1976; Wiener, 1977; Wiener & 
Longlands, 1977; Archer & Richardson，1980; Bailey, 1982). These improved 
methods offered improved sensitivity and specificity whereby paracetamol 
concentrations could be estimated in presence of its metabolites. 
Further improvement in the specificity of the colorimetric method was achieved by 
an enzymic approach. A bacterial enzyme, acyl amidase (aryl acylamide 
amidohydrolase), specifically converts free paracetamol to p-aminophenol (Hammond 
& Scawen, 1981). This enzymic hydrolysis of paracetamol was coupled with the 
colorimetric chemical reaction, whereby the p-aminophenol formed was reacted with 
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cresol to produce an indophenol dye. This method was evaluated and its sensitivity, 
linearity, precision and accuracy were found to be closely comparable to established 
HPLC methods (Brown, Campbell, Price, Rambohul, Widdop, Barbour, Roberts, 
Burnett, Atkinson, Scawen & Hammond, 1983; Price, Hammond & Scawen, 1983). 
This assay method was developed into a kit which has subsequently gained wide 
acceptance (Hallworth, 1983; Alkhayat, 1986). 
Non-specificity remained a problem in using colorimetric and spectrophotometric 
methods for the estimation of paracetamol in biological fluids. For the purpose of 
research, the criteria for a method to be used for the estimation of paracetamol are 
different from those used for clinical purposes. Apart from being specific, accurate 
and relatively rapid, the method must also be able to measure therapeutic 
concentrations. For a study in the area of the metabolism of paracetamol, the method 
to be used must also be able to separate and measure the main metabolites. 
Chromatographic methods were sought to fulfil these requirements. Thin layer 
chromatography (Andrews et al., 1976), ion-exchange chromatography (Mrochek, 
Katz, Christie & Dinsmore, 1974) and gas-liquid chromatography (Grove, 1971; 
Prescott, 1971; Stewart & Willis, 1975; Street, 1975; Dechtiaruk, Johnson & 
Solomon, 1976; Garland, Hsiao, Pantuck & Conney, 1977) have been used, but 
they suffer from various disadvantages including lengthy procedures, the need to use 
volatile solvents and to perform derivatisation. 
The development of high performance liquid chromatography (HPLC) has brought 
about significant progress in the analysis of paracetamol and its metabolites in 
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biological fluids due to its speed, accuracy, precision, selectivity and high sensitivity. 
The experimental procedures could be much simplified with minimal sample 
preparation and complete separation of the metabolites was possible. Knox and 
Jurand achieved separation of paracetamol and its major metabolites (but not 
quantification) by reversed-phase HPLC, which utilises a polar mobile phase with 
a non-polar support (Knox & Jurand, 1977). Since the conjugated metabolites of 
paracetamol are more polar than the unchanged drug, they are eluted first as their 
affinity for the eluent is greater. Chromatograms could be run with aqueous eluents 
and direct application of biological fluids without preliminary extraction was 
possible. They further modified this HPLC system to incorporate ion-pair systems 
to control the retention of the various metabolites (Knox & Jurand, 1978). A large 
number of HPLC methods for the estimation of paracetamol in biological fluids 
were published. Most of these only measured the unchanged drug but both 
therapeutic and overdose concentrations could be measured (Blair & Rumack, 1977; 
Gotelli, Kabra & Marton, 1977; Horvitz & Jatlow, 1977; Fletterick, Grove & 
Hohnadel, 1979; Korduba & Petruzzi，1984). Estimation of paracetamol and its 4 
major metabolites - glucuronide, sulphate, cysteine and mercapturate, in urine and 
plasma was successfully performed by both Howie et al. and Adriaenssens and 
Prescott, respectively (Howie, Adriaenssens & Prescott, 1977; Adriaenssens & 
Prescott, 1978). As more metabolites of paracetamol were discovered in very small 
quantities after overdosage, there were more attempts to completely separate these 
metabolites by HPLC, using gradient solvent systems (Aguilar, Hart & Calder, 
1988). 
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Immunoassays for the estimation of paracetamol have been available since 1983. 
Comparison of enzyme multiplied immunoassay technique (EMIT) with HPLC 
showed comparable precision and accuracy (Hepler, Weber, Sutheimer & Sunshine, 
1984). A fluorescence polarisation immunoassay (FPIA) was widely used in the 
U.S.A. despite its high cost as it was found to be extremely simple, requiring 
minimal skilled operator assistance (Keegan, Smith, Ungemach & Simpson，1984). 
EMIT and FPIA are used by about 75% of all laboratories which participate in the 
quality control programme provided by the American Association for Clinical 
Chemistry (Stewart & Watson, 1987). 
2.2.2 Analytical method 
Although many analytical methods exist for the assay of paracetamol in biological 
fluids, they may not suit the requirements of a particular study. As the present study 
involves estimation of paracetamol and its main metabolites in both plasma and urine 
and that sample preparation is hoped to be minimised, a specific method needs to be 
developed. An HPLC method is favoured because of the specificity and sensitivity 
offered and semi-automation is possible. Following development of a specific assay, 
validations are required to ascertain its accuracy, sensitivity and recovery. 
2.2.2.1 Materials 
I 
Paracetamol, paracetamol glucuronide, paracetamol sulphate, paracetamol cysteine 
and paracetamol mercapturate for reference standards were kindly donated by 
Sterling-Winthrop Research and Development Division, Alnwick, England. 
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Potassium dihydrogen orthophosphate, propan-2-ol and 60% perchloric acid were 
obtained from E.Merck, acetic acid from BDH Chemical Ltd. The internal standard 
2-acetamidophenol (AAP) was obtained from Sigma. Water was purified for HPLC 
by the Mi l l i Q Water Purification System (Millipore, U.S.A.). 
2.2.2.2 Instrumentation 
The HPLC system consisted of a Waters 501 pump which delivered the mobile 
phase, degassed by sonification, via a filter to the system. The mobile phase then 
passed to a Waters Intelligent Sample Processor 712 (WISP), an automatic sample 
injection module. 
Prior to passing through the analytical column, the solvent was passed through a 
Waters Guard-PAK precolumn containing the same packing material as the column. 
The column used was an 8 mm x 10 cm Waters Radial-PAK Cartridge. Packing 
material was Nova-Pak Qg, particle size 5 /xm. The cartridge was housed in a 
Waters Radial compression Module (RCM 8 x 10). 
From the column, the eluate then passed through an ultraviolet (U.V.) absorbance 
detector (Waters 440 absorbance detector). The U.V. detector output was connected 
to a Waters 745B Data Module to produce the chromatograms and peak areas. A 
I 
schematic presentation of the HPLC system is shown in Fig. 2.4. 
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2.2.2.3 Collection and storage of samples 
Prior to analysis, all samples were stored at -2(rc. Blood samples were collected 
into 10 ml heparinised tubes, centrifuged for 10 minutes at 1400 x发 and the plasma 
separated for storage. 
Urine volumes were recorded and a 20 ml aliquot stored. Paracetamol and 
paracetamol conjugates are stable under these conditions for a period of years 
(Adriaenssens, 1980). 
2.2.2.4 Chromatographic conditions 
For the estimation of paracetamol, paracetamol glucuronide, paracetamol sulphate, 
paracetamol cysteine and paracetamol mercapturate in urine and plasma, the 
following chromatographic conditions were used: 
Mobile phase: 0.1 M potassium dihydrogen orthophosphate containing 
0.1% acetic acid and 0.75% propan-2-ol 
Flow rate: 1.5 ml min.i 
Pressure: 1000 psi 
Detector wavelength: 254 nm 
2.2.3 Urine assay 
I 
2.2.3.1 Preparation of standards and test samples for urine assay 
For estimating paracetamol and its metabolites in urine, standard solutions of 
paracetamol in blank urine with the internal standard AAP were prepared. 
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Paracetamol standards: 25, 250, 1250 and 2500 /xg ml'^  
AAP (aq. solution): 250 fig ml"^  
The paracetamol standards and samples were prepared in the following way for 
analysis. To 500 of standard or sample, 1000 fd of water and 1000 •ul of AAP 
solution were added. Effectively, the standards or samples were diluted 5-fold. The 
injection volume was 3 Calibration standards were run with each batch of 
samples for calculation. 
2.2.3.2 Calculation of results for urine assay 
The concentrations of paracetamol and its metabolites in the samples were calculated 
in paracetamol equivalents from the peak area ratio of paracetamol and paracetamol 
conjugates to the internal standard AAP. The peak area alone instead of the peak 
area ratio was also used (see discussion). Standard curves were calculated by the 
least-squares regression analysis of the peak area ratio (or peak area) versus drug 
concentration. The reciprocal of the slope of the regression line is the factor by 
which the peak area ratios (or peak areas) are multiplied to give the paracetamol 
concentrations in ptg m l 、 
As only enough authentic paracetamol was available to be run as standards for each 
I 
batch of samples, values obtained were only accurate for paracetamol. The 
absorbance of the glucuronide and sulphate conjugates of paracetamol are not the 
same as paracetamol and correction factors of 0.909 for the glucuronide conjugate 
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and 0.945 for the sulphate conjugates at 254 nm must be applied. No correction 
factor was used for the cysteine and the mercapturate conjugates (Adriaenssens, 
1980). 
The peak area counts were used directly to calculate the percentage of each 
metabolite excreted in the 24 hour urine. 
2.2.3.3 Results of urine assay 
Chromatogram for a urine sample spiked with paracetamol and its metabolites is 
shown in Fig. 2.5. The retention times of paracetamol glucuronide, paracetamol 
sulphate, paracetamol cysteine, unchanged paracetamol, internal standard AAP and 
paracetamol mercapturates were 3.7, 9.1, 9.9, 11.8, 23.0 and 28.7 minutes 
respectively. The limit of detection for the assay was dependent on the presence of 
interferring peaks from endogenous material present in the urine. Generally, down 
to 1-2 ng of paracetamol can be detected distinctly as a single peak, but this small 
amount is unlikely to be encountered in urine collections. 
2.2.3.4 Validation of urine assay 
A stock solution of paracetamol in blank urine was serially diluted to give 
concentrations ranging from 5 - 500 ^g ml、Samples were assayed as described and I 
analysed 4 times over a period of a few days. 
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Fig. 2 .5 HPLC Chromatogram of Paracetamol and Its Glucuronide. 
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The results are shown in Table 2.1. The coefficient of variation was 0.2% - 1.7% 
using the peak area for calculation and 0.3 - 1.5% using the peak area ratio. The 
plot of mean peak area and mean peak area ratio against concentration was linear and 
passed through the origin. There was excellent agreement between the results 
obtained by the two methods of calculation (Fig. 2.6). 
The precision and linearity of the urine assay for the metabolites were also 
established. Serial dilutions of stock solutions of the glucuronide, sulphate, cysteine 
and mercapturate metabolites were made and each sample was analysed 5 times. The 
results are shown in Tables 2.2 to 2.5. The highest coefficients of variation obtained 
were 1.2%, 2.1%, 2.4% and 16.3% for the glucuronide, sulphate, cysteine and 
mercapturate conjugates, respectively. The peak areas all showed excellent linearity 
over the range of concentration studied (Fig. 2.7). 
2.2.4 Plasma assay 
2.2.4.1 Preparation of standards and test samples for plasma assay 
For estimating therapeutic concentrations of paracetamol and its metabolites, spiked 
plasma standards containing 5，15 and 25 fig ml ] of paracetamol were prepared. 
These were run in between every 4 samples. An internal standard was not used in 
the plasma assay (see under validation). The calibration standards and samples were 
I 
prepared in the following way for analysis. To 500 jwl of plasma in a 1.5 ml 
eppendorf tube, 50 /xl of 30% w/v aqueous perchloric acid was added with 
continuous mixing (Auto Vortex Mixer MT19, Chiltem Scientific) to precipitate the 
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Table 2.1a Precision of HPLC Urine Paracetamol Assay ^5-500 ml h Using-
Peak Area 
Paracetamol Paracetamol Peak Area Ratio Coefficient of 
Cone. Mean 土 SD Variation 
(/igml-丨） Run 1 Run 2 Run 3 Run 4 W 
5 6 4 0 8 2 6 4 7 9 5 6 3 1 6 7 65227 64318 土 901 1 .4 
25 2 96259 2 8 8 6 8 5 2 9 0 2 1 7 287074 290559 土 4011 1 .4 
50 627488 6 1 1 1 9 6 6 2 4 3 7 9 619946 620752 ± 7 0 8 3 1.1 
100 1168293 1161967 1175135 1155627 1165256土8374 0 . 7 
250 2817072 2 7 9 6 8 0 1 2 8 0 1 8 8 8 2900918 2829170士48601 1 .7 
350 3905591 3 9 0 2 2 9 2 3 9 1 7 4 6 0 3908555 3908475 土 6 5 1 4 0 . 2 
500 5579973 5 5 3 3 8 8 8 5 5 4 8 6 0 5 5558074 5555135土 19319 0 . 3 
Table 2.1b Precision of HPLC Urine Paracetamol Assay (5-500 fig ml"^) Using 
Peak Area Ratio 
Peak Area Ratio 
Paracetamol (Paracetamol /Internal Standard) Mean 土 SD Coefficient of 
Cone. Variation 
(Mg ml'') Run 1 Run 2 Run 3 Run 4 (%) 
5 0 . 189 0 . 1 9 7 0 . 1 8 8 0 . 194 0 .191 土 0 . 003 1 .5 
25 0 . 8 7 2 0 . 8 6 5 0 . 8 5 6 0 . 848 0 .860 土 0 . 011 1 .2 
50 1 .860 1 .831 1 .838 1 .834 1.841 士 0 . 013 0 . 7 
100 3 . 468 3 . 4 8 5 3 . 4 6 2 3 .458 3 .468 土 0 . 0 1 2 0 . 3 
250 8 .348 8 . 1 5 6 8 .393 8 .410 8 .327 土 0 . 117 ‘ 1 . 4 
350 11 .550 11 .453 11 .549 11 .400 11.488 士 0 . 0 74 0 . 6 
500 16 .354 16 .277 16 .610 16.097 16.335 土 0 . 213 1.3 
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Table 2 .2 Precision of HPLC Urine P . r .P . tamol Mpf.hni^t . Ac�巧 Glucuronirip, 
Paracetamol “ “ 
Glu^l^^ide Paracetamol Glucuronide Area Counts Mean Coefficient 
(,,a mi'-K "“ r — 土 SD Variation 
、 绍 , I Run 1 Run 2 Run 3 Run 4 Run 5 (%) 
5.70 107006 103769 104106 105005 105048 104897 L 2 ~ 
土 m 9 
11.39 207403 205034 204577 205689 206605 205862 ~ ^ ~ 
土 1150 
22.79 416881 414821 413995 414028 411584 414262 0.5 
土 1902 
45.57 826647 818805 821548 820336 819825 821432 0.4 
土 3078 
91.15 1664764 1638337 1637783 1639303 1647478 1645733 0.7 
土11500 
182.29 3283791 3282156 3326439 3309692 3310430 3302502 0.6 
土19050 
364.58 6445926 6443917 6446038 6448985 6456356 6448244 0.1 
土 4881 
729.17 12815758 12778500 12823056 12844220 12815254 12815358 0.2 
土23722 
1458.33 25525297 25633235 25645628 25610978 25664876 25616003 0.2 
土54350 
I I I I I I 
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Table 2.3 Precision of HPLC Urine Paracetamol Metabolite A以巧-Sulphate 
Paracetamol ^ • C I , . Coefficient ijuipnate Paracetamol Sulphate Area Counts Mean of 
, 士 SD Variation Qxg ml ) Run 1 Run 2 Run 3 Run 4 Run 5 (%) 
7.32 73189 72429 72569 72218 71927 72466 0.7 
士 4 7 1 
14.65 147790 147183 144811 146541 145739 146413 0.8 
土 1175 
29.30 298562 300676 295991 294772 292834 296567 1.0 
土 3096 
58.59 587567 580032 582675 588666 580884 583965 0.7 
土 3927 
117.19 1242396 1196237 1205563 1185318 1178841 1201671 2.1 
±24959 
234.38 2458523 2503400 2468020 2495488 2475759 2480238 0.8 
土18774 
468.75 4906596 4933380 4953472 4931486 4934060 4931799 0.3 
土16678 
937.50 9864999 10020934 9914212 9931312 9930866 9932465 0.6 
土56381 
1875.00 19834040 19826703 19767731 19847811 20004320 19856121 0.4 
土88314 




Table 2 .4 Precision of HPLC Urine Paracetamol Mpf .hni i f . Acc.y _ 
Cysteine 
Paracetamol ^ ™ . . . ^ Coefficient cysteine Paracetamol Cysteine Area Counts Mean of 
( 士 SD Variation 
丨 腕 J I Run 1 I Run 2 Run 3 Run 4 Run 5 (%) 
3 . 0 5 33428 31637 32805 33404 33505 32956 2 . 4 
土 7 89 
6 . 1 0 67825 6 6 8 0 5 68513 67909 67403 67691 0 . 9 
士 6 3 4 
12 .21 138332 135424 135537 134959 135138 135878 1 .0 
土 1391 
24 . 41 268057 275919 277748 275497 274659 274376 1 .4 
士 3 709 
4 8 . 8 3 546273 5 4 6 6 9 4 551185 550641 554254 549809 0 . 6 
土 3337 
9 7 . 6 6 1119533 1115887 1117896 1114787 1118304 1117281 0 . 2 
土 1914 
195 .31 2308590 2 2 9 9 5 7 4 2306469 2327945 2317761 2312068 0 . 5 
土11000 
3 9 0 . 6 2 4625395 4 6 2 7 3 5 5 4674038 4636319 4657658 4644153 0 . 5 
土21041 
7 8 1 . 2 5 9269628 9282387 9256645 9395146 9237146 9288190 0 . 7 
土62085 
1562 . 50 18665814 18635154 18555954 18577464 18640388 18614955 0 . 3 
土46174 




Table 2.5 Precision of HPLC Urine Paracetamol Metabolite Assay -
Mercapturate 
Paracetamol Coefficient 
Mercapturate Paracetamol Mercapturate Area Counts Mean of Variation 
Cone. 土 SD (%) 
(/xg ml ') Run 1 Run 2 Run 3 Run 4 Run 5 
5.86 19683 13031 19414 15659 17119 16981 16.3 
土 2765 
11.72 42112 40854 36883 36379 41520 39550 6.8 
土 2707 
23.44 89460 82531 79051 77000 76383 80885 6.6 
土 5361 
46.88 148118 165088 155663 161066 155324 157052 4.1 
土 6 431 
93.75 346258 334247 329887 324404 330005 332960 2.5 
土 8214 
187.50 691835 662512 677728 668098 672214 674477 1.7 
土11190 




Fig. 2 .7 Linearity o f H P L C Urine Assay of Paracetamol Metabolites 
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plasma proteins. The tubes were centrifuged for 10 minutes at 1400 xg and up to 30 
/ i l of the clear supernatant was injected directly into the HPLC system. 
2.2.4.2 Calculation of results for plasma assay 
Concentrations of paracetamol and its metabolites in plasma were calculated in 
paracetamol equivalents from the peak area values. Standard curves were calculated 
by the least-squares regression analysis of peak area versus drug concentration. The 
reciprocal of the slope of the regression line is the factor by which the peak area are 
multiplied to give the paracetamol concentrations in fig ml ^ 
As only enough authentic paracetamol was available to be run as standards for each 
batch of samples, values obtained were only accurate for paracetamol. The 
absorbance of glucuronide and sulphate conjugates of paracetamol are not the same 
as paracetamol and correction factors of 0.835 for the glucuronide conjugate and 
1.027 for the sulphate conjugates at 254 nm must be applied. No correction factor 
was used for the cysteine and the mercapturate conjugates (Adriaenssens & Prescott, 
1978). 
2.2.4.3 Results of plasma assay 
Chromatogram for a plasma sample spiked with paracetamol and its metabolites is 
I 
shown in Fig. 2.8. The retention times of paracetamol glucuronide, paracetamol 
sulphate, paracetamol cysteine, unchanged paracetamol and paracetamol mercapturate 
were essentially the same as in the urine assay as the chromatographic conditions 
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Fig. 2.8 H P L C Chromatogram of Paracetamol and Its Glucuronide. 
Sulphate, Cysteine and Mercapturate Metabolites in Plasma 
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were almost identical. They were 3.7, 9.1，9.9，11.8 and 28.7, respectively. 
Paracetamol cysteine and paracetamol mercapturate could be detected by this HPLC 
system but they exist only in very low concentrations following therapeutic doses. 
The paracetamol cysteine pc^k could be seen in some of the plasma samples 
following a therapeutic dose in our study subjects but the paracetamol mercapturate 
peak was not seen in any of the plasma samples. The absence of the mercapturate 
conjugate in the plasma samples of our study subjects is most likely due to the 
extremely low concentrations. Most previous studies could only detect the 
glucuronide and sulphate conjugates of paracetamol in the plasma following 
therapeutic doses. In the present study, the plasma assay developed could detect the 
cysteine conjugate in some of the plasma samples. The non-detection of the 
mercapturate metabolite in all plasma samples under study indicate that it can only 
exist in minute quantity. 
The detection limit of paracetamol was about 1 - 2 ng and there was no interference 
from commonly used medications. 
2.2.4.4 Validation of plasma assay 
1. Precision 在 linearity. The linearity and the precision for the plasma assay was 
determined by repeated analysis of plasma paracetamol standards, with I 
concentrations ranging from 5 - 25 m ” . Samples were assayed as described and 
analysed 6 times over a period of 2 days. The results are shown in Table 2.6a. The 
coefficients of variation ranged from 0.1 • 3.3% using the peak area counts for 
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Table 2.6a Precision of HPLC Plasma Parace tamol Assay IJsinp ve^^v 
Area Counts 
Cone. _ „ . ( Coefficient 
(Mg ml ) Paracetamol Peak Area Counts Mean of Variation 
土 SD (%) 
Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 
5 558775 504427 549119 550004 550602 542721 542608 3.3 
士17702 
10 1205727 1208426 1208321 1214228 1211151 1208136 1209332 0.2 
士2694 
15 1793812 1813156 1810012 1806486 1800857 1800821 1804191 0.4 
土 6451 
20 2401440 2406252 2406346 2407065 2406207 2409202 2406085 0.1 
±2322 
25 3059761 3061039 3057895 3065258 3051001 3041512 3056078 0.3 
士 7786 
Table 2.6b Precision of HPLC Plasma Paracetamol Assay Using Peak 
Area Ratio 
Paracetamol Paracetamol Peak Area Ratio Coefficient 
Cone. (Paracetamol/Internal Standard) Mean of 
(Mg ml-') 土 SD Variation 
Run 1 Run 2 Run 3 Run 4 Run 5 W 
5 0.536 0.492 0.486 0.503 0.467 0.497 5.1 
土 0 . 0 2 5 
10 0.951 0.971 1.008 0.992 0.929 0.970 3.3 
土 0 . 0 3 2 
15 1.416 1.403 1.466 1.464 1.354 1.421 3.3 
士 0 . 0 4 6 
2 0 1 . 9 0 9 1 . 8 8 7 1 . 943 1 . 8 6 0 1 . 8 29 1 . 8 8 5 2 . 3 
. 土 0.044 
25 2.359 2.294 2.268 2.572 2.311 2.361 5 .2 
土0.123 
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calculation, while the calibration plots were linear and passed through the origin 
(Fig. 2.9). 
In comparison with another set of precision tests using the peak area ratios 
(paracetamol peak area to internal standard peak area) for calculations, the variation 
in the peak areas of the internal standard has a larger percentage of error. The 
coefficient of variation in this case varied from 2.3 - 5.1%. The coefficient of 
variation of the peak area counts of the internal standard was 3.8% (Table 2.6b). 
Although the standard of accuracy and precision of modem laboratory pipette are 
extremely good, the introduction of another variable, the dispensing of the internal 
standard in this case, is still liable to produce a slight increase in the coefficient of 
variation in the calculated result. 
2. Recovery, Using the method of standard addition, the percentage of recovery was 
found to be consistently high, being very close to 100% (Table 2.7). 
Another set of recovery tests was done using commercially available plasma 
paracetamol standards for an ELISA method for the estimation of paracetamol 
concentrations, routinely employed by the Chemical Pathology Department of the 
Prince of Wales Hospital, Hong Kong. The concentrations of these standards 
estimated by the HPLC method were very close to their nominal value, as used in 
the ELISA assays, giving recoveries ranging from 94.9 - 96.3% over a range of 10 -
200 fig ml-i (Table 2.8). 
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Fig. 2 .9 Linearity of HPLC Plasma Assay of Paracetamol 
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™ e 2.7 Recovery of HPLC Plasma Paracetp^mnl Assay Tk ing 
Method of Standard Addition 
Paracetamol Calculated Expected Recovery 
Area Paracetamol Paracetamol (%) 
Counts Concentration Concentration 
Oug mri) (fig ml-i) 
Baseline (B) 1357881 13.58 
500 fi l of 15 fig ml ' 1347283 13.47 98.8 
+ 1343479 13.44 98.5 
50 /xl blank plasma 1332395 13.33 97.7 
B + 1593451 15.91 15.91 100.0 
1.25 fig/ 50 Ail 1580693 15.79 99.2 
1570506 15.68 98.6 
1561082 15.59 98.0 
B + 1823175 18.18 18.18 100.0 
2.5 /xg/ 50 1809284 18.05 99.3 
1795566 17.91 98.5 
1783409 17.79 97.9 
B + 2262295 22.53 22.73 99.1 
5.0 fig! 50 fi l 2244680 22.36 98.4 
2235913 22.27 98.0 
2230630 22.22 97.8 
Sample preparation-. To 500 ixl of a paracetamol plasma sample (15 fig ml'^), 50 /xl 
of plasma containing different amounts of paracetamol 
standard was added. 50 jjlI of blank plasma was added to the 
baseline sample. Sample volume was effectively increased to 




Table 2.8 Recovery of HPLC Plasma Paracetamol Assay Using 
Commercially Available Paracetamol Standards 
Peak Area Calculated Nominal 
Sample of Paracetamol Paracetamol Recovery 
Paracetamol Concentration Concentration (%) 
(Mg ml“） (ixg ml-i) 
” A 0 0 0 -
A O 0 0 
A O 0 0 
B 964167 9.49 10.00 94.9 
B 969433 9.54 10.00 95.4 
B 962742 9.48 10.00 94.8 
1948185 19.18 20.00 95.9 
C 1946623 19.16 20.00 95.8 
C 1936329 19.06 20.00 95.3 
D “ 4908800 48.32 50.00 96.6 
D 4859982 47.84 50.00 95.1 
D 4864914 47.89 50.00 95.8 
E 9 7 7 4 9 7 2 96.22 100.00 96.2 
E 9825479 96.72 100.00 96.7 
E 9783287 96.30 100.00 93.3 
F ~ 19638342 193.31 200.00 96.7 
F 19402915 191.00 200.00 95.5 
F 19388033 190.85 200.00 95.4 
I 
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It was deemed satisfactory to use the area counts for all calculations instead of the 
area ratio. The coefficient of variation of the area ratio (2.3 % - 5.2 %, median 3.3%) 
was found to be higher than the coefficient of variation of the area counts (0.1% _ 
3.3%, median 0.3%). As precision, linearity and recovery were all above the 
required standard, it was decided not to use the internal standard. Thus standard 
curves calculated by the least-squares regression analysis of the peak area count 
versus drug concentration were used. 
The linearity of the plasma assay for the metabolites was also established up to about 
25 ixg ml-i, greater concentrations are unlikely to be reached after a therapeutic dose 
of paracetamol. The coefficients of correlations are shown in Table 2.9. The 
linearity of all the metabolites and of paracetamol was found to be excellent (Fig. 
2.10). 
The peak area counts obtained from paracetamol spiked in plasma and in water were 
found to be different when they were subjected to identical sample treatment. Peak 
area counts from paracetamol standards spiked in plasma were consistently lower 
than those spiked in water (Table 2.9). However, all reference standards to be run 
with plasma samples were prepared in the same matrix. 
2.2.5 Summary 
Many analytical methods are available for the estimation of paracetamol 
concentrations in biological fluids. HPLC assays are sensitive and accurate and they 
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Table 2 .9 Linearity of HPLC Paracetamol Metabolite Away 
Using Peak Area Counts and Peak A r e � R a t i o , in AgnpmiQ 
and in Plasma 
a. glucuronide b. sulphate 
p — � u s Plasma Aqueous P h ^ 
Cone. — Cone. 
(Mg ml-') Peak Peak Area Peak Peak (^g ml ') Peak Peak Peak Peak 
Area Ratio Area Area Area Area Area Area 
Ratio Ratio Ratio 
4 . 6 7 1 6 8 2 5 4 0 . 2 9 1 9 8 1 7 8 ^ 5 . 0 0 0 . 5 5 2 7 3 4 9 2 0 . 5 0 
9 - 3 3 3 3 1 2 5 8 0 . 5 8 3 8 3 9 1 9 0 . 7 1 ~ 1 0 . 0 0 6 2 4 9 3 6 L I O 5 4 2 3 5 8 T ^ 
14.00 494995 0.88 580447 “ 1 5 . 0 0 “ 9 3 0 9 6 5 lTG 8 2 ^ T T T " 
18.67 663463 1.16 784790 1.42 20.00 1260614 I 2 I 1106928 2.00 
23.33 822570 1.50 943690 ” 2 5 . 0 0 1 5 8 2 3 8 4 2.88 1347861 2.49 
：/^：卑彳 ^ I T 1:060 0.999 1.000 ~ r “ o ! ^ TSSS 
c. cysteine d. paracetamol 
Aqueous Plasma Aqueous Plasma 
Cone. Cone. 
(Hg ml ') Peak Peak Area Peak Peak (^g ml ') Peak Peak Peak Peak 
Area Ratio Area Area Area Area Area Area 
Ratio Ratio Ratio 
5 . 0 0 3 1 8 7 8 7 o l ? 3 2 8 2 9 7 533 4 4 1 4 3 4 0 . 7 7 ~ 4 2 5 2 ^ 0 . 7 7 
10.00 653574 1.15 679938 1.26 10.67 868628 LSi 835922 1.54 
1 5 . 0 0 9 6 3 2 7 4 1.71 1 0 2 8 1 9 5 1 . 9 0 1 6 . 0 0 1 2 9 1 4 4 3 2 J 0 1 2 6 4 0 8 2 2 . 3 3 
20.00 1314422 2.31 1405652 ”""2M""“ 2 1 . 3 3 1 6 1 7 6 6 9 2M 1472114 2.66 
2 5 . 0 0 1 6 1 3 7 7 4 2 . 9 4 1 6 8 3 0 4 6 3 . 1 1 2 6 . 6 7 2 1 5 8 7 5 3 2 0 6 1 3 6 8 3 . 8 1 




(^ ig ml ') Peak Peak Area Peak Peak 
Area Ratio Area Area 
Ratio 
I " " “ " " ” 2 5 8 1 4 0 ~ ^ 2 4 3 7 3 6 ~ ^ " " “ 
9 . 9 7 5 0 7 6 3 6 0 . 8 9 4 8 8 1 9 1 0 . 9 0 ‘ 
1 4 . 9 5 7 5 5 0 3 5 1 . 3 4 7 4 5 1 5 5 1 . 3 7 
1 9 . 9 3 “ 1 0 0 1 3 7 9 1 . 7 6 1 0 0 0 0 6 6 1 . 8 0 
2 4 . 9 2 1 2 8 8 7 3 7 2 . 3 5 1 2 1 6 8 6 9 2 . 2 5 
… : - r ” 一 1 . 0 0 0 0 . 9 9 8 1 . 0 0 0 1 . 0 0 0 
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can be employed to measure both therapeutic and overdose concentrations of 
paracetamol, but only methods where the major metabolites of paracetamol, the 
glucuronide, sulphate, cysteine and mercapturate conjugates can also be co-
chromatographed in the same assay can fulfil the requirements of a study involving 
its in vivo metabolism. 
An HPLC method with excellent performance in precision, accuracy and linearity 
for the estimation of paracetamol and its metabolites is described. The same assay 
can be used to analyse both plasma samples and urine samples. The method 
described above required minimal sample preparation with a relatively short run 
time. Validation tests showed that this assay method for plasma and urine samples 
is reliable. This assay was used throughout for the study on the metabolism of 
paracetamol in healthy subjects and in patients with liver diseases and hepatocellular 
carcinoma. 
I 
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2.3 The pharmacokinetics of paracetamol in healthy subjects 
2.3.1 Introduction 
Although many studies on paracetamol metabolism in healthy subjects have been 
previously reported, it is unclear as to the most suitable duration of plasma sampling 
in such studies. In some studies, plasma samples were taken up to 8 hours after a 
dose of paracetamol while in others, blood samples were taken up to 24 hours after 
the dose. In some of the published studies, a terminal elimination half-life value was 
quoted, but it was not clear which period of time this value referred to. 
As a forerunner for the main pharmacokinetic study, a study was carried out on 
healthy control subjects to evaluate the differences in the pharmacokinetic parameters 
calculated using different sampling regimens. This would help in choosing the most 
appropriate sampling regimen for the study which followed. 
2.3.2 Study protocol 
Al l studies were carried out in the Clinical Pharmacology Studies Unit, Department 
of Clinical Pharmacology, The Chinese University of Hong Kong, at the Prince of 
Wales Hospital, Shatin, Hong Kong. 
2.3.3 Methods I 
2.3.3.1 Subjects 
Subjects for the healthy control study were volunteers responding to recruitment 
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appeal posters for clinical research posted around the Hospital. Fourteen healthy 
Chinese males with a mean age of 29.4 土 11.6 years, mean body weight 57.9 ± 8 . 3 
kg and mean height 164 士 8 cm were entered into the study. Each was given a 
physical examination and screening tests for plasma biochemistry and haematology 
were performed, together with urinalysis. The results in all subjects were normal. 
Details of the age, body weight and height of the subjects are shown in Table 2.10 
and the plasma biochemistry and haematology screen data are shown in Tables 2.11 
and 2.12. None of the subjects was on any medication and none smoked or 
consumed alcohol regularly. Informed consent was given by each subject and the 
study was approved by the Hospital Ethics Committee. 
2.3.3.2 Drug administration and sampling 
The subjects attended the Clinical Pharmacology Studies Unit in the Department of 
Clinical Pharmacology in the morning after an overnight fast. An in-dwelling cannula 
(Angiocath 20G 2 inch, Becton Dickson) was inserted into a forearm vein. The 
cannula stayed in situ until after the 12 hour sample was drawn. The 24 hour blood 
sample was taken at a different site by venepuncture. Paracetamol was administered 
as the syrup (Panadol Syrup 160 mg ml S Sterling Drug (Malaya) Sdn., Bhd., Kuala 
Lumpur for Winthrop Product Inc., New York, U.S.A.) at a dose of 20 mg/kg body 
I 
weight, together with 150 ml of water. Food and beverages were withheld for at 
least 3 hours after drug administration and only water was allowed. Lunch was 
available at 4 hours and after that fluid and food intake were unrestricted. 
105 
Table 2 .10 Details of 14 Chinese HenUhy .^nKj^^ts 
Subject Number Sex Age Body Weight (kg) Height (cm) 
1 M 21 69.4 175 
2 F 32 46.1 
3 M 26 56.3 160 
4 F 26 47.4 161 
5 F 22 48.9 156 
6 F 23 48.1 154 
8 M 23 70.5 178 
10 F 23 60.1 157 
11 F 23 52.8 161 
14 M 22 61.2 175 
15 M 22 60.8 169 
23 M 42 68.2 163 
24 F 54 63.0 162 
25 M 53 57.6 167 
Mean 7M/7F 29.4 57.9 163.8 
S.D. 11.6 8.3 7.9 
I 
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Table 2.11 Plasma Biochemistry Screen in 14 Chinese Healthy Snhjprfg 
Mean Range Normal Range* 
Total Protein (g 1]) 76.2 70 - 84 66 - 81 
Albumin (g 46.0 42 - 50 36 - 48 
Total Bilirubin (^mo\ l'^) 10.2 6 - 16 0 - 15 
Alkaline Phosphatase ( lU 60.8 35 - 81 40 - 136 
ALT ( lU 1-1) 14.1 2 - 56 0 - 58 
Gamma GT (U 1-1) 11.0 4 - 21 0 - 84(F) 
0 - lOO(M) 
Fasting Glucose (mmol 1]) 4.9 4.2 - 5.8 3.5 - 6.0 
Sodium (mmol 1]) 139.6 137 - 142 134 - 145 
Potassium (mmol l )^ 3.9 3.4 - 4.8 3.5 - 5.1 
Urea (mmol 1]) 5.2 3.2 - 7.4 3.4 - 8.9 
Creatinine (jLtmol 78.8 64 - 96 44 - 107(F) 
57 - 126(M) 
Calcium (mmol 1-1) 2.31 2.17 - 2.46 2.13 - 2.51 
* From the Department of Chemical Pathology, Prince of Wales Hospital, Shatin 
I 
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Table 2 .12 Haemotology Screen in 14 Chinese Healthy Siibj^rfs 
Mean Range Normal Range* 
Haemoglobin (g dl'^) 14.6 12.0 - 17.5 11.5 - 14.3(F) 
13.2 - 16.7(M) 
Haematocrit 0.441 0.357 - 0.533 0.32 - 0.43(F) 
0.39 - 0.50(M) 
RBC (X 1012 1-1) 5.25 4.12 - 7.04 3.7 - 4.9(F) 
4.2 - 5.7(M) 
MCHC(gdl- i ) 33.1 30.9 - 34.2 32 - 35 
MCH(pg) 28.1 20.6- 31.5 27 - 33 
MCV (fl) 85 67 - 93 81 - 97 
Platelets (x 10' 1]) 213 153 - 275 140 - 380 
WBC (X 109 1-1) 5.6 3.2 - 7.9 4.0 - 10.8 
Neutrophils (%) 62.9 49 - 82 40 - 60 
Lymphocytes (%) 28.8 13 - 43 20 - 40 
Monocytes (%) 4.9 4 - 6 4 - 8 
Eosinophils (%) 1.8 1 - 5 1 - 4 
Basophils (%) 1.1 1 - 2 
* From the Department of Chemical Pathology, Prince of Wales Hospital, Shatin 
I 
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5 ml venous blood samples were drawn into heparinised tubes at 0, 0.5, 1, 1.5, 2， 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 24 hours after dosing. Blood samples were 
centrifuged at 1400 x容 for 10 minutes and the plasma separated for storage at -20°C 
prior to analysis. Urine was collected for the time period 0-4，4-8, 8-12 and 12-24 
hours after dosing. The volume of urine excreted at each time period was noted and 
a 20 ml aliquot was taken from each collection and stored at -20°C until analysis. 
2.3.3.3 Drug analysis 
The concentrations of paracetamol, the glucuronide, sulphate, cysteine and 
mercapturate metabolites in plasma and in urine were measured by the HPLC assay 
described in this chapter, section 2.2.2. Metabolite concentrations were expressed 
as paracetamol equivalents. 
2.3.3.4 Calculations 
Plasma concentrations of paracetamol and the glucuronide, sulphate and cysteine 
metabolites of individual subjects were calculated from the respective peak area 
counts and the paracetamol standards according to section 2.2.4.2. The recovery of 
paracetamol and its metabolites in the urine was calculated according to section 
2.2.3.2. The individual peak plasma concentrations (C^ax) and time to reach peak 
plasma concentrations ( t ^ were noted. 
I 
The metabolic clearance was calculated according to the method of Miners et al. 
(Miners et a l , 1983; Miners et a l , 1986). This calculation assumes that the 
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clearance of paracetamol (CI) is the sum of the individual clearances involved in 
paracetamol elimination, i.e. 
CI = Clp + Clo + Cls + Clc + CIm 
where CI is the overall clearance of paracetamol and Clp, Cl<3, Clg, Clc, and CIm are 
the metabolic clearances to unchanged paracetamol, the glucuronide, sulphate, 
cysteine and mercapturate conjugates, respectively. The metabolic clearance to each 
metabolite Cl^ was calculated as: 
CIm = f . CI 
where f^ is the fractional recovery of the respective metabolite in the urine. 
2.3.4 Pharmacokinetic analysis 
Pharmacokinetic analysis was done using the pharmacokinetic modelling programme 
SIPHAR/base, Version 4.0 (1991, SIMED, Cr^ei l , Cedex, France). 
Pharmacokinetic modelling and estimation of the pharmacokinetic parameters for 
individual plasma data were done as follows. The semilogarithmic plot of plasma 
concentrations against time was displayed on the screen. After visual inspection of 
the plot, the number of exponentials suitable to describe the data and the number of 
observations belonging to each exponential phase were decided. After having chosen 
these criteria, the goodness of fit of this model was verified by a visual analysis of 
the theoretical curve superimposed on the experimental data points. This was done 
I 
by the programme using the method of residuals, also known as peeling or feathering 
(SIMED, 1991; Shargel & Yu，1993). The parameters of each phase computed were 
then displayed and were used as the initial parameters for the next iterative 
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procedure in the data modelling. In the second stage of parameters estimation, the 
extended least squares method was used, and the minimization algorithm employed 
was that of Powell. Using the extended least squares method, both the structural 
model and the error model parameters were estimated simultaneously by minimizing 
the log-likelihood function L: 
N (Yi _ M)2 
L = D + log Vi 
Vi 
where N is the number of experimental points, Yj is the i-th observation, M； is the 
i-th predicted value and Vj is the error variance of the i-th observation. The error 
model utilised in the iteration was 
V = a M> 
where a and b are the two error model parameters. This model generalizes the usual 
weighting scheme applied to standard weighted regression analysis. 
Very often different equations can be used to fit the same data set. For each set of 
data and a chosen model, a number of fitted curves can be generated with slightly 
differing pharmacokinetic parameters. A plot of the residual versus time and/or the 
computed values are provided by SIPHAR for the assessment of the adequacy of the 
structural model. The residuals should be randomly distributed. Apart from the 
residual plot, the programme also computes firstly the correlation coefficient between 
the observed and theoretical values and secondly the coefficient of variation (CV) of 
each parameter. The value of the CV gives an indication of the accuracy of the 
estimate. 
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SIPHAR also provides three values for the assessment of the appropriateness of the 
model - the Akaike value, the Schwartz value and the Leonard value. The 
calculation of the Schwartz value takes into account the number of data points and 
was chosen as one of the criteria to decide the best-fit model. The Schwartz value 
is defined as 
S = -Log likelihood + Vi log N 
where N is the number of data points. 
The equations used to describe a 2 phase model and a 3 phase model are: 
2 phase model Y = -Ae't+Bebt 
3 phase model Y = -Ce-^^+Ae-'+Be''^' (C = A+B) 
A, B and C are the coefficients and a, b and c are the exponentials of the respective 
phases. Both equations describe curves which are forced through the origin. 
The following parameters are provided by the programme following data modelling: 
AUCT^x Total area under the curve extrapolated to infinity, calculated by the 
trapezoidal rule (model independent) 
AUC Total area under the curve of the fitted model 
t.^  Half-life, calculated as t.^  = 0.693/k, where k is the exponential of 
the phase to which the half-life refers 
CI Clearance, calculated as CI = Dose/AUCT^x (assuming complete 
absorption) 
Vd Volume of distribution of the terminal elimination phase (B phase), 
calculated as V^ == Cl/beta where beta is the terminal slope 
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MRT Mean residence time is defined as the average time that all the drug 
molecules reside in the body. It is a measure of the mean transit time 
of the drug molecules. The model independent MRT is normally 
calculated as MRT = AUMC/AUC, where AUMC is the area under 
the first moment versus time curve from t = 0 to infinity and AUG 
is also known as the zero moment curve. In this pharmacokinetic 
modelling programme, the MRT of the fitted model is calculated as 
MRT = D Coefj / Expi^, where Coefj and Expj are the coefficient 
and exponential of the ith phase, respectively 
To determine i f there was any difference in data modelling when the sampling times 
were different, 5 different models using different sampling times were compared. 
The parameters obtained from these 5 different curve fittings were analysed for any 
statistically significant difference. The sampling times used in these models were as 
follows: 
Model Sampling times (hour) No. of phases 
1 0, 0.5，1, 1.5, 2, 3, 4，5, 6，7，8，9，10, 11，12，24 3 
2 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8，9, 10，11，12 _ 3 
3 0, 0.5, 1, 1.5, 2，3, 4, 5, 6，7, 8, 24 — 3 
4 0, 0.5, 1，1.5，2, 3, 4，5，6, 7, 8, 9，10’ 11, 12 2 
5 0，0.5, 1，1.5, 2, 3，4, 5’ 6’ 7, 8 — 2 
！ 
In particular, a comparison between model 1 and model 2 was used to demonstrate 
the importance of the plasma level at 24 hour in influencing the pharmacokinetic 
parameters of a 3-phase model, whereas a comparison between model 1 and model 
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3 was used to show the importance of extra sampling times at 9, 10, 11 and 12 
hours. 
Model 2 and model 4 used the same sampling times and the former was fitted to a 
3-phase model with an initial elimination phase between about 2 to 8 hours and a 
terminal elimination phase following that. Model 4 was fitted using a 2-phase model 
with only 1 terminal elimination phase. A comparison between model 2 and model 
4 was used to demonstrate the difference in the pharmacokinetic parameters when 
the same sampling points were force-fitted to two different models. 
Sampling time was only taken up to 8 hours in model 5. A comparison between 
model 4 and model 5 was used to demonstrate i f the extra sampling times at 9，10, 
11 and 12 hours had any influence on the estimated pharmacokinetic parameters 
when the two models were both used to fit a 2-phase model. 
Therefore, the pharmacokinetic parameters estimated from these different models 
were compared together by analysis of variance but the following comparisons were 
also made in particular: 
model 1 vs model 2 
model 1 vs model 3 
model 2 vs model 4 
model 4 vs model 5 
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2.3.5 Statistical analysis 
Mean values with the standard deviation (SD) are presented. Al l statistical analyses 
were carried out using the computer statistics package SPSS for Windows (Version 
5, 1992, SPSS Inc., Chicago, U.S.A.), supplemented by SigmaStat (Version 1.01, 
1993，Jandel Scientific, San Rafael, California, U.S.A.) when the desired tests were 
not available on SPSS. Geigy Scientific Tables (Geigy Scientific Tables, 1982) was 
also consulted when the coefficient of correlation was tested for statistical 
significance. 
Bland-Altman plots (Bland & Altman, 1986) were done using a modification of the 
original authors，method (see results and discussion, sections 2.3.6.4 and 2.3.7). 
The calculations for the intraclass correlation coefficient of reliability was based on 
the method given in Chapter 1 (p. 11) of The Design and Analysis of Clinical 
Experiments (Fleiss, 1986). 
2.3.6 Results 
2.3.6.1 Plasma Results 
Mean plasma concentrations of paracetamol and its metabolites following oral 
administration of a 20 mg kg i body weight dose to 14 healthy subjects are shown 
in Table 2.13. and Fig. 2.11. The mercapturate conjugate was not detected in any 
of the plasma samples, probably due to very low concentrations. Plasma 
concentrations for each subject are shown in Appendices 2.2-2.5. Individual values 
for peak concentration ( C ^ and time to reach peak concentration ( 。 a r e shown 
in Table 2.14. 
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Table 2 .13 Mean Plasma Concentrations of Paracetamol and the 
Glucuronide. Sulphate and Cysteine Conjugates in 14 
Healthy Subjects Following Ingestion of a 20 mp kp i Body 
Weight Dose 
Time Plasma Concentration (^g ml'^) 
After p 
Dosing Paracetamol Glucuronide Sulphate Cysteine 
(hr) 
Mean 士 SD Mean 士 SD Mean 士 SD Mean 士 SD 
0 0 0 0 0 
0.5 20.99 士 7.20 2.05 士 1.00 2.90 土 1.12 0.01 士 0.02 
1 19.21 士 4.02 5.60 土 1.48 4.66 土 1.35 0.04 士 0.05 
1.5 16.58 ± 3.31 7.63 土 2.23 5.08 土 1.37 0.08 士 0.06 
2 14.23 ± 2.79 8.78 土 2.57 5.03 土 1.30 0.10 土 0.05 
3 11.21 土 2.37 9.47 ± 2.60 4.71 土 1.28 0.14 土 0.07 
4 8.54 ± 1.86 9.31 ± 2.57 4.07 ± 1.19 0.19 士 0.07 
5 6.36 ± 1.35 8.18 ± 2.06 3.47 ± 1.04 0.19 ± 0.06 
6 4.84 ± 1.17 6.93 ± 1.80 2.96 ± 1.01 0.16 ± 0.05 
7 3.80 ± 0.94 5.58 ± 1.53 2.45 ± 0.84 0.13 ± 0.08 
8 2.96 ± 0.79 4.53 ± 1.41 1.98 士 0.72 0.12 士 0.07 
9 2.19 土 0.61 3.62 ± 1.07 1.56 ± 0.60 0.11 ± 0.08 
10 1.90 士 0.57 3.58 土 1.96 1.62 士 1.21 0.11 土 0.07 
11 1.40 ± 0.44 2.44 ± 0.84 1.02 土 0.37 0.08 土 0.06 
12 1.13 ± 0.36 1.96 ±0.71 0.86 ± 0.32 0.07 土 0.05 
24 0.24 士 0.07 0.32 士 0.12 0.17 ± 0.08 0.01 士 0.02 
116 
Fig. 2.11 Mean Plasma Concentration of Paracetamol. Paracetamol 
Glucuronide and Paracetamol Sulphate in 14 Healthy 
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™ e 2 . 1 4 Peak Plasma Concentration and Time to Rp.^rh Pp^I. 
Plasma Concentrations ( T � J of Paracetamol and It^ Glucuronide and Sulphate Metabolites in 14 Subjects Following a 20 mg kg i Dose 
Paracetamol Glucuronide Sulphate 
Subject Cmax Tmax Cmax Tmax ~ C m a x ” T m a x 
(Mg ml-1) (hr) (jig mI-1) ^ (jig ml-1) ^ ~ 
CWH 21.16 0.50 11.79 3 m 4 ^ 4 3 " " ” “ 1.50 
WR 17.66 1.00 6.30 4.00 2.85 1.00 
WKKW 16.53 0.50 12.23 2.00 3.88 1.50 
KWSC 17.55 1.50 8.25 3.00 4.25 1.50 
CSYC 23.55 0.50 7.45 2.00 6.22 1.50 
LHY 19.44 1.00 5.65 3.00 5.35 1.50 
CWSD 19.75 1.00 12.57 4.00 3.12 2.00 
NPSD 28.88 0.50 8.89 2.00 5.49 1.00 
LCKY 28.81 1.00 8.76 4.00 7.15 1.50 
WP 18.59 1.00 10.63 4.00 6.10 1.50 
WH 31.23 0.50 9.40 3.00 5.78 1.50 
YAS 16.77 1.50 7.56 3.00 5.20 1.50 
SPY 21.18 1.50 15.10 3.00 5.28 2.00 
KKH 33.83 0.50 10.15 3.00 6.89 1.50 
Mean 22.50 0.89 5J4 L 5 Q ~ 
SD 5.81 0.40 2.64 0.73 1.30 0.28 
Min 16.53 0.50 5.65 2.00 2.85 1.00 
Max 33.83 1.50 15.10 4.00 7.15 2.00 
I 
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The absorption of paracetamol was rapid with a mean C脆 of 22.5 ± 5.81 ng mH 
(range 16.53 - 33.83), occurring at a mean t ^ of 0.89 土 0.40 hr (range 0.5 - 1.5). 
A semilogarithmic plot of paracetamol concentrations against time showed a linear 
decline up to around 8 - 12 hr post dose. Beyond this period, the decline in 
paracetamol concentration seemed to be much slower as the plasma concentration at 
24 hr did not seem to fit with a single elimination phase. 
The mean plasma concentration of paracetamol glucuronide rose steadily and peaked 
at 3.07 士 0.73 hr (range 2.0 - 4.0 hr). The C ^ ranged from 5.65 - 15.10 /xg ml-i 
(mean 9.62 土 2.64 /xg ml"^). After paracetamol glucuronide t ^ , the plasma 
concentration of the glucuronide conjugate was always higher than the parent drug. 
In contrast, the mean plasma concentration of paracetamol sulphate was always lower 
than paracetamol, with mean C隱 5.14 士 1.30 jxg ml'^ (range 2.85 - 7.15). The time 
to peak concentration was reached early, mean t ^ was at 1.50 士 0.28 hr (range 1.0 -2.0). 
Only very low concentrations of the cysteine conjugate were detected in the plasma 
samples (see Appendix 2.5). 
2.3.6.2 Urine Results 
Table 2.15 shows the overall recovery and fractional recovery of paracetamol and 
its four major metabolites in the 24 hour urine collections of the 14 healthy subjects. 
The mean total recovery of paracetamol and all metabolites in the 24 hour urine 
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Table 2.15 Urinary Recovery of Paracetamol and Its Glucuronide. 
Sulphate. Cysteine and Mercapturate Metabolites in 24 h 
Following Ingestion of a 20 mg k g ] Dose in 14 Healthy 
Subjects 
Percentage of Total Amount Recovered in Urine Over Total 
24 hours Recovery 
Subject G I S I C I P I M I M + C as % of 
Dose 
CWH 63.9 ^ ^ T 2 3 . 2 6.7 69.0 
WR 56.2 30.3 5.0 5.4 3.2 8.1 63.6 
WKKW 67.1 24.9 2.5 3.1 2.4 4.9 96.8 
KWSC 56.5 30.0 5.0 6.1 2.4 7.4 94.2 
CSYC 44.2 46.4 2.2 5.4 1.8 4.0 81.3 
LHY 40.7 43.7 4.2 9.0 2.3 6.5 79.9 
CWSD 68.6 22.3 2.1 5.0 2.0 4.1 113.7 
NPSD 55.0 36.7 2.0 4.8 1.6 3.6 99.6 
LCKY 45.5 45.9 2.5 4.2 2.0 4.5 112.9 
WP 52.5 37.5 3.5 4.1 2.5 6.0 104.5 
WH 55.7 34.3 2.4 6.5 1.0 3.5 107.2 
YAS 49.3 35.3 4.4 6.5 4.5 8.9 95.4 
SPY 65.0 25.3 1.7 5.5 2.6 4.2 103.0 
KKH 47.5 35.7 4.7 8.1 4.1 8.7 98.2 
Mean 54.8 33.7 ^ 2.5 5.8 94.2 
SD 8.9 8.0 1.2 1.6 0.9 1,9 15.4 
G = paracetamol glucuronide 
S = paracetamol sulphate 
C = paracetamol cysteine 
P = paracetamol 
M = paracetamol mercapturate 
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collection was 94.2 土 15.4% of the administered dose. The mean fractional 
recovery in the 24 hr urine collection was 54.8 土 8.9%, 33.7 土 8.0%, 3.3 士 
1.2%, 2.5 士 0.9% and 5.6 士 1.6% for the glucuronide, sulphate, cysteine, 
mercapturate conjugate and unchanged paracetamol, respectively. For unchanged 
paracetamol and the glucuronide and sulphate conjugates, more than 70% of the 
recovered amount was excreted within 8 hours of the ingestion of paracetamol. More 
than 50% of the oxidative metabolites was also excreted within 8 hours and the 
proportion of the excreted cysteine conjugate and mercapturate conjugate was almost 
parallel at all stages. The mean cumulative recovery of paracetamol and its 
metabolites in the urine was shown in Table 2.16 and Fig. 2.12. Individual urinary 
excretion data are shown in Appendices 2.6 - 2.10. 
The mean percentages of total drug excreted as paracetamol and its metabolites in 
divided urine collections are shown in Table 2.17 and Fig. 2.13. At all times the 
greatest proportion was excreted as the glucuronide conjugate, the percentage being 
between 50 - 60%. There was a slight increase in the percentage recovery of 
glucuronide during the period between 4 to 8 hours, thereafter, it decreased again. 
This change in the percentage recovery was mirrored in the opposite pattern by that 
of the sulphate conjugate. 
The percentage recovery of unchanged paracetamol during the first urine collection 
period between 4 - 8 hours was high at 8.2% and then decreased rapidly to 3 - 4%. 
The excretion patterns of the cysteine and mercapturate conjugates were very similar. 

































































































































































































































































Fig* 2 .12 Mean Cuirmlative Percentage Recovery of Paracetamol and 
Its Metaholifps in 24 Hour Urine in 14 Healthy SiihjRrfg 
Following Ingestion of a 20 mg k g ] Body Weight Dns^p 
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朽� • 2 .13 -Mean Percentage Remvpry of P朴p^rpfamol ？ T f c Metabolites in Divided Urine Collections in M U^.i^i^y 
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increasing steadily to about 5 - 6%. 
2.3.6.3 Pharmacokinetic Results 
The pharmacokinetic parameters calculated for the different models are shown in 
Table 2.18 to Table 2.22, including AUG, CI, terminal t.^, MRT and Vd. 
As the AUC is that of the fitted model and also extrapolated to infinity, the values 
obtained from different models were quite different. The mean values for the 5 
models were 92 士 18.6, 87.8 土 17.7, 101.6 士 20.9, 86.2 士 17.4 and 85.7 士 17.3 
Mg ml-i hr, respectively (Table 2.18). The highest value was obtained in Model 3. 
The mean AUC values of Model 4 and Model 5 were very close, as well as the 
standard deviation. The only difference between these two models was that the 
sampling time was up to 12 hours in Model 4 and only up to 8 hours in Model 5. 
Clearance values for individual subjects in different fitted models are shown in Table 
2.19. The mean values for the 5 models were 3.80 士 1.01，3.98 土 1.05，3.45 土 
0.97，4.05 土 1.05 and 4.08 士 1.07，respectively. Again, the mean values between 
Model 4 and Model 5 were very close with similar standard deviations. As CI and 
AUC have an inverse relationship (CI = Dose/AUC), it was as expected that the 
mean CI value was found to be lowest in Model 3. 
I 
The terminal t.^  values tabulated in Table 2.20 refer to different time periods in the 
various models. In Models 1 to 3，where a 3-phase model was fitted, the terminal 
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Table 2.18 Area Under Curve (AllC) of the Plasma ConcenfrnHon-
Time Curves of Paracetamol of 5 Fitted Models in 14 
Healthy Subjects Following Ingestion of a 20 mg kg'^ Body 
Weight Dose 
Area Under Curve of Fitted Model 
(Mg ml-i hr) 
Subject Fitted Model 
J 1 2 3 4 5 
CWH ^ ~ 86.5 85.0 
WR 84.9 80.3 98.0 79.9 82.7 
WKKW 48.4 46.4 51.3 46.0 45.1 
KWSC 85.9 81.2 95.5 80.7 81.4 
CSYC 84.9 81.1 92.2 77.7 75.6 
LHY 95.5 94.9 104.5 88.2 87.1 
CWSD 94.3 91.8 103.7 89.8 88.6 
NPSD 90.0 86.6 98.4 85.2 74.0 
LCKY 118.8 112.3 130.1 110.7 110.4 
WP 86.8 82.1 96.0 81.7 81.1 
WH 75.4 70.9 84.3 69.7 80.8 
YAS 94.9 89.8 105.4 88.9 87.0 
SPY 112.7 106.0 126.5 105.7 106.0 
KKH 123.4 117.9 136.2 115.5 115.4 
Mean ST^ 101.6 ^ ~ 
SD 18.6 17.7 20.9 17.4 17.3 
I 
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Table 2.19 Clearance (C\) of P a 蒙 _ o l in 5 FiffeH Modek in M 
Healthy vSuhiects Following Ingestion of a 20 mp kp ] RnHy 
Weight Dose “ ‘ 
Clearance of Paracetamol in Fitted Model 
(ml min] kg'^) 
Subject 
Fitted Model 
~ 1 I 2 I 3 I 4 I 5 
™ ^ " 3.77 3.33 3.85 3.92 
WR 3.93 4.15 3.40 4.17 4.03 
WKKW 6.89 7.18 6.49 7.25 7.39 
KWSC 3.88 4.11 3.49 4.13 4.09 
CSYC 3.93 4.11 3.62 4.29 4.41 
LHY 3.49 3.51 3.19 3.78 3.83 
CWSD 3.54 3.63 3.21 3.71 3.76 
NPSD 3.71 3.85 3.39 3.91 4.51 
LCKY 2.81 2.97 2.56 3.01 3.02 
WP 3.84 4.06 3.47 4.08 4.11 
WH 4.42 4.70 3.95 4.78 4.13 
YAS 3.51 3.71 3.16 3.75 3.83 
SPY 2.96 3.14 2.64 3.15 3.15 
KKH 2.70 2.83 2.45 2.89 2.89 
Mean 3.80 3 M ^ 4.08 
SD 1.01 1.05 0.97 1.05 1.07 
I 
128 
Table 2 .20 Terminal Elimination Half-life of Paracetamol in 5 Fitted 
Models in 14 Healthy Subjects Following Ingestion of a 20 
mg kg-i Body Weight Dose 
Terminal Elimination Half-Life of Paracetamol (hr) 
, . Fitted Model 
Subject 
i I 2 � 3 4 5 
CWH 4^4 3.6 4,6 2.6 2.6 
WR 4.5 3.1 4.1 2.9 3.1 
WKKW 5.8 2.7 4.9 1.9 1.8 
KWSC 5.3 2.8 4.2 2.5 2.6 
CSYC 6.9 4.6 4.9 2.2 2.1 
LHY 5.3 5.9 4.6 2.9 2.8 
CWSD 3.8 3.8 3.8 2.8 2.7 
NPSD 3.9 4.0 3.6 2.5 2.6 
LCKY 7.5 3.4 4.6 2,2 2.2 
WP 5.1 2.9 4.1 2.6 2.5 
WH 6.9 3.3 4.5 2.3 2.3 
YAS 4.8 3.5 4.3 3.0 2.7 
SPY 5.6 2.8 4.4 2.6 2.6 
KKH 5.2 3.1 4.5 3.0 3.0 
Mean 5A ^ 4.3 2.6 2.6 
SD 1.1 0.9 0.4 0.3 0.4 
I 
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elimination t.^  refers to the time period around 7 to 8 hr to the last sampling time. 
For Models 1 and Model 3, this was 24 hr and for Model 2，the last sampling time 
was 12 hr. The terminal elimination t^ for Model 4 refers to the time about 2 to 12 
hr and for Model 5, about 2 to 8 hr. As a result, the terminal t,^  values of a 
particular subject in these different fitted models were very different. The mean 
terminal t^ estimated by these models were 5.4 土 1.1, 3.5 土 0.9, 4.3 士 0.4，2.6 
士 0.3 and 2.6 土 0.4 hr, respectively (Table 2.20). 
The mean t.^  estimated by Model 1 was the longest, followed by Model 3. In these 
two models, the last sampling time used was 24 hr. The plasma concentration at this 
terminal point seemed to contribute to the estimation of a longer t^ value. The 
difference between the mean estimated t,^  value in Model 4 and Model 5 was very 
small. It seemed that the sampling points at 9 to 12 hr, the extra sampling times used 
in Model 4，fitted very well into the elimination phase between 2 and 8 hr, the time 
period for the estimation of terminal t^ in Model 5. The mean in these two 
models were much lower than those estimated in Model 1 and Model 3. 
Model 2 used sampling time up to 12 hr and was fitted to a 3-phase model. The 
mean t,^  was between the longer values of Model 1 and 3, and the shorter value of 
Model 4 and 5. 
I 
The mean residence time (MRT), defined as the average time for all the drug 
molecules to reside in the body, is a measure of the mean transit time of the drug 
molecules. It takes into account all the different phases and not just the terminal 
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Table 2.21 Mean Residence Time of Paracetamol in 5 Fitted Models in 
14 Healthy Subjects Following Ingestion of a 20 mg kg^ 
Body Weight Dose 
Mean Residence Time of Paracetamol (hr) 
Subject Fined Model 
I 1 I 2 � 3 I 4 5 
CWH 4^9 4 1 4.0 
WR 5.3 4.6 5.3 4.6 4.9 
WKKW 3.9 3.2 3.9 3.0 2.9 
KWSC 4.8 4.0 4.8 3.9 4.0 
CSYC 5.3 4.5 5.0 3.8 3.5 
LHY 5.6 6.0 5.3 4.5 4.4 
CWSD 4.8 4.8 4.7 4.4 4.3 
NPSD 4.5 4.6 4.4 4.0 4.4 
LCKY 4.9 3.8 4.6 3.5 3.5 
WP 4.9 4.1 4.8 4.0 3.9 
WH 5.3 4.2 5.1 3.9 3.4 
YAS 5,6 5.0 5.4 4.9 4.6 
SPY 5.1 4.2 5.0 4.2 4.2 
KKH 5.2 4.3 5.0 4.3 4.3 
Mean 4A 4^9 4^0 
SD 0.5 0.6 0.4 0.5 0.5 
I 
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elimination phase. The mean MRT values estimated in the different models were 5.0 
土 0.5, 4.4 土 0.6, 4.9 土 0.4, 4.1 士 0.5 and 4.0 士 0.5, respectively (Table 2.21). 
When comparing the mean MRT in the different models, it was seen that the values 
estimated in Model 1 and Model 3 were close with comparable standard deviations 
with the mean values both at around 5 hr. Similar findings were seen with Model 4 
and Model 5, with mean MRT at around 4 hr. The mean MRT value in Model 2, 
like the mean t.^  again, lay midway between the values of the other models. 
The volume (Vj) of distribution of the terminal phase was calculated by dividing the 
clearance by the slope of the terminal phase. The mean values for V ,^ in the different 
models were 1.77 土 0.64, 1.20 士 0.33, 1.31 士 0.45，0.88 士 0.15 and 0.88 土 
0.151 kg-i, respectively (Table 2.22). Model 4 and Model 5, had the shortest t^ (and 
thus the largest terminal slope value), the mean V^ in these two models were the 
biggest. The mean values were actually identical in these two models. Since the 
mean t,^  estimated in Model 1 was longest, it was as expected that the mean V j was 
also largest among the 5 models. The V j values in Model 2 and Model 3 were in 
between. 
The metabolic clearances to the various metabolites of paracetamol estimated in the 
different models are governed by the plasma clearance of paracetamol; therefore, the 
comparisons of these metabolic clearance values in the different models were similar 
to the comparisons of the plasma clearance. The mean values are shown in Table 
2.23. The metabolic clearance to all the metabolites in the different models followed 
a similar pattern. The values between Model 4 and Model 5 were very close and so 
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y ^ i M l ^ o f Distrihmion nf IVrn^ — I Rlimin.finn 叶 ft^niol in 5 Fitted Models in M SiiH>rh 
Following Ingestion of a 20 mp T^ndv Weiphf Hhcp 
Volume of Distribution of the Terminal Elimination Phase 
of Paracetamol (1 kg-1) 
Fitted Model 
1 I 2 I 3 I 4 I 5 
™ 0 8 1 . 1 8 1.32 0.87 0.90 
WR 1.53 1.12 1.20 1.04 1.10 
WKKW 3.43 1.71 2.74 1.17 1.17 
KWSC 1.80 1.01 1.26 0.88 0.93 
CSYC 2.34 1.63 1.52 0.82 0.79 
LHY 1.59 1.80 1.26 0.95 0.94 
CWSD 1.15 1.21 1.06 0.89 0.88 
NPSD 1.27 1.32 1.04 0.85 1.01 
LCKY 1.83 0.87 1.02 0.58 0.58 
WP 1.71 1.01 1.23 0.91 0.87 
WH 2.65 1.36 1.54 0.95 0.81 
YAS 1.47 1.11 1.17 0.99 0.91 
SPY 1.44 0.75 1.00 0.71 0.70 
KKH 1.22 0.76 0.95 0.74 0.75 
Mean 1.77 L ^ O l 0 . 8 8 0.88 













































































































































































































































































































































































































































































































Chapter 2 134 
were the values between Model 2 and Model 4. The individual metabolic clearance 
values are shown in Appendices 2.11 - 2.15. 
2.3.6.4 Statistical Results 
Each of the pharmacokinetic parameters from the 5 different models was first 
compared by a global analysis using the one-way repeated measures analysis of 
variance (RM ANOVA) for a parametric comparison and a Friedman repeated 
measures analysis of variance (FRM ANOVA) for a non-parametric comparison. 
Multiple comparisons of paired models were done by the Student-Newman-Keuls 
(SNK) test. The results are shown in Table 2.24 and Table 2.25. 
In all the global analyses, the means of the various models were significantly 
different (p < 0.001). This is the same for both the parametric and non-parametric 
ANOVAs. Following the global analyses, multiple comparisons by the SNK test 
revealed that the various pharmacokinetic parameters were not significantly different 
between all the paired models. For all the parameters including AUG, CI, MRT, 
Vd and the metabolic clearance to various metabolites, there was no statistically 
significant difference between Model 4 and Model 5 by either the parametric or non-
parametric comparison. Any difference in the estimated parameters between these 
two models seemed to be attributable to random variation. 
I 
A statistically significant difference was found only in the terminal t^, MRT and Vd 
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parametric and non-parametric SNK tests. 
With the comparisons between Model 1 and Model 3, using parametric SNK test, 
it was found that all the pharmacokinetic parameters were significantly different 
except the MRT. But these statistically significant differences seemed to be 
borderline only as they became non-significant when the comparisons were done by 
the non-parametric SNK test using ranks only. i.e. the AUG, CI, t.^, V j and the 
metabolic clearances, which were significantly different between Model 1 and Model 
3 by the parametric SNK test, were all found not to be so by the non-parametric 
SNK test. 
Parametric SNK tests showed that all of the pharmacokinetic parameters were 
significantly different between Model 1 and Model 2. Again, some of these 
statistically significant differences might be borderline only as by non-parametric 
SNK tests, the AUG, CI, t.^, V j and the metabolic clearances to glucuronide and 
sulphate were no longer significantly different. 
The intraclass correlation coefficient of reliability (R) is a single quantity that can 
usefully express the magnitude of the two components of the variability among a 
series of measurements on different subjects - variability among their steady-state 
values and the variability of the random errors; or the between subject variation and 
the within subject variation. R is distinguished from the traditional product-moment 
correlation coefficient. It is directly interpretable as a proportion of variance. It is 
the proportion of the variance of an observation due to subject-to-subject variability 
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in error-free scores. Therefore, R approaches the maximum value of unity when 
variations due to random error decrease and the reliability of the measurement 
increases. R is calculated as: 
= (BMS - WMS) 
一 BMS + � - 1 ) WMS 
where 
WMS = within subject mean squares 
BMS = between subject mean squares 
Ko = number of comparisons (measurements) 
The R values calculated for the comparisons between Model 1 and Model 2, Model 
1 and Model 3, Model 4 and Model 5, and Model 2 and Model 4 for CI, terminal 
and AUC are tabulated in Table 2.26. For the clearance of paracetamol, the best 
R value was found in the comparison between Model 2 and Model 4 at 0.99, 
followed by the comparison between Model 1 and Model 2, then that between Model 
4 and Model 5. Since unity is the best reliability value that could be obtained, the 
R values of these 3 comparisons were quite high. The lowest R was obtained from 
the comparison between Model 1 and Model 3 at 0.88. 
The R values calculated for the different comparisons of AUC for Models 1 & 2, 2 
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Table 2.26 Statistical Analysis - Intraclass Correlation Coeffirient of 
Reliability 
1.ci 
Comparisons between models 4 VS 5 1 vs 2 1 v s 3 2 VS 4 
WMS ss 0.43 0.26 Q ^ 0.07 
clf 14 14 14 i T " 
ms 0.031 0.018 0.063 0.005 
BMS ss 14.44 13.75 12.68 14.37 
df 13 ~ 1 3 13 r T 
ms 1.111 1.058 0.975 1.105 
R 0.95 0.97 O M 0.99 
2. t.^  
Comparisons between models 4 VS 5 1 VS 2 1 VS 3 2 VS 4 
WMS ss 0.13 36.66 12.63 11.37 
clf 14 14 14 1 4 ~ 
ms 0.009 2.619 0.902 0.812 
BMS ss 1.51 6.32 Jm 3.15 
df 13 13 13 I T " 
ms 0.116 0.486 0.497 0.242 
R 0.85 -0.69 -0.29 -0.54 
3. AUC 
Comparisons between models 4 VS 5 1 VS 2 1 VS 3 2 VS 4 
WMS ss 135.58 140.07 694.10 38.25 
df 14 14 14 14 
'^s 9.685 10.005 49.579 2.732 
B ^ ^ 3827.49 4289.52 5059.55 3991.86 
_ — j3 13 13 
'^s 294.422 329.963 389.196 307.066 
I 
R 0.94 0.94 0.77 0.98 
WMS = within subject mean squares BMS = between subject mean squares 
ss = sum of squares df = degrees of freedom ms - mean squares 
R = intraclass correlation coefficient of reliability, calculated as 
— (BMS - WMS) 尺 = B M S + (K.-1) WMS 
K�=• number of comparisons 
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& 4, and 4 & 5 were high at 0.94, 0.98 and 0.94, respectively, similar to those for 
CI values . The lowest R again was obtained from the comparison between Model 
1 and Model 3 at 0.77. 
As mentioned before, the terminal t,^  in the different models referred to different 
time periods and there could be large differences in the mean values with different 
models. It was not unexpected that the reliability test showed that the t^ values in 
one model did not quite agree with the t^ values in another model. The R values in 
the comparison between Models 1 & 2，1 & 3 and 2 & 4 were negative and 
」 indicated that the variation between the two values from the same subject in the two 
models was far in excess of the between subjects variation. The only reasonable R 
value was 0.85, obtained from the comparison between Model 4 and Model 5. 
The Bland-Altman method is an assessment of the agreement between two sets of 
measurements on the same subjects. It is essentially a plot of the difference between 
the methods (models) against their mean. In the present study, instead of the absolute 
values of the difference between the models, the difference, as a percentage of the 
mean, was plotted against the mean. These modified Bland-Altman plots are shown 
in Fig. 2.14 to Fig. 2.16. The Mean 土 2SD lines gives the 95 % confidence intervals 
of the percentage differences. The acceptability of the agreement between two 
models was assessed by the confidence limits. The ideal would be a very small 
percentage difference of the means. A summary of the percentage differences of the 
means for AUG, CI and t.^  for the various comparisons between the models is shown 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.27 Statistical Analysis - Modified Bland-Altman Method for the 
Assessment of Agreement Between two Models 
Mean value of individual percentage difference of the mean 
(士 SD) 
Comparisons between models 
4 vs 5 1 vs 2 1 vs 3 2 vs 4 
CI 3.3 土 4.7 4.6 土 1.5 9.8 土 1.9 1.9 士 1.8 
3.9 土 3.1 42.7 士 25.3 20.1 ± 13.5 30.0 士 21.1 
AUC 3.3 土 4.6 4.6 士 1.4 9.8 士 1.9 1.9 土 1.8 
I 
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The percentage difference of the mean for the comparison between Model 4 and 
Model 5 was small for CI, t.^  and AUG. The mean values were 3.3 士 4.7%, 3.9 士 
3.1% and 3.3 土 4.6% respectively. For the other comparisons, the percentage 
difference of the mean were below 10% for CI and AUG, but an agreement between 
the compared models for t,^  was not expected as the mean % were high at 42.7%, 
20.1% and 30.0% for the comparisons of Models 1 & 2, Models 1 & 3 and Models 
2 & 4 respectively. 
From Fig. 2.14 to Fig. 2.16, it can be seen that the spread of the percentage 
differences for the different comparisons was not wide except for the comparison of 
t.^  for Models 1 & 2, Models 1 & 3 and Models 2 & 4. Except for these three 
comparisons, the 95% confidence interval lines were close to the mean, showing 
quite good agreement between the two models in comparison. 
2.3.7 Discussion 
The absorption of paracetamol in healthy volunteers in this study was rapid. The 
peak plasma concentration was reached early, mean W being 0.89 土 0.40 hr. Al l 
subjects were fasted overnight for the study and paracetamol was administered as a 
solution, therefore factors that could affect the rate of absorption were minimised. 
Following absorption, there was a very brief distribution phase which could be 
missed very easily as elimination also takes place at the same time. The half-life of 
this distribution phase was found to be only around 3 to 19 minutes (Prescott, 1980) 
and thus is not always characterised in pharmacokinetic studies of paracetamol. The 
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distribution phase is usually complete at approximately 1.5 hr when equilibrium is 
achieved between the tissues and the circulation. Paracetamol is distributed 
throughout most tissues but not fat. 
Plasma paracetamol is removed mainly by hepatic metabolism and the decrease in 
plasma paracetamol concentrations follows first order kinetics. On a semilogarithmic 
graph, the plasma concentration of paracetamol declined in a linear fashion against 
time up to around 8 - 12 hr. Using this part of the slope for estimation, the mean ‘ 
of paracetamol was 2.6 土 0.3 hr (range 1.9 - 3.0, Model 4). Beyond this period, 
the decline in paracetamol concentration seemed to be much slower as the plasma 
concentration at 24 hr did not seem to fit-in with a single elimination phase. The t^ 
of this apparently slower elimination phase between 8 - 24 hr was estimated to be 
5.4 土 1.1 hr (range 3.8 - 7.5, Model 1), but this estimation is dominated by the 24 
hr measurement. 
Metabolism of paracetamol by the gastrointestinal tract is insignificant in man 
(Clements et a l , 1984), but following absorption, which is almost complete, it 
reaches the systemic circulation. First pass metabolism of paracetamol is extensive 
and the oral bioavailability is about 70 _ 80% (Rawlins et al.，1977; Perucca & 
Richens, 1979; Clements et al； 1984). The extent of paracetamol metabolism was 
reflected in the finding that along with all metabolites excreted in the 24 hr urine 
collection (mean total recovery 94.2%), only 5.6% was recovered as unchanged 
paracetamol. The rate of metabolism was also high as over 40% of all metabolites 
was recovered within 4 hr in the urine and over 70% within 8 hr. 
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Forrest et a l found that approximately 85 - 95% of a therapeutic dose of 
paracetamol is excreted in the urine within 24 hr (Forrest et al” 1982). In the 
present study, the mean total recovery in the 24 hr urine collection was 94.2 士 
15.4% of the dose (63.6 - 113.7%). The mean value is comparable to published 
data. The between subject variation was likely due to inaccuracies or incompleteness 
in the collection of urine samples. 
The glucuronide and sulphate conjugates are the major metabolites of paracetamol. 
In this study, their sum represented a mean of 88.5% of all metabolites recovered 
in the 24 hr urine collection. The mean fractional recovery of the cysteine and 
mercapturate metabolites were 3.3% and 2.5%, respectively. The fractional 
recoveries of the various metabolites were comparable to published data in the 
Caucasians (Prescott, 1980) but with slightly lower values for the oxidative 
metabolites. The mean of the sum of the fractional recoveries of the cysteine and 
mercapturate metabolites in this study was found to be 5.8 土 1.9%, comparing to 
9.3% among Caucasians in Scotland (Critchley et a l , 1986). This genetic difference 
in the fractional recoveries of the oxidative metabolites of paracetamol was also 
found in a study among Chinese living in Singapore. The value was at 6.0% (Lee 
etal, 1992). 
Inter-individual variation in paracetamol metabolism is well recognised (Caldwell et 
al” 1980; Clements et al； ； Critchley et al., 1986). In the present study, the 
fractional recovery of the glucuronide conjugate ranged from 40.7% to 68.6% and 
that of the sulphate conjugate was 22.3 - 46.4%. Those subjects with lower 
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fractional recoveries of the glucuronide conjugate made up for it by producing more 
of the sulphate conjugate. Overall, the fractional recoveries of the cysteine conjugate, 
unchanged paracetamol and the mercapturate conjugate among the subjects varied by 
about 3 to 4 fold. Factors such as age and diet may influence the metabolism of 
paracetamol. 
In the different models for analysis in this study, though the same plasma 
concentration data were used, there was much difference in the estimated 
pharmacokinetic parameters, as different sampling times were used. Global analyses 
by repeated measures ANOVA showed that the AUC, CI, t^, MRT and V^ estimated 
in these 5 models were significantly different, but paired comparison between models 
revealed that some of the individual comparisons were not significantly different. 
The comparison between Model 1 and Model 2 was used to demonstrate the 
importance of the 24 hr point in influencing the pharmacokinetic parameters of a 3-
phase model. Al l the pharmcokinetic parameters estimated were significantly 
different between these 2 models. The AUC and V^ (terminal phase) were 
significantly larger and the terminal t.^  was significantly longer in Model 1. CI was 
thus found to be lower. It was evident that the contribution of the 24 hr point to the 
characterisation of a 3-phase model is important and a terminal phase could not be 
adequately described for sampling times up to 12 hr only. 
On the other hand, none of the pharmacokinetic parameters estimated was 
significantly different between Model 4 and Model 5. They were both describing a 
Chapter 2 149 
2-phase model but the sampling time was up to 12 hr in Model 4 and for Model 5， 
only up to 8 hr. This seems to indicate that the extra sampling points at 9, 10, 11 
and 12 hr did not affect the overall pharmacokinetic model at all when the model 
chosen was a 2-phase one. The parameters obtained in a 2-phase model (Model 4 or 
5), when compared to those in Model 1, the AUC and V^ (terminal phase) were 
smaller, the terminal t.^  and MRT were shorter and the CI was higher. 
Combining the findings from these two comparisons, it seemed that up to 12 hr after 
oral administration, the pharmacokinetics of paracetamol could be adequately 
described by a 2-phase model. The sampling times from 9 to 12 hr did not fit very 
well in the terminal elimination phase of a 3-phase model, but extremely well in the 
elimination phase of a 2-phase model. The existence of a second, slower elimination 
phase seemed to hinge on the existence of a higher than expected plasma 
concentration at 24 hr. I f the 24 hr plasma sample was not taken or i f this sampling 
time was ignored, then a 2-phase model could be used to describe the 
pharmacokinetics of paracetamol adequately, regardless of whether the sampling time 
was up to 8 or 12 hr. 
The comparison between Model 1 and Model 3 addressed the importance of extra 
sampling times between 9 to 12 hr in a 3-phase model. Al l pharmacokinetic 
parameters estimated, except MRT, were significantly different between the 2 
models. This indicated that there was a significant difference between fitting the 
terminal elimination phase through the sampling points at 8，9，10, 11, 12 and 24 
hours or just between the 8 and 24 hr points. In the comparison between Model 4 
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and Model 5, it has been demonstrated already that the sampling points from 9 - 12 
hr fitted almost perfectly in the terminal elimination phase of a 2-phase model. With 
that in mind, it was not surprising to find that the pharmacokinetic parameters 
between Model 1 and Model 3 were significantly different. 
The same sampling times were used in Model 2 and Model 4, the former fitted to 
a 3-phase model and the latter to a 2-phase model. A comparison between these 2 
models was used to demonstrate the difference in the pharmacokinetic parameters 
when the same sampling points were force-fitted to 2 different models. The AUC 
and CI were not significantly different between these 2 models but the terminal t^, 
Vd and MRT were. The force-fitting of the sampling points between 8 to 12 hr put 
these points into a second elimination phase and thus the terminal t^ in Model 2 and 
Model 4 were essentially describing a different time period. Nevertheless, this did 
not alter the AUC and CI significantly enough to produce a difference. 
The lack of difference between Model 4 and Model 5 was further demonstrated by 
the results of the intraclass correlation coefficient of reliability study. Among the 4 
different between-models comparisons, only that between Model 4 and Model 5 
scored a high R value with all 3 parameters studied - CI, t々  and AUC. This result 
indicated that Model 4 and Model 5 could quite reliably interchange with one 
another. It should also be noted that though R was a negative value in the 
comparison of between Model 2 and Model 4, the comparisons of CI and AUC 
scored excellent R values. There were similar findings for the comparison between 
Model 1 and Model 2. 
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The Bland-Altman method was originally devised as a statistical method for the 
assessment of agreement between two methods of clinical measurement (Bland & 
Altman, 1986), e.g. a comparison of a new measurement technique with an 
established one. The use of the product-moment correlation coefficient between the 
results of the two measurement methods is inappropriate because it measures the 
strength of a relation between the two sets of variables, not the agreement between 
them. Bland and Altman thus devised this method which is essentially a plot of the 
difference between the two methods against their mean, with the 95% confidence 
interval lines as an aid in assessing the agreement. I f the mean difference between 
the two sets of data in study is close to zero and the 95% confidence intervals are 
within tolerated limits, then the two methods show reasonable agreement and they 
are interchangeable. 
In this study, this plot was altered slightly. Instead of the absolute value of the 
difference, the percentage difference was plotted against the mean. This modification 
was realised to be necessary and would improve the presentation of results. For a 
parameter whose normal value is high, then a difference arising from two 
measurements would be of a small percentage of the mean value. Take AUG in this 
study, the commonly reported values was around 100 ^g ml'^  hr. A difference of a 
magnitude of 10 or below between two measurements in comparison would constitute 
only a 10% difference. On the other hand, a difference of 2 to 3 between two 
measurements of t,^  whose commonly reported value was only about 4 hr would be 
an unaceptably high percentage of difference of the mean value. To be able to 
evaluate the comparisons of pharmacokinetic parametejs betweeii two modelling 
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regimens in this study, which encompass parameters of varying magnitudes, it is 
necessary to find a common unit that would describe the differences of all 
parameters between the two regimens in comparison. By expressing the difference 
as a percentage of the mean instead of the absolute value, this became possible. This 
principle also applies to a parameter whose value can span over a wide range. The 
mean value between two particular methods may be much smaller than that of 
another two. It would be misleading to compare the absolute value of the difference 
and by expressing the difference as a percentage of the mean, this problem can also 
be negated. Thus, in this study, all Bland-Altman plots were presented and results 
calculated as the percentage differences versus the mean values of two regimens in 
comparison. This has made a major improvement in the presentation of comparative 
results. 
Like the intraclass correlation coefficient of reliability, the results of the Bland-
Altman comparisons again showed that there was excellent agreement between Model 
4 and Model 5. The mean percentage difference for CI, t^ and AUG were all below 
4%. For the comparison between Model 2 and Model 4，there was excellent 
agreement in CI and AUG with the mean percentage difference at below 2 %，but that 
for t^ stood out as high at 30%. This observation also applies to the comparisons of 
Model 1 & 2, and Model 1 & 3. 
I 
In summary, the results of this study indicate that up to 12 hr after oral 
administration, the pharmacokinetics of paracetamol could be adequately described 
by a 2-phase model. The sampling times from 9 to 12 hr did not fit very well in the 
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terminal elimination phase of a 3-phase model, but extremely well in the elimination 
phase of a 2-phase model. The existence of a second, slower elimination phase 
seemed to hinge on the existence of a higher than expected plasma concentration at 
24 hr. I f the 24 hr plasma sample was not taken or i f this sampling time was 
ignored, then a 2-phase model could be used to describe the pharmacokinetics of 
paracetamol adequately, regardless of whether the sampling time was up to 8 or 12 
hr. The intraclass correlation coefficient of reliability and the Bland-Altman plots 
showed excellent agreement between Model 4 and Model 5 for CI, t.^  and AUC, but 
not for other between-model comparisons. Model 5 is thus an adequate model for the 
study of the pharmacokinetics of paracetamol. 
In this study of 14 healthy Chinese subjects, the mean CI of paracetamol after an 
oral dose of 20 mg kg-\ estimated by Model 5 was 4.08 土 1.07 ml min"^ kg-i and 
mean terminal t.^  was 2.6 士 0.4 hr. The mean V j of this terminal phase was found 
to be 0.88 1 kg-i and the mean MRT was 4.0 土 0.5 hr. 
A prolonged second elimination phase in the pharmacokinetics of paracetamol has 
seldom been reported. The well published elimination t.^  usually refers to the period 
between 2 to 8 hr after drug administration. The reason for the higher than expected 
plasma level at 24 hr in this study was not clear. One suggestion is that previously, 
the detection limit of paracetamol in plasma might be higher than what can be 
achieved now. This low level at 24 hr might not be detectable in previous studies. 
Another explanation for this higher than expected plasma level at 24 hr may be that 
this is not entirely due to a slower, second elimination phase, but due to some 
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enterohepatic circulation. Biliary excretion and enterohepatic circulation of 
paracetamol has been shown both in the rat and in man (Siegers et al.，1983; Siegers 
et al.，1984). In man, 2.6% of an oral 1 g dose is excreted into bile within 8 hours. 
Bile has been shown to be an important route of elimination for the cysteine 
conjugate and it accounts for 19.4% of the total excretion of the metabolite 
(Jayasinghe et al” 1986), but the extent of enterohepatic circulation is not known. 
It may be possible that some of the paracetamol and its metabolites excreted in bile 
is recirculated, thus contributing to a prolonged, higher plasma concentration. 
I 
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2.4 The pharmacokinetics of paracetamol in healthy subjects, patients with 
liver disease and hepatocellular carcinoma 
2.4.1 Introduction 
Previous work in the Department of Clinical Pharmacology at The Chinese 
University of Hong Kong has shown that the percentage of urinary recovery of the 
oxidative metabolites of paracetamol in 24 hr urine collections was much greater in 
patients with hepatocellular carcinoma (Leung & Critchley, 1991). There were a few 
outliers in a group of patients with chronic hepatitis B infection who also excreted 
a much higher percentage as the oxidative metabolites than the rest of the group. 
This indicated increased microsomal cytochrome P450 activity. The patients with 
hepatocellular carcinoma had correspondingly reduced glucuronide conjugation but 
the proportions of the sulphate conjugate excreted were similar. These findings 
suggested that the increased production of oxidative metabolites was not a 
consequence of a primary impairment in glucuronidation because a corresponding 
increase in sulphate conjugation would be expected. Nevertheless, due to the 
limitations of this study, full interpretations could not be made as only 24 hr urine 
data was available. To make clearer interpretations of the finding of a much 
enhanced oxidative metabolism of paracetamol in patients with hepatocellular 
carcinoma, a full comparative study of the pharmacokinetics of paracetamol in 
healthy subjects and patients with liver disease or hepatocellular carcinoma is 
needed. Clearance and elimination half-lives calculated from the plasma data would 
provide more information about the mechanism of the altered metabolism. 
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In section 2.3, the differences in the estimated pharmacokinetic parameters in 
different models were assessed. Model 5 was chosen as a pharmacokinetic model that 
could be used to describe the pharmacokinetics of paracetamol adequately and this 
2-phase model would be used in the following study. 
2.4.2 Study protocol 
A l l studies were carried out in the Clinical Pharmacology Studies Unit, Department 
of Clinical Pharmacology, The Chinese University of Hong Kong, at the Prince of 
Wales Hospital, Shatin. 
2.4.3 Methods 
2.4.3.1 Subjects 
Subjects were recruited for 5 categories: 
Group A: Healthy controls 
Group B: Patients with alcoholic liver disease 
Group C: Patients with chronic hepatitis B infection/liver cirrhosis 
Group D: Patients with hepatocellular carcinoma 
Group E: Patients with renal impairment 
The healthy subjects were volunteers responding to recruitment appeal posters for 
clinical research posted around the Hospital, or patients attending other clinics at the 
Prince of Wales Hospital, who were not on any medication or suffering from any 
disease affecting liver function or drug metabolism. Subjects in Group B and Group 
C were patients recruited from the Liver Clinic at the L i Ka Shing Specialist Clinic, 
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Prince of Wales Hospital and those in Group D, from the Joint Hepatoma Clinic. 
These patients all had detail patient records and previous laboratory tests to confirm 
diagnoses and were referred by their physicians-in-charge. Subjects with renal 
impairment were added on as a group for interest of comparison. They were diabetic 
patients attending the Metabolic Investigation Unit at the Prince of Wales Hospital. 
It was aimed to recruit 8 subjects for each study group. Every subject was given a 
physical examination and screening tests for plasma biochemistry were performed 
together with urinalysis. Group D, the group of patients with hepatocellular 
carcinoma was later split into two. The first 8 subjects recruited remained as Group 
D. A further 8 patients with hepatocellular carcinoma were recruited later and they 
formed Group D，(see Discussions p. 195). 
A summary of the age, body weight and height of the subjects in each group is 
shown in Table 2.28 and the plasma biochemistry screen data are shown in Table 
2.29. Informed consent was given by each subject and the study was approved by 
the Hospital Ethics Committee. 
2.4.3.2 Drug administration and sampling 
The procedures were essentially the same as in 2.3.3.2 with a slight modification in 
the sampling times. The subjects attended the Clinical Pharmacology Studies Unit 
in the Department of Clinical Pharmacology in the morning, after an overnight fast. 
An in-dwelling cannula (Angiocath 20G 2 inch, Becton Dickson) was inserted into 


























































































































































































































































































































































Table 2 .29 Plasma Biochemistry Screen of Subject.^ in Differenf f^hiHy 
Groups 
Group A Group B Group C Group D Group R Group D' Normal 
I I Range. 
Na Mean ~ 1 4 0 . 9 ~ ~ 1 3 5 . 4 138.4 137.1 = 139.1 137.0 137 - 142 
(mmoll-i) SD 2.0 8.4 7.0 5.1 1.5 4.5 
Range 138 - 144 115 - 141 122 - 144 127 - 142 138 - 142 128 - 143 
K Mean 4 T ^ T T 4.3 4.5 = 3 . 5 - 5 . 1 
(mmol 1-1) SD 0.4 0.7 0.8 0.4 0.4 0.5 
Range 3.7 - 4.7 3.3 - 5.3 2.8 - 5.4 3.3 - 4.5 3.7 - 4.9 4.0 - 5.3 
Urea Mean J Z J l ^ s T 20. l" 8 . 3 = 3 . 4 - 8 . 9 
(mmoir �） SD 1.1 1.4 1.8 3.2 11.6 2.4 
Range 4.2 - 7.5 1.9 - 6.6 3.9 - 9.1 5.1 - 13.5 9.0 - 44.6 5.0 - 11.3 
Creatinine Mean 80^ 83^ s H 2 6 ^ 100.6 64 - 96 
(/xmol r') SD 9.8 7.4 8.2 9.0 159.2 10.4 
Range 62 - 90 70 - 95 70 - 94 72 - 93 128 - 609 88 - 115 
Total Protein Mean 81.1 82.6 79.1 7 ^ 4 i o o " 6 6 - 8 1 
(g 1 �） SD 2.0 6.6 8.8 8.3 7.0 6.7 
Range 77 - 83 72 - 93 65 - 91 67 - 92 64 - 82 72 - 90 
Albumin Mean 45.6 39.5 38.3 36.0 34.3 37.2 35 - 4 8 “ 
(g I') SD 2.4 5.0 9.1 6.2 19.3 5.3 
Range 42 - 49 29 - 44 22 - 50 29 - 47 5 - 64 29 - 45 
Total Mean 5 2 l T ^ 109.9 0 - 15 
Bilirubin SD 3.6 57.3 17.8 185.6 17.9 229.9 
(/imol 1') Range 5 - 16 7 - 165 4 - 52 14 - 550 3 - 45 6 - 630 
I Alkaline Mean 77.0 141.1 104.5 281.8 95.2 326.4 40 - 1 3 6 “ 
Phosphatase SD 20.1 46.9 45.6 306.3 38.2 261.3 
(lU 1') Range 58 - 116 84 - 223 68 - 210 99 - 902 59 - 162 2.5 - 785 
I ALT Mean 34.0 39.5 88.8 81.0 10.2 99.4 0 - 58 
(lU 1-1) SD 25.2 33.7 110.8 69.3 6.1 48.8 
Range 9 - 66 20 - 116 16 - 351 22 - 243 2 - 18 60 - 190 
Gamma GT Mean 328.3 T f f l 201.1 0 - 84 (F) 
(U r�） SD 23.5 239.1 297.2 155.5 0 - 100 (M) 
Range 11 - 68 53 - 739 18 - 778 52 - 466 
a-foetoprotein Mean 156936.7 < 10 
(lU ml-') SD 228374.5 
Range 10 -
563500 
' F r o m the Department o f Clinical Pathology, Prince of Wales Hospital, Shatin 
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The 24 hr blood sample was taken at a different site by venepuncture. Paracetamol 
was administered as the syrup (Panadol Syrup 160 mg ml'^, Sterling Drug (Malaya) 
Sdn., Bhd., Kuala Lumpur for Winthrop Product Inc., New York, U.S.A.) at a dose 
of 20 mg/kg body weight. Food and beverage were withheld for at least 3 hours 
after drug administration and only water was allowed. Lunch was available at 4 hour 
and after that fluid and food intake were unrestricted. 
5 ml venous blood samples were drawn into heparinised tubes at 0, 0.5, 1, 1.5, 2, 
3, 4, 5, 6, 7, 8, and 24 hours after dosing. Blood samples were centrifuged at 1400 
X容 for 10 minutes and the plasma separated for storage at -20°C prior to analysis. 
Urine was collected for the time periods 0-4, 4-8 and 8-24 hours after dosing. The 
volume of urine excreted at each time period was noted and a 20 ml aliquot was take 
from each collection and stored at -20^0 until analysis. 
2.4.3.3 Drug analysis 
The concentrations of paracetamol, the glucuronide, sulphate, cysteine and 
mercapturate metabolites in plasma and in the urine were measured by the HPLC 
assay as described in section 2.2.2 of this chapter. Metabolite concentrations were 
expressed as paracetamol equivalents. 
I 
2.4.3.4 Calculations 
Plasma concentrations of paracetamol and the glucuronide, sulphate and cysteine 
metabolites for each subject were calculated from the respective peak area counts and 
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the paracetamol standards according to section 2.2.4.2. The recovery of paracetamol 
and its metabolites in the urine was calculated according to section 2.2.3.2. The 
individual peak plasma concentrations (C薩）and time to reach peak plasma 
concentration (t^ ax) were noted. 
The metabolic clearance was calculated according to the Method of Miners et a l 
(Miners et al” 1983; Miners et al” 1986), as described in section 2.3.3.4. 
2.4.4 Pharmacokinetic analysis 
Pharmacokinetic analysis was done using the pharmacokinetic modelling programme 
Siphar/base, Version 4.0 (1991, SIMED, Cr6teil, Cedex, France). Pharmacokinetic 
modelling and estimation of the pharmacokinetic parameters of individual plasma 
data was done as described in section 2.3.4. The following parameters were 
calculated for each study subject: AUG, CI, t.^, V^ and MRT, as defined in section 
2.3.4. 
2.4.5 Statistical analysis 
Mean values with the standard deviation (SD) are presented. Al l statistical analyses 
were carried out using the computer statistics package SPSS for Windows (Version 
5，1992, SPSS Inc., Chicago, U.S.A.), supplemented by SigmaStat (Version 1.01, 
1993, Jandel Scientific, San Rafael, California, U.S.A.) when some of the tests were 
not available on SPSS. The Geigy Scientific Tables (Geigy Scientific Tables, 1982) 
was also consulted when the coefficient of correlation was tested for statistical significance. 
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2.4.6 Results 
2.4.6.1 Plasma Results 
Mean plasma concentrations of paracetamol and its metabolites following oral 
administration of a 20 mg kg i body weight dose in the different groups are shown 
in Table 2.30 to Table 2.33 and Fig. 2.17 to Fig. 2.20. The mercapturate conjugate 
was not detected in any of the plasma samples probably due to very low 
concentrations. Plasma concentrations for individual subjects are shown in 
Appendices 2.28 - 2.51. Individual values for peak concentration ( C ^ and time to 
reach peak concentration ( t ^ for paracetamol, paracetamol glucuronide and 
paracetamol sulphate are shown in Table 2.34 to Table 2.36. They are also shown 
as scattergraphs in Fig. 2.21. 
Mean C ^ and t ^ of paracetamol in Group A, the healthy controls, were 22.91 士 
4.57 fxg ml-i and 0.71 士 0.27 hr. These values are comparable to those of the 14 
healthy volunteers studied in section 2.3. The mean C紐 for the glucuronide and 
sulphate conjugates of Group A are 14.77 士 3.39 fig ml"^  and 6.55 土 1.23 fig ml-\ 
and the mean Ux 3.00 士 0.58 hr and 1.50 土 0.41 hr, respectively. As expected, 
only very low concentrations of the cysteine conjugate was detected in the plasma 
samples (see Appendices 2.46 - 2.51). 
I 
2.4.6.2 Urine Results 
Table 2.37 shows the overall recovery and fractional recovery of paracetamol and 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 口 Mean Plasma Concentration of Paracetamol in Snbjp.nfQ in 
Different Study Groups Following Ingestion of a 20 mg ky i 
Body Weight D舰 
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Fig. 2.18 Mean P~asma Concentration of Paracetamol Glucuronide in 
Subjects in Different Study Groups Following Ingestion of 
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Fig. 2.19 Mean Plasma Concentration of Paracetamol Sulphate in 
Subjects in Different Study Groups Following Ingestion of 
a 20 mg kg-i Body Weight Dose of Paracetamol 
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Fig' 2 .20 Mean Plasma Concentration of Paracetamol Cysteine in 
Subjects in Different Study Groups Following Ingestion of 
a 20 mg kg-i Body Weight Dose of Paracetamol 
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Fig. 2 .21 Scattergraphs of Maximum Plasma Concentration and 
Time to Reach f t ^ J of Paracetamol of Subjects in 
Different Study Groups Following Ingestion of a 20 mg kg] 
Body Weight Dose 
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The mean total recovery of paracetamol and all metabolites in the 24 hour urine 
collection were 89.8 士 10.7%, 94.4 士 18.8%, 85.9 土 20.8%, 99.7 士 28.6%, 
62.5 士 24.1% and 78.1 士 8.3% for Groups A, B, C, D, R and D’，respectively. 
The total recovery was much lower in the Group R, patients with renal impairment 
and this lower percentage of reocovery in the 24 hour urine collection is comparable 
to a previous study (Prescott et al” 1989). 
The percentage recovery as the glucuronide, sulphate conjugate and as unchanged 
paracetamol was comparable in the various groups. The mean percentage recovery 
as the glucuronide conjugate ranged from 42.9 士 10.86% to 58.50 土 5.18%, from 
31.22 土 11.58% to 36.24 土 9.98% as the sulphate conjugate and from 3.28 士 
1.79% to 4.95 士 1.62% as unchanged paracetamol. There was no significant 
difference in these mean values but the mean percentage as the cysteine and 
mercapturate conjugate was significantly higher in Group D，，the patients with 
hepatocellular carcinoma. The mean percentage recovery in this group was 18.39 士 
5.08% as compared to 5.05 士 1.60%, 6.69 士 2.85%, 6.51 土 3.52%，7.96 士 
3.57% and 6.20 土 2.16% in Groups A, B, C, D and R, respectively. 
The mean cumulative recovery of paracetamol and its metabolites in the urine is 
shown in Table 2.38 and Fig. 2.22. Individual urinary excretion data are shown in 
Appendices 2.52 - 2.57. 
176 
Table 2.37 Urinary Recovery of Paracetamol and Its Glucuronide. Sulphate. 
Cysteine and Mercapturate Metabolites in 24 h in Different Study 
Groups Following Ing:estion of a 20 mg kg'^  Body Weight Dose 
Percentage of Total Amount Recovered in Urine Over 24 hours Total 
Group Subject ~ 5 ~ ~ § ~ ~ C ~ ~ P ~ ~ M ~ m+C Recovery as 
% of Dose 
A i 64.53 27.09 1.84 4.28 2.25 TTT" 9IT" 
2 62.04 25.55 3.52 4.14 4.75 8.27 88.5 
3 52.70 38.81 2.49 3.70 2.29 4.78 99.0 
4 54.89 37.79 2.39 3.21 1.71 4.10 94.0 
5 55.12 36.50 1.94 4.27 2.18 4.12 68.9 
6 65.04 25.94 1.75 5.08 2.19 3.94 100.4 
7 55.18 34.63 3.66 4.17 2.37 6.02 85.1 
Mean 58.50 32.33 2.51 4.12 2.54 5.05 I 89.8 
SD 5.18 5.90 0.78 0.57 1.00 1.60 10.7 
B i 68.70 24.57 2.12 2 M 2.12 T I T ' l o T T 
2 59.60 29.07 3.20 4.95 3.17 6.37 64.9 
3 55.81 30.43 3.63 5.15 4.99 8.61 70.2 
4 73.66 19.64 1.59 2.29 2.82 4.41 114.8 
5 57.01 34.60 2.27 3.72 2.40 4.67 109.5 
6 50.27 34.64 4.55 5.64 4.90 9.45 104.0 
7 37.13 56.12 2.53 2.55 1.67 4.20 84.0 
8 65.55 20.67 7.39 2.19 4.20 11.59 104.9 
M ^ 58.47 31.22 3.41 3.28 9 4 T " 
SD 11.46 11.58 1.86 1.44 1.27 2.85 18.8 
C i 43.79 39.00 4.42 7.58 5.22 9：^ S O ^ 
2 41.28 44.46 4.65 6.91 2.70 7.35 80.0 
3 64.01 27.77 2.57 3.98 1.67 4.24 100.0 
4 38.08 41.46 8.11 6.12 6.23 14.35 71.7 
5 59.76 30.58 2.49 4.96 2.22 4.70 69.5 
6 75.27 15.90 2.28 4.63 1.92 4.20 104.6 
7 58.80 33.17 2.49 3.29 2.25 4.74 50.4 
8 54.55 35.08 2.74 4.34 3.29 6.03 101.4 
9 72.17 21.73 1.44 2.76 1.90 3.34 115.3 
M i ^ 56.41 32.13 3.47 4.95 3.04 6.51 85.9 
SD 13.26 9.28 2.02 1.62 1.62 3.52 20.8 
D i 42.46 45.34 6.38 2.48 0 4 9.72 I 110.8 
2 59.26 32.92 1.96 4.18 1.68 3.64 94.2 
3 60.17 32.42 2.36 3.31 1.75 4.10 136.0 
4 53.34 33.80 4.51 2.24 6.11 10.62 38.9 
5 66.91 23.78 1.70 5.74 1.87 3.57 119.8 
6 31.26 52.47 7.04 5.17 4.06 11.10 88.6 
7 58.92 25.67 6.60 3.54 5.27 11.87 104.6 
8 41.71 43.50 5.45 5.74 3.59 9.04 104.7 
Mi^~~ 51.75 36.24 Oo~l 4.05 3.46 7.96 99.7 
SD 12.06 9.98 2.21 1.39 1.66 3.57 28.6 
— R — i —43.17 42.41 o r n o r n stmh IO? 34.6 
2 49.47 38.98 1.80 2.49 1.52 3.32 64.7 
3 49.79 30.94 2.52 1.64 2.31 4.83 55.5 
4 47.94 24.29 1.79 2.68 1.67 3.46 55.8 
5 68.48 18.86 3.80 2.59 2.73 6.53 59.2 
6 53.84 35.16 3.11 2.76 3.07 6.19 107.5 
M^ 57：^ 33J7~| J lT l JWl I^T] 6.20 62.9 
SD 9.31 8.26 1.05 0.63 1 15 2.16 24.1 
D, i 23.01 48.82 19.25 OT l OTl~~~27.96 74.7 
2 60.58 23.22 7.49 2.23 6.48 13.97 71.4 
3 41.79 32.03 12.22 6.48 7.48 19.71 90.3 
4 37.45 41.04 10.63 3.84 7.05 17.68 66.8 
5 40.60 37.00 12.62 2.53 7.24 19.86 86.8 
6 41.80 33.42 12.66 3.18 8.94 21.60 84.8 
7 50.49 32.67 8.73 4.11 4.01 12.74 76.1 
g 47.57 35.12 8.05 3.69 5.57 13.62 73.5 
Mean 42.91 35.41 11.46 3.28 6.94 18.39 W T l 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2.22 Cumulative Urinary Recovery of Paracetamol and Its 
Metabolites in 24 hour Urine Collection of Subjects in 
Different Study Groups Following Ingestion of a 20 mg kg'^  
Body Weight Dose 
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2.4.6.3 Pharmacokinetic Results 
The pharmacokinetic parameters calculated for the different study groups are shown 
in Table 2.39 to Table 2.43, including AUG, CI, terminal t^, MRT and V^. 
Individual data are listed together with the mean value of each study group. 
Scattergraph of these parameters are shown in Fig. 2.23. It can be seen that both 
intra-group and inter-group variations were observed. The mean values of AUG 
varied from 64.4 土 29.0 ^g ml"^  hr (Group R) to 113.0 土 61.5 ixg ml"^  hr (Group 
C). Since CI is related to AUG by an inversely proportional relationship, the highest 
mean CI value was found in Group R (6.51 土 3.84 ml min] kg ) but the lowest was 
in Group D，，after having taken the body weight into account, at 3.66 士 1.02 ml 
min-i kg-i. 
The mean terminal t.^  in the study groups ranged from 2.1 土 0.2 hr (Group A) to 
3.2 土 1.4 hr (Group C). The largest inter-subject variation was also found within 
Group C, with the standard deviation at 1.4 hr as compared to the next highest 0.7 
hr in Group R. Within Group C，t., ranged from 1.9 to 5.7 hr. The mean MRT 
values in the study groups reflects a similar pattern to those of t , . Again the lowest 
mean value was found in Group A (3.3 土 0.3 hr) and the highest mean MRT was 
5.1 hr in Group C, with a standard deviation of 2.2 hr. 
The low mean AUG value in Group R was a result of the overall lower plasma 
concentrations achieved in the subjects studied. The high mean V, value in this group 
(1.23 土 0.45 1 kg-') was thus a related finding. The lowest mean V, was found in 
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Table 2.39 Area Under Curve (Al]C) of the Plasma Concentr^^finn-
Time Curves of Paracetamol in Different Study Groups 
Following Ingestion of a 20 mg kg i Body Weight Dose 
Area Under Curve of Study Groups (fig ml"^  hr) 
Subject 
Group A Group B Group C Group D Group R Group D， 
1 65.5 38.5 128.7 55.4 111.7 95.7 
2 60.6 116.4 232.2 104.5 36.5 76.0 
3 77.1 60.9 157.5 62.7 73.4 77.8 
4 67.2 56.6 78.0 153.1 56.3 150.1 
5 109.2 85.7 62.2 137.5 23.8 63.0 
6 86.2 137.9 87.7 80.6 72.1 122.2 
7 70.5 93.6 61.2 89.6 77.3 84.4 
8 52.4 162.2 90.6 115.0 
9 47.2 
Mean 76.6 80.2 113.0 96.7 64.4 98.0 
SD 16.6 34.4 61.5 34.1 29.0 29.0 
I 
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Table 2.40 Clearance (CA) of Paracetamol in Different Study Grnnp^ 
Following Ingestion of a 20 mg kg'^  Body Weight Dof^ p 
Clearance of Paracetamol in Different Study Groups (ml min ' kg ') 
Subject r — 
Group A Group B Group C Group D Group R Group D’ 
1 5.09 8.66 2.59 6 .02 2.98 3.48 
2 5.50 2.86 1.44 3.19 9.14 4.39 
3 4 .32 5.47 2.12 5.32 4.54 4.28 
4 4.96 5.89 4.27 2.18 5.92 2.22 
5 3.05 3.89 5.36 2.42 14.02 5.29 
6 3.87 2.42 3.80 4.14 4.63 2.73 
7 4.73 3.56 5.44 3.72 4.31 3.95 
8 6.36 2.05 3.68 2.90 
9 7.06 
Mean 4.50 4.89 3.79 3.83 6.51 3.66 
SD 0.83 2.09 1.90 1.32 3.84 1.02 
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Table 2.41 Terminal Elimination Half-life of Paracetamol in Different 
Study Groups Following Ingestion of a 20 mg kg:] Body 
Weight Dose 
Terminal Elimination Half-Life of Paracetamol (hr) 
Subject 
Group A Group B Group C Group D Group R Group D’ 
1 2.3 1.7 3.7 1.9 3.0 2.8 
2 1.8 2.8 5.7 3.2 2 .2 2.3 
3 2.0 2.4 4.6 2.0 2.5 2.5 
4 1.7 1.4 2.2 3.4 1.9 3.2 
5 2.4 2.3 2.3 2.3 1.6 2.6 
6 2.1 3.3 2.2 2.5 3.8 3.0 
7 2.0 2.8 1.9 3.1 2.3 3.2 
8 2.0 4.5 2.8 3.1 
9 1.6 
” 2 . 1 2.3 3.2 2.6 2.5 2.8 
SD 0.2 0.6 1.4 0.6 0.7 0.4 
I 
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Table 2.42 Mean Residence Time of Paracetamol in Different ShiHy 
Groups Following Ingestion of a 20 mg kg] Body Weight 
Dose 
Mean Residence Time of Paracetamol (hr) 
Subject 
Group A Group B Group C Group D Group R Group D， 
1 3.6 2.7 5.9 3.1 4.8 4.9 
2 3.1 4.7 8.8 4.9 3.9 3.6 
3 3.3 4.0 7.1 3.2 4.2 3.9 
4 2.8 2.3 3.6 5.5 3.2 4.9 
5 3.7 3.6 3.6 3.7 2.7 5.5 
6 3.4 5.2 3.6 3.9 5.7 4.5 
7 3.2 4.3 3.1 5 .2 4.0 4.9 
8 3.4 7.4 4.3 4.7 
9 3.1 
Mean 3.3 3.8 5.1 4.2 4.1 4.6 
SD 0.3 1.0 2.2 0.9 1.0 0.6 
I 
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Table 2.43 Volume of Distribution of Terminal Elimination Phase of 
Paracetamol in Different Study Groups Following Ingestion 
of a 20 mg kg] Body Weight Dose 
Volume of Distribution of Terminal Elimination Phase 
Subject of Paracetamol (1 kg-1) 
Group A Group B Group C Group D Group R Group D, 
1 1.00 1.26 0.84 0.97 0.78 0.85 
2 0.87 0.68 0.70 0.87 1.72 0.87 
3 0.76 1.13 0.84 0.90 0.98 0.91 
4 0.74 0.70 0.83 0.64 0.99 0.62 
5 0.62 0.79 1.08 0.49 1.88 1.19 
6 0.71 0.69 0.72 0.89 1.51 0.70 
7 0.83 0.86 0.89 1.00 0.86 1.08 
8 1.13 0.80 0.88 0.78 
9 1.00 
Mean 0.79 0.91 0.86 0.83 1.25 0.88 
SD 0.12 0.23 0.12 0.17 0.45 0.19 
I 
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Fig* 2.23 Scattergraphs of AUG, CK t,“ MRT and V, of Paracetamol 
Pf Subjects in Different Study Groups Following Ingestion 
of a 20 mg kg] Body Weight Dose 
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Group A, at 0.97 士 0.12 I k g i. 
The mean metabolic clearances to the various metabolites of paracetamol in the study 
groups are shown in Table 2.44. The metabolic clearance of a particular metabolite 
is a function of the plasma clearance of paracetamol and the urinary fractional 
excretion as that metabolite. Its value will be affected by both these factors. The 
scattergraph of the individual metabolic clearance values are placed together with the 
scattergraph of the percentage recovery for each metabolite, in Fig. 2.24 to 2.29. 
2.4.6.4 Statistical Results 
Each of the pharmacokinetic parameters was first compared by a global analysis of 
variance (ANOVA), The post hoc multiple range test for all possible comparisons 
between 2 groups was the Scheffe test. Significant results (p < 0.05) are indicated 
by asterisks in the scattergraphs, Fig. 2.23. C舰 and t^^ are not significantly 
different among the study groups. For the pharmacokinetic parameters CI, AUC, 
terminal t,^  and MRT, there was also no statistically significant difference found. The 
only significant difference was in the V j of Group R, the renal impairment group, 
which was significantly higher than that of the control group at 1.25 1 kg i vs 0.79 
1 kg-i (p < 0.05). 
I 
The percentage recovery of the different metabolites of paracetamol in the 24 hour 
urine collection and the corresponding metabolic clearance were also compared 


































































































































































































































































































































































































































































































































































Fig. 2.24 Percentage Recovery of Paracetamol Glucuronide in 24 
hour Urine Collection and Its Metabolic Clearance in 
Subjects of Different Study Groups Following Ingestion of 
a 20 mg kgfi Body Weight Dose 
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Fig. 2 .26 Percentage Recovery of Paracetamol Cysteine in 94 hnnr 
Urine Collection and Its Metabolic Clearance in Subjects of 
Different Study Groups Following Ingestion of a 20 mg Icg i 
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cysteine and mercapturate, in the 24 hour urine collection, was much higher in 
Group D，, patients with hepatocellular carcinoma. The mean percentage recovery as 
the mercapturate and cysteine conjugates was 18.39 士 5.08% as compared to 5.05 
士 1.60% in the control group. In fact the mean value in Group D，was significantly 
higher than every other study group. The partial metabolic clearance to the oxidative 
metabolites was, as expected, also high among the hepatocellular carcinoma patients. 
The mean metabolic clearance to the oxidative metabolites was 0.67 士 0.26 ml min i 
kg-i in Group D，compared to 0.23 土 0.11 ml min'^  kg i in the control group. 
Again, the mean value in Group D，was significantly higher than every other study 
group. 
2.4.7 Discussion 
This study was designed to find out the difference in the pharmacokinetics of 
paracetamol in different groups of subjects who excreted different proportions of 
oxidative metabolites, the cysteine and mercapturate conjugates. Previous work in 
the Department of Clinical Pharmacology at The Chinese University of Hong Kong 
has shown that the percentage of urinary recovery of the oxidative metabolites of 
paracetamol in the 24 hour urine collection was much greater in patients with 
hepatocellular carcinoma (Leung & Critchley, 1991). Due to the limitations of this 
study, it was not able to address any fundamental changes in the pharmacokinetics 
I 
of paracetamol leading to the finding of this altered metabolism in patients with 
hepatocellular carcinoma. This study aimed to find out i f there were any changes in 
other pharmacokinetic parameters including clearance, elimination half-life, volume 
192 
Fig. 2.28 Percentage Recovery of Paracetamol Mercapturate in 24 
hour Urine Collection and Its Metabolic Clearance in 
Subjects of Different Study Groups Following Ingestion of 
a 20 mg kg-i Body Weight Dose 
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Fig. 2.29 Percentage Recovery of Paracetamol Cysteine & 
Mercapturate in 24 hour Urine Collection and Its Metabolic 
Clearance in Subjects of Different Study Groups Following 
Ingestion of a 20 mg kg] Body Weight Dose 
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cysteine and mercapturate, in the 24 hour urine collection, was much higher in 
Group D，，patients with hepatocellular carcinoma. The mean percentage recovery as 
the mercapturate and cysteine conjugates was 18.39 士 5.08% as compared to 5.05 
土 1.60% in the control group. In fact the mean value in Group D，was significantly 
higher than every other study group. The partial metabolic clearance to the oxidative 
metabolites was, as expected, also high among the hepatocellular carcinoma patients. 
The mean metabolic clearance to the oxidative metabolites was 0.67 士 0.26 ml min"^  
kg-i in Group D，compared to 0.23 土 0.11 ml min"^  kg i in the control group. 
Again, the mean value in Group D，was significantly higher than every other study 
group. 
2.4.7 Discussion 
This study was designed to find out the difference in the pharmacokinetics of 
paracetamol in different groups of subjects who excreted different proportions of 
oxidative metabolites, the cysteine and mercapturate conjugates. Previous work in 
the Department of Clinical Pharmacology at The Chinese University of Hong Kong 
has shown that the percentage of urinary recovery of the oxidative metabolites of 
paracetamol in the 24 hour urine collection was much greater in patients with 
hepatocellular carcinoma (Leung & Critchley，1991). Due to the limitations of this 
study, it was not able to address any fundamental changes in the pharmacokinetics 
I 
of paracetamol leading to the finding of this altered metabolism in patients with 
hepatocellular carcinoma. This study aimed to find out i f there were any changes in 
other pharmacokinetic parameters including clearance, elimination half-life, volume 
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of distribution and metabolic clearances of various metabolites, which might offer 
clues to the mechanisms of the altered metabolism of paracetamol in these patients. 
For this comparative pharmacokinetic study of paracetamol, subjects were recruited 
in 5 groups. Group A served as the control group. Group B and Group C consisted 
of patients with some degree of liver function impairment due to alcoholism and 
chronic hepatitis B infection, respectively. The diagnoses were confirmed by patient 
history and biochemical tests. In addition, patients in Group C were all sero-positive 
for the surface antigen of the hepatitis B virus (HBsAg +ve). Group D patients were 
confirmed to have hepatocellular carcinoma by patient history, ultrasound scan, 
raised plasma a-foetoprotein level and/or liver biopsy. Group R was added on as a 
group of patients with renal function impairment, as confirmed by the plasma urea 
and creatinine levels, for comparison. It was intended to recruit 8 subjects in every 
group. 
As the study proceeded and some of the results were analysed, it was found that 
though some of the patients in Group D did have an increased recovery of the 
oxidative metabolites, in some of them, it was only slightly raised. The mean 
percentage recovery of the oxidative metabolites in Group D, though higher than the 
control, was not statistically different. It was known that some patients with 
hepatocellular carcinoma do have near to normal recovery of the oxidative 
metabolites. It was not known, however, the reason for a number of the subjects in 
Group D to have fallen into this category. As the main objective of the study was 
to look at the pharmacokinetics of paracetamol in a group of hepatocellular 
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carcinoma patients with enhanced oxidative metabolism, it was decided to recruit a 
further 8 patients with hepatocellular carcinoma patients as Group D，. As a result, 
there were all together 6 study groups instead of 5. At the close of the study, the 
number of subjects recruited for each group was not 8. Only 7 subjects were 
recruited for both Group A and Group R and 9 were recruited for Group C. 
In this study, the only difference in the pharmacokinetics of paracetamol between 
patients with hepatocellular carcinoma and other subjects was the enhanced oxidative 
metabolic pathway and thus increased metabolic clearance to the cysteine and 
mercapturate conjugates. There was no significant difference found in other 
pharmacokinetic parameters. The finding that the percentage recovery of the 
oxidative metabolites among patients with impaired liver function, including 
alcoholic liver disease and chronic hepatitis B infection, was not different from 
healthy subjects, was a confirmation of the our previous work (Leung & Critchley, 
1991). Forrest et a l also found no evidence of a significant alteration in the 
fractional urinary recovery of paracetamol metabolites (Forrest et a l , 1979). 
However, they did find a prolongation of plasma paracetamol half-lives in patients 
with severe but not with mild liver disease. Patients in our study, including those 
with liver function impairment and hepatocellular carcinoma, had plasma total 
protein and albumin levels within the normal range, indicating that their liver disease 
was not as severe as those in Forrest et al，s study with prolonged paracetamol half-
lives. In fact, the pharmacokinetic results showed that the mean elimination half-lives 
of paracetamol in all the study groups were not significantly different although there 
were a couple of outliers in Group C with much prolonged elimination half-lives. 
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There was also a significant correlation between the percentage recovery of the 
oxidative metabolites and the elimination half-life of paracetamol with p < 0.001 
when Group D，was excluded. The much raised percentage recovery of the oxidative 
metabolites in Group D，did not match proportionally with the prolongation of the 
elimination half-life. When the values in Group D，were also taken into account, 
there was still a significant correlation but p was only < 0.05 (Fig. 2.30). 
The plasma clearance of paracetamol was comparable in all study groups, indicating 
no impairment of clearance even in those subjects with liver diseases. The 24 hour 
urinary recovery of unchanged paracetamol is a direct function of the plasma 
clearance of paracetamol and this was shown by a significant correlation (Fig. 2.31). 
Although the average weight in other study groups was lower than the control groups 
and a smaller volume of distribution might be expected, the V^ values calculated 
were not lower. There was, however, a significantly higher mean V^ in Group R, 
patients with impaired renal function. It has been demonstrated that significant 
sodium and water retention can take place in patients with diabetic renal disease. 
This leads to increased exchangeable sodium and total body water and hence volume 
of distribution. This may explain the finding of increased V^ of paracetamol among 
patients with impaired renal function. Although mean C鎮 was lower in Group R 
compared to other groups, it did not reach a statistical significance (17.64 士 8.15 
in Group R vs 22.91 土 4.57 in Group A). The reduced C娜 in patients with renal 
impairment may be a result of a combination of delayed gastric emptying due to 
diabetic autonomic neuropathy and increased Vd. It was thus consequential that there 
was a tendency for the AUC to be lower in Group R. Paracetamol clearance and 
198 
Fig* 2.30 Correlation between Percentage Recovery of Paracetamol 
Cysteine and Mercapturate in 24 hour Urine Collection and 
Paracetamol Half-life in Subjects of Different Study Groups 
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elimination half-life were not affected by renal function since paracetamol is 
primarily metabolised in the liver, as shown by comparable elimination half-lives. 
On the other hand, the plasma concentration-time curves (Fig. 2.17 - Fig. 2.20) 
showed significant retention of the polar conjugates of paracetamol which were 
inefficiently excreted by the kidneys in patients with renal impairment. These 
findings were in agreement with previous similar studies (Lowenthal et a l , 1976; 
Martin et al” 1991). 
The fractional recovery of the metabolites of paracetamol was not different in Group 
R as compared to the healthy controls, though the total amount recovered in 24 hours 
was lower. The comparable fractional recovery of the different metabolites suggested 
that despite the presence of renal impairment, paracetamol was handled similarly and 
that the metabolic activation of paracetamol was of little clinical significance. These 
findings were in accordance with previous reports in non-diabetic patients with renal 
impairment (Prescott et al.，1989)，that glucuronide and sulphate conjugation remain 
as the predominant route of metabolism in these patients. These metabolites are inert 
and no adverse effect is expected. However, these data probably carry more 
significance for other drugs or chemicals dependent on metabolic activation. For 
agents that are biotransformed to active metabolites, accumulation of these toxic 
substances in patients with renal impairment could lead to serious adverse reactions. 
I 
In this study, although the patients in different study groups were older than the 
control subjects, this is unlikely to have affected the results. Triggs et al. found only 
a modest increase in the plasma half-life in geriatric subjects with a mean age of 81 
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years compared with subjects of mean age 24 years (Triggs et al.，1975). In 
addition, another in vitro study using liver fractions from subjects of a wide range 
of age also did not show fall in the glucuronidation and sulphation activities of 
paracetamol with increasing age (Herd et a / ” 1991). Therefore, age alone cannot 
account for the differences in metabolism of paracetamol among healthy subjects and 
patients with hepatocellular carcinoma. The overall pattern of the urinary excretion 
of metabolites in patients with impaired liver function but not hepatocellular 
carcinoma (Group B and Group C) did not differ from that observed in the healthy 
subjects. It was of particular significance that there was normal excretion of the 
cysteine and mercapturate conjugates. These two metabolites reflect conversion of 
paracetamol to the reactive hepatotoxic intermediate which undergoes conjugation 
with reduced glutathione (Jollow et al，1973; Mitchell et al, 1973a; Mitchell et al， 
1973b; Potter et a l , 1973). These findings are in support of the suggestion that a 
therapeutic dose of paracetamol is unlikely to cause liver damage in patients with 
mildly impaired liver function when the plasma albumin level is within the normal 
range. However, other factors may also contribute to the threshold dose of 
paracetamol required to produce liver damage e.g. the rate of paracetamol 
absorption, the rate of production of the toxic intermediate, hepatic glutathione stores 
and the rate of glutathione synthesis and all these factor may be affected in liver 
diseases. Repeated doses of paracetamol may be potentially even more damaging. 
Nevertheless, based on these findings, it seems unnecessary to implement dosage 
reduction in patients with mildly impaired liver function with normal serum albumin. 
Patients in Group D，，the hepatocellular carcinoma patients, had greatly enhanced 
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oxidative metabolism. The increase in the fractional recovery of the oxidative 
metabolites seemed to be at the expense of the fractional recovery of the glucuronide 
conjugate. The mean recovery of the glucuronide conjugate in Group D，was 42.91 
土 10.86% while that in Group A was 58.50 土 5.18%. This difference, though 
substantial, did not reach a statistical significance as the low mean value in Group 
D, was attributed, to a large extent, to one single low value of 23.01%. The mean 
fractional recovery of the sulphate conjugate was not very different in all the study 
groups with a narrow range of 31.22 土 11.58 to 36.24 土 9.98%. As the recovery 
of the sulphate conjugate was not increased significantly in Group D，，it suggested 
that the increased production of the oxidative metabolites was not a consequence of 
a primary impairment in glucuronidation as a corresponding increase in sulphate 
conjugation would be expected. Epileptic patients on anticonvulsant therapy have 
enhanced glucuronidation and correspondingly reduced sulphate conjugation with 
decreased plasma paracetamol half-lives (Prescott et al” 1981). In this study, the 
elimination half-lives of paracetamol in all the study groups were comparable and no 
statistical significance was found, indicating that there was no fundamental 
impairment in paracetamol metabolism. Furthermore, plasma clearance of 
paracetamol was shown to be normal in patients with hepatocellular carcinoma by 
the plasma data and also by unaltered fractional recovery of unchanged paracetamol 
in the 24 hour urine collection. This again suggests that there was no significant 
primary impairment of glucuronidation. Al l these data seem to indicate that there is 
a genuine increase in the oxidative metabolic pathway of paracetamol via the action 
of microsomal cytochrome P450 mixed function oxidase and thus the metabolic 
activation of paracetamol to the toxic intermediate, is enhanced in patients with 
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hepatocellular carcinoma. 
Among patients in Group B and Group C, there are a few outliers with the fractional 
recovery of the oxidative metabolites extending up into the range of the 
hepatocellular carcinoma patients. These elevated levels of mercapturate and cysteine 
conjugates in the 24 hour urine collection again reflect enhanced metabolic activation 
by microsomal cytochrome P450. This is of particular interest since the metabolic 
activation of xenobiotics by microsomal enzymes has been implicated in the 
formation of carcinogenic substances (Gonzalez, 1989) and possibly involved in the 
pathogenesis of hepatocellular carcinoma. 
2.4.8 Summary 
The pharmacokinetics of paracetamol was studied in different categories of subjects 
including healthy controls, alcoholic patients, patients with chronic hepatitis B 
infection, hepatocellular carcinoma and renal function impairment after a single oral 
20 mg kg-i dose, given as a syrup. Pharmacokinetic parameters estimated included 
the area under the plasma concentration-time curve from zero hour to infinity, 
plasma clearance, terminal elimination half-life, volume of distribution, mean 
residence time and the metabolic clearance to the various metabolites. Other 
parameters also compared were maximum concentration, the time to reach maximum 
concentration and the fractional recovery of the various metabolites in the 24 hour 
urine collection. 
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Apart from much enhanced oxidative metabolism of paracetamol among patients with 
hepatocellular carcinoma, there were virtually no significant difference in all the 
parameters studied among the different groups. The mean percentage recovery of the 
cysteine and mercapturate metabolites in the 24 hour urine collection was 18.39 士 
5.08% among patients with hepatocellular carcinoma (Group D，）and only 5.05 土 
1.60% among healthy subjects. There was a tendency for the fractional recovery of 
the glucuronide conjugate to be reduced among the hepatocellular carcinoma patients 
but the difference did not reach a statistical significance. There was no significant 
difference in the fractional recovery of the sulphate conjugate and unchanged 
paracetamol, nor was there any significant difference in any of the pharmacokinetic 
parameters estimated among the different study groups. 
Metabolic activation of paracetamol to the toxic intermediate seemed to be genuinely 
enhanced among patients with hepatocellular carcinoma and a small proportion of 
patients with chronic liver diseases e.g. chronic hepatitis B infection. It was 
postulated that metabolic activation by microsomal enzymes might be involved in the 
formation of carcinogenic substances from xenobiotics with some implications in the 
pathogenesis of hepatocellular carcinoma. 
I 
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Metabolic Activation of Aflatoxin B^  in Healthy 




Metabolic Activation of Aflatoxin B^  in Healthy Subjects and 
in Patients with Liver Disease & Hepatocellular Carcinoma 
3.1 General introduction 
Aflatoxins are a group of bisfuranocoumarin metabolites isolated from strains of the 
fungi Aspergillus flavus and A, parasiticus. This group of mycotoxins was first 
discovered in 1960 during the investigation of a dramatic form of mouldy feed 
toxicosis in England, which became known as "Turkey-X" disease. The early signs 
of disease were anorexia, lethargy and muscular weakness. Within a few days the 
birds died in opisthotonus. At autopsy, haemorrhages were seen in the liver, which 
was also necrotic. The kidneys were often engorged. Histopathological examination 
revealed parenchymal cell degeneration and extensive proliferation of bile duct 
epithelial cells. 
Apart from turkeys, there were also reports of other poultry, cattle, pigs and sheep 
being affected. Every outbreak was traced to flocks that had been fed rations 
containing groundnut meal newly imported from Brazil. The toxic substance isolated 
was found to be associated with A. flavus and this toxin was later named aflatoxin. 
They were found to be natural contaminants in many types of food, e.g. peanut, 
cottonseed meal, com and rice (Shank & Wogan, 1972a; Shank & Wogan, 1972b), 
particularly in tropical countries. For more history and progress on the research of 
aflatoxin, see Goldblatt and Wyllie et a l (Goldblatt, 1969; Wyllie & Morehouse, 
1977). Gradually over the years the motivation for research has shifted away from 
the purely animal production problem caused by aflatoxin poisoning to the greater 
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concern for the potential hazard to human health, including its carcinogenicity. The 
hazard posed to human may either be direct, where there is direct consumption of 
human foodstuff spoilt by the fungi; or indirect, where aflatoxin in animal feedstuff 
and its metabolites accumulate in the milk and meat for human consumption. 
3.1.1 Chemical structures and properties 
The aflatoxins are a group of bisfuranocoumarin metabolites isolated from strains of 
Aspergillus flavus group of fungi. There are 4 main naturally occurring aflatoxins 
(Fig. 3.1)，designated AFBj, AFB2, AFGi and AFG2. The aflatoxins fluoresce 
strongly in ultraviolet light; Bi and B2 produce a blue fluorescence whereas Gj and 
G2 produce a greenish yellow fluorescence (Nesbitt, O'Kelly, Sargeant & Sheridan， 
1962; Asao, Buchi, Abdel-Kader, Chang, Wick & Wogan, 1965). Four other minor 
metabolites were also isolated in small amounts from cultures of A. flavus and A. 
paraciticus: AFM!，M2, B!，and In some animal species, e.g. dairy cattle, AFB! 
and AFB2 are partially metabolised to give the hydroxylated derivatives AFM! and 
AFM2, respectively. 
The aflatoxins are soluble in methanol, chloroform, dimethyl sulphoxide and other 
organic solvents but only sparingly soluble in water (10 - 30 /ig/ml). They are very 
stable in dry heat up to the melting point. However, in the presence of moisture, 
I 
there is a destruction of aflatoxin over a period of time, most likely involving the 
opening up of the lactone ring. They are also deactivated by extremes of pH ( < 3 
or > 10)，oxidizing agents and ultraviolet radiation. A review of the chemical 
Fig- 3.1 Chemical and physical properties o f aflatoxins 208 
Aflatoxin Molecular Molecular Melting Ultraviolet Fluorescence 
formular weight point (°C) absorbance emission 
(362-363 nm) 
B, C n H i A 312 268 - 269 21,800 425 
B2 Q7H14O6 314 286 - 289 23,400 425 
Gi C17H12O7 328 244 - 246 16,100 450 
G2 C17H14O7 330 237 - 240 21,000 450 
Ml C17H12O7 328 299 19,000 425 
M2 C17H14O7 330 293 20,400 -
AFBi o ^ ^ ^ y ^ ^ 
9 ^ 
纖 o ^ 灣 A A 
O O AFP'! o o 
yH 丫 H 人 人 」 
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properties of the aflatoxins is given by Wyllie and Morehouse (Wyllie & Morehouse， 
1977). 
AFBi and to a lesser extent, AFGi were responsible for the extreme biological 
potency of aflatoxin-contaminated foodstuff and feeds. These two aflatoxins possess 
an unsaturated bond at the 8,9-position on the terminal furan ring. For AFB2 and 
AFG2, the bonds at this position are saturated and they are essentially biologically 
inactive unless these agents are first metabolically oxidized to AFBj and AFGj 
(Asao et al” 1965; Groopman, Cain & Kensler, 1988). 
3.1.2 Contamination of food by aflatoxins 
Many foodstuff have been shown to be contaminated by aflatoxins. The most 
commonly implicated commodities include peanuts, cassava, dried fish, rice and 
some alcoholic beverages fermented from maize (Shank & Wogan，1972b; Shank & 
Wogan, 1972a; Chu, 1991). These are usually a result of inadequate food storage 
facilities and preservation techniques, combined with hot, and humid weather and 
unhygienic environmental conditions, all of which are conducive to the growth of the 
fungus and the elaboration of aflatoxins on foodstuff. Apart from direct consumption 
of food spoiled by toxigenic strains of A. flavus or A. paraciticus，exposure to the 
mycotoxin can also result from consumption of products derived from animals fed 
I 
aflatoxin-contaminated feeds. These include meat and milk. Milk from village dairies 
in Iran has been found to contain high levels o fAFMi (Suzanger, Emami & Bamett， 
1976) and it has been found that some women from villages in Sudan and Zimbabwe 
Chapter 2 210 
excreted aflatoxins in breast-milk at levels similar to or higher than those considered 
safe in animal milk, for human consumption (Coulter, Lamplugh, Suliman, Omer 
& Hendrickse, 1984; Wild, Pionneau, Montesano, Mutiro & Chetsanga, 1987). 
The potential hazard of aflatoxins to human health has led to worldwide monitoring 
programmes of the toxin in various commodities as well as regulatory actions by 
most countries. Most countries have a regulatory level around 20 parts per billion 
(ppb). In Hong Kong, the limit is set at 20 ppb for peanuts or peanut products and 
15 ppb for any other food (Hong Kong Government, 1990). Preventive measures for 
controlling mycotoxin problems include use of resistant crops, crop rotation, 
avoiding mechanical damage and damage by birds or insects and drying the crop 
quickly to less than 10 - 30 % moisture content after harvesting. A number of 
detoxification methods have been used but may be difficult and not economically 
feasible in some cases. These methods include ammoniation, treatment with ozone 
and chlorine, etc (Chu, 1991). 
3.1.3 Metabolism of aflatoxins 
AFB i is actively metabolised by a variety of mechanisms in different animal species. 
The relative importance of each pathway is dependent on the animal species as well 
as the experimental conditions. Metabolites have been recovered from urine, milk 
I 
and various m vitro incubation systems containing liver slices, homogenates or sub-
cellular fractions. Essentially the initial metabolism of AFB! involves hydroxylation 
by the cytochrome P450 microsomal mixed-function oxidase system and a cytosolic 
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nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reductase. These 
enzymes are localized mainly on the endoplasmic reticulum of liver cells, but are 
also present in kidney, lungs, skin and other organs. Various hydroxylated 
derivatives result from the oxidative metabolism catalyzed by these enzymes and 
these metabolites may undergo phase I I metabolism to glucuronide or sulphate 
conjugates which are excreted in urine or bile (Wyllie & Morehouse, 1977; Metcalfe 
& Neal, 1983; Groopman et a l , 1988). The major metabolic pathway of AFB! is 
shown in Fig. 3.2. 
Early studies on the metabolism of AFBj were based on animal species whose 
metabolic pathways were subsequently found to be quite different from those of man 
and are therefore of limited help in understanding the relationship between its 
metabolism and toxicity in man. It was then found that the metabolic pathways in 
monkeys were similar to those of man and thus these have been used in later studies 
of aflatoxin metabolism. More recent research has used in vitro systems employing 
cultured tissue preparations especially those of the presumed target tissue, the liver, 
in the form of isolated hepatocyte cultures or subcellular fractions (Neal, 1987). 
The individual metabolism of AFBi is largely dependent on the cytochrome P450 
content, which is controlled by both endogenous and exogenous factors. Apart from 
inter-species and inter-strains differences, there is increasing evidence for 
polymorphism in the cytochrome P450 contents of human liver, in which the types 
of cytochrome present or their expression are genetically segregated in the general 
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Apart from genetically pre-determined factors which affect the susceptibility of 
humans to aflatoxins, environmental and other exogenous factors can also exert their 
effects. Diet is known to affect the general cytochrome P450 levels in animals and 
presumably humans. The influence of specific dietary constituents, tobacco smoking, 
alcohol intake and other xenobiotics, including drugs, can potentially modify the 
intrinsic capacity to metabolize environmental pollutants, including the aflatoxins. 
Hydroxylation of the AFBi molecule can take place at various positions. Although 
described many years after the isolation of other metabolites of AFBj, the 
hydroxylation product at the cyclopentone ring (3-carbon), named AFQi, has 
frequently been reported as the major metabolite in humans (Masri, Haddon, Lundin 
& Hsieh, 1974; Roebuck & Wogan, 1977; Moss & Neal, 1985)，though this is 
contradicted in one study (Merrill & Campbell, 1974). AFQ! was first identified in 
monkeys. The high metabolic production of this metabolite seems to be specific to 
primates as similar high metabolic production were also demonstrated in in vitro 
studies using hepatic microsomal fractions from rhesus and marmoset monkeys 
(Masri et a l , 1974; Makarananda, 1989). The percentage conversion to AFQ! from 
AFBi metabolism in human microsomal fractions was 60 - 90% (Moss & Neal， 
1985). Ramsdell and Eaton suggested that the high conversion to AFQi by primate 
microsomes divert a significant portion of the AFBi dose away from more toxic 
intermediates (see below for epoxide formation), providing a protective effect 
(Ramsdell & Eaton, 1990b). 
Early in the study of aflatoxin metabolism, it was found that a toxic metabolite was 
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excreted into the milk when cows were fed rations known to contain aflatoxin. This 
was not a detoxification product because when the milk was fed to ducklings, the 
pathological changes induced in the liver were indistinguishable from those caused 
by aflatoxin itself (Allcroft & Camaghan, 1966). This was referred to as the milk 
toxin and was later found to be the 10-hydroxylated metabolite of AFBj, named 
AFMi. AFMi has generally been regarded as a minor metabolite in human liver 
systems with some individual variation (Moss & Neal, 1985). It probably comprises 
1 - 4% of consumed AFBi (Campbell, Caedo, Bulatao-Jayme, Salamat & Engel, 
1970; Sun & Chu, 1984) but despite the low level of production, AFMi appears to 
be the only primary metabolite of AFBi to be excreted in an unconjugated form and 
may therefore be useful in assessing aflatoxin consumption (Denning, 1987). 
AFPj is formed by oxidative demethylation of AFBi, catalysed by mixed-function 
oxidase. Oxidative demethylation of AFBj has been shown in in vitro studies using 
liver tissue from goats, sheep, rats, mice, rabbits and golden hamsters but not from 
guinea pigs or dogs (Bassir & Emafo, 1970). Studies using liver slices and liver 
microsomes from these animal species demonstrated that oxidative demethylation was 
the major metabolic pathway, whereas lO-hydroxylation was the minor. In the rat, 
88.8% of the metabolism of AFBi was via oxidative demethylation and only 1.7% 
via lO-hydroxylation (Bassir & Emafo, 1970). In human in vitro studies, results were 
more variable. AFPi was found to be a principal metabolite in some studies, but only 
a minor one, i f present at all, in others (Merrill & Campbell, 1974; Roebuck & 
Wogan, 1977; Moss & Neal, 1985). Inter-individual sample variation within a single 
study was also high. Nevertheless, the conjugated forms of AFP!，the glucuronide 
Chapter 2 215 
and sulphate, were frequently detected in the urine of animals treated with AFBi, 
especially in rhesus monkeys (Bassir & Emafo, 1970; Dalezios & Wogan, 1972). 
AFBja (or 8-hydroxyaflatoxin Bj), a minor metabolite dependent on hepatic 
NADPH, was found to be a relatively non-toxic metabolite of AFBj in both animal 
and human studies, but a later study suggested that it might be a misidentification of 
another metabolite, 8,9 -dihydro-8,9-dihydroxy-aflatoxin Bj, also known as the 
dihydrodiol (Patterson & Roberts, 1972; Neal, Judah, Stripe & Patterson, 1981). 
AFB i was also found to be metabolised by cytosol fractions to aflatoxicol, the 
formation of which was also NADPH-dependent. This reduction process was first 
reported by Patterson and Roberts and was also demonstrated in human in vitro 
studies (Patterson & Roberts, 1971; Salhab & Edwards, 1977). The process was 
found to be reversible with AFB! and AFM, as the metabolism products (Patterson 
& Roberts, 1972). 
Probably the most important AFB! metabolism pathway involves the epoxidation at 
the 8,9 position. There is much evidence to indicate that AFBi requires metabolic 
activation to exert its biological and biochemical effects as a potent hepatocarcinogen 
and toxin (Campbell & Hayes, 1976). This epoxidation is considered an activation 
rather than detoxification process in the metabolism of AFB,. During the course of 
AFBi metabolism, the reactive electrophilic epoxide can covalently react with various 
nucleophilic centres in cellular macromolecules including DNA, RNA and proteins. 
This poses a potential biological hazard to the cell or organism, and constitutes a 
putative mechanism by which AFB, and other xenobiotics exert toxic, carcinogenic 
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and genotoxic effects. 
Following the formation of the AFB「8,9-epoxide, the only detoxification pathway, 
other than possible macromolecular binding not involving a toxic response, is by 
conjugation with glutathione to form AFB,-glutathione (AFBi-GSH). A very minor 
pathway may involve the spontaneous or epoxide hydrolase-catalysed reaction of the 
epoxide with water, producing 8,9-dihydro-8,9-dihydroxy-AFBi (AFB! dihydrodiol). 
This reaction is probably not catalysed by epoxide hydrolase as induction of this 
enzyme in rats by pre-treatment with antioxidants did not result in corresponding 
decreased DNA-binding (Kensler, Egner, Trush, Bueding & Groopman, 1985). The 
dihydrodiol is not a predominant metabolite in laboratory animals and has not been 
detected in human urine (Gorelick, 1990). It has been suggested that the capacity of 
humans to detoxify AFB! by conjugation with glutathione is low, as very little AFBj-
GSH is produced (Moss & Neal，1985). In AFBi-treated marmoset monkeys in 
which a similar low level of AFBi-GSH was found, the mercapturate conjugate of 
AFBj has been detected in the urine but this has not been the case in humans (Moss, 
Neal & Judah，1985). 
Using human microsomal systems in vitro and assaying for AFBi-dihydrodiol, it was 
found that 10 - 20% of the soluble metabolites of AFBi were formed via epoxidation 
(Moss & Neal, 1985). The first AFBi-DNA adduct was identified by Essigmann et 
al as the 8,9-dihydro-8-(A^'^-guanyl)-9-hydroxy AFB, (AFBrA^^-Gua), the major 
product liberated from DNA modified in vitro with AFB! and a rat liver microsomal 
activation system (Essigmann, Croy, Nadzan, Busby Jr, Reinhold, Buchi & Wogan， 
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1977). This has been subsequently confirmed in vivo (Croy, Essigmann, Reinhold 
& Wogan, 1978). The structure and properties of the AFB广DNA adduct were 
studied by in vitro formation by incubation of calf thymus DNA with activated 
AFBi. Using UV spectra, proton NMR spectroscopy and mass spectroscopy, it was 
confirmed that the major AFB「DNA adduct was the //''-guanine adduct (Wood, 
Smith & Gamer, 1988; Shaulsky, Johnson, Shockcor, Taylor & Stark, 1990). 
The most studied animal model for the formation of AFBj-DNA adducts has been 
the rat, using DNA extracted from liver tissues of treated animals and subsequent 
detection by following radioactivity, immunological detection (ELISA and 
immunocytochemistry) and synchronous fluorescence spectrophotometry (Harris, 
Laveck, Groopman, Wilson & Mann, 1986; Nakatsuru, Qin, Masahito & Ishikawa, 
1989; Wild, Montesano, Van Benthem, Scherer & Den Engelse, 1990c; Zhang, 
Chen, Haghighi, Yang, Hsieh, Wang & Santella, 1991). Other animals susceptible 
to AFBj have also been studied, including rainbow trout and coho salmon (Nakatsuru 
et al” 1989). Specific monoclonal antibodies have been produced (Hertzog, Smith 
Sc Gamer, 1982). The formation of AFB^-DNA adducts was shown to be a dose-
dependent response (Appleton, Goetchius & Campbell，1982; Wild, Gamer, 
Montesano & Tursi, 1986; Buss, Caviezel & Lutz, 1990) over a dose range of 10 -
1000 ng kg-i. The responses were not found to be different between rats depleted of 
glutathione by diethyl maleate pre-treatment and control rats, indicating hepatic 
glutathione offered little protection against DNA-binding of AFBi (Appleton et al., 
1982)； but in another study, DNA-binding was increased in rats pretreated 6 hours 
ahead (the time of maximal glutathione depletion) with a toxic dose of ethanol but 
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not 18 hours (time with approximately normal glutathione levels) before AFBj 
administration (Wang, Wang, Shiah & Lin, 1990). DNA-binding of AFBi seemed 
also to be highly specific to liver tissues, where detection of the DNA adduct by 
immunocytochemical methods showed much more homogeneous binding than kidney 
tissues. In the same study, no adducts were detected in other organ tissues studied, 
including the oesophagus, forestomach, colon, spleen and testes (Wild et a l , 1990c). 
DNA binding has been demonstrated in cultured human bronchus and colon tissues 
incubated with AFBi (Autrup, Essigmann, Croy, Trump, Wogan & Harris, 1979) 
and binding was shown to be dose-dependent. The AFBi-N^-guanine adduct could 
be detected in the urine of people who had dietary exposure to the carcinogen, 
including people from Kenya and China (Groopman, Donahue, Zhu, Chen & 
Wogan, 1985; Autrup, Seremet, Wakhisi & Wasunna, 1987), using affinity 
chromatography and high performance liquid chromatography. More recently, direct 
demonstration of AFB广DNA adducts formed in vivo in liver tissues were reported 
by many groups, either in patients known to have hepatocellular carcinoma or people 
accidentally poisoned by AFB! (Hsieh, Hsu, Chen & Santella，1988; Lee, Sarosi & 
Vyas, 1989; Harrison & Gamer, 1991). 
The binding of ^H-AFBi to ribosomal RNA added to in vitro human liver 
microsomal incubations have also been reported and the in vivo binding to nucleic 
acid via AFBrepoxide was found to have a higher activity than binding to protein 
(Swenson, Miller & Miller, 1974; Swenson, Lin, Miller & Miller, 1977). Similar 
to DNA-binding, binding of AFB! to serum albumin has also been widely studied in 
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both animals and human. It was shown that AFBi binds primarily to serum albumin 
and very little to other plasma proteins (D in & Schabort，1986), in a dose-dependent 
manner (Wild et al” 1986). The adducts were sufficiently stable to allow 
accumulation to steady-state levels upon chronic exposure. For many animal species, 
between 1 - 3% of a dose of AFBj was found to bind to plasma albumin. Based on 
the half-life of plasma albumin being around 20 days in human, AFBi-albumin 
adducts was expected to be a useful tool in following AFBi exposure (Wild et aL, 
1986; Groopman et a l , 1988). 
The major serum albumin adduct of AFBi was isolated and characterised to be 
AFBi-lysine by Sabbioni (Sabbioni, Skipper, Buchi & Tannenbaum, 1987), who later 
elucidated the structure, chemical and physical properties (Sabbioni, 1990). AFBr 
lysine was subsequently demonstrated in human serum from various African 
countries, Thailand (Wild, Jiang, Allen, Jansen, Hall & Montesano，1990a) and the 
Guangxi Province of China (Sabbioni, Ambs, Wogan & Groopman, 1990). It was 
suggested to be an excellent dosimeter for exposure assessment as there were highly 
significant correlations between the adduct level following AFBi intake and urinary 
excretion of AFMi (Gan, Skipper, Peng, Groopman, Chen, Wogan & Tann⑶bmim, 
1988). 
A lysine adduct of AFG!，an aflatoxin of lower biological potency than AFBi, was 
also identified and was found to be formed at a level 3 - 6 fold lower than with 
equivalent doses of AFBi (Sabbioni & Wild, 1991). It was suggested that this AFG! 
adduct could be added as an internal standard for methods using the measurement 
Chapter 2 220 
of aflatoxin-albumin adducts to quantitate human exposure to aflatoxin. 
The metabolic activation of AFBj to the active, DNA-binding 8,9-epoxide is now 
known to be mediated by cytochrome P450s. They are a large family of isoenzymes 
catalysing a diverse spectrum of reactions including endogenous substances and 
xenobiotics. Many different P450 isoenzymes have been purified from human liver, 
their corresponding cDNAs cloned and classified into families and subfamilies. For 
a detailed review, see that by Gonzalez (Gonzalez, 1989). Those P450 enzymes that 
catalyze the metabolic activation of AFBi to the reactive 8,9-epoxide have been 
identified primarily in livers from humans, rodents and fish. Even in a single tissue, 
multiple P450s have been shown capable of activating AFBi. Before studies on 
specific cytochrome P450s, the activation of AFBi was investigated using 
microsomes or their partially purified fractions. A lot of these studies employed 
microsomes from animals pretreated with P450 inducers e.g. 3-methylcholanthrene 
(Neal, Judah & Green，1986) or phenobarbitone (Metcalfe, Colley & Neal, 1981), 
in which only certain P450 activities were specifically, but not always selectively, 
amplified. The usefulness of these studies was limited by the fact that concurrent 
expression or induction of multiple metabolic activities might result and hence limit 
their usefulness for assigning aflatoxin activation to specific P450 isoenzymes. 
Although the available data seemed to indicate that phenobarbitone-induced 
microsomes mediated the highest rate of binding of DNA by AFBi, the relative lack 
of selectivity for mediating DNA binding and the presence of multiple isoenzymes 
in these preparations prevented the identification of the most effective isoenzyme. 
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Studies with specific cytochrome P450s help provide more information on the 
relative importance of various cytochrome P450s in the bioactivation of AFBi but 
quantitative comparisons are still restricted to comparing the metabolism between 
different species and only qualitative comparisons can be made for individual 
pathways of AFBi metabolism. As a result, a quantitative assessment of the relative 
risk to people from the carcinogenic effect of AFBi based on estimates of its 
metabolism could not be made. An epidemiological study reported a possible 
association between the poor metaboliser phenotype for debrisoquine oxidation and 
resistance to the formation of hepatic tumours presumed to be caused by the 
ingestion of AFBi in the diet (Idle, Mahgoub, Sloan, Smith, Mbanefo & Bababunmi, 
1981). One possible explanation for this observation was that the specific cytochrome 
P450 which was impaired in poor metabolisers of debrisoquine was also responsible 
for the metabolic activation of AFBi to a carcinogenic intermediate. This was refuted 
by Plummer et a l who concluded different isoenzymes of cytochrome P450 were 
responsible for the metabolic activation of AFBi and the 4-hydroxylation of 
debrisoquine in both the rat and in man. This was based on evidence that the 
addition of debrisoquine to incubation systems did not alter the rate of covalent 
binding of activated AFBi to microsomal proteins (Plummer, Boobis & Davies， 
1986). 
On the other hand, evidence was provided for nifedipine oxidase, now known as 
CYP3A4 in the nomenclature recommended by Nebert et al (Nebert, Nelson, Coon, 
Estabrook, Feyereisen, Fujii-Keriyama, Gonzalez, Guengerich, Gunsalus, Johnson, 
Loper, Sato, Waterman & Waxman，1991)，being the principal enzyme involved in 
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the metabolic activation of aflatoxins in human liver (Shimada & Guengerich，1989). 
Various P450 isoenzymes were purified from human liver samples. There were good 
correlations between levels of immunochemically determined CYP3A4 and rates of 
metabolic activation of AFBi which was also inhibited by polyclonal antibodies 
raised against this isoenzyme. The use of an assay for CYP3A4 activity as an 
indication of the relative extent of potential metabolic activation of AFBi in different 
species or individuals, is only valid i f other isoenzymes of P450 do not significantly 
or variably contribute to the metabolic activation of AFBj. As research in this area 
continued, it was found not to be the case. Not only was there evidence emerging 
for the involvement of multiple forms of cytochrome P450 in the metabolic 
activation of AFBi (Aoyama, Yamano, Guzelian, Gelboin & Gonzalez, 1990; 
Forrester, Neal, Judah, Glancey & Wolf, 1990), but also that CYP3A isoenzymes 
on the whole as a family, could only effectively catalyze the formation of AFB广8，9_ 
epoxide from AFBi at relatively high substrate concentration (Ramsdell, Parkinson, 
Eddy & Eaton, 1991). Ramsell and Eaton concluded from their study that at tissue 
levels expected from dietary AFBi exposure, CYP3A enzymes, including CYP3A4, 
would not be expected to substantially contribute to the metabolic activation of AFBi 
to AFBi-8,9-epoxide. Another isoenzyme(s) of cytochrome P450 appeared to be 
principally responsible at low AFBi levels (Ramsdell et al” 1991). Although the 
study of Forrester et a l , using antibodies against specific cytochrome P450s to 
inhibit metabolic activation of AFBi, provided data on the strong correlation with 
CYP3A expression, it was thought to be only because they represent the major 
cytochrome P450 forms in the human liver. The correlation between CYP3A3 and 
CYP3A4 expression and AFBi metabolism was due to the fact that they are present 
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in high concentration and not because they are the only P450 with the capacity to 
metabolize this substrate. In addition, antibodies against CYP3A1, CYP2A1 and 
CYP1A2 also inhibited AFBi-8,9-epoxide formation but there was significant 
variability in the effectiveness of these antibodies (Forrester et al” 1990). These data 
seemed to support the involvement of multiple forms of P450 in the metabolic 
activation of AFBi in human liver. Although the CYP3A gene family plays an 
important role in the metabolic activation of AFBi, other species of cytochrome can 
also play a major role. Different levels of expression may account for the variability 
in the relative roles of different isoenzymes. Since the expression of these 
cytochromes are highly inducible by environmental and/or hormonal factors, these 
factors would play a part in determining the metabolism of AFBj in an individual. 
Involvement of genetic factors has yet to be established. 
On a similar line but using a different study method, Aoyama reported contribution 
to the metabolic activation of AFBi by five isoenzymes of cytochrome P450: 
CYP1A2, CYP2A3, CYP2B7, CYP3A3 AND CYP3A4 (Aoyama et a l , 1990). 
Using human cell lines that stably expressed human cytochrome P450s, Crespi et a l 
were able to confirm the role of metabolic activation of AFBi by CYP3A4, CYP1A2 
and CYP2A3 (Crespi, Penman, Steimel, Gelboin & Gonzalez, 1991). 
Conjugation with glutathione has been regarded as a detoxification pathway of AFBi 
as A F B i - G S H is non-reactive. The conjugation of A F B � 8，9 -epox ide with glutathione 
is catalyzed by glutathione 5-transferases (GST). The GST comprise a large family 
of enzymes divided into 5 classes: alpha, mu, pi, theta and microsomal. Little is 
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known about the identity of the GST which are responsible for the detoxification of 
activated AFB!. At present, the study of the catalytic conjugation of AFBi-8,9-
epoxide with glutathione has mainly been done with GST isolated from rat and 
mouse, and studies of GST from other animal species in this area have been few. By 
modifying the diet, levels or activities of GST could be altered in experimental 
animals and it has been shown that feeding with ethoxyquin, an antioxidant, 
increased GST activity in rats and resulted in reduced in vivo binding of AFBj to 
DNA of liver and kidney (Mandel, Manson, Judah, Simpson, Green, Forrester, Wolf 
& Neal, 1987). This was also accompanied by reduced hepatocarcinogenesis which 
was attributed to a reduction in DNA-adduct formation resulting from increased 
detoxifying metabolism. Other dietary antioxidants also shown to induce GST and 
mitigate the tumourigenic effect of AFBi include 2(3)-tert-butylhydroxyanisole 
(BHA), butylated hydroxytoluene (BHT) and oltipraz see (Gorelick, 1990). These 
all had similar effects on the metabolism of AFBi to ethoxyquin and induced the 
biliary excretion of the AFB广GSH conjugate. 
\ 
Studies with cytosolic fractions from different species suggest that activities of 
cytosolic GST for AFBi conjugation are higher in species which are more resistant 
to the carcinogenic effects of AFBi, such as the mouse and the hamster, compared 
to rats. GST in vitro activity towards AFBi-8,9-epoxide has been associated with 
multiple isoenzymes from the alpha class including YaYa, YaYc and YcYc (Coles, 
Meyer, Ketterer, Stanton & Gamer, 1985). Quinn et al. showed that purified GST 
from normal rat liver, rainbow trout liver and human liver had much less AFB「 
specific DNA protective activity than GST from mouse liver preparations (Quinn, 
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Crane, Kocal, Best, Cameron, Rushmore, Farber & Hayes, 1990). It was also 
demonstrated that the resistance of mouse liver to AFBi could be explained by a 
single GST isoenzyme of the alpha class (YaYa) with a relatively high activity 
towards DNA-binding metabolites of AFBi, but GST with such high DNA protective 
activity against AFBi was not evident in humans. The finding of GST of the alpha 
class having the highest AFBi-8,9-epoxide conjugating activity was also confirmed 
by Ramsell and Eaton (Ramsdell & Eaton, 1990a). In another study, cytosolic 
glutathione transferase activity toward microsomally activated AFBj was studied. 
They found that human microsomes were only one-fourth as efficient in activating 
AFBi to the 8,9-epoxicle as rat microsomes, which was still less than mouse 
microsomes. But mice are resistant to the carcinogenic effects of AFBi due to 
efficient conjugation of the epoxide with GSH. In contrast, humans appear to lack 
substantial capacity for GSH conjugation with AFBi-8,9-epoxide and so human liver 
tissue may be relatively efficient at generating AFBi-DNA adducts when exposed to 
dietary levels of AFBi (Moss & Neal, 1985; Ramsdell & Eaton, 1990b). 
In contrast to the relatively large amount of information from in vitro studies of GSH 
activities in AFBi-epoxide conjugation, in vivo studies are few. By studying 
breakdown products of AFBi-GSH in body fluids e.g. urine, a useful method may 
be provided for the study of the relative formation of the GSH conjugate in different 
species or different subjects. However, few studies has been done in this area, 
especially, as we would expect, in humans. The mercapturate conjugate of AFBi has 
been detected in the urine of AFBi-treated marmoset monkeys but this has not been 
the case in human systems (Moss et a l , 1985). 
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One study addressed the possible genetic pre-disposition of humans towards AFB! 
susceptibility. It was found that GST of the mu class was also active in AFBrGSH 
conjugation and the mu form is polymorphic in human liver, characterised by high 
or low rates of conjugation of trans-stilbene oxide or benzo[a]pyrene-4,5-oxide. The 
results of this study showed that human liver cytosols prepared from individuals with 
a high rate of glutathione conjugation inhibited AFB「DNA adduct formation in vitro, 
while those prepared from individuals with low GST mu activity did not inhibit 
adduct formation (Liu, Miller, Taylor, Nagomey, Lucier & Thompson, 1990). 
Since GST activities are apparently inducible by exogenous factors, extrapolation of 
animal studies to man may not be substantiated as humans may be exposed to various 
environmental inducing or inhibitory factors that would affect the conjugation of 
AFBi-epoxide by GST, analogous to the metabolic activation of AFBj. 
3.1.4 Human diseases possibly related to exposure to aflatoxins 
3.1.4.1 Acute aflatoxicosis 
Outbreaks of acute poisoning in specific communities have been rare. There are 
several well documented reports which provide evidence of acute aflatoxicosis in 
man. One of these came from an occurence in two Taiwanese farming villages 
(Ling, Wang, Wu, Tung, Lin, Lin & Lin, 1967). A total of 27 people became i l l 
I 
with 3 deaths and it was traced back to mouldy rice found to contain approximately 
200 fig AFBi/kg. As postmortem examinations could not be done, the 
histopathological changes were not known and thus AFB! could only be suspected 
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of being causally related to the illness. A similar report came from Uganda in which 
mouldy cassava found to contain 1.7 mg aflatoxins/kg was involved in the acute 
death of a 15-year old boy (Serck-Hanssen, 1970). In 1981, 12 people from nearby 
area in Kenya died after eating maize which contained up to 12,000 ppb of AFBj 
(Ngindu, Johnson, Kenya, Ngira, Ocheng, Nandwa, Omondi, Jansen, Ngare, Kaviti, 
Gatei & Siongok，1982). Liver tissue at necropsy was found to contain up to 89 ppb 
of AFBi. In these reports, the affected individuals suffered from vomiting, abdominal 
pain, pulmonary oedema and fatty infiltration and necrosis of the liver. 
A more extensive report came from western India in which a total of 397 patients 
were involved with 106 deaths, mainly due to massive gastrointestinal bleeding 
(Krishnamachari, Bhat, Nagarajan & Tilak，1975). Males were affected twice as 
much as were females. Maize was found to be heavily contaminated with Aspergillus 
flavus. Analysis showed that the average consumption of aflatoxin could be up to 2 -
6 mg over a period of a month. Liver biopsies showed bile duct proliferation and 
giant cells. 
3.1.4.2 Reye's syndrome 
Reye，s syndrome is an acute, often fatal disease affecting infants and young children. 
It is largely of unknown etiology which involves encephalopathy and fatty 
degeneration of the viscera. The disease often progresses from a mild prodromal 
viral illness to severe cerebral involvement with coma (Reye, Morgan & Baral, 
1963). The aetiology is unknown but current postulates incriminate the interaction 
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of a reaction to viral infection, environmental factors and a genetic predisposition. 
Salicylates, aflatoxin, insecticides, outdated tetracyclines, valproate, warfarin, etc, 
have all been implicated by epidemiological observations which have many 
imperfections (Mowat, 1987). Nevertheless, the association with Reyes's syndrome 
has led to the withdrawal of aspirin products for children in both the U.K. and the 
U.S.A. 
The evidence for aflatoxins to be associated as one of the factors in the causation of 
Reye's syndrome is mainly circumstantial. There has been clusters of Reye's 
syndrome observed in northeast Thailand, predominantly in rural areas, and which 
were geographically and seasonally related to heavy contamination of food with 
aflatoxins (Olson, Bourgeois, Cotton, Harik^, Grossman & Smith, 1971; Shank, 
Bourgeois, Reschamras & Chandavimol, 1971). Incidentally Thailand is one the 
countries in the world where exposure to aflatoxins is very high. In some studies, 
presence of aflatoxins was demonstrated in autopsy specimens (Shank et fl/” 1971). 
3.1.4.3 Kwashiorkor 
Kwashiorkor is a disease of young children in some developing countries where 
malnutrition is a problem. It affects mainly recently weaned children, typified by 
oedema, hypoalbuminaemia, skin and hair changes and an accompanying immune 
I 
deficiency leading to susceptibility to infections. Patients often also have 
hepatomegaly and fatty changes in the liver. It was believed to be a result of protein 
deficiency in the presence of energy sufficiency in the diet but that is no longer 
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widely supported (Jackson & Golden, 1987). Epidemiological evidence indicated that 
the geographical and seasonal variation in the incidence of kwashiorkor parallels 
aflatoxin contamination of foodstuffs (Hendrickse, 1984). The possible involvement 
of aflatoxins in the condition has also been indicated by the presence of aflatoxins 
in biospy or autopsy liver specimens from affected individuals (Coulter et al” 1984; 
Hendrickse, 1984). Nevertheless, the relationship between aflatoxins and 
kwashiorkor is still unclear (Editorial, 1984). 
3.1.4.4 Impaired immune function 
In experimental animals, ingestion of aflatoxin has been found to exert modifications 
on the immune system, including depressed antibody formation, complement and 
phagocytosis, as well as cell-mediated immunity (Wyllie & Morehouse, 1977). These 
findings were probably related to the inhibitory effects of aflatoxins on protein 
synthesis. These findings bear rather significant implications on human health 
especially when considering the factors associated with the development of 
hepatocellular carcinoma. Infection with the hepatitis B virus (HBV) is highly 
associated with the development of hepatocellular carcinoma. An efficient cell-
mediated immune system is required for the elimination of this virus. I f the immune 
system is impaired due to aflatoxin ingestion, there would be an additive effect of 
aflatoxin in the aetiology of hepatocellular carcinoma in areas of high HBV 
I 
prevalence since AFBi itself is also considered a factor in hepatocarcinogenesis. 
Prolonged persistence of the HBV may be enhanced due to the immunosuppression 
with the consequent development of cirrhosis, which could facilitate further 
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carcinogenic changes. 
Immunosuppression due to the presence of aflatoxins could influence the pattern of 
infection with other infectious diseases, including the human immunodeficiency virus 
(Hendrickse & Maxwell, 1988). 
3.1.4.5 Hepatocellular carcinoma 
The association of exposure to aflatoxins and the development of hepatocellular 
carcinoma (HCC) has been studied in many populations. Evidence of aflatoxin 
cancer risk for humans has been issued by various institutions including the 
International Agency for Research on Cancer (lARC) and the World Health 
Organisation (WHO). 
In 1976, the lARC suggested "a causal relationship" between liver cancer and 
aflatoxin intake (IARC, 1976) and WHO concluded in 1979 that "aflatoxin ingestion 
may increase the risk of liver cancer" (World Health Organization Task Group on 
Environmental Health Criteria for Mycotoxins, 1979). In 1987, another working 
group of the I ARC, based on more recent information, produced the statement that 
there was "sufficient evidence that aflatoxin is a probable human carcinogen" (lARC, 
1987). This conclusion would mean that "a positive relationship has been observed 
I 
between exposure to the agent and cancer in studies in which chance, bias and 
confounding, could be ruled out with reasonable confidence". Most of the evidence 
implying the causative role of aflatoxins in HCC came from epidemiological studies, 
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which established a positive association between the geographic distribution of 
areas/countries of high incidence of HCC and the level/prevalence of aflatoxin-
contaminated foodstuffs. Evidence from such studies and studies on the monitoring 
of aflatoxin metabolites excretion are now available from Uganda (Alpert, Hutt, 
Wogan & Davidson, 1971), Swaziland (Peers, Gilman & Linsell, 1976; Peers, 
Bosch, Kaldor, Linsell & Pluijmen, 1987), Kenya (Peers & Linsell, 1973; Autnip 
etal” 1987), Mozambique (van Rensburg, Cook-Mozaffari, van Schalkwyk, van der 
Watt, Vincent & Purchase, 1985), Thailand (Shank & Wogan, 1972b; Shank & 
Wogan, 1972a; Wild etal” 1990a), the Philippines (Bulatao-Jayme, Almero, Castro, 
Jardeleza & Salamat, 1982) and China (Gan et a l , 1988). Although information on 
the latent period is lacking such that definite proof of a principal aetiologic role for 
aflatoxins in HCC is not possible, there is strong circumstantial evidence. 
There is, however, some lingering scepticism regarding the agreement to this 
certainty (Campbell, Chen, Liu, L i & Parpia，1990). The reservations about the 
change of the strength of the evidence from "circumstantial" to "sufficient" by the 
lARC seemed to centre around the failure to take into account the contribution by 
persistent infection with hepatitis B virus. There seemed to be equally compelling 
epidemiological evidence for the involvement of chronic HBV infection in the 
aetiology of HCC and it is likely that the different factors act synergistically. The 
demonstration of the N^-guanyl adduct of AFB, in urine and liver tissues of 
populations exposed to AFB^ and patients with HCC add to the evidence that not 
only has exposure to AFB! taken place, but also that it has been metabolically 
activated and covalently bound to genetic material (Groopman et a l , 1985; Autrup 
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et al” 1987; Hsieh et al” 1988; Lee et al” 1989 ). 
A detailed discussion on the aetiological factors for hepatocellular carcinoma 
including chronic HBV infection, dietary aflatoxins, cirrhosis, cigarette smoking and 
alcohol intake is given in Chapter 1 of this thesis. 
3.1.5 Biochemical and molecular epidemiology of aflatoxins 
Hepatocellular carcinoma is one of the leading causes of cancer mortality in Asia and 
Africa. In China, it is the third leading cause of cancer deaths in males and accounts 
for more than 120,000 deaths per year. The incidence is highest around the southeast 
coast, particularly the Shanghai, Guangxi, Fujian, Jiangsu and Guangdong provinces 
where the mortality rate of HCC can be up to 300 per 100,000/year for males (Yeh， 
Yu, Mo, Luo, Tong & Henderson, 1989). Similar high rates have been reported for 
some parts of western Africa. In contrast, the incidence of HCC in the U.S.A. is 
very low, around 2.6 cases per 100,000/year for males. Thus, the incidence of HCC 
around the world varies by at least 100 - 10,000 fold. The incidence of HCC is also 
high in Hong Kong. The rate for males in 1987 was about 30/100,000 per year. 
Since many studies have provided data on the positive association between high 
intakes of aflatoxin and high incidence rates of HCC and that dosimetry data are also 
available, there is a strong motivation to investigate further the circumstantial 
relationship between aflatoxin ingestion and HCC incidence by monitoring aflatoxins 
and its metabolites in human body fluids (Gamer, Ryder & Montesano, 1985). The 
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application of these monitoring methods to field studies would generate further 
biochemical and molecular epidemiological data. The main goal of such field studies 
would be to identify individuals at high risk of HCC by obtaining evidence of high 
exposure to AFB” The latter may lead to pathobiological lesions in target cells 
and/or increased oncogenic susceptibility due to host factors. 
Methods have been developed for the study of AFBi, its metabolites (e.g. AFMi) 
and adducts (protein and nucleic acid) in human body fluids and tissues, including 
chemical and immunological assays (Campbell et a l , 1970; Siraj, Hayes, Unger, 
Hogan, Ryan & Wray, 1981; Tsuboi, Nakagawa, Tomita, Seo, Ono, Kawamura & 
Iwamura, 1984; Groopman et al” 1985; Autrup et “1” 1987; Wild et al” 1987; 
Hsieh et a l , 1988; Wilkinson, Denning & Morgan, 1988; Lee et a l , 1989; Wild, 
Jiang, Sabbioni, Chapot & Montesano, 1990b; Harrison fc Gamer, 1991; Olubuyide, 
Makarananda, Judah & Neal, 1991). These methods could be applied to populations 
with possible exposure to AFB, and patients with HCC with regard to possible 
previous AFBi exposure. 
In China, there is geographical variation in the incidence of HCC. The provinces 
along the southeast coast have the highest clustering of cases. In Fusui County in 
southern Guangxi, the HCC rate among men is 120/100,000 per year and role of the 
dietary AFB, has been studied in this endemic area. Urinary excretion of AFM, from 
local inhabitants was found to be significantly elevated compared to other areas in 
the country with lower HCC rates. There was an almost perfect linear relationship 
between the estimated AFB, in the diet of each subpopulation and the respective 
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HCC rates. Furthermore, the level of serum albumin adducts correlated highly with 
urinary excretion of AFMi, as well as the estimated AFBi intake (Gan et “1” 1988; 
Yeh et aL, 1989). Yeh et al. did not find any significant association between the 
prevalence of hepatitis B surface antigen (HBsAg) positivity in the subpopulations 
and the corresponding HCC mortality rates. It was estimated that about 10% of 
adults living in the endemic areas had an intake of more than Img of AFBj per year. 
The primary source of contamination was com and rice; the second was the local 
undistilled alcoholic beverage produced from these grains. Since men generally 
consumed more food and alcohol than women, it seemed that the higher prevalence 
of HCC among males and in the age group between 40 - 50 could partly be 
attributed to exposure to AFEj and could not be explained by viral aetiology alone. 
In addition, AFBi-N^-Gua, the major AFB,-nucleic acid adduct was identified in the 
urine samples of people from the Guangxi province (Groopman et al.，1985). 
An epidemiological study conducted in Swaziland, a country where HCC is one of 
the commonest malignancies, was published by Peers et al. in 1987 (Peers et al” 
1987). Data were collected to assess the relationship between aflatoxin exposure, 
HBV infection and the incidence of HCC. Across 4 broad geographic regions, there 
was a more than 5-fold variation in the estimated daily intake of aflatoxins but the 
proportion of HBsAg carriers varied very little. It was found that the HCC incidence 
varied by 5-fold and was strongly associated with the estimated level of aflatoxin 
intake. In an analysis involving 10 smaller subregions, aflatoxin exposure emerged 
as a more important determinant of the variation in HCC incidence than the 
prevalence of HBV infection. 
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The problem of food stuff contamination by aflatoxins in relation to HCC was also 
addressed in Kenya. A population based study was carried out by Peers and Linsell 
(Peers & Linsell, 1973). Food samples collected in Murang'a District were 
demonstrated to be contaminated with aflatoxins and there was a statistically 
significant association between aflatoxin ingestion levels and the number of liver 
cancer cases, but the authors did recognise certain limitations in the study e.g. data 
obtained from cancer registries might not be complete. Nevertheless, AFBi-N^-Gua 
has also been detected in human urine collected in this region of high cancer risk 
(Autrup et a l . , 1987). The seasonal variation in aflatoxin exposure was most 
probably due to extended storage of foodstuffs under improper conditions favouring 
the growth of A. flavus. Continuing biochemical epidemiological investigation 
showed a corresponding seasonal variation in the urinary excretion of AFBi-iV^-Gua 
adducts. More recently, antibody activity against an aflatoxin epitope has been 
detected in serum from inhabitants in Kenya who had experienced high exposure to 
AFB i, though the biological consequences of these antibodies remain unknown 
(Autrup, Seremet & Wakhisi，1990). 
The importance of the presence of AFB^-DNA adducts in human tissues and body 
fluids is that they are an indication that not only was exposure to AFBi 
demonstrated, but also its metabolic activation and interaction between the ultimate 
carcinogenic form of AFBi and genetic material in vivo. 
Since AFBi is a procarcinogen which requires metabolic activation before exerting 
its biological potency in attacking cellular macromolecules, including protein and 
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genetic material, the inter-individual variation in this specific enzymic activity would 
have an influence on the susceptibility to AFBi. Similarly, conjugation of AFBi-8,9-
epoxide with glutathione is a detoxification pathway and inter-individual variation in 
the activity of this metabolism may also be a determinant in AFBi susceptibility. It 
would be of considerable interest to compare the rates of metabolic activation of 
AFBi in individuals with normal livers with those in patients with chronic HBV 
infection, which has a close association with the development of HCC, and also with 
patients with HCC. These studies may help provide information on possible 
synergism between HBV and AFBi in HCC (Ayoola, 1984). 
I 
Chapter 2 237 
3.2 Development of an ELISA method to monitor AFBj exposure in human 
serum 
3.2.1 Introduction 
Various methods of aflatoxin exposure assessment have been used. In a number of 
AFBi exposure-HCC incidence correlation studies, the methods used for the 
estimation of exposure were based on those for the monitoring of food sample 
contamination (Peers & Linsell, 1973; Peers et al” 1987; Yeh et al.，1989). 
Common methods used to analyse samples for the presence of aflatoxins include thin 
layer chromatography (TLC) or HPLC of extracted samples. Although the 
methodology for measuring aflatoxin levels in food by TLC and HPLC is well 
established, it can be time consuming, costly and requires technical skill. Thus, these 
methods have not been widely applied to the measurement of aflatoxin metabolites 
in the human body. In addition, these data provide no information on the biologically 
effective dose of aflatoxin at the individual level i.e. the amount of the activated 
agent that has actually reacted with critical cellular targets, such as DNA, protein or 
RNA，which may be influenced by intake, distribution, metabolic (in)activation and 
excretion of aflatoxin. 
One of the desirable features of a laboratory assay for aflatoxin exposure would be 
that of providing a long-term exposure assessment in a sample obtained non-
I 
invasively. With the development of more sensitive assays using immunological 
methods, it has been possible to measure aflatoxin metabolites and nucleic acid 
adducts in human urine, serum and milk (Sizaret, Malaveille, Montesano & 
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Frayssinet, 1982; Groopman et al.，1985; Wild et al,, 1987; Gan et a l , 1988). 
However, rapid excretion means that their measurements reflect only exposure over 
a very short period of time prior to the measurement. Therefore, it is necessary to 
look for a more stable marker of exposure. 
It has been demonstrated that AFB, binds to peripheral plasma albumin in a dose 
related manner and the accumulated binding level after repeated exposure parallels 
the binding to liver DNA (Dirr & Schabort, 1986; Sabbioni et al” 1987; Wild et a l , 
1986). A good correlation was also seen between AFBj intake, calculated from food 
analysis, and AFB「albumin addduct levels (Gan et a l , 1988). The major aflatoxin-
albumin adduct was characterised to be an AFBi-lysine residue (Sabbioni, 1990). As 
the half-life of albumin in human is about 20 days, aflatoxin-albumin seems to be a 
promising long term marker of aflatoxin exposure which took place during the prior 
weeks (Groopman et a l , 1985; Wild et al” 1990b). 
Since 1980，the development of immunoassays for the detection of AFBi and its 
metabolites have been promising with various antibodies being successfully raised 
against the different immunogens. Polyclonal antibodies appear to be particularly 
suitable for the measurement of exposure since various aflatoxin-derived materials 
can be assayed, giving a more representative picture of the exposure. On the other 
hand, a range of monoclonal antibodies might be advantageous in determining at an 
individual level the pattern of aflatoxin metabolites present. 
Both radioimmunoassay (RIA) and enzyme^linked immunosorbent assays (ELISA) 
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have been used to assay aflatoxins in biological samples. Despite the high specificity 
of antibodies and the sensitivity afforded by radiolabelled tracers permitting the use 
of RIA to measure very low levels of aflatoxins, this technique has several 
drawbacks. It requires radiolabelled substrates, access to scintillation counters and 
skilled personnel. The short half life of the isotopes used limits the shelf life of the 
reagents. The need for 7-emitting isotopes also subjects the operators of RIA to 
radiation hazards. In comparison, ELISA requires no radioactivity, expensive 
analytical equipment or highly trained technical personnel. It is just as sensitive, if 
not more sensitive, than RIA. It is generally agreed that the development of ELISA 
methods should be concentrated on for routine monitoring work. 
The principles of ELISA depends on the reaction between an antigenic compound 
and an antibody with specificity against a particular part of the antigenic molecule. 
In the double sandwich technique, a secondary antibody is then added which has 
specificity against the primary antibody. This secondary antibody is conjugated with 
an enzyme. Upon the addition of a chromogenic substrate for the enzyme, the colour 
produced will be used for the quantification of the original antigen. When this 
technique is used, the intensity of the colour produced will be proportional to the 
original amount of antigen present and this is termed ‘non-competitive，. In 
‘competitive ELISA', the intensity of the colour produced is inversely proportional 
to the original amount of antigen present. This involves a pre-incubation step of the 
sample under study with a fixed amount of the primary antibody and the ligand is 
immobilised on ELISA plates. 
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The sensitivity of ELISA is partly attributed to the ability of a molecule of the 
conjugated enzyme catalysing the reaction of many substrate molecules, thus 
amplifying the reaction signal. This technique of double sandwich competitive ELISA 
is used in this study. 
Aflatoxin Bi after transformation by the mixed function oxidase cytochrome P450s, 
forms the reactive 8,9-oxide. This was found to be the reactive species that binds to 
serum albumin. The chemistry of the adduct and its formation was elucidated by 
Sabbioni et al (Sabbioni, 1990). The adduct is formed by the binding of AFBr8,9-
epoxide, forming initially the dihydrodiol with sequential oxidation to the dialdehyde 
and condensation with the e-amino group of lysine. The structure of this adduct is 
shown in Fig. 3.3. Though the aflatoxin structure of this adduct is highly modified, 
what remain are the coumarin and cyclopentenone rings which are still recognised 
by the antibody raised. An analysis of human serum samples obtained from an 
exposed population revealed a highly significant correlation coefficient between 
aflatoxin-lysine adduct levels and AFB^ consumption (Gan et aL，1988). Therefore, 
estimation of aflatoxin-albumin adducts is a good dosimeter for exposure over the 
previous few weeks. It was estimated that 1-3% of ingested AFB, becomes 
covalently bound to serum albumin. This value was very similar to that observed 
when rats were administered AFBi (Wild et al” 1986). 
I 
It has been found that the detection of the intact AFBralbumin by ELISA was not 
very sensitive. The recognition of isolated AFBi-lysine residues is about 30 fold 
greater (Wild et al” 1990b). A more sensitive assay for the detection of AFB, 
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albumin adducts would be to subject the modified albumin to hydrolysis to release 
AFBi-lysine residues employing a suitable hydrolytic enzyme. Although AFB^-lysine 
is probably not the only aflatoxin molecule present after hydrolysis (e.g. AFB!-
peptides may occur), it has been observed that a dilution curve of a digested rat 
albumin sample in ELISA had a very similar slope to AFBi-lysine itself, suggesting 
similar antigenicity of all residues after hydrolysis (Wild et al.’ 1990b). 
This approach is in contrast to the measurement of AFBi-lysine adducts following 
enzyme digestion of serum albumin by HPLC and fluorescence detection. By HPLC 
and fluorescence detection, only one precise species of AFBi-lysine can be measured 
at a particular retention time and not other hydrolysis products. Thus it is expected 
that ELISA apparently detects higher levels of adducts when compared to 
fluorescence and that some positive samples by ELISA may be determined as 
negative by fluorescence. It is possible to combine the two methods. Initially, 
samples will be screened by ELISA after hydrolysis of albumin. HPLC fluorescence 
detection can then be used to confirm the presense of AFBi-lysine. 
To avoid non-specific inhibition in ELISA, digested albumin samples must be 
subjected to clean-up procedures. These may include Sep-pak Qg cartridge and 
specific immunoaffinity column purifications. 
I 
The objective of this study is to develop a protocol to study the presence of AFBj-
lysine adduct in human serum sample using ELISA on digested serum albumin with 
clean-up steps, as an index to both AFB! exposure and its in vivo metabolic 
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activation. The antibody eventually used was a monoclonal one but preliminary 
studies with a polyclonal antibody raised in rabbits was also used (see discussion 
section 3.2.5.13). Both of them were able to recognise a range of aflatoxins, 
metabolites and adducts, giving a representative estimation of exposure. It was also 
hoped that the level of aflatoxin exposure could be correlated to other parameters of 
the human subjects e.g. the hepatitis B virus status, alcohol and cigarette 
consumptions, etc. 
3.2.2 Preparation of all the components necessary for analysing AFBi-albumin 
adducts by ELISA 
3.2.2.1 Materials 
AFBi was purchased from Sigma Chemical Company (St. Louis, USA). ^H-AFBj 
(specific activity approximately 18 Ci/mmol) was purchased from Morevak 
Biochemicals (Brea, California, USA). AFBi-lysine was kindly supplied by Dr. G.E. 
Neal, Toxicology Unit, Medical Research Council, Carshalton, Surrey, England. 
Bovine serum albumin (BSA), Tween 20，3,3',5,5'-tetramethylbenzidine (TMB), 
trichloroacetic acid, proteinase K (Protease Type XXVIII) and gelatin were obtained 
from Sigma Chemical Company (St. Louis, USA). PBS (phosphate buffered saline) 
tablets were purchased from Oxoid Ltd (Basingstoke, Hants, U.K.) and dimethyl 
I 
sulphoxide (DMSO) of ‘Spectrosol, grade was from BDH Chemicals Ltd. (Poole, 
Dorset, U.K.). All other chemicals and organic solvents used in all experiments were 
of analytical or HPLC grade. 
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3-2.2.2 Preparation of rabbit AFBi antiserum 
Sandy half-lop female rabbits were immunised with AFBi conjugate by injecting 500 
Axg protein of immunogen (prepared from AFB, bound to quail liver microsomal 
protein by metabolic activation (Makarananda, 1989)) mixed 50/50 (v/v) with 
Freund's complete adjuvant intramuscularly into the front and hind limbs of each 
animal. Subsequent injections were given four weeks apart on 3 occasions, each of 
500 fxg protein of immunogen mixed with an equal volume of Freund's incomplete 
adjuvant. Each animal was bled via an ear vein to obtain 30 ml blood samples ten 
days after the last injection. 
After collection, the blood was allowed to clot for 2 hours at room temperature. The 
clot was loosened from the sides of the collection vessel using a Pasteur pipette and 
placed at 4°C overnight to allow it to contract. The serum was then removed from 
the clot and the insoluble material was removed further by centrifugation at 10,000 
xg for 10 minutes at 4°C. 
The antibody titre of the antiserum obtained was evaluated using the competitive 
ELISA binding assay (section 3.2.3.1). Every six months, each animal was given a 
booster dose of 500 fig protein of immunogen mixed with an equal volume of 
Freund's incomplete adjuvant. Each batch of antiserum collected was tested for its 
I antibody titre. 
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3.2.2.3 Preparation of the rat monoclonal antibody 
Three rats were immunised with AFBj conjugate by injecting 100 /xg protein of 
immunogen (prepared from AFBi bound to quail liver microsomal protein by 
metabolic activation (Makarananda, 1989)) mixed 50/50 (v/v) with Freund's 
complete adjuvant subcutaneously. Subsequent injections were given 2 weeks apart 
on 2 occasions, each of 100 /-tg protein of immunogen mixed with an equal volume 
of Freund's incomplete adjuvant. After each immunisation, blood was drawn to assay 
for antibody titre by ELISA. After 8 weeks, the animal which consistently showed 
the highest titre was given an intravenous booster dose and the spleen was removed 
3 days later for fusion with a myeloma cell line, Yj-Ag 1.2.3, a myeloma tumour 
cell line from the Lou strain of rat. This myeloma cell line secretes K light chain 
immunoglobulin and has been used successfully in the derivation of rat x rat hybrid 
myelomas (Galfr ,^ Milstein & Wright, 1979). Before fusion, the myeloma cells were 
grown continuously in a spinner flask and about 5 x 10^  cells were used in fusion. 
The spleen from the selected immunised rat was removed rapidly and asecptically, 
and rinsed in serum free medium. It was gently teased to free cells which were 
transferred to a tube and spun at about 2,000 x^ for 5 minutes. The supernatant was 
removed and the pellet of cells resuspended in serum free medium and spun again. 
After this wash, the cells were resuspended in 10 ml of serum free medium and 
‘ I 
mixed with the myeloma cells which were also suspended in 10 ml of the same 
medium. The ratio of myeloma cells to spleen cells should be about 1:5. The mixture 
of cells was spun to remove the medium and with a pasteur pipette, 50% 
polyethylene glycol (1 ml/Iff cells) was added drop by drop over 1 minute with 
contant stirring with the pipette. It was then incubated for 30 seconds at 3TC, The 
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cell suspension was diluted 1:1 with prewarmed serum free medium every minute 
to a final volume of 20 ml. 
These cells were then spun to remove the supernatant and resuspended in HAT 
(Hypoxanthine Aminopterin Thymidine) medium to give a concentration of 5 x 10^  
to 10^  cells/ml. Two 24-well culture plates were half-filled with this cell suspension, 
topped up with HAT medium and incubated. The HAT medium was used to select 
out successful hybridomas. Aminopterin inhibits the de novo synthesis of purines by 
impairing tetrahydrofolate metabolism. In normal cells a second scavenging pathway 
of purine synthesis, using the enzyme hypoxanthine guanine phosphoribosyl 
transferase (HGPRT) is present. Hybridoma cells derived from splenocytes can thus 
still grow in the presence of aminopterin when the scavenging pathway is boosted 
by exogenous additions of hypoxanthine and thymidine. However, the myeloma cells 
used are deficient in the enzyme HGPRT, and they eventually die in the presence of 
HAT medium. Fused cells, or successful hybridomas were picked out and cultured 
in separate dishes. The procedures in the production of monoclonal antibody is 
outlined in Fig. 3.4. Cell culture supernatant of successful hybridoma was 
concentrated by ammonium sulphate precipitation and the antibody titre tested by 
ELISA. 
3.2.2.4 Concentration of cell culture supernatant by ammonium sulphate 
precipitation 
The hybridoma cell culture supernatant from section 3.2.2.3 was centrifuged for 30 
minutes at 3,000 x容 to remove debris. It was then transferred to a large beaker with 
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Fig. 3.4 Schematic Presentation of the Procedures in the Production 
of a Monoclonal AntihnHy 
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a stirring bar over a magnetic stirrer. A same volume of saturated ammonium 
sulphate solution (761 g/L, pH 4.1M, corrected to neutrality with HCl) was added 
slowly to avoid high local concentration. It was kept at 4 � - 6�C overnight before 
being centrifuged at 3,000 x^ for 30 minutes and the supernatant was discarded. 
The pellet was resuspended in the miniumum volume of PBS, usually about 0.1 
volume of the starting volume, taking care to avoid frothing and bubbles. The 
concentrated antibody solution was transferred to a dialysis tubing and dialysed 
versus 3 changes of PBS over 1 day. Enough space in the dialysis tubing must be 
allowed for volume expansion during dialysis. The protein concentration of the final 
monoclonal antibody solution was determined according to the method of Lowry 
(Lowry, Rosenbrough, Farr & Randall, 1951) and stored in aliquots at -70PC. 
3.2.2.5 Preparation of the BSA-AFB! coiyugate 
Bovine serum albumin modified by AFB, (BSA-AFB,) for use as coating antigen in 
the ELISA binding assay was prepared according to the method of Sizaret et al. with 
further modifications (Sizaret et aL, 1982). 
6.5 mg of AFBi was dissolved in 3 ml dichloromethane which had been dried 
overnight by molecular sieve beads type 3A (BDH Chemical Ltd., Poole, Dorset, 
U.K.). Chlorine gas was allowed to bubble into the AFB, solution in a stoppered 
glass tube with a side arm until a yellow colour appeared, signifying saturation of 
the gas. Without delay, 9.3 mg BSA in 4.5 ml O.OIM sodium phosphate buffer (pH 
7.4) was added followed by 0.5 ml DMSO dropwise with magnetic stirring. The 
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mixture was kept at 37�C with shaking for 30 minutes. The insoluble material was 
then removed by centrifugation at 3,500 xg for 15 minutes. 
The conjugate was precipitated by the sequential addition, with magnetic stirring, of 
43 mg NaCl, 6 ml ethyl acetate and 12 ml acetone. This mixture was kept on ice for 
15 minutes before centrifuging again for 15 minutes at 3,500 xg. The precipitate was 
washed once with 22 ml ethanol, same volume of 1:1 ether and ethanol and finally 
same volume of ether. After each wash, the precipitate was re-dispersed and re-
centrifuged. After the ether wash, the precipitate was swirled round the tube before 
drying overnight in a desiccator. This was to prevent it drying into a tightly-packed 
pellet. 
After drying, the conjugate was dissolved in 10 ml PBS with the aid of sonication. 
The volume may have needed to be adjusted if dissolution was difficult. The BSA-
AFBi solution was stored in aliquots at -lOTC, 
The protein content of the conjugate was determined according to the method of 
Lowry et al, (Lowry et al” 1951) using bovine serum albumin as the standard and 
the absorbance read by an LKB Ultrospec II with an LKB Autofill II (Pharmacia). 
The UV absorbance of the conjugate was scanned from 200nm-405nm (UVIKON 
860，Kontron Instruments, Watford, Herts., U.K.). The ratio of the number of 
molecules of AFBi to BSA was then calculated. 
A, H 
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3.2.2.6 Preparation of the immunoaffinity gel 
The immunoaffinity gel was prepared as recommended by the literature 
accompanying the purchase of CNBr-activated Sepharose 4B gel from Pharmacia. 
Basically, the biospecific ligand, the antibody, is covalently attached to a 
chromatographic bed material, the matrix. The immobilised ligand should retain the 
specific binding affinity for the substance of interest, which can then be selectively 
desorbed by altering the eluting solvent. 
The required amount of freeze-dried powder of CNBr-activated Sepharose 4B gel, 
6 g, (Pharmacia, Milton Keynes, Herts., U.K.) was swollen in ImM HCl for 15 
minutes. One gram of freeze-dried material gave about 3.5 ml of final gel volume. 
The swollen gel was then washed and reswollen using the same solution on a 
sintered glass filter of porosity G3. About 200 ml was used per gram of dry powder 
in several aliquots and the supernatant was sucked off between successive additions. 
The use of an acidic solution preserves the activity of the reactive groups which 
hydrolyse at high pH. 
The gel was then washed with the coupling buffer (O.IM NaHCOj buffer, pH 8.3, 
containing 0.5M NaCl) using 5 ml per gram dry gel. It was then immediately 
transferred to a solution of 6 ml rabbit anti-AFBj serum diluted to 18 ml with the 
I 
coupling buffer or an appropriate amount of the monoclonal antibody. The coupling 
reaction was allowed to proceed at room temperature for 2 hours in an end-over-end 
rotor. The coupling reaction was then effectively completed. After coupling, residual 
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active groups remaining on the gel were hydrolysed by standing the gel in a blocking 
buffer (Tris-HCl buffer, pH 8 with 0.2M glycine) for 2 hours. 
After the blocking step, the gel was washed alternately with buffers of high and low 
pH to remove excess uncoupled ligand. O.IM acetate buffer, pH 4 and the coupling 
buffer, each containing 0.5M NaCl were used, four or five cycles each. The gel was 
finally suspended in PBS containing 0.02% sodium azide as preservative and stored 
at 4®C until use. 
The same procedure was followed for affinity gel coupled with the rat monoclonal 
antibody with 10 mg of protein for each ml of swollen gel. 
3.2.2.7 Preparation of the ELISA plates 
Immulon I flat bottom plates (Dynatech Laboratories Inc., Virginia, USA) were 
coated with 10 ng of BSA-AFB! (prepared in section 3.2.2.5) in 50 …of PBS in 
each well. The outer rows of the 96 well plates were not used as they gave rise to 
variable results. 
The plates, lightly covered with foil, were allowed to dry at ZTC overnight or 
longer. When they are completely dried, the plates were stored at -20>0 for extended 
period of time without apparent loss of binding capacity. When the plates were 
required, they were removed from cold storage and washed with 0.05% Tween 20 
in PBS (PBS-Tween 20) (8 successive wash/suck cycles using an Immunowash 
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[NUNC, Denmark]). 
Non-specific binding sites were blocked by adding 100 /xl of 0.25% gelatin in PBS 
(PBS-gelatin) and left at room temperature for 60 minutes. The plates were then 
washed again with PBS-Tween 20 before use (4 successive washes). 
3.2.3 General procedures used in the analysis of AFB广albumin adducts 
All glass tubes used in competitive ELISA binding assays were washed with 6M HQ 
after normal glassware cleaning, followed by 4 rinses each of tap water and distilled 
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3.2.3.1 Competitive ELISA binding assay 
An aliquot of the test solution (200 /xl) was incubated with the same volume of 
diluted rabbit anti-AFBi serum (1:2,500 with PBS-gelatin) or monoclonal antibody 
(1:5,000) on a shaking plate at 37�C for 60 minutes. The glass tubes should be 
covered to avoid evaporation. At the end of the incubation period, the contents of 
the glass tubes were mixed. 50 ptl of each incubation mixture was dispensed into 
replicate of 6 wells on prepared ELISA plates which were then sealed with plate 
sealing tapes (Titertek, Flow Laboratories, Herts, U.K.) to prevent evaporation. 
They were placed on a Vari-Shaker (Dynatech Laboratories Ltd., Sussex, U.K.) with 
continuous shaking for 90 minutes at room temperature. After 90 minutes, the 
contents of the wells were discarded into a waste bucket containing bleach solution 
to destroy any toxin. The plates were washed using an Immunowash (NUNC, 
Denmark) for 10 successive wash/suck cycles. 
The secondary antibody, anti-rabbit IgG-peroxidase conjugate, for the rabbit 
polyclonal antibody, or anti-rat IgG-perioxidase conjugate, for the monoclonal 
antibody (Sigma Chemical Company, St. Louis, USA) was diluted 1:5,000 with 
PBS-gelatin. 50 was added to each well and the plates were sealed again. They 
were incubated at room temperature for 90 minutes with continuous shaking. The 
plates were washed again with 10 successive wash/suck cycles, followed by 2 washes 
I 
with distilled water. The substrate was prepared by warming 24.75 ml of O.IM 
sodium acetate buffer, pH 6.0，to approximately 40°C for 30 minutes, then adding 
250 /xl of 3,3',5,5'-tetramethylbenzidine solution (10 mg in 1 ml DMSO) and 
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warming for another 30 minutes. Just before use, 10 of 100 volume hydrogen 
peroxide was added. 50 /xl of the substrate solution was dispensed into each well and 
the plates were left for 30 minutes at room temperature. At the end of the reaction 
time, 50 /xl of 2M H2SO4 was added into each well to stop the reaction. After 15 
minutes, the absorbance at 450 nm was read using a microtitre plate reader (Titertek 
Multiscan MCC, Flow Laboratories, Rickmansworth, Herts., U.K.). 
The percentage inhibition of the sample was calculated as compared to the 
absorbance of a blank solution (zero inhibition). The value of AFB! equivalent 
present in the sample was calculated from a standard inhibition curve constructed 
from a range of AFBj concentrations ranging from 0.001 ng/ml to 100 ng/ml, 
Each sample was diluted many fold to obtain a reading which would fall within the 
range of proportionality. Included in each plate were standards at 3 points of the 
range of proportionality and a blank. These standards helped to negate variations 
between the plates. 
3.2.3.2 Sep-pak Cig cartridge 
Sep-pak C18 cartridges (Millipore UK, Middlesex, U.K.) were activated with 10 ml 
of methanol, followed by 10 ml of distilled water to dilute the concentration of 
methanol. The sample (usually 1 ml) was loaded onto the cartridge which was then 
washed with 5 ml of distilled water. The retained material was then eluted with 5 ml 
of methanol. 
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The cartridge could be reused by reactivating with 10 ml methanol and 10 ml 
distilled water. It could be reused up to 4 times. 
3.2.3.3 Immunoaffinity column 
Disposable polystyrene columns (Pierce & Warriner (U.K.) Ltd., Chester, U.K.) of 
2 ml size were filled with 1 ml bed volume of immunoaffinity gel as prepared in 
section 3.2.2.6. The gel was washed with 20 ml of PBS to remove sodium azide 
which was present as a preservative. 
The sample (usually 1 ml) was loaded onto the column and washed with 5 ml PBS. 
The retained material was then eluted with 5 ml 85% methanol in PBS. The column 
was washed again with 20 ml PBS before reusing once more. 
3.2.3.4 Evaporation process 
In most of the procedures mentioned in the above sections, the study sample was 
contained in a volume of about 5 ml. This needed to be concentrated in order to be 
presented for the next step. In other cases, the organic solvents required to be 
removed to prevent interference in the other analytic steps. The evaporation process 
was carried out in a vacuum concentrator (HS-1-110, Heto Lab Equipment, 
Denmark) at 40°C. 
I 
When evaporating samples in 100% methanol, 0.5 ml PBS was added to each tube 
to prevent rapid evaporation to dryness and thus avoid variable recoveries. 
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3.2.3.5 HPLC 
Samples for HPLC were introduced into the system via a Rheodyne 7120 injection 
valve (Berkeley, California, USA). The system consisted of two chromatographic 
pumps Model 6000 and a solvent programmer Model 660 (Waters Associate, 
Millipore UK, Middlesex, U.K.). The column used was a Chromsphere Qg 
(Chrompack UK, Ltd.). The column was eluted with a linear 15-40% methanol in 
water gradient containing 0.02% phosphoric acid and 8% acetonitrile at a flow rate 
of 1 ml min-i. The gradient elution took 6 minutes followed by maintenance of 40% 
methanol for 3 minutes. The gradient was then reversed to 15% methanol in 1 
minute. The system was kept at 15% methanol to equilibrate for 3 minutes before 
the next injection. 
Fluorescence was monitored by a fluorescence detector Model 420 (Waters 
Associates, Millipore UK, Middlesex, U.K.) with excitation at 365nm and emission 
at 425nm. 
1 ml (1 minute) fractions were collected from the HPLC using an LKB 2112 Redirac 
Fraction Collector (Bromma, Sweden) in 5 ml plastic scintillation minivials. 13 
fractions were collected for each sample. 
I 
3.2.3.6 Radioactive counting 
Samples were counted in 5 ml plastic scintillation minivials. 4 ml of scintillant 
(Monofluor, National Diagnostic, Aylesbury, Bucks., U.K.) was added to each vial 
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and counted in a Wallac 1410 liquid scintillation counter (Pharmacia Diagnostic). 
Counting time was 10 minutes for each sample. All samples were counted in 
duplicate. 
3.2.3.7 Albumin isolation 
Albumin was isolated essentially by the method of Quinn et cil” with further 
modifications (Quinn, Gamble & Judah, 1975). 0.5 ml of serum was routinely used 
as the starting material. 1 % trichloroacetic acid in ethanol was added to make up to 
10 ml. The precipitated immunoglobulins were removed by centrifuging at 10,000 
xg for 20 minutes. To the supernatant was added 2 volumes (20 ml) of ether. The 
albumin was precipitated and was collected by centrifuging at 10,000 xg for 10 
minutes. The precipitate was washed once with 2 volumes of 1:1 ether and ethanol 
and the suspension was again centrifuged to collect the albumin. It was drained and 
kept briefly in a desiccator to remove most of the volatile solvents. The albumin was 
dissolved in 10 ml PBS. The protein content was determined by the method of 
Lowry (Lowry et al, 1951), using BSA as standard and the absorbance read by an 
LKB Ultrospec II with an LKB Autofill II (Pharmacia). 
3.2.3.8 Digestion of albumin 
15 mg albumin in 1.0 ml PBS was digested with proteinase K. 200 of a 5 mg/ml 
solution was added at 0 hr and 4 hr. The samples were incubated at 3rC for a total 
of 24 hours. 200 /U of isopropanol was also added to each digestion. Following 
hydrolysis, 2 mg of BSA was added to improve precipitation and removal of excess 
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enzyme, followed by 2 volumes of cold ethanol. The samples were kept at -20°C for 
2 hours and then centrifuged at 1,500 x容 for 15 minutes. The precipitate was 
removed and ethanol in the supernatant was removed by a vacuum concentrator 
(Heto Lab. Equipment, Denmark). The sample was reconstituted to 1 ml with PBS, 
ready for the next step. 
3.2.3.9 Animal procedures 
Male Porten-Wistar rats (approx. 250g each) were injected with ^H-AFB, to obtain 
radiolabelled serum albumin for use in the development of a method to monitor 
AFBi-albumin adducts. Three dosage regimens were used to obtain adequately 
modified rat serum albumin: 
AFBi Dose (>g kg h Radioactivity (^Ci k^ "^ ) Treatment Time (hrs) 
100 20 24 
100 100 4 
400 600 4 
The animals were housed in grid-bottomed cages and received food and water ad 
libitum. The animals (2 in each dosage regimen) were given the dose by intra-
peritoneal injection. At the end of the treatment time, the animals were anaesthetised 
by exposure to diethyl ether until respiration stopped. The thorax was opened up 
quickly and blood was collected by cardiac puncture. The serum was prepared as in 
section 3.2.2.2. Blood from animals in each dosage regimen was pooled and albumin 
prepared from each sample. 
I 
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The ^H-AFBi solutions used to inject the animals, the serum samples and the 
prepared albumin solutions were all counted for radioactivity. The protein 
concentration of serum albumin solution was estimated by the method of Lowry's 
(Lowry et al” 1951). The level of modification of rat serum albumin by ^H-AFBi 
was calculated for each dosage regimen. 
3.2.4 Validations 
3.2.4.1 Analysis of standard AFB! and AFBi-lysine in ELISA 
Standard solutions of AFBi ranging in concentration from 0.01 ng/ml to 100 ng/ml 
were prepared in PBS, using a stock solution of 10 辟/ml. The concentration of 
standard AFB广lysine solutions ranged from 0.001 ng/ml to 100 ng/ml and were 
prepared from a stock of 17.5 /txg/ml stock solution. Competitive ELISA (section 
3.2.3.1) were performed on these samples and the percentage inhibition was 
calculated with reference to PBS control. 
3.2.4.2 Optimisation of antiserum dilution and concentration of coating 
antigen in ELISA 
Each ELISA plate was coated with BSA-AFBi (prepared as in section 3.2.2.5), the 
concentration of which varied in each row of the plate as shown in Fig. 3.5. The 
plates were allowed to dry completely and prepared as in section 3.2.2.7. Rabbit 
I 
anti-AFBi serum was diluted in concentrations from 1:5,000 to 1:20,000. The diluted 
antiserum solutions were added to the plates directly (50 /il/well) and the ELISA 
procedures were carried out as described in section 3.2.3.1. ELISA was done in 4 
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Fig- 3.5 Optimisation of antiserum dilution and concentration of 
coating antigen in RLTSA 
‘Checker Board’ 
Amount of coating 
antigen/well 
_X__^ x x x x x x x x x x 
20 ng X 7 
15 ng X X 
12.5 ng X X 
10 ng X X 
7.5 ng X X 
5 ng X X 
x x x x x x x x x x x x 
Rabbit antiserum i:20,000 i:i5,ooo i:io,ooo i:7,500 1:5,000 
dilution 
I 
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replicate plates. From this ‘checker board，，the optimal concentrations of the coating 
antigen and anti-AFBi serum were selected. 
3.2.4.3 Elution characteristics and capacity of the immunoaffinity column 
Disposable plastic columns of 2 ml capacity were packed with immunoaffinity gel 
(prepared as in section 3.2.2.6) to 1 ml bed volume. Each column was washed with 
20 ml PBS to remove sodium azide. Standard ^H-AFBi solutions were prepared in 
two concentrations - 20 ng/ml and 40 ng/ml, each containing about 5x10^ DPM/ml. 
The columns were loaded with 1 ml of the ^H-AFBi sample and then washed with 
20 ml of PBS and 15 ml of 85% methanol. The void volume and washings were 
collected in 2 ml fractions. They were dried in a vacuum concentrator to less than 
1 ml and then the volume was adjusted to 1 ml with PBS. 250 /xl of each fraction 
was taken for radioactivity counting. Each column was washed with 20 ml of PBS 
and the experiment repeated with the other concentration of 屯-AFB! sample. 
Immunoaffinity gels prepared with both rabbit antiserum and rat monoclonal antibody 
were tested. 
3 2.4.4 Comparison of immunoaffinity gels prepared with different 
affinity gels 
Immunoaffinity gel was prepared using two different types of affinity gels - CNBr-
Sepharose 4B gel and EAH-Sepharose 4B gel. Coupling of rabbit anti-AFB, serum 
with CNBr-Sepharose 4B gel was as described in section 3.2.2.6. The coupling 
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procedures of antiserum with EAH-Sepharose 4B gel was carried out following 
instructions accompanying purchase. It required a carbodiimide coupling reaction. 
The gel was supplied pre-swollen in 0.9% NaCl. The required amount of gel, 6 g 
dry powder or 24 ml swollen gel volume, was washed on a sintered glass filter, 
porosity G3, with 0.5M NaCl, using 50 ml per gram of gel, followed by the same 
volume of distilled water adjusted to pH 4.5. The required amount of EDC (1-ethyl-
3-(dimethylaminopropyl)-carbodiimide), 10 mg/ml of swollen gel, was dissolved in 
water and the pH adjusted to 4.5. 6 ml of rabbit anti-AFBj serum, the EDC solution 
and gel suspension were mixed to give a total volume of about 50 ml. It was mixed 
in an end-over-end mixer at room temperature for 24 hours. After the coupling 
period, the gel was washed alternately with 0. IM sodium acetate buffer (pH 4.0) and 
O.IM bicarbonate buffer (pH 8.3), each containing 0.5M NaCl to remove excess 
ligand, urea derivatives and unreacted carbodiimide. The gel was suspended in PBS 
containing 0.02% sodium azide and stored at 4�C. 
Four immunoaffinity columns were prepared, two with immunoaffinity gel prepared 
from CNBr-Sepharose 4B gel and two with immunoaffinity gel prepared from EAH-
Sepharose 4B gel, each of 1 ml bed volume, prepared according to section 3.2.3.3. 
One of each type of the immunoaffinity column was loaded with 1 ml of a 20 ng/ml 
3 H - A F B i solution and the other with 1 ml of a 40 ng/ml solution, each solution 
containing about 5 x Itf DPM/ml. Each column was eluted with 20 ml of PBS, 
followed by 15 ml of 85% methanol. The void volume and all washings were 
collected in 2 ml fractions. They were dried in a vacuum concentrator to less than 
1 ml volume and adjusted to 1 ml with PBS. 250 /xl of each fraction was taken for 
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counting for radioactivity. 
3.2.4.5 Immunoaffinity column experiment of AFBi-lysine 
An immunoaffinity column was prepared using antibody coupled CNBr-Sepharose 
4B gel. A sample of 40 ng/ml of lysine-AFBi was prepared from a stock of 17.5 
Mg/ml soluton. 1 ml of the sample was loaded onto the column. It was washed with 
20 ml of PBS followed by 15 ml of 85% methanol. The void volume and all 
washings were collected in 2 ml fractions. They were dried in a vacuum concentrator 
to less than 1 ml volume and adjusted to 4 ml with PBS. The fractions were read by 
a fluorescence spectrometer (Perkin-Elmer LS-5 Luminescence Spectrometer). The 
excitation and emission maxima of the stock AFBi-lysine sample were determined 
and the fluorescence of each fraction at these settings were read. 
3.2.4.6 HPLC Analysis of fractions from immunoaffinity column 
To investigate whether the radioactivity in the post-immunoaffinity column fractions 
was actually associated with AFBi，these fractions were analysed by HPLC. The ^ H-
AFBi solutions loaded onto the immunoaffinity column and other fractions under 
study were injected into the HPLC system as described in section 3.2.3.5. The 
sample size was 20 pX. 1 ml/min fractions were collected into plastic scintillation 
minivials. 4 ml of scintillant (Monofluor, National Diagnostic, U.K.) was added to 
I 
each vial and the radioactivity counted. The percentage of radioactivity in each 
HPLC fraction was calculated and compared to the retention time of AFBi. 
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3.2.4.7 Elution characteristic and capacity of Sep-Pak cartridge 
Sep-pak C,8 cartridges were prepared as in section 3.2.3.2. ^H-AFBi solutions of 
20 ng/ml and 40 ng/ml were prepared, each containing about 5 x 10^  DPM/ml. 1 ml 
of the solution was loaded onto an activated cartridge using a syringe. It was then 
washed with 10 ml distilled water followed by 10 ml of methanol. The void volume 
and all washings were collected in 1 ml fractions. 250 /xl of each fraction was taken 
for radioactivity counting with the addition of 4 ml scintillant. The percentage of 
radioactivity in each fracion was calculated. 
3.2.4.8 HPLC analysis of fractions from Sep-Pak C,8 cartridge 
To investigate whether the radioactivity in the fractions eluted from Sep-Pak Qg 
cartridges was actually associated with AFBi, these fractions were analysed by 
HPLC. The ^H-AFBi solutions loaded onto the Sep-Pak Qg cartridge and other 
fractions under study were injected into the HPLC system as described in section 
3.2.3.5. The sample size was 20 yX. 1 ml/min. fractions were collected into plastic 
scintillation minivials and the radioactivity counted. The percentage of radioactivity 
in each HPLC fraction was calculated and compared to the retention time of AFBi. 
3 2.4.9 Digestion of serum albumin by proteinase K 
A proteolytic enzyme, once activated, will begin to catalyse the hydrolysis of itself, 
thus terminating its action. Therefore, different digestion regimens, whereby more 
enzymes were added at intervals, were set up to select the most efficient digestion 
regimen on serum albumin. 
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Rat serum albumin modified by ^H-AFBi (section 3.2.3.9 and section 3.2.3.7) was 
used. Starting material was 1.5 mg in 1 ml PBS. Four regimens were set up: 
A No proteinase K 
B proteinase K at Ohr, 4hr 
C proteinase K at Ohr, 2hr, 4hr 
D proteinase K at Ohr, 2hr, 4hr, 24hr 
At the appropriate time, 200 jiil of a 5 mg/ml solution of proteinase K in PBS was 
added to each digestion. Each digestion also contained 200 isopropanol and the 
incubation was carried out at 37�C. All samples were processed after 28 hours. At 
the end of the incubation, the rest of the albumin digestion was carried out as 
described in section 3.2.3.8. The radioactivity of the starting material and the final 
hydrolysates were counted by taking 50 n\ samples. The recoveries were calculated. 
3.2.4.10 Effect of ethanol in samples to be loaded onto Sep-Pak Cig 
cartridge 
After digestion of serum albumin, BSA and cold ethanol were added to the digestion 
mixture to improve precipitation of excess enzyme. It was necessary to investigate 
the effect of ethanol in the subsequent clean-up step, whether it was necessary to 
remove ethanol before applying the sample onto an immunoaffinity column. An 
alternative might have been dilute the concentration of ethanol in the sample. 
I 
Digestion of rat serum albumin modified by ^H-AFB^  was as described in Regimen 
B in section 3.2.4.9. i.e. enzyme was add^ at 0 hr and 4 hr and incubated for 24 
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hours. BSA and cold ethanol were added to each digestion mixture as described. In 
regimen A, the ethanol was removed by a vacuum concentrator and the final volume 
adjusted to 1 ml with PBS (A). In regimen B, PBS was added to a final volume of 
25 ml (B). In regimen C, PBS was added to a final volume of 50 ml (C). Samples 
A, B and C were loaded onto activated Sep-Pak Qg cartridges. In B and C, where 
the ‘void volume, was large, it was collected in 5 ml fractions. Each cartridge was 
then washed with 5 ml PBS, followed by 5 ml methanol. All fractions were dried in 
a vacuum concentrator and the final volume adjusted to 1 ml. Aliquots were taken 
for radioactivity counting and the percentage recovery of radioactivity in each 
fraction was calculated. 
3.2.4.11 Effect of drying in a vacuum concentrator on recovery of 
radioactivity of ^H-AFBi 
During the validation process, the recovery at each step was followed by radioactive 
counts of ^H-AFBj. A concentration step was necessary in between each step to 
prepare the sample in a small volume, usually 1 ml, for the next step. In order to 
test whether drying in a vacuum concentrator would affect the recovery of 
readioactive counts, the following experiment was set up. Three sets of samples were 
set up: 
A counted directly 
B 5 ml methanol and 0.5 ml PBS added to each tube and evaporated in a 
vacuum concentrator 
C 5 ml PBS added to each tube and evaporated in a vacuum concentrator 
After evaporation (not to complete dryness), the volume of each tube was adjusted 
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to 1 ml. 200 was taken for counting and the recovery was calculated compared 
to the control (A). There were 4 tubes in each set: 




3.2.4.12 Evaluation of the overall procedure for the analysis of serum 
albumin adducts of AFBi 
Digestion of rat serum albumin (modified by ^H-AFBi) was set up as in section 
3.2.4.9 according to the 4 regimens. At the end of the incubation period, the 
hydrolysates were processed as described. 2 x 20/d of each sample were taken for 
radioactivity counting. The rest of each sample was loaded onto an activated Sep-Pak 
Ci8 cartridge. It was washed with 5 ml distilled water, followed by 5 ml methanol. 
0.5 ml PBS was added to each methanol fraction and they were concentrated to less 
than 1 ml. The volume was adjusted to 1 ml with PBS. 2 x 20 pi of these methanol 
fractions from Sep-Pak Cig cartridges were taken for radioactivity counting and the 
rest loaded onto anti-AFBi immunoaffinity columns. They were washed with 5ml 
PBS followed by 5ml 85% methanol. The methanol fractions were collected and 
evaporated to less than 1 ml. The volume was adjusted to 1 ml with PBS. 2x20 til 
samples of each methanol fraction from the immunoaffinity columns were taken for 
radioactivity counting. 
The overall recovery of the clean-up steps in these four digestion regimens were 
calculated. 
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3.2.4.13 HPLC analysis of samples obtained after digestion and all clean-
up procedures 
Rat serum albumin, modified by ^H-AFB,, was taken through the whole process of 
albumin isolation, digestion and clean-up by Sep-Pak Cjg cartridge and anti-AFBi 
immunoaffinity column as in section 3.2.4.12. The final sample obtained was 
injected into the HPLC system as described in section 3.2.3.5. 1 ml/min fractions 
were obtained and the radioactivity was counted. 
3.2.5 Results and discussion 
3.2.5.1 BSA-AFBi conjugate 
The presumed structure of BSA-AFB! is shown in Fig. 3.6. The reaction between 
BSA and AFB! was found to be via one or more residues of lysine. Therefore, for 
each batch of BSA-AFB! prepared, the ratio of AFBi to BSA may be different. The 
extinction coefficient of AFB! at 363 nm = 20,150 mortem ^ i.e. the absorbance of 
1 nmole of AFBi in 1 ml of solution is approximately 0.02. The UV scan of the 
BSA-AFBi prepared showed a maximum at 404 nm. This shift was due to the 
conjugated state and the higher pH. According to Beer-Lambert，s law, 
Absorbance = e c 1 where e = extinction coefficient 
c = concentration of sample 
1 = length of path 
The absorbance at 404nm was 1.421. The estimated concentration of AFBi in the 
solution 1.421/0.02 nmol ml 
= 71.05 nmol ml'* 
The protein concentration of the conjugate was estimated by the method of Lowry 
\ 
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Fig. 3 .6 Structure of BSA-AFBi 
I ° 
H J H 
BSA, T 
(From Sizaret et al., 1982) 
I 
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to be 350 jLtg/ml. The molecular weight of BSA is 66,200. Therefore, the 
concentration of BSA in the conjugate solution = 350 x 1000/66,200 nmol ml'^  
= 5 . 3 nmol ml"* 
Ratio of AFBi : BSA = 71.05 : 5.3 
=13 .4 : 1 
3.2.5.2 Treatment of experimental animals with ^H-AFB| 
The amount of AFBi associated with rat serum albumin was calculated from the 
radioactivity associated with the ^H-AFBi solution for injection and the radioactivity 
of the modified rat serum albumin. The level of modification in the three dosage 
regimens was shown in Table 3.1. 
The level of modification of rat serum albumin by ^H-AFBi depends on many 
factors. Depending on the strain of experimental animal used, the extent of metabolic 
activation of AFBi to the reactive metabolite, the ability to conjugate the reactive 
metabolite, the turnover of serum albumin, etc, will all affect the level of 
modification. In the same strain of experimental animal, a linear relationship was 
observed between the level of AFB! bound to serum albumin and the dose of AFBi 
administered. It was estimated that about 2-3% of the initial dose was bound to 
albumin at 48 hours. 
I 
In the 3 dosing regimens in this experiment, the exposure period of the first regimen 
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albumin would be excreted. The level of modification was thus fairly low. The 
objective of this dosing experiment was to obtain rat serum albumin of an adequately 
modified level so that it could be used as the starting material in the validation of a 
method to monitor plasma albumin adducts of AFBi. Regimen C gave a level of 
modification of about 25 ng AFBi/mg albumin. This was used as the starting 
material for other experiments. 
3.2.5.3 Optimisation of antiserum dilution and concentration of coating 
antigen in ELISA 
In the checker board described in section 3.2.4.2, a gradation of colour was 
observed in each ELISA plate. The general trend was that the larger amount of 
coating antigen used and the higher the concentration of antiserum, the colour 
produced would be more intense (higher absorbance). 
The objective of this experiment was to find the lowest amount of coating antigen 
and rabbit anti-AFBi antiserum that would produce the highest absorbance, thus 
optimising the performance of ELISA. The absorbance produced at different 
concentrations of coating antigen and antiserum diluton was shown in Fig. 3.7. It 
was expected that as the amount of coating antigen used was increased, at a given 
dilution of antiserum, the absorbance would also increase as more antigen would 
react with the antibodies. Similarly, at fixed amount of coating antigen, when the 
concentration of antiserum was increased, the absorbance produced was also 
expected to rise. But these increases were not expected to be infinite. The rise in 
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over a certain range and then it would reach a plateau. This was because there were 
other constraints such as the capacity of the ELISA wells to adsorb coating antigen, 
the concentration of the secondary antibody and the concentration of the substrate. 
Therefore, within the constraints of these other conditions, it was able to select the 
optimal concentrations of coating antigen and antiserum dilution, i.e. the lowest 
amounts of these that could be used to produce the highest absorbance. A high 
absorbance is desirable as during competitive ELISA, the inhibition would be much 
more pronounced. 
From Fig. 3.7, it could be observed that there was a general trend for the 
absorbance to rise as the concentration of the antiserum was increased and it began 
to level off at dilution 1:7,500 and above. But at antiserum dilution 1:5000 and 
coating antigen concentration at 10 ng/well, the absorbance seemed to be at the 
maximal. Therefore, these conditions were selected as the experimental conditions 
for future ELISA. 
In this ‘checker board’ exercise, antiserum was added directly onto the coated 
ELISA plates, i.e. the competition step was omitted. In the analysis employed for 
the study of AFB, albumin adducts, competitive ELISA was used. The sample under 
study was first incubated with an anti-AFBi antiserum or monoclonal antibody in 
equal volumes before the mixture was loaded in ELISA wells. This step effectively 
doubled the dilution of the antiserum used. Therefore, when we have selected an 
antiserum dilution of 1:5,000 from this ‘checker board，exercise, in practice, a 
dilution of 1:2,500 would be required in future ELISA. The condition selected for 
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competitive ELISA for the study of AFBi albumin adducts were thus: 
Coating antigen BSA-AFBi 10 ng/well 
Rabbit anti-AFBj antiserum 1:2,500 
This exercise was not repeated completely for the rat monoclonal antibody as the 
optimum amount of coating antigen was already determined to be 10 ng/well. This 
amount was also used in ELISA with the rat monoclonal antibody and the optimal 
monoclonal antibody dilution for ELISA was determined to be 1:5,000 using a range 
of dilution of the monoclonal antibody from 1:10 to 1:1,000,000 (Fig. 3.8). 
3.2.5.4 Analysis of standard AFBj and AFBi-lysine in ELISA 
The digestion end product of AFBj serum albumin adducts was putatively AFBj-
lysine if digestion was, in the ideal case, complete. In practice, it was expected that 
a range of AFB广peptides as well as AFBj-lysine were released from the modified 
serum albumin. The immunogen used for the immunisation of rabbits to produce 
anti-AFBi serum was AFBi bound to microsomal proteins. Thus the antibody 
produced was a polyclonal antibody, capable of recognising a range of AFBi-related 
structures. In actual fact, it was shown that the major epitope for antibody 
recognition of aflatoxin lies in the coumarin and cyclopentonone rings of the 
aflatoxin molecules. A previous study indicated that the rabbit anti-AFBi serum 
could detect other metabolites of AFBi, including AFB广NAcCys，AFBrGSH, AFB� 
FAPy, AFBj-Cys, AFMi, AFB�CysGly and AFB2, all with approximately the same 
































































































































































Chapter 3 277 
In another study, rabbit anti-AFBi serum was obtained by injecting animals with a 
similar immunogen (Sizaret et al” 1982). It was found that AFB广lysine adduct was 
approximately 6-fold more reactive with the antiserum than was AFBi itself. As in 
our study, AFBi-lysine and other modified peptides were the anticipated end products 
of digestion, it was essential that they were recognised by the antiserum. The ELISA 
competition curves for AFBi 油d lysine-AFBi 虹e shown in Fig. 3.9a. The 
recognition of AFBi-lysine by the rabbit antiserum was slightly more sensitive 
compared to AFBi itself. A good steep slope of proportionality was obtained. 
Although AFBi-lysine could be successful recognised by the rabbit anti-AFBj serum, 
the recognition of other AFB广modified peptides may not be of the same order of 
sensitivity. This was because, though the epitope for antibody recognition was 
identical (the coumarin and cyclopentenone rings), in these larger molecules of 
peptides, the epitope may be partially obstructed due to the stereochemistry of the 
attached groups. Therefore, in future ELISA studies, the AFB! content of the 
samples would be expressed in lysine-AFBi equivalents. 
The recognition of AFBj and AFBi-lysine by the rat monoclonal antibody was also 
very sensitive, even more so than the rabbit anti-serum (Fig. 3.9b). The sensitivity 
to AFBi-lysine was approximately 10 times that of AFBi itself. This was as expected 
as the original immunogen was an AFBrprotein. The proportional part of the ELISA 
competition curve of the rat monoclonal antibody has a steeper slope than that of the 
rabbit anti-serum. This indicated that the monoclonal antibody was more specific 
against the two substrates tested - AFBi and AFBrlysine. The dilution of the 
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Fig. 3.9 Standard ELISA Inhibition Curves Using AFBt and AFBi-
Ivsine as Substrates with a). Rabbit Antiserum and b � . Rat Monoclonal Antibody 
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monoclonal antibody used in ELISA (1:5,000) was also higher than that of the rabbit 
anti-serum (1:2,500). 
3.2.5.5 Sep-Pak Cig cartridge _ elution characteristics and capacity 
The elution profile of AFBi from Sep-Pak Qg cartridges was shown in Fig. 3.10. 
It can be seen that when a sample of ^H-AFBj was loaded onto a Sep-Pak Qg 
cartridge, it was retained on the cartridge even after being washed with 10 ml of 
PBS. About 95% of the total radioactivity was recovered in the first 2 ml of 
methanol washing. There was little difference between the elution profile obtained 
for a 20 ng/ml sample and a 40 ng/ml sample, indicating that the AFBi retention 
capacity of the cartridge was not exceeded even at 40 ng/ml. In practice, it was 
expected that quantities exceeding 40 ng of AFBi would seldom be encountered in 
the samples that we would be handling. 
The radioactivity of the methanol fraction was shown to be associated with AFBi by 
HPLC analysis. Fraction 2 (first PBS fraction) and fraction 12 (first methanol 
fraction) from the Sep-Pak cartridge were injected into the HPLC system as 
described in section 3.2.3.5 for analysis. A standard 'H-AFBi sample was also 
injected for comparison. Each 1 ml fraction from the HPLC was collected into mini 
scintillation vials for radioactivity counting. The radioactivity of these HPLC 
I 
fractions are shown in Fig. 3.11. 
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minutes, i.e. it was eluted in the 7th fraction (1 ml/fraction). When the methanol 
fraction from the Sep-Pak cartridge was injected into the HPLC, it has a profile 
corresponding to that of a standard sample of ^ H-AFBi. The fraction with the highest 
percentage of radioactivity of both of these samples being the 7th HPLC fraction, 
corresponding to the retention time of AFBj. When the unretained fraction from the 
Sep-Pak cartridge was injected into the HPLC, most of the radioactivity was eluted 
in the first two fractions. This radioactivity represented tritium exchanged from the 
AFBj. Therefore, although the radioactivity in the first few ml of methanol washing 
was about 95% of the total radioactivity, it represented almost 100% retention of 
AFB” 
In this elution experiment, 10 ml of PBS and 10 ml of methanol were used to 
characterise the whole elution profile of ^H-AFBi from a Sep-Pak C^ cartridge. In 
practice, to prepare the sample for the next step, it was necessary to reduce the 
volume of the methanol fraction to below 1 ml. It was much more convenient to 
handle a volume of 5 ml instead of 10 ml in a vacuum concentrator. From Table 
3 2, it was shown that if only 5 ml PBS and methanol were used, the percentage of 
radioactivity recovered in these two fractions were 3.8% and 94.1% respectively. 
Thus, it was decided that in future studies, 5 ml of PBS and 5 ml of methanol would 
be used. 
I 
3 2.5.6 Elution characteristics of immunoaffiiiity columns 
Different affinity gels are available for immobilising ligands. The correct choice of 
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Table 3.2 Radioactivity in fractions from Sep-Pak C^^ cartridges 
obtained after loading with 1 ml sample containing 40 ng of 
H-AFB| 
Radioactiviy Fraction from Sep-Pak 
Total eluted (DPM) % of total eluted 
Void (unretained) 6,099 1.07 
PBS washing (first 5 ml) 21,713 3.82 
Methanol washing (first 5 ml) 53,484 94.13 
I 
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coupling method depends on the substance to be immobilised. Two gels were chosen 
for the coupling of rabbit anti-AFBi serum. CNBr-activated Seharose 4B gel enables 
ligands containing primary amino groups to be rapidly immobilised by a spontaneous 
reaction, whereas EAH-Sepharose 4B gel requires cyanogen bromide activation. This 
latter gel has a six-carbon long spacer arm and permits coupling via a carboxyl 
groups. Cyanogen bromide is an extremely toxic and unpleasant chemical. The use 
of CNBr-activated gel will negate the need for handling this chemical in the 
laboratory. 
Cyanogen bromide reacts with hydroxyl groups on sepharose and converts these 
groups into imidocarbonate which can then react with nucleophiles. The activated 
groups react with primary amino groups of the ligand to form isourea linages. The 
activation procedure also cross-links sepharose and thus enhances its chemical 
stability. 
EAH-Sepharose 4B gel has free primary amino groups at the end of 6-carbon spacer 
arms for coupling ligands containing free carboxyl groups. It is formed by covalent 
linkage of 1,6-diaminohexane to sepharose 4B gel using cyanogen bromide. The 
coupling of ligands with EAH-Sepharose gel requires a carbodiimide which promotes 
condensation between a free amino and a free carboxyl group to form a peptide link. 
The carbodiimide yields an isourea upon hydration. Therefore, EAH-Sepharose 4B 
gel, which contains a free amino group, can be coupled with carboxyl-containing 
ligands. 
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Since the rabbit anti-AFBi serum and rat monoclonal antibody were shown to have 
high affinity for AFBi, it was expected that AFB, would be retained on a column 
packed with this immunoaffinity gel if the coupling reaction was successful. With the 
right solution, the immobilised AFBi would be desorbed and eluted. 
The elution profiles of AFBi from the two kinds of immunoaffinity columns are 
shown in Fig. 3.12. In CNBr-Sepharose 4B gel (Fig. 3.12a), over 90% of the total 
radioactivity was eluted in the first two methanol fraction. A very small amount of 
radioactivity (about 4%) appeared in the first PBS fraction. There was virtually no 
difference observed between the elution profiles of a 20 ng/ml sample and a 40 
ng/ml sample, indicating that even at the higher amount of sample, the capacity of 
the immunoaffinity column was not exceeded. 
Fraction 2 (first PBS fraction) and Fraction 12 (first methanol fraction) were 
analysed by HPLC to confirm the association of radioactivity with AFBi. These two 
fractions and a standard AFBi sample were injected into the HPLC system and 
fractions were collected at 1 ml/min into mini scintillation vials for radioactivity 
counting. The percentage of radioactivity of these HPLC fractions are shown in Fig. 
3.13. It can be seen that the profile of the methanol fraction corresponded to that of 
the standard AFBi sample, whereas the PBS fraction produced a very different 
profile. This represented exchanged radioactivity material from AFBj： Therefore, an 
immunoaffinity column prepared from CNBr-Sepharose gel was able to retain AFBj 
successfully even when the loading sample size was 40 ng. Although it retained 
about 95% of the total radioactivity, this represented almost 100% retention of AFBi 
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Fig. 3.12 Elution Characteristics of ^H-AFB^ from Immunoaffinity 
Columns Prepared from Two Different Kinds of Affinity 
Gel Coupled with Rabbit Anti-AFB^ Anti-serum 
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as verified by HPLC. 
When an immunoaffinity column was prepared from rabbit anti-AFBi serum coupled 
to EAH-Sepharose 4B gel, the elution profile of ^H-AFBi was very different. It can 
be seen from Fig. 3.12b that a large percentage of the radioactivity appeared in the 
PBS fractions, indicating that the sample was not adsorbed onto the affinity gel and 
was easily eluted by just PBS. A small percentage of the radioactivity was retained 
and was subsequently eluted by methanol. This was probably due to a small amount 
of ligand being successfully coupled with the gel. However, this only gave a very 
small retention capacity for the affinity gel and such a gel was very unsatisfactory 
for the clean-up of AFBi samples. 
The flow of solution through the immunoaffinity columns was only by the force of 
gravity and thus was fairly slow. The collection of a volume of 10 ml was not 
efficient and to evaporate 10 ml in a vacuum concentrator was inconvenient. The 
percentage recovery of radioactivity in the void (unretained) fraction, the first 4 ml 
of the PBS fraction and the first 4 ml of the methanol fraction are shown in Table 
3 3 As about 93% of the total radioactivity could be recovered in the first 4 ml of 
the methanol fraction, it was decided that only 5 ml of PBS and methanol would be 
used in future analyses when eluting AFB! from immunoaffinity columns. 
I 
In this experiment, eluates from the immunoaffinity columns were collected in 2 ml 
fractions. They were concentrated to about 0.5 ml and then the volume adjusted to 
1 ml with PBS. This concentration procedure did not seem to affect the recovery of 
�289 
Table 3.3 Radioactivity in fractions from immunoaffinity column. 
obtained after loading with 1 ml sample containing 20 ng or 
4 0 n g o f 3 H - A F B I 
CNBr-Sepharose 4B Gel 
% of total radioactiviy eluted Fraction from affinity column 
20 ng/ml 40 ng/ml 
Void (unretained) 0.08 0.11 
PBS washing (first 4 ml) 3.68 4.35 
Methanol washing (first 4 ml) 93.51 93.10 
EAH-Sepharose 4B Gel 
Radioactiviy Fraction from affinity column , 
20 ng/ml 40 ng/ml 
Void (unretained) 0.11 0.06 
PBS washing (first 4 ml) 56.23 66.47 
Methanol washing (first 4 ml) 25.54 1^.51 
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radioactivity or AFB! (see section 3.2.5.10). 
For the same experiment using columns packed with immunoaffinity gel coupled 
with the rat monoclonal antibody, each column was eluted with only 5 ml of PBS 
and 5 ml of methanol after loading sample as this volume was sufficient. The elution 
profiles are shown in Fig. 3.14. Over 90% of the radioactivity was eluted in the 
methanol fractions. 
3.2.5.7 Immunoaffinity column experiment of AFBj-lysine 
Most aflatoxins and related compounds exhibit a strong fluorescence when viewed 
under ultraviolet light. AFBi was found to have a maximum fluorescence emission 
at 425 nm (blue colour) whereas the maximum fluorescence emission for AFGj was 
found to be at 450 nm (green colour). In previous experiments, ^H-AFBi was used 
in the investigation of AFBi in Sep-Pak C^ cartridges and immunoaffinity columns. 
It was necessary to confirm that lysine-AFBi, the putative end product of AFBi 
albumin adduct digestion, would behave in a similar manner. Previously, the 
recovery of AFBi could be calculated from the associated radioactivity. Since 
tritiated AFBj-lysine was not available, other physical and chemical properties of 
AFBi-lysine must be employed. AFBrlysine was also found to be a fluorescent 
compound and thus its behaviour in immunoaffinity column was studied by 
determining the fluorescence of the different fractions collected. 




























































































































































































Chapter 3 292 
to be at 403 nm and 466 nm respectively. The fluorescence at these conditions was 
determined for all the fractions collected from the immunoaffinity column. It was 
found that under these conditions, PBS gave a fluorescence value of 14.5 (fixed scale 
13). This was taken as the baseline value which was subtracted from the fluorescence 
readings of all other fractions. The fluorescence profile of the fractions are shown 
in Fig. 3.15. It can be seen that of all the fractions collected from the 
immunoaffinity column, only fraction 12 and 13, i.e. the first two methanol 
fractions, showed a significant fluorescence. It was evident that the sample of AFBi-
lysine, after being loaded onto the immunoaffinity column, was immobilised onto the 
gel. Even after being washed with 20 ml of PBS, it was not desorbed from the 
column. The ligand (anti-AFBj antibodies) coupled onto the gel thus showed a high 
affinity for AFB,-lysine. The desorption of immobilised AFB广lysine was effected 
by washing with methanol. The recovery was 84.4% in the first 3 methanol fractions 
(Table 3.4). Since the recovery was high in this volume, it was decided that in future 
analyses, the column would be washed with 5 ml of PBS and 5 ml of methanol, to 
facilitate the concentration process. 
Although this experiment was not repeated using a column packed with 
immunoaffinity gel prepared with the rat monoclonal antibody, since this monoclonal 
antibody was shown to have high specificity and sensitivity towards AFBi-lysine 
(section 3.2.5.4), it was satisfactory to assume the same high retention of AFBr 






































































































































Table 3.4 Fluorescence in fractions collected from immunoaffinity 
column, obtained after loading with 1 ml sample containing 
40 ng of AFBplysine 
Eluant Fraction (2 ml each) Fluorescence Percentage Remarks 
Void 1 ^ = = = 
PBS 2 2.2 2.07 4.43% eluted in first 
3 2.3 2.17 6 ml PBS 
4 0.2 0.19 
5 1.4 1.32 
6 0.4 0.38 
7 0.4 0.38 
8 0.2 0.19 
9 0.4 0.38 
10 0.0 0.00 
11 0.2 0.19 
Methanol 12 7 5 . 5 7 1 . 2 2 84.42% eluted in 
13 10.2 9.62 first 6 ml methanol 
14 3.8 3.58 
15 1.2 1.13 
16 2.8 2.64 
17 1.1 1.04 
18 2.8 2.64 
I 
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3.2.5.8 Digestion of serum albumin by proteinase K 
The recoveries of serum albumin digestion and the subsequent precipitation step (to 
remove excess enzyme) of the 4 different regimens are shown in Table 3.5. 
The modified rat serum albumin was found to have a level of modification of about 
25 ng AFBi/mg of albumin (section 3.2.5.2). The enzymatic action of proteinase K 
was a non-specific one and it would bring about proteolysis of any peptide linkage 
which it came across randomly. It is known that AFB, modifies serum albumin via 
the lysine residues. Therefore, during proteolysis by proteinase K, it could not be 
guaranteed that all the peptide linkages at the lysine residues would be broken up. 
Thus, not only lysine-AFBi would be released but also a variety of other modified 
or unmodified peptides. Also due to its non-specificity, proteinase K would 
hydrolyse other molecules of the enzyme, as well as serum albumin. The enzymatic 
action might terminate quite soon. Therefore, excess enzymes might be required to 
further the digestion process. But the duration of action depends on a number of 
factors including the type of enzyme, the digestion conditions e.g. pH and 
temperature, the amount and nature of the substrate present, etc. The requirement 
for the optimal performance of a digestion thus needed to be evaluated individually. 
In this experiment, the substrate was about 1.5 mg of ^H-AFBi modified serum 
albumin. After the digestion procedure, excess enzymes, whole digested serum 
albumin and some larger peptides would be precipitated by cold ethanol and 
freezing. The addition of a small amount of BSA would help precipitate these 
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Table 3.5 Recovery of digested rat serum albumin modified by ^H-
AFB,-lysine in different digestion regimens 
Radioactivity of digested 
Regimen material Recovery 
(DPM/ml)* (%)** 
A 7,423 7.2 
B 70,528 68.9 
C 69,170 67.6 
D 69,550 67.9 
Regimens 
A No Proteinase K 
B Proteinase K at 0 hr and 4 hr 
C Proteinase K at 0 hr, 2 hr and 4 hr 
D Proteinase K at 0 hr, 2 hr and 24 hr 
* Mean of duplicate readings 
** Recovery calculated from the radioactivity of rat serum albumin solution at 
102,373 DPM/ml 
I 
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materials. The radioactivity in the end product represented released ^H-AFBj-lysine 
residues and other short peptides. 
From Table 3.5, it can be seen that without any proteolytic enzymes (Regimen A), 
almost all ^H-AFB广modified serum albumin was removed in the precipitation step. 
Only 7% of the original radioactivity of the starting material was recovered. 
Albumin is not soluble in ethanol and would be precipitated by cold ethanol. In the 
other 3 regimens, the recoveries were very similar, all at around 67-68%. It 
indicated that the amount of ^H-AFBj in the post-digestion sample was similar. But 
at this stage, it was not possible to differentiate if the product of digestion was the 
same in these three samples. There might be more fully digested product i.e. AFB,-
lysine in one sample and in another more AFBi-peptides. All that could be concluded 
was that the total amount of radioactive AFBi, irrespective of the form it was 
contained, was about the same in the digestion end products of regimen B, C and D. 
Theoretically, with more enzyme added at regular intervals, the digestion of the 
substrate (serum albumin in this case) would be more complete. It might be expected 
that in regimen D, the recovery was higher than that in regimen B. This was not the 
case found in this experiment. This could be because the enzyme was in excess 
already or the digestion was complete already with the least amount of enzyme. This 
calls for further investigation. 
1 
3.2.5.9 Effect of ethanol in samples to be applied onto Sep-Pak Qg 
cartridges 
The percentage of recovery in the respective fractions of the three regimens is shown 
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in Table 3.6. 
After digestion and removal of excess enzymes, there was still a lot of unwanted 
material in the reconstituted sample, e.g. large peptides and other water soluble 
materials. It was possible to remove these by a reverse phase Sep-Pak cartridge. ^H-
AFBi-modified material e.g. lysine or peptides are water insoluble and would be 
retained by the cartridge. They could be recovered by eluting the Sep-Pak cartridge 
with methanol. The presence of organic solvent e.g. ethanol or methanol in the 
sample to be applied on the cartridge would affect the adsorption of ^H-AFBi-
modified material onto the solid support. 
In regimen A, the ethanol in the post digestion sample was removed in a vacuum 
concentrator. When this sample was applied onto a Sep-Pak cartridge, 75.8% of the 
total recovered radioactivity was retained and was present in the methanol fraction. 
When comparing the results to that in regimen B, it can be seen clearly that the 
ethanol present prevented the adsorption of ^H-AFBi-modified material, most of 
which subsequently appeared in the ‘void，fraction. The small percentage of 
radioactive material adsorbed onto the cartridge was eluted by methanol. Clearly, 
dilution of the post-digestion sample to 25 ml was not able to negate the interfering 
action of ethanol present. Further dilution of the sample to 50 ml brought the 
recovery in the methanol fraction up to 44.5%, although this was not a good 
working regimen as the ‘void，volume was excessively large and the recovery was 
still low. To ensure a good recovery in the methanol fraction, it was necessary to 
remove all ethanol in the sample to be applied onto a Sep-Pak Qg cartridge. 
2PP 
Table 3 .6 Recovery of radioactivity in different fractions from .^pp-
cartridges ahtmned after loading digested ^T-AFR^-
modified rat serum albumin - effect of concenfrpHnn nf 
ethanol in samples 
Radioactivity recovered in fractions (% of total) Protocol 
Void PBS Methanol 
A 13.1 (1 ml) 11.1 75.8 
B 80.8 (25 ml) 2.5 19.2 
C 53.2 (50 ml) 2.4 44.5 
I 
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3.2.5.10 Recovery of radioactivity after drying in a vacuum concentrator 
The effect of drying in a vacuum concentrator on the recovery of the radioactivity 
of ^H-AFBj is shown in Table 3.7. Drying samples of radioactive AFB! in a vacuum 
concentrator seemed to reduce a small percentage of the radioactivity. Part of this 
loss could be accounted for by non-exchange tritium which evaporated with the 
solvent. Nevertheless, this percentage was less than 10% for a range of AFBi 
concentrations. 
3.2.5.11 Recovery of the overall clean-up procedure for the analysis of 
serum albumin adducts of AFBi 
The analysis of serum albumin AFBi adducts involved a number of clean up steps 
before the detection by ELISA or HPLC. It was necessary to determine the recovery 
of the individual steps, such that an overall recovery, as an indication of the 
sensitivity of the analytical procedure, could be obtained. From the detection method 
alone i.e. the ELISA or HPLC, a detection limit could be read directly from the 
detection results. The detection limit refers to the actual level measured by the 
detection method. It must be considered in the context of the percentage recovery of 
that particular method in order to obtain the ‘real，level that needs to exist in the 
sample before detection is possible. For example, if in an analytical procedure, the 
detection limit of the detection method was 5 ng of the substance in question, it 
meant that during the detection, a sample containing 5 ng or more of the substance 
would be picked up as a ‘positive，sample. However, it did not directly imply that 
if there was a study sample containing 5 ng of the substance, it would be detected 
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Table 3.7 Percentage recovery of radioactivity of a sample of ^H-
AFBi following drying in a vacuum concentrator 
Volume of ^H-AFBj Radioactive counts Recovery compared 
Sample spiked to A 
Oa) (DPM/ml) (%) 
A l 100 176912 -
A2 50 90410 -
A3 20 37718 -
A4 0 58 
B1 100 160245 90.6 
B2 50 84357 93.3 
B3 20 36258 96.1 
B4 0 79 -
'ci 100 148807 84.1 
C2 50 87517 96.8 
C3 20 34894 92.5 
C4 0 57 
A Counted directly 
B 5 ml methanol, 0,5 ml PBS added for evaporation 
C 5 ml PBS added for evaporation 
I 
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as positive by the analytical procedure. If the recovery of the overall analytical 
procedure, i.e. all the different steps that a sample must be taken through, was 10%, 
then the ‘real，level in the original study sample needed to be at least 50 ng or more 
in order to be detected. This would be known as the absolute detection limit. 
Therefore, the percentage recovery is an important factor contributing to the 
sensitivity of an analytical procedure. 
In this study of AFBi serum albumin adducts, a study sample needed to be taken 
through the steps of albumin isolation, albumin digestion with proteinase K, clean-up 
by a Sep-Pak Qg cartridge and clean-up by an anti-AFB! immunoaffinity column 
before any AFBi-albumin adducts could be detected by either ELISA or HPLC. The 
percentage recovery at each step, for each fraction, and the overall percentage 
recovery of the 4 different digestion regimens are shown in Table 3.8. In regimen 
A, where no enzyme was present in the digestion process, the recovery of 
radioactivity following removal of insoluble proteins in ethanol was so low that the 
amount of radioactivity was extremely small. Although this sample was taken 
through the following steps, the percentage recovery calculated were unreliable as 
the counts were not much more than the background radioactivity. The results in 
regimen A were included for completeness rather than as an indication of the 
efficiency of the digestion process. It should, therefore, not be taken into serious 
consideration. 
Regimens B, C and D all produced similar percentage recovery following the 
digestion process. In fact, the recoveries for the Sep-Pak cartridge clean up and the 
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Table 3.8 Percentage recovery at each step for each fr^cfmn fnr 
different study regimens; 
Percentage recovery (%) 
A^  B C D 
Albumin digestion & 7.25 68.9 67.7 67.9 
removal of excess 
enzyme 
Sep-Pak Cjg cartridge 
void 24.6 9.4 8.9 10.7 
PBS 28.7 8.0 6.9 9.5 
methanol 46.4 54.6 58.3 45.7 
total recovery 99.7 72.0 74.1 65.9 
Immunoaffinity column 
void 26.0 3.0 2.4 3.1 
PBS 33.0 12.0 11.8 12.4 
methanol 61.9 61.9 57.2 59.4 
total recovery 120.9 76.9 71.4 74.9 
Overall recovery of clean 20.8 23.3 22.5 18.4 
Up steps 
* Results for regimen A not reliable (see text) 
Regimens 
A No proteinase K 
B Proteinase K at 0 hr & 4 hr 
C Proteinase K at 0 hr，2 hr & 4 hr D Proteinase K at 0 hr, 2 hr, 4 hr & 24 hr 
I 
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immunoaffinity column clean up did not differ by a wide margin among these three 
regimens. The overall recovery of the digestion and clean up steps of Regimen B, 
C and D were 23.3%, 22.5% and 18.4% respectively. The slightly lower value for 
regimen D was due to a lower percentage recovery at the Sep-Pak cartridge step. 
This was not anticipated. The total recovery of radioactivity from the Sep-Pak 
cartridge in regimen D was also lower than in regimens B and C. It was not known 
whether this was due to an artifact or the fact that the addition of too much enzyme 
added actually impaired the recovery. Other than this point, the recoveries in various 
fractions were very similar in these three regimens. 
From Table 3.8, it can be seen that maximum recovery was obtained with regimen 
B. i.e. when proteinase K was added to the system at 0 hr and 4 hr and the 
incubation continued for a total of 28 hours. Further addition of enzymes did not 
increase the recovery further. Since maximum recovery was achieved in regimen B, 
there was no need to increase the amount of enzyme to be added. The recovery was 
maximized in regimen B when the starting material was 1.5 mg of serum albumin. 
The amount of enzyme required and how often it is necessary to add more enzyme 
into the digestion mixture will vary with the amount and nature of the starting 
material, the type of enzyme used and other incubation conditions. In this case, it 
was not known whether digestion was maximum or the enzyme was in excess. In any 
ease, no improvement in the recovery could be achieved with more enzyme. 
Therefore, it has been decided to choose regimen B for further studies. 
In this experiment, all the digestion regimens were incubated for a total of 28 hours. 
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This was because enzyme was added at 24hr in regimen D and so another 4 hours 
were allowed. Since regimen B was chosen as the digestion regimen for future 
studies, it was decided for convenience purpose to allow a total of 24 hours for 
incubation. It was anticipated that beyond this length of time, further incubation 
would not improve digestion or recovery. Therefore, the chosen digestion regimen 
was: Starting material 1.5 mg serum albumin; 
1 mg proteinase K added at 0 hr & 4 hr; 
Total incubation period 24 hours. 
3.2.5.12 HPLC analysis of samples obtained after all clean-up procedures 
It has been discussed previously that the end product of digestion of AFBi-modified 
serum albumin was putatively AFBi-lysine if digestion were complete (see section 
3.1.3. and section 3.2.1 •). In practice, it is expected that AFBi-lysine will not be the 
only product of digestion. Instead, a range of AFBrpeptides will be released. In a 
study by Wild et al previous study, the recovery from a method involving albumin 
hydrolysis and detection by ELISA was 23%, compared to a recovery of only 5.5% 
if the detection method was HPLC with fluorescence detection (Wild et al” 1990b). 
This was explained by the fact that in detection by HPLC and fluorescence detector, 
only one distinct entity, AFBi-lysine was measured, whereas the anti-AFBi antibody 
used in ELISA was able to recognised a range of AFB�modified materials, although 
the inhibition produced may differ from the major adduct, AFBrlysine. This basic 
difference in the principle of detection of the two methods gave rise to the 
difference in the percentage recovery. 
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Detection by HPLC is no doubt a very precise method. It would be the method of 
choice when the amount of lysine-AFBj contained in a sample was known to be 
above the detection limit. Since a proportion of the AFB, adducted to serum albumin 
would end up in peptides following digestion, a falsely low reading would be 
produced if detection relied on HPLC/fluorescence alone. 
When AFBi-modified serum albumin samples were studied using ELISA after having 
been taken through the many steps of digestion and clean up, they produced 
inhibition in ELISA which allowed estimation of AFBj equivalent that existed. These 
same samples were studied by HPLC by injecting 100 into the system. 
The chromatograms produced for samples from regimens B, C and D are shown in 
Fig. 3.16. A standard sample of lysine-AFBi was detected by this system and was 
eluted at retention time 6.6 minutes. Converting from the radioactivity, in 1 ml of 
the sample from regimen B, there should be about 8 ng of AFBi. If 100 i^X was 
injected into the HPLC, there should be about 0.8 ng of AFBi applied. It was shown 
previously in this HPLC set up that the absolute detection limit was about 0.08 ng 
of AFBj-lysine. Therefore, it was expected that if all the radioactivity in the sample 
from regimen B was in the form of AFBj-lysine, there should be a very distinct 
peak, representing AFB,-lysine being eluted at 6.6 minutes. This was not the case. 
Instead, no clearly visible peaks were seen. Fluorescent materials were eluted at a 
range of retention times but there was no distinct peaks that could be integrated. 
These could be AFBrpeptides. Similar chromatograms were obtained for samples 
from regimens C and D. 
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Fig. 3.16 HPLC Chromatograms of Authentic AFB^lysine and 
Samples Ready for ELISA from Digestion Regimens B. C 
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It can be seen that though these samples produced inhibition in ELISA, indicating 
recognition by anti-AFBi antibodies, the results were negative in HPLC analyses. 
This disagreement can partly be explained by the principle outlined above, in that 
most of the digestion products in these regimens existed not as lysine-AFBi but some 
as peptides. 
Perhaps it would be possible to combine these two detection methods after the 
digestion and clean up of serum albumin samples. Initially the sample could be 
screened by ELISA for inhibition. Positive samples could then be confirmed for 
AFBi-lysine by HPLC. 
3 2.5.13 The use of rabbit anti-AFBi anti-serum and rat anti-AFBi 
monoclonal antibody 
All through the validation process, both the rabbit anti-serum and the rat monoclonal 
antibody were mentioned and studied. In fact, all validation processes for using the 
rabbit anti-serum were finished before those for the monoclonal antibody. At that 
stage, it was then found that there might have been a change in the characteristics 
of the rabbit anti-serum produced by the animal as new batches of anti-serum failed 
to couple with affinity gel on consecutive occassions. This change in anti-serum 
characteristics has been encountered before when animals have been immunised for 
a prolonged period of time (personal communication, Dr. G.E. Neal). As a result, 
it was necessary to change over to a more constant and reliable source of supply of 
antibody - a monoclonal antibody. 
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It has been demonstrated by the various validations that the rat monoclonal antibody 
possesses high specificity and sensitivity towards AFBj and AFBi-lysine, even more 
so than the rabbit anti-serum. Most of the validations were repeated using the rat 
monoclonal antibody to ensure that it could safely and reliably replace the rabbit 
anti-serum in our study regimen for AFBi-albumin adducts in human serum. 
3.2.6 Summary 
Various methods of aflatoxin exposure assessment have been used. Measurement of 
AFBi levels in food does not provide any information on the biologically effective 
dose of this mycotoxin at the individual level, whereas the measurement of the 
AFBi-DNA or protein adducts circulating in body fluids or tissues can serve as a 
marker for both AFB, exposure and in vivo metabolic activation. Immunological 
assays employing polyclonal antibody or monoclonal antibody are able to measure 
very low levels of AFB! and adducts. 
In this study, a method was successfully developed and validated for the assay of 
AFBi-albumin adducts in serum, employing both a rabbit anti-AFBi anti-serum and 
a rat anti-AFBi monoclonal antibody. In the end, a rat monoclonal antibody was used 
for the study. The study regimen involved firstly the isolation of serum albumin 
which was digested by a protease proteinase K to release the major serum albumin 
I 
adduct - AFBi-lysine together with other AFBi-peptides. This was followed by clean-
up steps by a Sep-Pak Qg cartridge and a specific immunoaffinity column. The final 
sample was studied by ELISA and HPLC. The study by HPLC, due to its intrinsic 
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properties, could only separate and quantify AFBi-lysine as one entity. On the other 
hand, because the rat monoclonal antibody was capable of recognising AFBi, AFBi-
lysine and a range of other AFB! metabolites, study by ELISA could give a 
representative estimation of exposure. 
The optimal digestion process was determined to be a 24 hr digestion with proteinase 
K added at O hr and 4 hr. The capacity was over 40 ng of AFBi for both the Sep-
Pak Ci8 cartridge and the immunoaffinity column. The overall process including the 
isolation of albumin from serum, digestion of albumin to release AFBi-modified 
adducts and the clean-up process was validated using ^H-AFBi-modified animal 
serum by injecting them with ^H-AFBi. The overall percentage recovery of 23.3%, 
although low, was comparable to some similar studies (Wild et al, 1990b). 
The rat monoclonal antibody was found to have high specificity and sensitivity 
towards both AFBi, AFBi-lysine and some other AFBi metabolites and adducts. It 
could be diluted 1:5,000 for use in the competitive ELISA assay developed in this 
study. 
This regimen was used in the study of possible AFBi exposure in man. 
I 
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3.3 Monitoring of AFBi-albumin adducts in plasma of patients with liver 
disease and hepatocellular carcinoma 
3.3.1 Introduction 
There is considerable evidence indicating an association between aflatoxin exposure 
and hepatocellular carcinoma in man (see section 3.1.4.5). Epidemiology studies 
correlating the dietary levels of AFBi and the incidence of HCC have been carried 
out in China, Swaziland and Kenya, providing positive association and dosimetery 
data between high intakes of aflatoxins and high incidence rates of HCC. However, 
these data could not provide information on the biologically effective dose of 
aflatoxin at the individual level, i.e. the amount of activated agent that has actually 
reacted with critical cellular targets, including nucleic acids and proteins, which may 
be influenced by intake, distribution, metabolic activation and excretion of aflatoxin. 
Thus there is a strong motivation to investigate further the circumstantial relationship 
between aflatoxin ingestion and HCC incidence by monitoring aflatoxin and its 
metabolites and adducts in human body fluids, in order to compile biochemical and 
molecular epidemiological data. The main goal of these studies is to identify 
individuals at high risk of HCC by obtaining evidence of high exposure to AFBi, 
leading to pathobiological lesions in target cells, and/or increased oncogenic 
susceptibility due to host factors including chronic hepatitis B infection, consumption 
of alcohol or cigarettes and other possible pro-carcinogenic substances. 
I 
Monitoring of AFBi exposure or any other suspected carcinogen in man provides 
evidence of possible pathobiological lesions in target cells at an individual level and 
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also a bridge between laboratory animal and human studies. However, since there 
may be a lag time, possibly of decades, between exposure and effects, biological 
exposure monitoring should ideally be parallelled with environmental monitoring. 
To detect these extremely low levels of the carcinogen in human body fluids or 
tissues, the method used must be sensitive and specific. Possible modifying and 
confounding factors must also be taken into account when analysing the results of 
exposure monitoring which may affect their interpretation. For the association 
between AFBi and HCC, modifying factors include diet (especially the protein 
content), smoking habit, intake of alcohol and other drugs. These may play a role 
in the metabolic activation or detoxification of AFB! by affecting the various enzyme 
systems involved. When other confounding factors were removed, cigarette smoking 
was found to have a protective effect against HCC in Fujian Province of China 
where incidence of both HCC and dietary contamination by AFB, were high (Lin, 
Yang, Ye, Xu, Yang, Zhang, Wu & Nebert, 1991). A suggested possible mechanism 
was that cigarette smoking induced CYP1A2 and diverted the metabolism of AFBi 
to the less toxic AFM! and thus less of AFBr8,9-epoxide was produced. 
Confounding factors which were known to be associated with HCC include hepatitis 
B infection and liver cirrhosis. 
The southeast coast of China, including Hong Kong is considered to be an endemic 
area for HCC. The mortality rate of HCC could be up to 300 per 100,000/year for 
males in some parts of China. In Hong Kong, the rate is about 30 per 100,000/year 
for males. Shank and Wogan surveyed foodstuffs on the market in Hong Kong in the 
70，s and found evidence of contamination by AFBj (Shank & Wogan, 1972b). 
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However, standards of living and the general storage of food and hygiene have much 
improved since then. In a case-control study conducted in Hong Kong where 107 
HCC patients and 107 controls were studied, the relative risk of HCC was not 
related to the dietary intake of com or beans, which were found to be the chief 
sources of AFB, contamination in Hong Kong. The relative risk was found to be 
increase by a factor of 2.2, though not significantly, for consumption of other grains, 
including wheat, barley and oats (Lam, Yu, Leung & Henderson, 1982). 
The objective of the present study was to determine whether exposure to AFBi was 
an important factor associated with the high incidence of HCC in Hong Kong. An 
assay for AFBi-albumin adducts in human serum employing an ELISA method was 
developed successfully (section 3.2) and was applied to the estimation of possible 
exposure to AFB! among patients with HCC, other liver diseases and also patients 
without liver disease. As this was the first study of its kind in Hong Kong looking 
at human exposure to AFB! on an individual basis by monitoring AFBi-albumin 
adducts in the serum, it was difficult to make a prediction of the probable levels of 
measurement, if the adduct was detectable. Both patients with and without liver 
diseases were recruited into this study for comparison as their involvement with the 
study was very little - only 10 ml whole blood to be taken at the same time of their 
other routine blood tests and some questions to be answered on their diet. 
I 
Nevertheless, since it is well established that cancer is a disease with a very long 
latent period, it is not to be expected that the presence of AFB! or its adducts in the 
blood samples would have any particular relevance in terms of the carcinogenic 
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process in any individual patient. However, if the dietary patterns of the Hong Kong 
people have not changed dramatically during the past years, and especially for the 
liver disease/cancer patients, despite their illness, the data obtained may provide 
valuable information on probable HCC risk due to exposure to AFB! and its in vivo 
metabolic activation. 
3.3.2 Material and methods 
3.3.2.1 Subject 
Subjects were recruited for 3 main categories: 
Group A: Subjects with no history or obvious evidence of liver disease 
Group B: Patients with various liver diseases 
Group C: Patients with hepatocellular carcinoma 
All subjects were Chinese. Group B subjects were further divided into Group Bl, 
B2 and B3. They were patients with chronic hepatitis B infection, alcoholics and 
other liver diseases (mostly Non A - Non B hepatitis), respectively. Group A 
subjects were either patients attending other clinics at the Li Ka Shing Specialist 
Clinics or patients and volunteers visiting the Clinical Pharmacology Studies Unit 
and the Metabolic Investigation Unit at the Prince of Wales Hospital. They might 
suffer from other medical problems including hypertension and diabetes, but had no 
I 
history or obvious evidence of liver disease. Details of their past medical history and 
current medications were noted. Subjects in Group B and Group C were patients of 
the Liver Clinic and the Joint Hepatoma Clinic at the Li Ka Shing Specialist Clinic, 
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respectively. These patients all had detailed patient records and previous laboratory 
tests to confirm diagnoses and were referred by their physicians-in-charge. It was 
intended to recruit about 50 patients in each group. The final numbers recruited for 
Groups A, B and C were 51, 47 and 49, respectively. 
A summary of the details of age, body weight and height of the subjects in each 
group are shown in Table 3.9 and the plasma biochemistry screen data are shown 
in Table 3.10. The study was explained in outline to each patient who was recruited 
for the study and informed consent was given by each subject. They were each 
questioned on their smoking and drinking habits and also on their diet, assisted by 
relatives when required. 
3.3.2.2 Sample collections 
10 ml venous blood sample was drawn from each subject into a heparinised tube 
either at the Li Ka Shing Specialist Clinics or The Clinical Pharmacology Studies 
Unit. The blood samples were kept on ice until returned to the laboratory within an 
hour. They were centrifuged at 1,400 xg for 10 minutes and the plasma separated i 
for storage at -70�C prior to analysis. A urine sample of 20 ml was also collected 
from each subject for reference. 
I 3 3 2.4 Assay for AFBi-albumin adducts 
Plasma samples (0.5 ml) were used in the assays for AFBi-albumin adducts. Plasma 








































































































































































































































Table 3.10 Plasma Biochemistry Screen of Subjects in Different Study 
Groups 
Group A Group Bl Group B2 Group B3 Group C Normal 
(n = 51) (n = 20) (n = 18) (n = 9 ) (n = 49) Range* 
Na Mean 139.4 140.1 137.7 138.5 136.7 137 - 142 
(mmol 1') SD 2.5 2.5 4.0 2.9 4.0 
Range 134 - 144 135 - 144 130 - 142 134 - 142 126 - 144 
K Mean 4.1 3.9 3.8 4.0 J T ] 3 . 5 - 5.1 “ 
(mmol r') SD 0.6 0.5 0.5 0.9 0.5 
Range 2.6 - 5.6 3.0 - 4.5 2.9 - 4.6 3.5 - 6.1 2.9 - 5.3 
Urea Mean 6.3 6.6 4.9 5.9 5.9 3.4 - 8.9 
(mmol 1') SD 1.4 1.9 1.6 2.5 1.8 
Range 3.4 - 9.9 4.3 - 11.9 2.0 - 8.6 3.8 - 11.5 3.2 - 9.9 
Creatinine Mean 96.6 94.2 87.7 93.5 85.8 64 - 96 
(limol r') SD 31.4 17.1 8.2 41.3 16.4 
Range 55 - 194 56 - 115 70 - 94 62 - 192 52 - 137 
Albumin Mean 46.8 39.4 38.3 41.0 36.6 35 - 48 
(g 1 ') SD 3 . 6 8 .1 9 . 1 5 .8 6 .3 
Range 38 - 57 2 0 - 48 22 - 50 3 2 - 48 23 - 50 
I Total Mean 11.5 24.8 18.9 18.4 22.4 0 - 15 
Bilirubin SD 7.2 19.5 17.8 18.0 18.8 
Oxmol 1') Range 5 - 46 8 - 78 4 - 52 7 - 64 4 - 99 
Alkaline Mean 74.5 159.0 104.5 94 171.8 40-136 
Phosphatase SD 22.7 108.3 45.6 33.3 114.7 
(lU 1') Range 36 - 166 59 - 444 68 - 210 58 - 167 56 - 564 
T L T M ^ 2 5 T 41.9 88.8 30.7 71.33 0 - 58 
(lU 1 �） SD 23.5 40.8 110.8 19.1 61.0 
Range I - 148 8 - 140 16 - 351 13 - 75 11 -272 
a-foetoprotein Mean I 2 I 石 9861.8 < 10 
(lU ml-') SD 11.9 3191 72.9 24036 
Range 2 - 43 2 - 12800 2 - 223 3 - 132000 
I 
* From the Department of Clinical Pathology, Prince of Wales Hospital, Shatin 
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K (section 3.2.3.8) then subjected to clean-up procedures (section 3.2.3.2 and section 
3.2.3.3) before analysing for AFBi-albumin adducts by ELISA (section 3.2.3.1), 
using 6 replicates for each sample. Additional HPLC analyses would be done on 
positive samples (section 3.2.3.5). AFBi-albumin adducts concentrations were 
expressed in AFBi-lysine equivalents on a per mg of serum albumin basis. 
3.3.2.5 Statistical analysis 
Results were represented as mean 土 standard deviation (SD) with the range. 
Descriptive statistics for each group and comparisons between groups were done by 
one way analysis of variance (ANOVA) with the computer statistics package 
SigmaStat (Version 1.01, 1993, Jandel Scientific, San Rafael, California, U.S.A.). 
3.3.3 Results and discussion 
The details of subjects in the study groups are shown in Table 3.9. The age, sex 
distribution and weight of the different groups were comparable. The mean age of 
subjects in each group was in the fifties but the range could be quite large. Male 
subjects in all Groups A, B and C outnumbered female subjects by a factor of 4 to 
6. This ratio was expected for the incidence of HCC. Since none of the subjects was 
actually an in-patient of the hospital, their diet was essentially the same as the 
normal population except for some of the control subjects who might suffer from I 
diabetes mellitus. Nevertheless, the appetite of the patients suffering from chronic 
illness might be impaired and the mean weights of subjects in Group B and Group 
C were lower than that of subjects in Group A. It was very difficult to obtain 
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information on their diet from the patients. Rice is the staple food amongst the 
population in Hong Kong but not com, peanuts and beans and a majority of the 
patients interviewed indicated intake of rice everyday. 
The biochemistry screen of the subjects in different study groups is shown in Table 
3.10. The mean results in each group were grossly normal except for elevated liver 
enzymes levels among patients with various liver diseases. The HCC group was also 
characterised by a much elevated serum a-foetoprotein of near 10,000 lU ml]. 
From Fig. 3.9, it can be seen that the steep slope of the standard ELISA curves, 
representing the proportional region, lies between the percentage of inhibition of 
20% to 80% and this is the most reliable portion of the standard curves to be used 
in the conversion to concentrations of the detected substances - AFBi and AFB^ 
lysine. Using these standard curves, inhibition below 20% could still be detected but 
was not reliable. Therefore, a cut off point was taken at 20% inhibition. This 
corresponded to a concentration of approximately 0.03 ng ml.i of AFB^lysine 
equivalent in the test samples. When converted to the actual amount of AFBi-lysine 
loaded into the wells of ELISA plates, this was approximately 0.75 pg of AFBi-
lysine (volume loaded into each well was 50 of the 1:1 diluted original sample). 
This was the absolute detection limit of the assay which referred to the actual level 
measured and must be considered together with the percentage recovery in order to 
obtain the ‘real’ level required to be present in a sample for detection to be possible. 
The recovery of the whole assay process was found to be 23.3% (section 3.2.5.11), 
therefore, the detection limit would be approximately 3.2 pg AFBrlysine present in 
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1.5 mg albumin (starting material in validation). This was equivalent to 
approximately 2 pg AFBi-lysine/mg albumin. 
Under these assay conditions and detection limits, it was found that none of the 147 
serum samples studied in the 3 study groups showed a percentage of inhibition 
higher that 20%. The distribution of the percentage of inhibition of the serum 
samples from subjects in these 3 study groups is shown in a box plot in Fig. 3.17 
and there was no statistically significant difference between the 3 groups. Most of 
the results were near zero or just slightly negative and only a very small number of 
samples with values around 10% inhibition. A number of the samples showed a 
negative percentage of inhibition. This was due to the fact that the percentage of 
inhibition was calculated using a blank PBS solution as the level of zero inhibition. 
When a control human serum sample or a study human serum sample produced a 
slightly more intense colour on the ELISA plate, the calculated pecentage of 
inhibition would be negative. But the difference was very small and the largest 
negative value was only around -10%. Due to the low levels of inhibition by the 
study samples, it was not possible to convert them into AFBj-lysine equivalent 
concentrations as they were below the proportional range of the standard ELISA 
curve. In other words, it could be said that all the samples presented for ELISA were 
of a concentration below 0.03 ng ml] of AFBi-lysine equivalent or the serum 
samples of all the study subjects contained less than 2 pg AFB^lysine per mg of 
albumin, which was the detection limit of this assay. As expected, no identifiable 
peaks could be detected when these samples were injected into the HPLC system 
(section 3.2.3.5). The chromatograms resembled those shown in Fig 3.16 with no 
y 
321 
Fig. 3.17 Box Plot Showing the Distribution of the Percentages of 
Inhibition in ELISA Produced by Serum Samples of the 
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distinguishable peaks eluted at the retention time of AFBi-lysine. 
The objective of this study was to determine whether exposure to AFBi was an 
important factor associated with the high incidence of HCC in Hong Kong by 
monitoring AFBi-lysine from serum albumin. In trying to produce such retrospective 
or prospective epidemiological data, the laboratory assay used for analysis is 
required to possess several properties - sensitivity, specificity, noninvasive sampling, 
large sample capacity, inexpensive and easy to perform (Wild et al.’ 1990b). 
Analysis of AFBi-albumin adducts has been considered to be a most promising 
approach in the study in this area, but an unreasonably high number of false 
positives were found when an ELISA was done directly on serum albumin without 
previous hydrolysis or digestion (Wild et al., 1990b). These false positives were 
from subjects whose serum albumin showed yellow green colour, suggesting a high 
level of bound bilirubin which may be interfering in ELISA. Therefore, direct 
ELISA has the inherent property of non-specificity and could not be used in serum 
samples from patients with liver diseases, who very often have elevated bilirubin 
levels. It has also been found that recognition by specific anti-AFBi antibodies of the 
isolated AFBi-lysine adduct was more than 30-fold greater than when the adduct is 
present in the intact albumin molecule (Wild et al., 1990b). This could be due to the 
steric arrangement of the adduct when it is still attached to albumin whereby the 
specific antibody could not get to the epitope that it recognises. Thus, ELISA for 
AFBi-lysine after hydrolysis or digestion is a superior study method to direct ELISA 
on serum albumin in terms of both specificity and sensitivity. 
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Serum samples from study subjects were required for the AFB^lysine ELISA assay 
used in this study. Blood-taking is an invasive procedure but most of these subjects 
were due for some routine blood tests when they visited the clinics. Therefore, they 
were not subjected to an extra invasive procedure. A large number of samples can 
be processed on the same ELISA plate but usually, a number of replicate wells are 
used. The entire experimental procedure of this study, starting from albumin 
isolation, to digestion by proteinase K, clean-up by Sep-Pak cartridge and 
immunoaffinity column, then finally to detection by ELISA, is a very long and 
‘labour intensive’ process. In particular, the loading of samples onto ELISA wells 
requires a high degree of concentration and clear documentation to avoid mix-up. 
Nevertheless, it does not require very expensive equipment or instrumentation except 
an ELISA plate reader. 
In summary, this study employed a sensitive and specific method for the monitoring 
of AFBi-lysine adducts in human serum samples through their recognition by a rat 
anti-AFBi monoclonal antibody developed specially for this study in an ELISA assay. 
The detection limit of this assay was found to be approximately 2 pg AFBj-lysine per 
mg of albumin. Nevertheless, even with this very high sensitivity, the assay failed 
to detect significant amounts of the adduct amongst the 147 serum samples collected 
for this study. These serum samples came from three groups of patients: a group of 
control patients who did not have any history or evidence of liver disease, a group 
of patients with various liver diseases including chronic hepatitis B infection and 
alcoholic liver disease and finally a group of patients diagnosed to suffer from HCC. 
Chapter 3 324 
There could be several reasons for the non-detection of AFBi-albumin adducts in the 
serum of the subjects in this study. One of the most easily explained reasons would 
be a low sensitivity of the assay used, thereby producing a large number of false 
negatives. This could result from a low level of recognition of AFBi-lysine and 
related albumin adducts by the rat monoclonal antibody used and/or a low percentage 
of recovery of the assay process such that a large proportion of the adducts was lost 
during the process. Looking at the validations carried out on the assay process, these 
explanations might not be substantiated. The monoclonal antibody was found to be 
very specific and sensitive towards AFBrlysine. In the ELISA standard curves, the 
proportion part of the curve has a very steep slope. This signifies high specificity of 
the monoclonal antibody against the substrate, AFB广lysine. The dilution used for the 
assay was 1:5,000 and using this dilution in ELISA, levels down to 0.75 pg of 
AFB广lysine could be detected. Although the overall recovery of the preparation and 
clean-up process was 23.3%, it is comparable to that of a similar study (Wild et al.’ 
1990b) and in fact the detection limit was approximately 2 pg AFBrlysine per mg 
of albumin. In the study of Wild et al, 17 out of 19 serum samples from Gambia 
and 5 out of 38 serum samples from Thailand were shown to contain measurable 
amounts of AFBrlysine, but not in any of 14 serum samples from France. The 
detection limit of our assay method was even lower than that of Wild et al. Thus 
the non-detection of AFBrlysine in our Hong Kong serum samples was likely to be 
a real phenonmenon and not a false negative result due to the assay having low 
sensitivity and specificity. 
It follows that the actual amounts of AFBi-albumin adducts that exist in the serum 
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of our subjects were of an extremely low level, if they existed at all. Very little 
work has been carried out on the aflatoxins in Hong Kong since Shank and Wogan 
conducted surveys on the contamination of foodstuffs available on the Hong Kong 
market in the 70，s (Shank & Wogan, 1972b). The general standards of living and 
hygiene and the facility for food storage have much improved since then, but part 
of the population still live in poor conditions with some still in rural areas. The 
Harmful Substances in Food Regulations of the Public Health and Municipal Service 
Ordinance in Hong Kong stipulate that the amount of AFBi in foodstuffs in Hong 
Kong should not exceed 15 ppb (Hong Kong Government, 1990). Enquiries were 
made at the Hygiene Division of the Department of Health, the department 
responsible for the enforcement of this regulation, regarding the actual frequency and 
results of test purchases and the analysis of AFBi in foodstuffs from the general 
market in Hong Kong. They replied that adherence to these regulations was 
voluntary from the manufacturer's and importer's part. Test purchases and analyses 
carried out by the department were done infrequently and the normal work schedule 
was impaired lately by the problem of organophosphate pesticides contamination of 
vegetables, which was very time consuming. Also, they would not disclose the 
results of previous analyses claiming to want ‘to avoid misintepretation'. Therefore, 
although a regulation exists to control the level of AFBi that can exist in foodstuffs 
on the market in Hong Kong, it might not be fully enforced. If the subjects recruited 
for our study were representative of the whole population in Hong Kong, then it 
would be truly fortunate that according to the findings of this study, exposure to 
AFBi was not found to be a health hazard in the local scene. 
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Several studies have tried to correlate the dietary intake of AFBi with serum albumin 
adducts (Gan et al, 1988; Sabbioni et al” 1990; Wild et al., 1990a) and a highly 
significant association has been shown. A functional relationship describing adduct 
levels under conditions of chronic exposure to xenobiotics which form covalent 
bonds to serum albumin has been derived (Sabbioni et al, 1987). The two important 
parameters are the dose-adduct relationship for single doses and the chronic average 
daily dose. The former parameter was determined using a rat model (Sabbioni et al., 
1987) and Gan et al. determined that the rat is an appropriate surrogate for humans 
with respect to this parameter (Gan et al” 1988). When studying subjects from 
Gangxi Province, China, Gan et al. constructed a regression line between the level 
of AFBj-albumin adduct and daily AFBi intake with a slope of 1.05 ng adduct (per 
g albumin) per 1 ^g AFBi intake/day (Gan et al” 1988). Using this as the basis of 
conversion, the detection limit of 2 pg AFB^lysine equivalents per mg of serum 
albumin in our assay would indicate an ingestion level of about 1.9 ng AFBi per day 
on the average. A correction factor of 3 - 5 was also proposed to take into account 
underestimation of the amount of AFB! ingested. The subjects that we studied from 
Hong Kong thus should have a daily ingestion of approximately 2 ng AFB” 
The other constraint of our study was that assumptions were made that the diet of 
the study subjects was not modified significantly as compared to the normal 
population. Nevertheless, the majority of these subjects were patients attending the 
Li Ka Shing Specialist Clinics with various disorders, including hypertension, 
diabetes and liver diseases. There is a tendency for Chinese patients to take special 
care of their diet irrespective of what kind of disease they suffer from and so they 
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might be taking ‘better quality food，as compared to the general population. Also, 
there might be subtle changes in their diet over the years if their illnesses were 
chronic. The half-life of albumin in man is about 20 - 30 days and so the monitoring 
of AFB,-albumin adducts, including AFB,-lysine, can reflect dietary exposure to 
AFBi during the past few months at the most. Possible exposure months or years 
before would not be revealed by this assay method. 
Monitoring of AFBi-DNA adducts measures even more recent AFB^  exposure as the 
major DNA adduct AFB,-Ar^ -Gua adduct is rapidly excised from DNA and excreted 
in the urine with a half-life of about 12 hours. The demonstration of actual 
mutational hotspot in genetic material would be a more long-lasting and definite 
proof of carcinogenesis (Bressac, Kew, Wands & Ozturk, 1991; Hsu, Metcalf, Sun, 
Welsh, Wang & Harris, 1991). The p53 gene is a putative tumour-suppressor gene 
and mutational hot spot in this gene has been reported in carcinoma of human lung, 
colon, oesophagus, breast and also liver. It was found that mutations ofp53 in HCCs 
are preferentially G—T or G—C substitutions at codon 249. These HCC samples 
came from southern Africa and Qidong, China, where dietary exposure to AFB! was 
evident; therefore these findings were of much interest as AFEj is known to bind 
preferentially to G residues of genetic material and induces G->T substitutions almost 
exclusively. 
I 
Our study revealed no circulating AFBi-albumin adduct detectable by our assay. It 
was planned to further this study by monitoring AFBpDNA adducts freed from 
isolated heptic DNA and immunocytochemical studies as well if there was evidence 
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that exposure to AFB! was a sizable problem in Hong Kong. Since the results of the 
AFBi-albumin adduct study were mostly negative, this was not pursued further. 
Perhaps a study of the mutational hotspot of HCC from Hong Kong would be of 
more value. However, these studies all involve the difficulty of obtaining liver 
tissues, tumour and non-tumour, from study subjects. This would have to rely on 
biopsy materials and resected tissues from suitable patients. HCC patients who 
cannot undergo surgery or chemotherapy would ultimately be incurable. Organ 
donation from patients of Chinese origin is especially difficult due to cultural beliefs 
and thus poses further hindrance to studies requiring human tissues. 
I 
CUmjpikF 4 
Summary and Ideas for Further Studies 
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Chapter 4 
Summary and Ideas for Further Studies 
The theme of this PhD thesis is on the metabolic activation of drugs and carcinogens 
in relation to toxicity and carcinogenesis. The two xenobiotics studied in this project 
were paracetamol and aflatoxin B!. For the first part of the project, we hoped to 
determine whether patients with hepatocellular carcinoma (HCC), who also have 
evidence of increased metabolic activation of paracetamol, have normal or prolonged 
plasma paracetamol half-lives and also confirm that there is a close relationship 
between plasma paracetamol half life, the plasma paracetamol AUC and the urinary 
recovery of unchanged paracetamol. A study was done to assess the full 
pharmacokinetics of paracetamol in these patients and the differences, if any, 
between healthy subjects and patients with other liver diseases. The results were used 
to help explain the mechanism and significance of the finding of increased metabolic 
activation of paracetamol in patients with HCC. The other xenobiotic whose 
metabolic activation was studied in this project was the mycotoxin aflatoxin Bp For 
this part of the project, a study was carried out to monitor the levels of the major 
albumin adduct of aflatoxin Bi in the serum of healthy individuals and patients with 
HCC and other liver disease. 
The results of the comparative pharmacokinetic study of paracetamol including 
different groups of patients showed that the metabolic activation of paracetamol was 
genuinely enhanced in most patients with HCC and a small proportion of patients 
with chronic liver diseases. The increased urinary recovery of the products of 
paracetamol metabolic activation was not due to an impairment of other metabolic 
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pathways. It was postulated that metabolic activation by microsomal enzymes might 
be involved in the formation of carcinogenic substances from xenobiotics with some 
implications in the pathogenesis of HCC. Although it was shown clearly that the 
oxidative pathway of paracetamol was enhanced amongst these patients, it was not 
known which specific metabolising enzymes were involved. It was known that 
cytochrome P450 enzymes, most probably CYP2E1 and CYP1A2, are involved in 
the metabolic activation of paracetamol, however, an enhancement of their activity 
has not been demonstrated amongst patients with HCC. It is also not known whether 
the activity of other families of cytochrome P450 enzymes are enhanced. To find out 
the identity of the cytochrome P450 enzyme(s) which is causing the enhanced 
metabolic activation of paracetamol in HCC patients, a study on the enzyme content 
of liver tissues from these patients is needed. The relative expression of various 
microsomal enzymes can be studied by separation by gel electrophoresis with 
Western blots and the rate of metabolism of known specific substrates to assess 
individual subject's capacity for the metabolic activation of paracetamol. 
Although our study on the metabolic activation of AFBi-albumin adduct showed that 
even with a high sensitivity of detection, we failed to detect significant amounts of 
the adducts in any of the plasma samples studied. It follows that the actual amounts 
of any AFBi-albumin adducts that may exist in the serum of our subjects were of an 
extremely low level, if they were present at all. It was planned to study this further 
by monitoring AFB�DNA adducts freed from isolated hepatic DNA. 
Immunocytochemical studies were planned as well to see if there was evidence that 
exposure to AFB! was a sizable problem in Hong Kong. Since the results of the 
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AFBi-albumin adduct study was mostly negative, this was not further pursued since 
the half-life of AFB^DNA adducts in human body is even shorter. Perhaps a study 
of the mutational hotspot of HCC, a more long-lasting and definite proof of 
carcinogenesis, would be of more value. Mutation of the p53 gene, a putative 
tumour-supressor gene, has been reported in carcinoma of human lung, colon, 
oesophagus, breast and also liver. It was found that mutations of p53 in HCCs are 
preferentially G->T or G—C substituions at codon 249 (Bressac et aL, 1991; Hsu et 
al.y 1991) and these findings are of much interest as AFBi is also known to induce 
G—T substitutions in genetic material. 
AFBi-lysine is one of the end products of the in vivo metabolic activation of AFBj. 
Another way of assessing the status of metabolic activation of AFB^  in individuals 
is to study the specific cytochrome P450 enzymes responsible for this process. It has 
been shown that multiple forms of cytochrome P450 are involved in the metabolic 
activation of AFB! (Forrester et al.，1990), which are also highly sensitive to 
environmental factors such as diet and cigarette smoking and are subject to 
considerable inter-individual variations. Identification and quantification of their 
relative expression by Western blots and the rate of metabolism of known specific 
substrates (drugs and other xenobiotics) (Forrester, Henderson, Glancey, Back, Park, 
Ball, Kitteringham, McLaren, Miles, Skett & Wolf, 1992) would be another method 
of assessing an individual's capacity for the metabolic activation of AFB, in vivo. 
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Appendix 2.1 Chemical and pharmacokinetic data of paracetamol 
HNCOCH3 
OH 
Paracetamol [acetaminophen, N-acetyl-p-aminophenol, 4-hydroxyacetanilide, N-(4-
hydroxyphenyl) acetamide] is an antipyretic and analgesic agent 
Description: White odourless crystalline powder with bitter taste 
Molecular weight: 151.2 
Melting point: 168 - 172�C 
pKa: 9.5 
Soluble in: 70 parts water, 7 parts alcohol, 13 parts acetone, 40 parts 
glycerol, 9 parts propylene glycol, 50 parts chloroform and 10 
parts methyl alcohol 
Insoluble in: Ether, pentane and benzene 
Oral bioavailability 70 -80% 
Plasma clearance 5.0 土 1.4 ml min'^  kg'^  
Vd 0.95 ± 0.12 1 kg-i 
t.^  2.0 土 0.4 hr 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 2.11 Metabolic Clearance of Paracetamol and Its 
Glucuronide. Sulphate. Cysteine and Mercapturate 
Conjugate in 14 Healthy Subjects Following Ingestion 
of a 20 mg kg i Body Weight Dose 
Model 1 
Metabolic Clearance of Paracetamol and Metabolites 
Subject 
T G S C P M M+C 
CWH 3.62 2.32 0.87 0.13 0.19 0.12 0.24 
WR 3.93 2.21 1.19 0.20 0.21 0.12 0.32 
WKKW 6.89 4.62 1.72 0.17 0.22 0.17 0.34 
KWSC 3.88 2.19 1.16 0.20 0.24 0.09 0.29 
CSYC 3.93 1.74 1.82 0.09 0.21 0.07 0.16 
LHY 3.49 1.42 1.53 0.15 0.32 0.08 0.23 
CWSD 3.54 2.42 0.79 0.08 0.18 0.07 0.14 
NPSD 3.71 2.04 1.36 0.08 0.18 0.06 0.13 
LCKY 2.81 1.28 1.29 0.07 0.12 0.06 0.13 
WP 3.84 2.02 1.44 0.14 0.16 0.09 0.23 
WH 4.42 2.46 1.52 0.11 0.29 0.05 0.15 
YAS 3.51 1.73 1.24 0.16 0.23 0.16 0.31 
SPY 2.96 1.92 0.75 0.05 0.16 0.08 0.13 
KKH 2.70 1.28 0.96 0.13 0.22 0.11 0.24 
Mean 2.12 1.26 0.12 0.21 0.09 0.22 
SD 1.01 0.82 0.33 0.05 0.05 0.04 0.08 
T = Total clearance � G = Metabolic clearance to the glucuronide conjugate S Metabolic clearance to the sulphate conjugate C = Metabolic clearance to the cysteine conjugate P = Metabolic clearance to unchanged paracetamol M = Metabolic clearance to the mercapturate conjugate M + C = Sum of the metabolic clearances to the cysteine and mercapturate conjugate 
375 
Appendix 2.12 Metabolic Clearance of Paracetamol and Its 
Glucuronide, Sulphate, Cysteine and Mercapturate 
Conjugate in 14 Healthy Subjects Following Ingestion 
of a 20 mg kg i Body Weight Dose 
Model 2 
Metabolic Clearance of Paracetamol and Metabolites 
Subject 
T G S C P M M+C 
CWH 3.77 2.41 0.91 0.13 0.20 0.12 0.25 
WR 4.15 2.33 1.26 0.21 0.22 0.13 0.34 
WKKW 7.18 4.82 1.79 0.18 0.23 0.17 0.35 
KWSC 4.11 2.32 1.23 0.21 0.25 0.10 0.31 
CSYC 4.11 1.82 1.91 0.09 0.22 0.07 0.16 
LHY 3.51 1.43 1.54 0.15 0.32 0.08 0.23 
CWSD 3.63 2.49 0.81 0.08 0.18 0.07 0.15 
NPSD 3.85 2.12 1.41 0.08 0.18 0.06 0.14 
LCKY 2.97 1.35 1.36 0.07 0.13 0.06 0.13 
WP 4.06 2.13 1.52 0.14 0.17 0.10 0.24 
WH 4.70 2.62 1.61 0.12 0.31 0.05 0.16 
YAS 3.71 1.83 1.31 0.16 0.24 0.17 0.33 
SPY 3.14 2.04 0.80 0.05 0.17 0.08 0.13 
KKH 2.83 1.34 1.01 0.13 0.23 0.12 0.25 
Mean 3.98 2 . 2 2 0 . 1 3 0.22 0.10 0.23 
SD 1.05 0.86 0.35 0.05 0.05 0.04 0.08 
T = Total clearance ‘ 
G = Metabolic clearance to the glucuronide conjugate 
S = Metabolic clearance to the sulphate conjugate 
C = Metabolic clearance to the cysteine conjugate 
P 二 Metabolic clearance to unchanged paracetamol M = Metabolic clearance to the mercapturate conjugate 
M + C = Sum of the metabolic clearances to the cysteine and mercapturate conjugate 
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Appendix 2.13 Metabolic Clearance of Paracetamol and Its 
Glucuronide. Sulphate, Cysteine and Mercapturate 
Conjugate in 14 Healthy Subjects Following Ingestion 
of a 20 mg kg] Body Weight Dose 
Model 3 
Metabolic Clearance of Paracetamol and Metabolites 
Subject 
T G S C P M M+C 
CWH 3.33 2.13 0.80 0.12 0.17 0.11 0.22 
WR 3.40 1.91 1.03 0.17 0.18 0.11 0.28 
WKKW 6.49 4.35 1.62 0.16 0.20 0.16 0.32 
KWSC 3.49 1.97 1.05 0.18 0.21 0.08 0.26 
CSYC 3.62 1.60 1.68 0.08 0.20 0.07 0.14 
LHY 3.19 1.30 1.40 0.14 0.29 0.07 0.21 
CWSD 3.21 2.20 0.72 0.07 0.16 0.06 0.13 
NPSD 3.39 1.86 1.24 0.07 0.16 0.05 0.12 
LCKY 2.56 1.17 1.18 0.06 0.11 0.05 0.11 
WP 3.47 1.82 1.30 0.12 0.14 0.09 0.21 
WH 3.95 2.20 1.35 0.10 0.26 0.04 0.14 
YAS 3.16 1.56 1.12 0.14 0.21 0.14 0.28 
SPY 2.64 1.71 0.67 0.04 0.15 0.07 0.11 
KKH 2.45 1.16 0.87 0.11 0.20 0.10 0.21 
Mean 3.45 1.14 0.11 0.19 0.09 0.20 
SD 0.97 0.78 0.31 0.04 0.05 0.03 0.07 
T = Total clearance i 
G = Metabolic clearance to the glucuronide conjugate 
S = Metabolic clearance to the sulphate conjugate 
C = Metabolic clearance to the cysteine conjugate 
P = Metabolic clearance to unchanged paracetamol 
M = Metabolic clearance to the mercapturate conjugate M + C = Sum of the metabolic clearances to the cysteine and mercapturate conjugate 
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Appendix 2.14 Metabolic Clearance of Paracetamol and Its 
Glucuronide. Sulphate. Cysteine and Mercapturate 
Conjugate in 14 Healthy Subjects Following Ingestion 
of a 20 mg kg i Body Weight Dose 
Model 4 
Metabolic Clearance of Paracetamol and Metabolites 
Subject 
T G S C P M M+C 
CWH 3.85 2.46 0.93 0.14 0.20 0.12 0.26 
WR 4.17 2.35 1.27 0.21 0.22 0.13 0.34 
WKKW 7.25 4.86 1.81 0.18 0.23 0.17 0.35 
KWSC 4.13 2.33 1.24 0.21 0.25 0.10 0.31 
CSYC 4.29 1.90 1.99 0.09 0.23 0.08 0.17 
LHY 3.78 1.54 1.65 0.16 0.34 0.09 0.25 
CWSD 3.71 2.55 0.83 0.08 0.19 0.07 0.15 
NPSD 3.91 2.15 1.43 0.08 0.19 0.06 0.14 
LCKY 3.01 1.37 1.38 0.07 0.13 0.06 0.13 
WP 4.08 2.14 1.53 0.14 0.17 0.10 0.24 
WH 4.78 2.66 1.64 0.12 0.31 0.05 0.17 
YAS 3.75 1.85 1.32 0.17 0.24 0.17 0.33 
SPY 3.15 2.05 0.80 0.05 0.17 0.08 0.13 
KKH 2.89 1.37 1.03 0.13 0.23 0.12 0.25 
Mean 4.05 2.26 1.35 0.13 0.22 0.10 0.23 
SD 1.05 0.86 0.36 0.05 0.06 0.04 0.08 
T = Total clearance , 
G 項 Metabolic clearance to the glucuronide conjugate S = Metabolic clearance to the sulphate conjugate C = Metabolic clearance to the cysteine conjugate P = Metabolic clearance to unchanged paracetamol M = Metabolic clearance to the mercapturate conjugate M + C = Sum of the metabolic clearances to the cysteine and mercapturate conjugate 
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Appendix 2.15 Metabolic Clearance of Paracetamol and Its 
Glucuronide. Sulphate. Cysteine and Mercapturate 
Conjugate in 14 Healthy Subjects Following Ingestion 
of a 20 mg kg'^ Body Weight Dose 
Model 5 
Metabolic Clearance of Paracetamol and Metabolites 
Subject = j = ^ = l = j = P = l = ^ = = 
T G S C P M M+C 
CWH 3.92 2.51 0.95 0.14 0.20 0.12 0.26 
WR 4.03 2.27 1.22 0.20 0.22 0.13 0.33 
WKKW 7.39 4.95 1.84 0.18 0.23 0.18 0.36 
KWSC 4.09 2.31 1.23 0.21 0.25 0.10 0.30 
CSYC 4.41 1.95 2.05 0.10 0.24 0.08 0.18 
LHY 3.83 1.56 1.67 0.16 0.35 0.09 0.25 
CWSD 3.76 2.58 0.84 0.08 0.19 0.07 0.15 
NPSD 4.51 2.48 1.65 0.09 0.21 0.07 0.16 
LCKY 3.02 1.37 1.39 0.08 0.13 0.06 0.13 
WP 4.11 2.16 1.54 0.15 0.17 0.10 0.25 
WH 4.13 2.30 1.41 0.10 0.27 0.04 0.14 
YAS 3.83 1.89 1.35 0.17 0.25 0.17 0.34 
SPY 3.15 2.04 0.80 0.05 0.17 0,08 0.13 
KKH 2.89 1.37 1.03 0.14 0.24 0.12 0.25 
Mean 4 . 0 8 2 . 2 7 1.35 0.13 0.22 0.10 0.23 
SD 1.07 0.87 0.37 0.05 0.05 0.04 0.08 
T = Total clearance ‘ 
G � Metabolic clearance to the glucuronide conjugate S = Metabolic clearance to the sulphate conjugate C = Metabolic clearance to the cysteine conjugate P = Metabolic clearance to unchanged paracetamol M = Metabolic clearance to the mercapturate conjugate M + C = Sum of the metabolic clearances to the cysteine and mercapturate conjugate 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
1. Clearance 
Subject Cl^ odei 4 ClModei 5 6 mean % of 5 mean b mean h 
(ml min-i kg"^ ) (ml min"^  kg ') as mean - 2SD + 2SD 
CWH 3.85 3?89 1.78 -0.51 0.47 
WR 4.17 4.03 0.14 4.10 3.46 
WKKW 7.25 7.39 -0.14 7.32 1.93 
KWSC 4.13 4.09 0.04 4.11 0.90 
CSYC 4.29 4.41 -0.12 4.35 2.71 
LHY 3.78 3.83 -0.05 3.80 1.24 
CWSD 3.71 3.76 -0.05 3.74 1.31 
NPSD 3.91 4.51 -0.60 4.21 14.14 
LCKY 3.01 3.02 -0.01 3.02 0.23 
WP 4.08 4.11 -0.03 4.10 0.76 
WH 4.78 4.13 0.65 4.45 14.69 
YAS 3.75 3.83 -0.08 3.79 2.22 
SPY 3.15 3.15 0.01 3.15 0.19 
KKH 2.89 2.89 0.00 2.89 0.07 
_ _ _ .0.02 3.26 
SD 0.25 4.65 
5 = ClModel 4 - ClModel 5 
I 
380 
Appendix 2.17 Comparison between Model 4 and Model 5 for 
Modified Bland-Altman Plot 
Subject t.^  Model 4 t,^  Model 5 b mean % of 5 mean b mean b 
(hr) (hr) as mean - 2SD + 2SD 
~ C ^ T m 1.47 -0.26 0.28 
WR 2.88 3.15 -0.27 3.02 8.79 
WKKW 1.86 1.83 0.03 1.85 1.63 
KWSC 2.45 2.63 -0.17 2.54 6.76 
CSYC 2 .22 2.06 0.15 2.14 7.18 
LHY 2.89 2.84 0.05 2.86 1.73 
CWSD 2.78 2.72 0.06 2.75 2.21 
NPSD 2.50 2.59 -0.10 2.55 3.75 
LCKY 2 .22 2.20 0.02 2.21 0.89 
WP 2.58 2.45 0.13 2.52 5.25 
WH 2.30 2.28 0.02 2.29 0.85 
YAS 3.05 2.74 0.31 2.89 10.62 
SPY 2 .62 2.58 0.03 2.60 1.34 
KKH 2.96 3.01 -0.05 2.99 1.76 
Mean 0.01 3.87 
SD 0.13 3 . i 4 
5 = t,^  Model 4 -1,^ Model 5 
1 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
3. AUC 
Subject AUCModei 4 AUCModei 5 6 mean % of 5 mean 6 mean 5 
(fig ml-i hr) (fig ml-i hr) as mean - 2SD + 2SD 
~ C ^ 86l 85^ n 85^ LS Ts ^ " “ 
WR 79.9 82.7 -2.8 81.3 3.5 
WKKW 46.0 45.1 0.9 45.6 1.9 
KWSC 80.7 81.4 -0.7 81.1 0.9 
CSYC 77.7 75.6 2.1 76.7 2.7 
LHY 88.2 87.1 1.1 87.7 1.2 
CWSD 89.8 88.6 1.2 89.2 1.3 
NPSD 85.2 74.0 11.3 79.6 14.1 
LCKY 110.7 110.4 0.3 110.5 0 .2 
WP 81.7 81.1 0.6 81.4 0.7 
WH 69.7 80.8 -11.0 75.3 14.7 
YAS 88.9 87.0 1.9 88.0 2.2 
SPY 105.7 106.0 -0.2 105.9 0.2 
KKH 115.5 115.4 0.1 115.5 0.1 
Mean 0.4 3.3 
SD 4.4 4.6 
5 = AUCModel 4 - AUCModel 5 
I 
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Appendix 2.25 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
1. Clearance 
Subject ClModei 1 ClModei 2 5 mean % of 6 mean 6 mean b 
(ml min-i kg"^ ) (ml min"^  kg"^ ) as mean - 2SD + 2SD 
~ C W H T m ^ ^ 3 ? ^ 4 I 4 -0.32 -0.04 
WR 3.93 4.15 -0.22 4.04 5.55 
WKKW 6.89 7.18 -0.29 7.04 4 .12 
KWSC 3.88 4.11 -0.23 3.99 5.66 
CSYC 3.93 4.11 -0.19 4 .02 4.63 
LHY 3.49 3.51 -0.02 3.50 0.60 
CWSD 3.54 3.63 -0.10 3.58 2.73 
NPSD 3.71 3.85 -0.14 3.78 3.79 
LCKY 2.81 2.97 -0.16 2.89 5.61 
WP 3.84 4 .06 -0.22 3.95 5.57 
WH 4.42 4 .70 -0.28 4.56 6.20 
YAS 3.51 3.71 -0.20 3.61 5.57 
SPY 2.96 3.14 -0.19 3.05 6.13 
KKH 2.70 2.38 -0.13 2.77 4.59 
Mean -0.18 ( 6 3 
SD 0.07 L47 
5 = ClModel 1 - ClModel 2 
I 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
2. t.^  
Subject tvi Model 1 t � � Model 2 8 mean % of 5 mean 6 mean b 
(hr) (hr) as mean - 2SD + 2SD 
CWH 4 3 9 ^ 19.76 -0.92 4.58 
WR 4.49 3.11 1.38 3.80 36.30 
WKKW 5.75 2.75 3.01 4.25 70.76 
KWSC 5.34 2.83 2.51 4.09 61.42 
CSYC 6.89 4.58 2.30 5.74 40.16 
LHY 5.25 5.91 -0.66 5.58 11.77 
CWSD 3.77 3.84 -0.07 3.81 1.86 
NPSD 3.95 3.97 -0.02 3.96 0.51 
LCKY 7.54 3.41 4.13 5.47 75.52 
WP 5.15 2.86 2.28 4.00 56.99 
WH 6.92 3.34 3.58 5.13 69.76 
YAS 4.83 3.45 1.38 4.14 33.23 
SPY 5.64 2.77 2.87 4.21 68.16 
KKH 5.22 3.10 2.12 4.16 51.00 
Mean ^ i T 42.66 
SD 1.38 25.26 
d = ti力 Model 1 - M o d e l 2 
I 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
3. AUC 
Subject AUCModei i AUCModei 2 5 mean % of 6 mean 5 mean 6 
(fig ml-i hr) (^g ml-i hr) as mean - 2SD + 2SD 
CWH 8 8 3 3 J ^ T a ^ T A " " 
WR 84.9 80.3 4.6 82.6 5.5 
WKKW 48.4 46.4 2.0 47.4 4.1 
KWSC 85.9 81.2 4.7 83.5 5 .6 
CSYC 84.9 81.1 3.9 83.0 4 .7 
LHY 95.5 94.9 0.6 95.2 0 .6 
CWSD 94.3 91.8 2.5 93.0 2 .7 
NPSD 90.0 86.6 3.3 88.3 3.8 
LCKY 118.8 112.3 6.5 115.6 5 .6 
WP 86.8 82.1 4.7 84.4 5 .6 
WH 75.4 70.9 4.5 73.1 6 .2 
YAS 94.9 89.8 5.1 92.4 5.6 
SPY 112.7 106.0 6.7 109.4 6.1 
KKH 123.4 117.9 5.6 120.6 4 .6 
Mean 4.2 4 .6 
SD 1.6 
5 = AUCModei 1 - AUCModei 2 
I 
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Appendix 2.25 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
1. Clearance 
Subject ClModei 1 ClModei 3 5 mcaii % of 5 mean 5 mean 6 
(ml min-i kg i) (ml min"^  kg i) as mean - 2SD + 2SD 
CWH 3 3 3 ^ 3^7 8.46 0.20 0.50 
WR 3.93 3.40 0.53 3.67 14.35 
WKKW 6.89 6.49 0.40 6.69 5.95 
KWSC 3.88 3.49 0.39 3.69 10.64 
CSYC 3.93 3.62 0.31 3.77 8.22 
LHY 3.49 3.19 0.30 3.34 8.98 
CWSD 3.54 3.21 0.32 3.37 9.51 
NPSD 3.71 3.39 0.32 3.55 8.94 
LCKY 2.81 2.56 0.24 2.68 9.09 
WP 3.84 3.47 0.37 3.66 10.12 
WH 4.42 3.95 0.47 4.19 11.20 
YAS 3.51 3.16 0.35 3.34 10.46 
SPY 2.96 2.64 0.32 2.80 11.52 
KKH 2.70 2.45 0.25 2.57 9.83 
Mean ^ 9 ,80 
SD 0.08 1.85 
5 = ClModel 1 “ Clwodel 3 
I 
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Appendix 2.25 Comparison between Model 2 and Model 4 for Modified Bland-Altman Plot 
2. t々  
Subject tvi Model 1 t,^  Model 3 5 mean % of 6 mean 8 mean 6 (hr) (hr) as mean - 2SD + 2SD 
CWH 4 3 9 4^59 ^ ^ 4 4 9 " Z l l 2.76 
WR 4 .49 4 .06 0.44 4.28 10.17 
WKKW 5.75 4.87 0.89 5.31 16.67 
KWSC 5.34 4.17 1.18 4.76 24.72 
CSYC 6.89 4.87 2.02 5.88 34.28 
LHY 5.25 4.58 0.68 4.91 13.75 . 
CWSD 3.77 3.79 -0.02 3.78 0 .62 
NPSD 3.94 3.56 0.39 3.75 10.38 
LCKY 7.54 4.58 2.95 6.06 48.76 
WP 5 .14 4 .09 1.06 4.62 22.86 
WH 6.92 4 .49 2.43 5.70 42.57 
YAS 4 .83 4.27 0.56 4.55 12.22 
SPY 5.64 4 .38 1.26 5.01 25.21 
KKH 5.22 4 .48 0.74 4.85 15.32 
Mean 2 (U4 
SD 0.87 13.46 
6 = t,^  Model 1 - tv4 Model 3 
I 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
3. AUC 
Subject AUCModel i AUCModei 3 6 mean % of 6 mean 8 mean 6 
(fjLg ml-i hr) (/xg ml 1 hr) as mean - 2SD + 2SD 
CWH ~ i 100.2 s T -14.9 -4.3 
WR 84.9 98.0 -13.1 91.4 14.3 
WKKW 48.4 51.3 -3.0 49.9 5.9 
KWSC 85.9 95.5 -9.6 90.7 10.6 
CSYC 84.9 92.2 -7.3 88.6 8.2 
LHY 95.5 104.5 -9.0 100.0 9.0 
CWSD 94.3 103.7 -9.4 99.0 9.5 
NPSD 90.0 98.4 -8.4 94.2 9.0 
LCKY 118.8 130.1 -11.3 124.5 9.1 
WP 86.8 96.0 -9.2 91.4 10.1 
WH 75.4 84.3 -8.9 79.9 11.2 
YAS 94.9 105.4 -10.5 100.2 10.5 
SPY 112.7 126.5 -13.8 119.6 11.5 
KKH 123.4 136.1 -12.7 129.8 9.8 
Mean — -9.6 9.8 
SD 2.6 
6 = AUCModel 1 - AUCModel 3 
I 
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Appendix 2.25 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
1. Clearance 
Subject ClModei 2 ClModei 4 6 mcaii % of d mean d mean 5 
(ml min-i kg" )^ (ml min"^  kg i) as mean - 2SD + 2SD 
CWH 3 T 7 ^ ^ J T l 2.05 -0.21 0 .06 
WR 4.15 4.17 -0.02 4.16 0.48 
WKKW 7.18 7.25 -0.07 7.21 0.92 
KWSC 4.11 4.13 -0.02 4.12 0.58 
CSYC 4.11 4 .29 -0.18 4.20 4.24 
LHY 3.51 3.78 -0.27 3.65 7.35 
CWSD 3.63 3.71 -0.08 3.67 2.18 
NPSD 3.85 3.91 -0.06 3.88 1.60 
LCKY 2.97 3.01 -0.04 2.99 1.47 
WP 4.06 4.08 -0.02 4.07 0.47 
WH 4.70 4.78 -0.08 4.74 1.60 
YAS 3.71 3.75 -0.04 3.73 0.97 
SPY 3.14 3.15 -0.01 3.15 0.25 
KKH 2.83 2.89 -0.06 2.86 1.86 
Mean -0.07 1.86 
SD 0.07 1.81 
5 = ClModei 2 _ ClModel 4 
I 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
Subject t.^  Model 2 Model 4 6 mean % of 6 mean 6 mean 8 
(hr) (hr) as mean - 2SD + 2SD 
CWH 2^60 LOO 3 I 0 32.24 -0.68 2 .62 
WR 3.11 2.88 0.23 3.00 7.65 
WKKW 2.75 1.86 0.88 2.31 38.30 
KWSC 2.83 2.45 0.38 2.64 14.29 
CSYC 4.58 2.22 2.37 3.40 69.64 
LHY 5.91 2.89 3.02 4.40 68.64 
CWSD 3.84 2.78 1.06 3.31 32.14 
NPSD 3.97 2.50 1.47 3.23 45.37 
LCKY 3.41 2.22 1.18 2.81 41.98 
WP 2.86 2.58 0.28 2.72 10.26 
WH 3.34 2.30 1.04 2.82 36.91 
YAS 3.45 3.05 0.41 3.25 12.48 
SPY 2.77 2.62 0.16 2.70 5.82 
KKH 3 .10 2.96 0.14 3.03 4.60 
Mean " " “ ^ 30,02 
SD 0.82 21.12 
d = t,^  Model 2 - Model 4 
I 
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Appendix 2.27 Comparison between Model 2 and Model 4 for 
Modified Bland-Altman Plot 
3. AUC 
Subject AUCModei 2 AUCwodei 4 6 mean % of 6 mean 6 mean d 
(fig ml-i hr) (fig ml 1 hr) as mean - 2SD + 2SD 
CWH 883 LS 8^4 H ~ 
WR 80.3 79.9 0.4 80.1 0.5 
WKKW 46.4 46.0 0.4 46.2 0.9 
KWSC 81.2 80.7 0.5 80.9 0.6 
CSYC 81.1 77.7 3.3 79.4 4.2 
LHY 94.9 88.2 6.7 91.5 7.3 
CWSD 91.8 89.8 2.0 90.8 2.2 
NPSD 86.6 85.2 1.4 85.9 1.6 
LCKY 112.3 110.7 1.7 111.5 1.5 
WP 82.1 81.7 0.4 81.9 0.5 
WH 7 0 . 9 69 .7 1.1 70 .3 1.6 
YAS 89.8 88.9 0 .9 89.4 1.0 
SPY 106.0 105.7 0.3 105.9 0.3 
KKH 117.9 115.5 2.4 116.7 2.0 
Mean 1.7 1.9 
SD 1.6 1.8 
d = AUCModei 2 - AUCModei 4 
I 
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Appendix 2.28 Individual Plasma Paracetamol Concentrations 
Following Ingestion of a 20 mg kg i Body Weight 
Dose - Group A 
Plasma Paracetamol Concentration (/xg ml“) 
Time 
(hr) Group A Subject 
1 2 3 4 5 6 7 
0 0 0 0 0 0 0 0 
0.5 15.52 19.72 19.28 23.59 25.14 20.37 26.87 
1 14.51 15.28 21.23 19.69 29.21 24.26 17.42 
1.5 12.21 - - 16.38 123.00 19.45 13.90 
2 13.67 12.22 15.05 12.85 19.39 16.28 12.07 
3 9.56 8.13 10.15 9.24 13.66 11.43 8.73 
4 6.76 5.24 7.89 5.76 10.35 8.31 6.51 
5 4 .76 4.17 5.24 3.79 7.06 5 .86 4.91 
6 3.38 2.91 3.73 2.66 5.83 4 .14 3.47 
7 2.63 1.94 2.72 1.96 4.43 3.01 2.58 
8 1.87 1.48 1.97 1.45 3.59 2.56 1.79 
24 0 .09 0.14 0.10 0.15 0.17 0 .16 0.17 
1 
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Appendix 2.28 Individual Plasma Paracetamol Concentrations 
Following Ingestion of a 20 mg kg i Body Weight 
Dose - Group A 
Plasma Paracetamol Concentration (ug m-1) 
Time — 
(hr) Group B Subject 
1 2 3 4 5 6 7 8 
0 0 0 0 0 0 0 0 0 
0.5 12.57 26.92 15.39 13.41 30.24 20.38 18.39 8.90 
1 12.49 20.34 13.23 31.38 19.86 24.39 19.53 14.69 
1.5 9.57 17.14 11.15 17.91 16.02 23.65 - 11.51 
2 7.52 15.89 9.57 11.01 13.72 20.93 15.26 11.56 
3 5.29 13.98 7.59 6.43 10.09 16.34 12.25 8.11 
4 3.49 11.24 5.78 3.80 7.97 13.33 9.82 5.26 
5 2.24 9.21 4.51 2.38 6.02 10.72 6.80 3.58 
6 1.31 7.92 3.99 1.39 4.08 8.54 5.23 2.61 
7 0.98 6.87 2.89 1.29 2.93 7.05 4.57 1.80 
8 0.75 5.15 2.32 0.68 2.89 6.06 3.51 1.40 
24 ND ND 0.09 ND ND 0.35 0.15 0.15 
1 
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Appendix 2.28 Individual Plasma Paracetamol Concentrations 
Following Ingestion of a 20 mg kg i Body Weight 
Dose - Group A 
Individual Plasma Paracetamol Concentration (jxg ml'') 
Time 
(hr) Group C Subject 
1 2 3 4 5 6 7 8 9 
0 0 0 0 0 0 0 0 0 0 
0.5 15.10 21.59 15.43 15.77 19.84 21.31 3.68 13.54 15.29 
1 22.93 20.18 15.59 17.55 23.51 21.22 17.73 21.88 29.15 
1.5 19.84 15.73 12.78 27.15 12.18 19.17 15.38 18.24 20.07 
2 18.20 13.89 10.80 17.47 9.31 18.08 11.00 17.57 20.71 
3 15.88 9.99 8.20 12.41 6.80 13.34 6.25 14.58 22.37 
4 13.53 7.03 6.50 8.66 4.96 12.85 5.02 13.02 18.34 
5 11.54 5.29 4.40 5.98 3.72 10.53 2.63 10.87 18.01 
6 9.67 4.01 3.34 4.41 2.83 9.48 1.88 8.01 13.59 
7 8.52 3.16 2.58 3.39 2.22 8.76 1.31 6.27 11.85 
g 7.85 2.52 1.86 2.61 1.84 9.00 1.22 6.11 11.57 
24 0.56 0.13 0.09 0.04 0.08 1.63 0.04 0.35 3.03 
1 
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Appendix 2.28 Individual Plasma Paracetamol Concentrations 
Following Ingestion of a 20 mg kg i Body Weight 
Dose - Group A 
Plasma Paracetamol Concentration (jig ml'') 
Time 
(hr) Group D Subject 
1 2 3 4 5 6 7 8 
0 0 0 0 0 0 0 0 0 
0.5 22.49 18.88 20.23 19.82 28.27 23.89 6.65 25.03 
1 15.26 19.73 18.61 29.30 30.81 17.98 12.85 18.12 
1.5 11.35 17.60 13.08 31.05 29.22 14.59 16.29 15.04 
2 9.30 15.70 10.90 21.07 27.35 12.56 14.86 13.27 
3 6.01 13.02 8.07 16.56 19.46 9.74 11.53 10.36 
4 4.62 10.18 5.11 12.80 13.89 7.93 9.87 8.69 
5 3.39 8.11 4.03 10.80 11.01 6.12 8.00 6.68 
6 2.70 6.55 3.02 9.37 6.59 4.29 6.22 5.47 
7 1.99 5.28 2.35 8.38 6.13 3.69 5.01 4.41 
8 1.62 4.25 1.79 7.23 4.07 2.73 4.01 3.56 
24 0.40 2.22 0.11 1.41 0.17 0.07 0.08 0.20 
1 
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Appendix 2 . 2 8 Individual Plasma Paracetamol Concentrations 
Following Ingestion of a 20 mg kg i Body Weight 
Dose - Group A 
Plasma Paracetamol Concentration (jj.g ml'') 
Time 
(hr) Group R Subject 
1 2 3 4 5 6 7 
0 0 0 0 0 0 0 0 
0.5 17.32 0.63 17.85 18.52 11.35 10.66 33.51 
1 19.11 9.82 14.74 15.70 8.02 11.67 16.81 
1.5 20.74 9.43 12.56 13.50 5.16 10.23 12.97 
2 18.05 7.68 12.45 9.90 3.68 8.06 10.68 
3 15.33 5.74 9.29 6.72 2.46 9.06 7.89 
4 11.68 4.07 7.19 4.82 1.77 7.64 5.91 
5 8.31 2.84 5.16 3.32 1.16 6.03 2.08 
6 6.83 1.90 4.33 2.51 0.86 4.66 2.60 
7 5.55 1.55 3.46 2.08 0.65 3.71 3.33 
8 4.48 1.28 2.93 1.70 0.68 3.13 4.15 
24 1.64 0.20 0.34 0.06 0.10 0.41 0.09 
1 
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Appendix 2.28 Individual Plasma Paracetamol Concentrations 
Following Ingestion of a 20 mg kg i Body Weight 
Dose - Group A 
Plasma Paracetamol Concentration (/xg ml"^ ) 
Time 
(hr) Group D' Subject 
1 2 3 4 5 6 7 8 
0 0 0 0 0 0 0 0 0 
0.5 8.41 2.48 18.00 13.60 29.90 31.63 12.24 30.30 
1 15.21 5.78 20.12 19.44 30.83 22.70 15.90 22.60 
1.5 - - - - - - - -
2 17.13 7.34 13.35 14.75 20.75 17.79 12.96 15.68 
3 13.92 8.78 9.96 9.70 16.93 14.62 10.62 12.55 
4 10.27 8.74 7.29 7.61 14.17 11.26 8.40 10.03 
5 7.66 7.69 5.28 5.82 11.66 9.41 7.01 8.53 
6 6.11 6.10 4.21 4.77 9.17 7.40 5.54 6.71 
7 5.14 4.67 3.06 3.41 7.88 6.01 4.34 5.81 
8 4.34 3.28 2.29 2.58 6.11 4.75 3.44 4.71 
24 0.38 0.26 0.10 0.11 0.29 0.14 0.16 0.35 
1 
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Appendix 2 . 4 9 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration (jxg ml ') Time 
(hr) Group A Subject 
1 2 3 4 5 6 7 
0 0.00 0.00 0.00 0.00 1.73 0.00 0.00 
0.5 6.02 7.39 3.33 1.95 4.71 4.47 3.82 
1 12.26 17.55 6.04 6.46 9.56 11.64 7.68 
1.5 13.90 - - 9.06 12.98 14.09 9.41 
2 14.91 20.41 10.60 10.24 14.31 15.40 10.48 
3 16.40 17.57 13.10 10.79 15.95 15.37 11.08 
4 13.10 13.13 12.86 9.67 15.68 15.64 10.47 
5 11.22 9.76 10.66 8.18 14.10 13.97 9.43 
6 8.92 7.51 8.90 6.26 12.28 11.80 8.07 
7 7.17 5.78 7.39 4.74 10.64 9.94 6.69 
8 5.61 4.59 5.89 3.64 9.19 8.26 4.99 
24 0.34 1.00 0.94 0.28 1.39 1.08 1.06 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Sulphate Concentration (/xg m l ’ 
Time 
(hr) Group A Subject 
1 2 3 4 5 6 7 
0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 5 6 0 . 0 0 0 . 0 0 
0 . 5 3 . 9 8 4 . 2 6 5 . 0 4 3 . 4 2 4 . 6 9 2 . 9 4 3 . 8 5 
1 5 . 3 3 7 . 2 5 7 . 0 6 6 . 0 7 7 . 0 5 5 . 2 9 5 . 1 5 
1 5 5 . 2 3 - - 6 . 4 8 7 . 9 8 5 . 5 4 5 . 2 6 
2 5 . 3 4 6 . 8 5 7 . 6 4 6 . 0 5 8 . 3 3 5 . 4 7 5 . 1 8 
3 4 . 7 6 5 . 3 0 7 . 3 3 5 . 2 5 7 . 8 8 5 . 0 0 4 . 7 0 
4 3 . 9 6 3 . 8 7 6 . 8 2 4 . 2 3 7 . 4 1 4 . 4 1 4 . 0 5 
5 3 . 2 4 3 . 0 6 5 . 2 4 3 . 1 2 6 . 4 5 3 . 7 0 3 . 3 5 
6 2 . 4 9 2 . 3 5 4 . 0 9 2 . 2 1 5 . 3 4 2 . 8 4 2 . 6 5 
7 2 . 0 2 1 . 6 6 3 . 0 9 1 . 5 2 4 . 3 4 2 . 4 0 2 . 0 0 
8 1 .54 1 . 2 9 2 . 3 6 1 . 0 7 3 . 6 8 1 . 8 9 1 . 46 
2 4 0 . 0 0 0 . 0 9 0 . 1 2 0 . 0 6 0 . 2 7 0 . 0 8 0 . 1 0 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Cysteine Concentration (jxg ml"') 
Time 
(hr) Group A Subject 
1 2 3 4 5 6 7 
0 0.00 0.00 0.00 0.00 0.08 0.00 0.00 
0 . 5 0 . 0 4 0 . 1 3 0 . 0 9 0 . 0 0 0 . 0 8 0 . 0 6 0 . 0 5 
1 0 . 1 0 0 . 2 8 0 . 0 3 0 . 0 0 0 . 0 9 0 . 0 7 0 . 1 3 
1 .5 0 . 1 3 - - 0 . 0 3 0 . 2 3 0 . 1 3 0 . 1 9 
2 0 . 1 3 0 . 4 4 0 . 0 8 0 . 1 3 0 . 1 0 0 . 1 2 0 . 2 4 
3 0 . 1 6 0 . 4 8 0 . 1 4 0 . 1 3 0 . 1 5 0 . 1 6 0 . 2 6 
4 0 . 1 7 0 . 4 1 0 . 1 7 0 . 1 4 0 . 3 3 0 . 1 5 0 . 2 6 
5 0 . 1 3 0 . 4 4 0 . 1 7 0 . 1 2 0 . 1 9 0 . 2 2 0 . 2 6 
6 0 . 1 2 0 . 4 5 0 . 2 6 0 . 0 0 0 . 1 8 0 . 1 6 0 . 2 4 
7 0 . 1 2 0 . 3 7 0 . 2 2 0 . 1 0 0 . 1 6 0 . 1 9 0 . 2 3 
8 0 . 1 2 0 . 3 4 0 . 1 8 0 . 0 8 0 . 1 4 0 . 1 1 0 . 2 0 
24 0.00 0.08 0.00 0.00 0.06 0.00 0.00 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration (/xg ml ') Time 
(hr) Group B Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 4 . 3 0 2 . 3 7 3 . 6 6 3 . 6 7 7 . 4 4 3 . 7 3 2 . 7 2 3 . 5 9 
1 1 3 . 2 3 6 . 2 4 5 . 9 7 16 . 64 1 3 . 0 6 9 . 5 6 5 . 2 4 9 . 5 9 
1 . 5 1 8 . 3 7 8 . 8 8 6 . 5 1 3 0 . 5 1 1 4 . 2 8 1 2 . 0 3 - 18 . 55 
2 1 9 . 0 2 1 0 . 7 0 7 . 0 0 3 0 . 5 2 1 4 . 4 8 1 3 . 9 7 6 . 6 5 17 . 50 
3 1 8 . 3 7 1 3 . 9 8 7 . 1 9 2 6 . 5 3 1 3 . 5 4 1 4 . 1 5 7 . 7 5 17 .03 
4 1 5 . 9 5 13 . 51 6 . 5 1 2 0 . 2 9 1 1 . 9 7 1 4 . 1 5 8 . 3 8 14 . 20 
5 1 2 . 1 5 1 2 . 2 6 5 . 5 5 14 .51 9 . 3 4 1 3 . 0 2 7 . 6 2 11 .11 
6 9 . 4 3 1 1 . 1 2 5 . 1 6 9 . 6 0 7 . 4 9 1 1 . 0 5 6 . 2 8 8 . 6 0 
7 6 . 8 5 1 0 . 2 3 4 . 6 1 7 . 9 5 5 . 4 9 9 . 1 6 5 . 8 1 6 . 7 8 
8 5 . 2 7 8 . 3 6 3 . 6 8 4 . 7 0 4 . 2 1 8 . 8 5 4 . 4 5 5 . 5 3 
2 4 0 . 0 0 0 . 7 3 0 . 2 0 0 . 2 6 0 . 4 3 0 . 6 5 0 . 2 5 0 . 2 5 
I 
. 401 
Appendix 2.38 Ind iv idua l P lasma Pa race t amo l Sulphate 
Concentrations Following Ingestion of a 20 mg kg"^  
Body Weight Dose - Group B 
Plasma Paracetamol Sulphate Concentration (jxg ml"') 
Time 
(hr) Group B Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 3 . 2 5 1 . 5 3 1 . 85 2 . 5 0 4 . 6 1 3 . 4 7 4 . 3 6 1 . 1 2 
1 6 . 0 6 3 . 4 1 2 . 5 4 6 . 4 6 6 . 0 0 5 . 8 3 7 . 1 9 2 . 1 5 
1 .5 5 . 6 6 3 . 7 0 2 . 6 0 7 . 5 7 6 . 2 2 6 . 5 9 - 3 . 5 9 
2 5 . 0 6 3 . 8 5 2 . 7 2 6 . 4 6 5 . 9 6 6 . 7 6 8 . 3 3 3 . 3 8 
3 4 . 0 3 4 . 0 5 2 . 6 5 4 . 7 7 5 . 4 9 5 . 7 4 8 . 0 5 3 . 6 4 
4 3 . 0 6 3 . 2 9 2 . 1 9 3 . 2 8 . 4 . 7 6 6 . 0 8 7 . 4 1 2 . 9 7 
5 2 . 1 0 2 . 6 2 1 . 9 6 2 . 2 4 3 . 7 9 5 . 5 5 6 . 2 8 2 . 5 3 
6 1 . 4 2 2 . 1 7 1 . 83 1 . 48 2 . 7 3 4 . 3 8 5 . 0 1 1 . 96 
7 0 . 9 7 1 . 8 6 1 . 38 1 . 17 1 . 99 3 . 5 2 4 . 4 3 1 .53 
8 0 . 7 1 1 . 53 1 . 1 2 0 . 6 6 1 .51 3 . 1 9 3 . 3 8 1 . 26 
2 4 0 . 0 0 0 . 1 5 0 . 0 9 0 . 0 3 0 . 0 0 0 . 2 3 0 . 2 3 0 . 0 0 
‘ I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Cysteine Concentration (jig ml"') 
Time 
(hr) Group B Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 0 . 0 7 0 . 0 3 0 . 0 6 0 . 0 5 0 . 0 8 0 . 2 4 0 . 0 9 0 . 1 3 
1 0 . 1 2 0 . 0 5 0 . 1 6 0 . 0 9 0 . 1 8 0 . 2 7 0 . 1 3 0 . 2 7 
1 . 5 0 . 2 1 0 . 0 8 0 . 1 2 0 . 3 0 0 . 2 3 0 . 3 4 - 0 . 0 0 
2 0 . 2 2 0 . 0 6 0 . 1 3 0 . 2 4 0 . 2 7 0 . 3 7 0 . 1 3 0 . 5 2 
3 0 . 2 6 0 . 1 3 0 . 2 4 0 . 2 8 0 . 3 3 0 . 4 9 0 . 2 1 0 . 7 4 
4 0 . 2 2 0 . 0 5 0 . 2 0 0 . 1 8 0 . 7 0 0 . 5 2 0 . 2 3 0 . 7 1 
5 0 . 1 9 0 . 0 0 0 . 2 9 0 . 2 2 0 . 9 3 0 . 5 0 0 . 2 0 0 . 5 7 
6 0 . 1 1 0 . 0 0 0 . 6 2 0 . 1 6 0 . 2 0 0 . 4 5 0 . 1 9 0 . 5 2 
7 0 . 1 1 0 . 0 3 0 . 1 4 0 . 1 4 0 . 1 9 0 . 3 3 0 . 1 5 0 . 4 7 
8 0 . 1 0 0 . 0 8 0 . 0 9 0 . 0 9 0 . 1 4 0 . 2 9 0 . 1 6 0 . 3 8 
2 4 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 9 0 . 0 3 0 . 0 0 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration (/xg ml"') 
Time 
(hr) Group C Subject 
1 2 3 4 5 6 7 8 9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 0 . 6 4 1 . 40 6 . 4 9 0 . 5 3 4 . 0 8 5 . 0 6 6 . 1 4 2 . 6 0 1 . 1 0 
1 2 . 9 8 3 . 5 3 1 4 . 6 7 2 . 7 3 8 . 7 7 1 3 . 6 2 1 2 . 7 0 5 . 1 5 1 0 . 7 6 
1 . 5 4 . 1 0 5 . 2 8 1 7 . 0 3 2 . 7 1 1 2 . 5 0 2 0 . 1 1 1 6 . 4 4 6 . 9 1 2 0 . 5 6 
2 5 . 2 9 5 . 8 3 1 7 . 1 3 3 . 3 7 1 3 . 2 3 2 2 . 5 0 1 5 . 5 6 7 . 4 8 2 4 . 8 8 
3 6 . 3 4 6 . 3 4 1 7 . 7 8 4 . 6 0 12 . 71 2 3 . 2 1 1 2 . 7 2 8 . 1 2 2 3 . 4 1 
4 6 . 4 3 7 . 7 6 1 7 . 3 9 4 . 6 8 1 2 . 4 7 2 1 . 5 0 1 0 . 7 7 8 . 2 5 2 0 . 1 3 
5 5 . 9 4 7 . 7 7 1 5 . 9 8 5 . 8 0 9 . 5 4 1 7 . 7 7 8 . 6 2 7 . 1 2 1 3 . 4 6 
6 5 . 4 1 7 . 3 2 1 3 . 9 8 4 . 6 3 8 . 0 3 1 4 . 2 0 6 . 9 1 6 . 8 1 9 . 4 9 
7 4 . 4 2 7 . 0 1 1 1 . 5 7 4 . 4 7 6 . 5 7 11 . 43 5 . 5 0 6 . 5 9 7 . 2 8 
8 4 . 0 1 5 . 9 0 9 . 5 9 4 . 9 2 4 . 8 8 9 . 7 0 4 . 7 3 6 . 3 7 5 . 6 3 
2 4 0 . 2 8 0 . 3 0 1 .25 1 . 95 0 . 3 1 0 . 3 4 1 . 03 1 . 07 0 . 2 1 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration (jxg ml"^ ) 
Time 
(hr) Group C Subject 
1 2 3 4 5 6 7 8 9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 1 . 3 8 1 . 0 4 3 . 1 3 0 . 4 9 3 . 7 5 1 . 94 4 . 9 8 1 . 2 4 0 . 7 0 
1 3 . 3 4 2 . 3 3 5 . 1 2 1 . 97 5 . 7 1 7 . 2 4 3 . 3 8 2 . 1 1 4 . 8 2 
1 . 5 3 . 8 6 2 . 9 6 5 . 5 7 1 . 93 5 . 9 2 4 . 4 4 6 . 5 9 2 . 5 5 6 . 8 4 
2 4 . 2 0 3 . 2 0 5 . 3 0 2 . 1 1 5 . 4 8 4 . 2 0 5 . 8 1 2 . 6 3 7 . 1 6 
3 3 . 9 1 3 . 3 9 4 . 7 7 3 . 0 2 4 . 9 6 3 . 5 2 4 . 5 5 2 . 6 9 5 . 4 8 
4 4 . 3 2 4 . 0 5 3 . 8 4 2 . 8 7 4 . 1 6 2 . 8 6 3 . 7 7 3 . 0 5 4 . 5 7 
5 3 . 8 0 4 . 1 6 3 . 2 0 3 . 7 1 3 . 3 1 2 . 3 6 2 . 9 2 2 . 8 3 2 . 9 5 
6 2 . 9 9 3 . 9 0 2 . 5 9 2 . 8 3 2 . 6 8 1 .77 2 . 3 5 2 . 5 8 2 . 0 9 
7 2 . 4 5 3 . 5 6 2 . 0 1 2 . 4 7 2 . 0 8 1 .43 1 . 8 6 2 . 5 6 1 . 5 4 
8 2 . 3 3 3 . 0 4 1 . 64 2 . 3 9 1 . 5 6 1 . 12 1 . 51 2 . 4 7 1 . 3 0 
2 4 0 . 0 0 0 . 4 6 0 . 0 0 0 . 8 8 0 . 0 0 0 . 0 0 0 . 0 9 0 . 4 8 0 . 1 3 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration (jxg ml ') Time 
(hr) Group C Subject 
1 2 3 4 5 6 7 8 9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 0 . 0 0 0 . 0 2 0 . 1 9 0 . 0 0 0 . 0 0 0 . 0 8 0 . 0 4 0 . 2 4 0 . 1 3 
1 0 . 0 1 0 . 0 7 0 . 3 4 0 . 1 4 0 . 0 1 0 . 0 9 0 . 1 3 0 . 2 1 0 . 1 1 
1 . 5 0 . 0 8 0 . 1 0 0 . 3 0 0 . 1 2 0 . 0 9 0 . 2 3 0 . 1 6 0 . 2 3 0 . 2 1 
2 0 . 1 4 0 . 1 5 0 . 2 5 0 . 1 6 0 . 0 7 0 . 3 0 0 . 2 4 0 . 2 6 0 . 2 2 
3 0 . 1 7 0 . 2 2 0 . 3 4 0 . 2 8 0 . 1 7 0 . 2 7 0 . 2 0 0 . 1 6 0 . 1 9 
4 0 . 2 3 0 . 3 1 0 . 2 4 0 . 3 4 0 . 1 7 0 . 2 9 0 . 2 1 0 . 1 2 0 . 2 4 
5 0 . 2 3 0 . 3 5 0 . 2 5 0 . 5 3 0 . 1 6 0 . 2 5 0 . 1 8 0 . 0 8 0 . 1 9 
6 0 . 1 8 0 . 3 8 0 . 2 1 0 . 3 2 0 . 1 6 0 . 2 2 0 . 1 4 0 . 1 1 0 . 1 7 
7 0 . 2 0 0 . 2 9 0 . 1 9 0 . 3 2 0 . 1 4 0 . 2 0 0 . 1 2 0 . 1 5 0 . 1 5 
8 0 . 1 9 0 . 2 9 0 . 1 5 0 . 3 5 0 . 1 7 0 . 1 8 0 . 1 1 0 . 1 5 0 . 1 6 
2 4 0 . 0 0 0 . 0 9 0 . 0 0 0 . 2 9 0 . 0 0 0 . 0 3 0 . 0 4 0 . 0 6 0 . 0 5 
I 
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Appendix 2.43 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg] 
Body Weight Dose - Group D 
Plasma Paracetamol Glucuronide Concentration (/xg ml ') 
Time -
(hr) Group D Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 3 . 0 6 3 . 5 4 5 . 5 1 1 .53 6 . 4 4 2 . 8 1 0 . 9 2 3 . 7 6 
1 6 . 6 8 8 . 1 6 15 . 05 4 . 8 3 1 4 . 1 0 3 . 9 4 2 . 2 9 5 . 7 5 
1 . 5 8 . 4 7 9 . 3 5 16 .41 7 . 4 6 1 8 . 5 1 4 . 7 4 3 . 9 4 6 . 5 7 
2 9 . 3 8 1 0 . 9 5 15 . 91 12 . 67 2 1 . 0 4 5 . 0 5 6 . 0 4 7 . 2 0 
3 1 0 . 2 8 1 2 . 3 2 1 3 . 5 4 14 . 95 2 0 . 2 5 5 . 1 4 8 . 4 0 7 . 3 5 
4 9 . 7 6 12 . 61 10 . 53 18 .25 1 7 . 9 3 4 . 8 2 9 . 1 5 4 . 5 2 
5 9 . 1 9 12 . 01 8 . 6 5 18 . 44 1 5 . 1 1 4 . 1 9 9 . 5 5 5 . 9 5 
6 7 . 8 3 11 .1 6 . 9 0 17 .75 1 1 . 2 9 3 . 4 0 9 . 1 9 5 . 2 5 
7 6 . 8 5 9 . 8 1 5 . 9 5 18 .84 9 . 8 9 3 . 0 4 8 . 2 3 4 . 6 0 
8 6 . 4 3 8 . 4 5 5 . 0 2 17 . 44 7 . 3 5 2 . 9 5 7 . 3 2 4 . 1 4 
2 4 1 . 5 6 5 . 8 5 0 . 1 8 10 .93 0 . 3 3 0 . 1 3 0 . 4 0 0 . 8 8 
1 
407 
Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Sulphate Concentration (/ig ml'') Time 
(hr) Group D Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 3 . 9 3 1 . 9 8 2 . 4 4 0 . 9 7 3 . 1 6 5 . 6 4 0 . 8 8 3 . 0 1 
1 5 . 6 4 3 . 7 5 4 . 8 9 2 . 3 6 4 . 6 8 5 . 9 3 1 . 8 2 4 . 0 9 
1 .5 5 . 9 5 3 . 9 8 4 . 7 5 3 . 3 6 5 . 3 8 6 . 3 1 2 . 6 7 4 . 1 1 
2 5 . 8 0 4 . 3 0 4 . 1 4 5 . 3 7 5 . 5 7 6 . 0 7 3 . 4 1 3 . 6 8 
3 5 . 3 9 4 . 2 8 3 . 2 1 6 . 2 6 4 . 9 6 5 . 6 9 3 . 6 1 3 . 7 5 
4 4 . 7 1 3 . 8 7 2 . 2 7 7 . 1 6 4 . 5 9 5 . 2 0 3 . 6 3 3 . 4 5 
5 3 . 8 6 3 . 3 5 1 . 8 2 7 . 4 8 4 . 0 0 4 . 3 5 3 . 4 4 2 . 9 2 
6 2 . 9 8 2 . 9 2 1 .31 7 . 3 3 3 . 4 2 3 . 2 8 3 . 0 8 2 . 3 0 
7 2 . 2 2 2 . 3 3 1 .03 7 . 5 2 3 . 1 8 2 . 8 6 2 . 6 2 2 . 0 1 
8 1 . 9 0 1 . 8 9 0 . 7 9 6 . 5 6 2 . 3 4 2 . 1 0 2 . 2 2 1 . 64 
2 4 0 . 2 2 2 . 5 3 0 . 0 9 3 . 4 5 0 . 1 5 0 . 1 2 0 . 1 0 0 . 1 2 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Cysteine Concentration (jig ml'') Time 
(hr) Group D Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 0 . 1 0 0 . 0 0 0 . 0 5 0 . 3 0 0 . 1 7 0 . 0 6 0 . 0 8 0 . 1 0 
1 0 . 1 8 0 . 0 8 0 . 1 7 0 . 1 4 0 . 1 9 0 . 1 5 0 . 2 0 0 . 2 0 
1.5 0.24 0.09 0.32 0.20 0.18 0.22 0.26 0.22 
2 0 . 3 3 0 . 0 6 0 . 2 2 0 . 4 2 0 . 2 5 0 . 2 5 0 . 3 6 0 . 2 8 
3 0 . 3 8 0 . 0 7 0 . 2 3 0 . 6 0 0 . 3 3 0 . 3 6 0 . 4 9 0 . 2 7 
4 0 . 3 5 0 . 0 8 0 . 2 1 0 . 7 8 0 . 3 0 0 . 3 7 0 . 5 1 0 . 2 8 
5 0 . 3 5 0 . 1 0 0 . 1 9 0 . 8 1 0 . 2 8 0 . 4 3 0 . 5 3 0 . 2 5 
6 0 . 3 0 0 . 0 8 0 . 1 6 0 . 7 7 0 . 1 7 0 . 4 0 0 . 4 9 0 . 2 1 
7 0 . 2 8 0 . 0 8 0 . 1 5 0 . 8 3 0 . 1 6 0 . 3 8 0 . 4 5 0 . 1 9 
8 0 . 2 8 0 . 0 6 0 . 1 2 0 . 7 0 0 . 1 3 0 . 3 6 0 . 4 3 0 . 2 2 
2 4 0 . 0 0 0 . 3 8 0 . 0 3 0 . 3 4 0 . 0 0 0 . 0 5 0 . 0 5 0 . 0 5 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration (jxg ml"') 
Time 
(hr) Group R Subject 
1 2 3 4 5 6 7 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 2 . 7 0 2 . 6 0 5 . 1 0 7 . 6 2 7 . 0 5 2 . 7 3 5 . 6 3 
1 4 . 9 1 8 . 5 3 10 . 85 1 5 . 3 7 15 . 51 6 . 9 8 1 3 . 1 4 
1 . 5 9 . 0 1 1 2 . 9 9 1 5 . 3 6 1 8 . 9 7 1 8 . 6 7 1 1 . 2 9 1 5 . 7 0 
2 1 1 . 1 7 1 6 . 2 6 1 9 . 0 8 2 4 . 1 7 1 8 . 6 9 15 . 41 1 8 . 3 2 
3 1 5 . 6 4 2 0 . 8 5 2 3 . 5 9 2 8 . 3 2 1 8 . 7 6 2 0 . 8 8 2 0 . 7 7 
4 1 8 . 4 0 2 1 . 1 7 2 6 . 1 7 2 9 . 9 3 18 . 03 2 6 . 2 2 2 0 . 6 8 
5 2 2 . 4 7 1 9 . 6 6 2 7 . 2 6 2 9 . 2 4 15 . 21 2 8 . 3 0 14 . 31 
6 2 4 . 0 4 1 8 . 8 5 2 7 . 9 4 2 7 . 6 4 13 . 51 2 9 . 9 7 1 5 . 9 6 
7 2 4 . 7 8 1 8 . 4 6 2 6 . 5 2 2 6 . 1 3 1 1 . 8 0 2 9 . 9 5 1 7 . 5 6 
8 2 4 . 6 6 16 . 83 2 5 . 6 3 2 4 . 1 6 1 0 . 0 8 2 9 . 3 5 18 . 55 
2 4 1 9 . 1 4 4 . 9 8 7 . 3 0 6 . 1 9 1 . 10 11 . 51 1 . 97 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Sulphate Concentration (jxg ml"^ ) 
Time — 
(hr) Group R Subject 
1 2 3 4 5 6 7 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 5 . 2 1 4 . 7 5 5 . 5 1 6 . 6 3 3 . 9 5 2 . 5 4 9 . 0 8 
1 8 . 4 5 9 . 5 0 ‘ 8 . 5 0 9 . 7 3 5 . 8 7 4 . 9 3 13 . 11 
1 .5 1 2 . 6 8 1 1 . 4 4 1 0 . 1 3 1 1 . 4 9 5 . 6 9 6 . 3 0 1 3 . 2 7 
2 1 4 . 6 7 1 1 . 6 7 1 1 . 4 6 1 2 . 9 2 4 . 8 3 6 . 8 1 1 3 . 1 9 
3 18 . 75 1 3 . 2 5 1 3 . 5 8 1 3 . 2 9 4 . 0 8 8 . 6 7 12 . 58 
4 2 1 . 3 0 1 2 . 0 6 1 3 . 0 8 1 3 . 0 2 3 . 5 6 9 . 4 8 1 0 . 4 9 
5 2 6 . 3 4 9 . 9 5 1 2 . 4 4 11 . 80 2 . 7 1 9 . 1 0 5 . 6 4 
6 2 7 . 5 7 8 . 7 6 1 2 . 1 7 10 . 84 2 . 1 6 8 . 8 7 6 . 6 5 
7 2 8 . 3 3 7 . 8 5 1 0 . 8 5 10 . 00 1 .75 8 . 3 1 7 . 7 2 
8 2 7 . 3 3 6 . 9 2 9 . 9 7 8 . 8 1 1 .45 7 . 9 3 8 . 6 9 
2 4 1 6 . 5 2 1 . 1 4 1 . 35 1 . 28 0 . 0 7 1 . 3 6 0 . 4 3 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Cysteine Concentration (jxg ml"') 
Time — 
(hr) Group R Subject 
1 2 3 4 5 6 7 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 0 . 2 2 0 . 0 4 0 . 1 4 0 . 0 8 0 . 1 1 0 . 0 0 0 . 2 1 
1 0 . 3 1 0 . 1 0 0 . 1 8 0 . 1 7 0 . 3 2 0 . 1 2 0 . 1 9 
1 .5 0 . 6 7 0 . 1 6 0 . 0 9 0 . 4 0 0 . 3 9 0 . 1 5 0 . 2 6 
2 0 . 7 0 0 . 3 1 0 . 1 8 0 . 4 7 0 . 3 7 0 . 2 0 0 . 3 4 
3 1 . 18 0 . 2 6 0 . 2 5 0 . 5 2 0 . 3 6 0 . 3 7 0 . 4 6 
4 1 . 28 0 . 4 3 0 . 4 1 0 . 5 2 0 . 3 4 0 . 2 7 0 . 4 9 
5 1 . 6 6 0 . 4 1 0 . 4 4 0 . 5 1 0 . 2 7 0 . 3 9 0 . 4 3 
6 1 . 8 0 0 . 2 6 0 . 5 7 0 . 4 9 0 . 2 1 0 . 4 1 0 . 4 6 
7 1 . 8 9 0 . 2 5 0 . 5 2 0 . 4 7 0 . 1 9 0 . 4 2 0 . 4 6 
8 1 .91 0 . 2 9 0 . 4 7 0 . 4 6 0 . 2 2 0 . 4 1 0 . 5 1 
2 4 1 . 17 0 . 1 3 0 . 1 4 0 . 1 6 0 . 0 0 0 . 1 1 0 . 0 4 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Glucuronide Concentration {jxg ml"') 
Time 
(hr) Group D' Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 5 0 . 8 3 2 . 5 4 1 . 80 2 . 1 6 4 . 6 0 3 . 4 4 3 . 0 5 4 . 6 0 
1 1 . 88 8 . 0 0 4 . 6 7 4 . 7 4 8 . 4 8 6 . 6 5 6 . 9 1 8 . 4 8 
2 5 . 1 1 1 4 . 7 3 6 . 9 3 6 . 8 2 1 1 . 1 7 1 1 . 1 7 9 . 4 7 1 1 . 1 7 
3 6 . 4 6 1 7 . 0 9 5 . 7 8 7 . 2 2 1 0 . 7 4 1 2 . 5 4 10 . 25 1 0 . 7 4 
4 7 . 4 1 1 6 . 8 8 4 . 8 9 6 . 9 0 10 . 73 1 2 . 7 8 8 . 9 5 1 0 . 7 3 
5 8 . 1 3 1 5 . 6 9 3 . 9 3 6 . 4 1 1 0 . 2 9 1 2 . 1 6 7 . 8 8 1 0 . 2 9 
6 7 . 5 6 1 3 . 9 0 3 . 3 2 5 . 4 3 9 . 0 0 11 . 1 2 6 . 7 7 9 . 0 0 
7 7 . 2 7 1 1 . 7 0 2 . 7 1 4 . 9 5 8 . 9 4 1 0 . 1 4 5 . 8 6 8 . 9 4 
8 7 . 6 8 9 . 7 3 2 . 1 0 4 . 2 4 7 . 9 2 8 . 6 3 4 . 9 6 7 . 9 2 
2 4 1 . 3 6 0 . 6 2 0 . 2 2 0 . 2 5 1 .15 0 . 8 1 0 . 6 4 1 . 1 5 
I 
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Appendix 2.49 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Plasma Paracetamol Sulphate Concentration (/xg ml"') 
Time 
(hr) Group D，Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.70 0.00 0.00 0.00 
0.5 1.39 1.77 2.69 2.24 0.99 3.09 2.15 4.62 
1 3.69 3.63 4.36 3.90 2.53 4.80 3.87 6.54 
2 7.73 4.54 4.65 4.75 3.99 6.17 4.41 7.37 
3 9.08 5.21 3.45 4.60 4.66 6.68 4.72 7.01 
4 9.99 4.64 2.90 4.26 4.92 6.30 4.36 7.20 
5 9.93 3.78 2.30 3.67 4.79 5.61 3.59 6.80 
6 9.52 3.05 1.90 3.14 4.14 4.90 3.02 5.72 
7 8.39 2.38 1.54 2.97 3.28 4.08 2.62 5.53 
g 7.97 1.78 1.20 2.36 2.44 0.34 2.19 4.78 
24 0.85 0.10 0.08 0.13 0.34 0.18 0.10 0.60 
I 
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Appendix 2.43 Individual Plasma Paracetamol Glucuronide 
Concentrations Following Ingestion of a 20 mg kg] 
Body Weight Dose - Group D 
Plasma Paracetamol Cysteine Concentration (p.g ml，） Time 
(hr) Group D' Subject 
1 2 3 4 5 6 7 8 
0 0.00 0.00 0.00 0.00 0.10 0.00 0.00 0.00 
0 . 5 0 . 0 8 0 . 0 6 0 . 0 5 0 . 0 4 0 . 2 5 0 . 2 9 0 . 1 4 0 . 0 7 
1 0 . 2 4 0 . 2 0 0 . 2 1 0 . 1 9 0 . 3 9 0 . 5 0 0 . 2 9 0 . 1 8 
2 0 . 6 7 0 . 4 0 0 . 3 7 0 . 3 6 0 . 4 8 0 . 9 3 0 . 4 6 0 . 4 0 
3 1 . 1 5 0 . 6 5 0 . 5 1 0 . 4 2 0 . 8 4 1 .03 0 . 5 8 0 . 5 4 
4 1 . 49 0 . 6 4 0 . 5 0 0 . 4 3 1 . 2 2 1 . 0 2 0 . 5 8 0 . 6 7 
5 1 . 7 4 0 . 6 0 0 . 4 6 0 . 4 9 1 . 23 0 . 9 6 0 . 4 9 0 . 7 0 
6 1 . 8 2 0 . 5 5 0 . 4 5 0 . 4 8 1 . 14 0 . 8 9 0 . 4 1 0 . 7 1 
7 1 . 7 7 0 . 5 8 0 . 4 3 0 . 4 7 1 . 06 0 . 8 4 0 . 4 4 0 . 7 8 
8 1 . 7 7 0 . 5 3 0 . 3 6 0 . 4 3 0 . 7 9 0 . 7 4 0 . 3 9 0 . 7 8 
2 4 0 . 2 4 0 . 0 8 0 . 0 0 0 . 0 4 0 . 1 2 0 . 0 5 0 . 0 7 0 . 1 5 
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Appendix 2.57 Urinary Recovery of Paracetamol and Metabolites in 
Each Sample Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Time Urinary Recovery of Paracetamol and Metabolites in Individual Subjects (mg) 
After Group A Subject ‘ Dosing 1 2 3 4 5 6 7 
Glucuronide 
279 .42 0 .00 214 .48 296 .05 161.07 371 .60 305 .64 
4-8hr 281.74 410.35 295.76 216.28 177.43 283.44 112.89 
8-24hr 172.81 166.00 134.57 108.87 155.37 224.79 182.22 
0-24hr 733.98 576.36 644.81 621.20 493.87 879.83 600.76 
Sulphate 
0-4hr 132.09 aOoH 209.01 253.96 133.28 174.79 232.02 
4-8hr 108.88 172.55 189.95 113.23 104.94 99.41 53.58 
8-24hr 67.15 64.81 75.92 60.54 88.81 76.74 91.45 
0-24hr 308.12 237.36 474.88 427.72 327.03 350.94 377.05 
Cysteine 
0-4hr = 4 . 7 6 0 . 0 0 5 . 5 2 6 . 4 9 3 . 4 1 5 . 5 4 1 5 . 5 6 
4-8hr 6.66 17.13 10.69 8.98 4.98 7.51 7.17 
8-24hr 9.56 15.53 14.23 11.60 8.99 10.56 17.07 
0-24hr 20.97 32.66 30.44 27.06 17.38 23.61 39.80 
Paracetamol 
0-4hr 21.47 o W l 21.00 15.20 18.34 24.25 
4.8hr 14.40 24.98 14.74 11.27 11.09 10.08 6.89 
8-24hr 12.82 13.45 9.58 9.90 8.83 9.47 14.30 
0-24hr 48.69 38.44 45.32 36.38 38.27 68.79 45.44 
Mercapturate 
6171 0:00n 4：^  s i r ] 4.21 I 7：^  12.53 
4-8hr 10.25 21.46 12.22 6.62 5.92 9.32 4.89 
8.24hr 9.21 22.70 11.20 6.88 9.37 12.39 8.34 
0-24hr 25.63 44.16 28.07 19.38 19.50 29.64 25.76 
Total 
0-4hr 443.92 0.00 454.66 577.57 320.32 609.09 590.00 
4 8hr 421.92 646.48 523.36 356.37 304.36 409.76 185.42 
8.24hr 271.55 282.49 245.49 197.80 271.38 333.95 313.38 
0.24hr 1137.39 928.97 1223.51 1131.74 896.06 1352.80 1088.81 
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Appendix 2.57 Urinary Recovery of Paracetamol and Metabolites in 
Each Sample Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Time Urinary Recovery of Paracetamol and Metabolites in Individual Subjects (mg) 
� r Group B Subject Dosing 1 2 3 4 5 6 7 8 
Glucuronide 
0-4hr 356.19 44.97 154.40 45.18 404.16 103.02 248.96 150.74 
4-8hr 248.71 83.78 160.41 652.93 204.80 153.58 119.67 472.95 
8-24hr 100.65 231.21 142.57 147.44 102.50 138.64 86.48 168.67 
0-24hr 705.55 359.96 457.38 845.54 711.46 395.24 455.10 792.36 
Sulphate 
0-4hr 167.74 42.40 95.31 31.41 265.66 91.84 440.62 ~ 4 5 . 2 4 
4-8hr 61.18 39.26 88.69 163.33 112.65 98.14 144.93 149.29 
8-24hr 23.43 93.92 65.33 30.74 53.49 82.42 102.41 55.31 
0-24hr 252.34 175.58 249.33 225.49 431.80 272.40 687.96 249.84 
Cysteine 
0-4hr : 8.45 1.73 8.87 0.86 12.99 6.38 14.17 12.00 
4-8hr 8.19 3.35 10.86 11.71 9.31 10.05 8.37 55.90 
8-24hr 5.13 14.23 10.00 5.69 6.00 19.33 8.43 21.43 
0-24hr 21.76 19.31 29.72 18.27 28.31 35.75 30.97 89.33 
Paracetamol 
0-4hr 11.16 5.59 10.00 4.50 18.07 10.73 16.30 7.53 
4—8hr 7.60 5.43 17.56 14.37 14.74 15.44 7.67 13.73 
8-24hr 6.73 18.89 14.62 7.40 13.55 18.16 7.24 5.21 
0-24hr 25.49 29.91 42.19 26.28 46.37 44.33 31.22 26.47 
Mercapturate . 
~ — o n — T ^ T ] 1 0 ： ^ " W ] ~ ~ r r i r r t j t i 1 0 . 3 4 JW 
4-8hr 8.20 3.67 14.02 21.78 9.97 10.76 6.17 32.26 
8-24hr 4.78 13.56 16.25 9.86 8.12 22.96 4.01 12.68 
0-24hr 21.79 19.16 40.87 32.38 29.99 38.55 20.52 50.73 
Total 
0-4hr 552.34 96.61 279.18 82.69 712.78 216.80 730.39 221.30 
4.8hr 333.88 135.48 291.54 864.12 351.47 287.96 286.81 724.12 
8.24hr 140.72 371.82 248.76 201.14 183.68 281.51 208.57 263.30 
0.24hr 1026.94 603.92 819.49 1147.95 1247.93 786.28 1225.77 1208.72 
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Appendix 2.57 Urinary Recovery of Paracetamol and Metabolites in 
Each Sample Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Time Urinary Recovery of Paracetamol and Metabolites (mg) 
After Group C Subject Dosing ^ 1 2 3 4 5 6 7 8 9 
Glucuronide 
0-4hr 91.26 89.61 251.32 ~ 3 0 . 3 3 245.33 487.84 318.02 76.50 641.13 
4-8hr 148.24 114.96 283.84 75.97 127.93 279.60 34.12 199.23 344.47 
8-24hr 145.92 144.19 161.31 193.84 86.11 293.64 143.46 301.77 189.07 
0-24hr 385.41 348.76 696.47 300.14 459.37 1061.09 495.60 577.50 1174.66 
Sulphate 
0-4hr “ 1 0 7 . 5 7 112.80 136.22 40.78 143.58 127.05 188.34 222.68 
4-8hr 117.08 120.35 98.60 91.52 55.08 49.82 18.52 122.66 86.14 
8-24hr 118.58 142.43 67.38 194.50 36.39 47.25 72.69 194.20 44.89 
0-24hr 343.24 375.58 302.19 326.81 235.05 224.12 279.55 371.38 353.70 
Cysteine 
4 . 0 0 6 .11 9.25 3 .53 6 .48 11.38 9 .22 2 .15 8 .72 
4-8hr 10.55 11.69 8.89 11.80 3.97 6.59 1.21 7.33 7.68 
8-24hr 24.33 21.46 9.82 48.63 8.68 14.23 10.53 19.54 7.06 
0-24hr 38.88 39.26 27.96 63.96 19.12 32.19 20.96 29.02 23.46 
Paracetamol 
0-4hr " " " i H T ] ~ T s W l ~ ~ i T ^ ^^T]""“24.31 38.14 ~~14.79 6.43 25.03 
4-8hr 28.66 16.27 15.09 10.25 8.65 13.56 1.79 11.26 10.32 
8-24hr 19.58 26.83 13.43 33.68 5.20 13.63 11.19 28.21 9.51 
0-24hr 66.68 58.40 43.32 48.24 38.16 65.33 27.77 45.90 44.87 
Mercapturate 
~ ~ n r i 6 ： ^ I s T I ~ ~ T a T I 8 ： 6 1 ~ | " " " " o T I 1 . 8 5 11.78 
4-8hr 14.67 8.06 6.86 8.69 4.36 5.88 1.26 9.69 10.36 
8-24hr 26.69 11.61 4.55 38.10 8.18 12.54 8.85 23.25 8.77 
0-24hi 45.97 22.84 18.15 49.13 17.04 27.02 18.95 34.79 30.91 
Total 
0-4hr 225.90 226.99 418.32 81.28 424.19 673.03 539.22 141.47 909.33 
4.8hr 319 19 271.33 413.27 198.24 199.99 355.44 56.90 350.16 458.97 
8-24hr 335.10 346.51 256.49 508.75 144.57 381.28 246.72 566.97 259.30 
0.24hr 880.19 844.83 1088.09 788.27 768.75 1409.75 842.84 1058.59 1627.60 
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Appendix 2.57 Urinary Recovery of Paracetamol and Metabolites in 
Each Sample Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Time Urinary Recovery of Paracetamol and Metabolites (mg) 
After Group D Subject Dosing 1 2 3 I 4 5 6 7 8 
Glucuronide 
0-4hr 140.17 191.33 490.93 28.21 501.65 105.05 140.04 152.23 
4-8hr 69.33 398.70 209.41 0.00 378.68 96.98 66.88 150.94 
8-24hr 131.21 289.42 68.92 257.30 48.19 62.85 359.85 159.62 
0-24hr 340.71 879.45 769.27 285.50 928.52 264.87 566.76 462.79 
Sulphate 
0-4hr ” 2 0 3 . 4 1 ""“146.61 ~ 3 0 4 . 1 3 ""“ 20.65 180.67 210.46 75.27 208.68 
4-8hr 62.45 213.50 85.95 0.00 132.69 141.81 33.76 138.55 
8-24hr 97.96 128.42 24.43 160.25 16.62 92.35 137.89 135.40 
0-24hr 363.82 488.53 414.52 180.90 329.99 444.63 246.91 482.63 
Cysteine 
0-4hr = 16.00 5.11 I 16.47 2.17 9.93 10.84 15.50 15.68 
4-8hr 9.31 11.52 7.45 0.00 9.55 19.71 7.22 15.85 
8-24hr 25.87 12.53 6.21 21.95 4.09 29.07 40.78 28.99 
0-24hr 51.18 29.16 30.13 24.12 23.58 59.62 63.50 60.52 
Paracetamol 
0-4hr 7.72 18.13 23.35 4.06 38.47 20.86 9.68 16.96 
4-8hr 2.83 21.61 12.04 0.00 37.14 9.23 4.57 19.52 
8-24hr 9.38 22.28 6.87 7.91 4.04 13.67 19.80 27.18 
0-24hr 19.94 62.03 42.27 11.97 79.65 43.77 34.05 63.66 
Mercapturate 
~ — 6 ：^ JJT] r r ^ ^ i r i 1 0 . 7 5 9：^  
4-8hr 5.22 9.82 8.51 0.00 11.28 12.74 5.33 11.61 
8-24hr 14.66 11.74 4.04 30.99 2.68 16.18 34.59 18.78 
0-24hr 26.83 24.91 22.32 32.72 25.94 34.44 50.68 39.82 
Total 
0-4hr 374.25 364.53 844.65 56.81 742.72 352.73 251.24 402.99 
4.8hr 149.14 655.15 323.37 0.00 569.33 280.47 117.75 336.46 
8.24hr 279.07 464.40 110.48 478.39 75.63 214.12 592.91 369.97 
0-24hr 802.47 1484.08 1278.50 535.20 1387.68 847.32 961.90 1109.42 
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Appendix 2.57 Urinary Recovery of Paracetamol and Metabolites in 
Each Sample Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Time Urinary Recovery of Paracetamol and Metabolites (mg) 
_ . Group R Subject Dosing ‘ 1 2 3 4 5 6 
Glucuronide 
0-4hr 5.62 92.00 4.35 12.26 42.84 61.96 
4-8hr 34.77 145.81 171.82 53.99 95.14 448.90 
8-24hr 98.15 330.01 210.49 336.23 236.21 254.98 
0-24hr 138.54 567.82 386.66 402.48 374.20 765.84 
Sulphate 
0-4hr 7 ? ^ 118.11 4.54 8.07 74.50 
4-8hr 38.54 136.29 139.52 32.47 31.34 301.46 
8-24hr 89.83 192.97 96.19 163.43 52.21 124.20 
0-24hr 136.12 447.36 240.25 203.97 103.04 500.16 
Cysteine 
0-4hr r 0 8 ~ l T^T"! 0.02 1.01 2 M 4.55 
4..8hr 4 . 3 4 5 . 32 7 .60 2 .61 5 .25 24 .45 
8-24hr 10.58 12.65 11.95 11.38 13.02 15.30 
0-24hr 16.00 20.72 19.57 15.00 44.31 
Paracetamol 
T ^ t I s T l 9：98~| O W I 2 . 6 2 1 - 9 0 7.56 
4-8hr 5.35 5.78 5.73 4.54 3.26 18.95 
8.24hr 5.32 12.80 6.66 15.30 8.98 12.81 
0-24hr 13.98 28.56 12.77 22.46 14.14 39.32 
Mercapturate 
- T ^ t oWl 0 .08 o l T i T i i " ] 2.21 
4-8hr 3.22 4.68 7.05 1.80 4.54 25.82 
8-24hr 12.70 10.22 10.78 12.00 8.51 15.66 
0-24hr 16.31 17.39 17.91 14.06 U.93 43.69 
Total 
0-4hr 18.15 225.33 9.37 24.22 68.58 150.78 
4-8hr 86.22 297.88 331.72 95.41 139.54 819.58 
8-24hr 216.58 558.64 336.07 538.34 318.93 422.95 
0.24hr 320.95 1081.85 677.16 657.97 527.05 1393.31 
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Appendix 2.57 Urinary Recovery of Paracetamol and Metabolites in 
Each Sample Following Ingestion of a 20 mg kg i 
Body Weight Dose - Group D， 
Time Urinary Recovery of Paracetamol and Metabolites (mg) After — Dosing Group D: Subject 
I 1 I 2 I 3 I 4 I 5 6 7 8 
Glue 
0-4hr 9.16 57.58 133.81 59.23 0.00 “""“100.99 139.53 125.80 
4-8hr 39.00 205.80 192.75 129.74 172.06 116.77 86.96 147.31 
8-24hr 116.93 208.60 148.89 114.19 163.29 186.06 216.86 139.63 
0-24hr 165.09 471.99 475.46 303.16 335.34 403.82 443.35 412.73 
Sulp 
0-4hr 26.89 37.79 128.83 73.26 ^ 103.60 106.45 104.65 
4-8hr 108.12 86.33 145.23 157.88 183.12 92.73 54.44 109.70 
8-24hr 215.31 56.84 90.32 101.06 122.52 126.56 125.94 90.31 
0-24hr 350.32 180.96 364.38 332.19 305.64 322.90 286.84 304.67 
Cyst 
0-4hr 3 M s ! ^ 20.93 25.25 16.75 10.77 
4-8hr 32.66 19.07 58.23 33.60 56.01 30.29 12.12 20.81 
8-24hr 101.65 33.38 59.91 44.63 48.24 66.76 47.79 38.25 
0-24hr 138.15 58.35 139.07 86.06 104.25 122.30 76.66 69.83 
Para 
0-4hr 1.51 2.66 22.20 4.61 0.00 6.99 ^ 10.91 
4-8hr 0.00 6.25 30.09 12.53 11.77 8.12 7.03 12.78 
8-24hr 0.00 8.45 21.44 13.91 9.15 15.58 19.46 8.32 
0-24hr 1.51 17.36 73.73 31.05 20.93 30.70 36.06 32.01 
Merc 
0 - 4 h r LsTI 2 . 8 1 I ~ 9 . 4 7 4 . 4 7 0 . 0 0 6 . 7 3 
4-8hr 15.96 20.65 33.61 20.32 28.63 22.67 7.48 15.30 
8-24hr 44.93 27.05 42.08 32.27 31.16 47.31 19.52 26.30 
0-24hr 62.46 50.51 85.16 57.06 59.79 86.41 35.19 48.33 
Total 
0-4hr 42.97 106.74 315.24 149.39 0.00 ""“253.26 280.50 258.86 
4-8hr 195.73 338.10 459.92 354.08 451 .59 270.59 168.04 305.90 
8-24hr 478.83 334.32 362.64 306.05 374.36 442.28 429.57 302.80 
0.24hr 717.53 779.16 1137.80 809.52 825.96 966.13 878.11 867.57 
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